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Abstract 
The placenta acts as a life support system maintaining the fetus throughout gestation. Inadequate 
implantation and insufficient development of the placenta are known to be linked to preeclampsia 
(PE) and intrauterine growth restriction (IUGR) of the developing fetus. Throughout gestation the 
placenta needs to continually grow and differentiate to increase its functional capacity in order to 
meet the needs of the fetus during its growth.  
 
Myostatin was initially identified as a negative regulator of muscle development. Without 
functional myostatin a doubling of muscle tissue is observed. For example a young boy had 
increased muscle development and extraordinary strength due to a homozygous mutation (G to A 
transition in the first intron-exon region) of the myostatin gene leading to a truncated myostatin 
protein. 
 
Myostatin is a distinct member of the Transforming Growth Factor-β (TGF-β) superfamily. 
Members of this superfamily are known to function in the development of the placenta. In the 
human placenta, myostatin protein expression decreases with gestational age. Myostatin treatment 
alters glucose uptake of placental explants and cells. In complicated pregnancies, higher myostatin 
has only been reported in placentae and serum of pregnancies complicated with PE. No difference 
in the serum concentrations of myostatin was observed in gestational diabetes mellitus (GDM) and 
placental expression of myostatin in GDM is not reported. Due to the limited information and the 
apparent expression and function of myostatin in the placenta further investigations were needed to 
better understand the role of myostatin in the human placenta.  
 
Firstly, the localization of myostatin in first and third trimester human placentae was investigated 
using immunohistochemistry. Third trimester extravillous trophoblast (EVT) stained most strongly 
for myostatin. This led to the isolation of EVT (from first trimester tissues) and confirmation of 
myostatin by immunocytochemistry. Following this, the potential for myostatin to affect the 
proliferation and migration was investigated in an EVT cell line and isolated EVT. The findings of 
this research were the first to demonstrate that myostatin could positively affect both proliferation 
and migration of placental cells. 
 
Secondly, the ability of myostatin to modulate cytokine release from placental explants was 
investigated. First trimester placental explants were maintained under hypoxic (1%), 
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physiologically relevant oxygen (3%) and standard culture conditions (21%)  myostatin treatment. 
Pro-inflammatory cytokine (IL-8, IFN-γ, TNF-α) production was significantly lower in the presence 
of myostatin whereas anti-inflammatory IL-4 was higher.   
 
Thirdly, myostatin concentrations were measured by ELISA in the plasma of pre-symptomatic 
women (12-14 weeks gestation) who later developed PE, IUGR and in women with normal 
pregnancies. Higher myostatin concentrations were found in plasma of pre-symptomatic women 
who later developed PE compared to IUGR and normal pregnancies. Investigations by western blot 
identified higher active myostatin dimer protein expression in placental tissue of pregnancies 
complicated with PE, IUGR, PE with IUGR (PE-IUGR) compared to gestational age matched 
women (PTB control).  
 
In the fourth study, similar analyses as described above were performed in plasma of pre-
symptomatic women who later developed GDM and in placentae of diet and insulin treated GDM 
women compared to women with normal glucose tolerance (NGT). No difference was observed in 
plasma of pre-symptomatic women who later developed GDM compared to NGT. In comparison to 
placentae of NGT women, higher myostatin precursor and lower dimer expression was observed. 
Furthermore, lower precursor and higher dimer expression were observed in placental tissues of the 
insulin treated compared to diet treated women with GDM.  
 
Finally, the possibility of developing a more sensitive and specific detection method for myostatin 
utilising mass spectrometry was investigated. Based on the digestion and discernment of 
recombinant myostatin proteins, the method developed can clearly distinguish specific peptides of 
the mature (dimerization of which yields the active protein) and pro-peptide regions of the 
myostatin protein (myostatin inhibitory protein). This method enables the detection of the myostatin 
forms independent of antibodies on which current gold standard protein methods heavily rely. The 
next step to the utility of this method is to develop a protocol for the preparation of biological 
samples for use with this method of detection.  
 
In summary, in this thesis I identified that myostatin is localised in EVT and that myostatin could 
increase the proliferative and migrative capacities of EVT. Myostatin can modulate cytokine 
production in a manner that would support normal pregnancy. In complicated pregnancies, higher 
myostatin concentrations were evident in plasma of pre-symptomatic PE women and myostatin 
protein expression in placentae of women with PE, IUGR, PE-IUGR complicated pregnancies. 
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Significant differences of myostatin protein were also observed in placentae of GDM complicated 
pregnancies compared to placentae of normal pregnancies and depending on the treatment (insulin 
and diet) received for GDM. Furthermore, a new more sensitive method of myostatin detection is 
well under development. In all, I believe this thesis has advanced the knowledge of myostatin’s role 
in the human placenta and provides a necessary platform from which further studies can be 
implemented.     
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 Introduction  Chapter 1.
This introduction consists of segments from the first author publications published*, publications 
submitted for consideration
† 
(please refer to page v for full details) and additional paragraphs:  
Placenta 2012 (33) 902-907* 
Journal of Proteome Research 2014 13 (8):3802-3809* 
The Journal of Clinical Endocrinology & Metabolism 2014:jc.2014-2615* 
Reproductive Sciences 2014
†
  
Placenta 2014* 
 Introduction 1.1 
Myostatin, also known as Growth Differentiating Factor 8 (GDF-8), is a member of the 
transforming growth factor beta superfamily (McPherron, Lawler et al. 1997). Myostatin is highly 
conserved (Rodgers and Garikipati 2008) and expressed in a number of tissues including muscle 
(McPherron, Lawler et al. 1997), adipose (Allen, Cleary et al. 2008), cardiac (Sharma, Kambadur et 
al. 1999), mammary (Manickam, Pena et al. 2008) and in the human placenta (Mitchell, Osepchook 
et al. 2006). Alterations to myostatin expression have been identified in human subjects who were 
obese (Hittel, Berggren et al. 2009), had type 2 diabetes (Palsgaard, Brøns et al. 2009), muscle 
wasting (Gonzalez-Cadavid, Taylor et al. 1998, Yarasheski, Bhasin et al. 2002) and pregnancies 
complicated with preeclampsia (Guo, Tian et al. 2012).  
 
Myostatin is best known as a negative regulator of muscle development (McPherron, Lawler et al. 
1997). Inhibition of this protein increases muscle and decreases adipose tissues (McPherron, Lawler 
et al. 1997). An improved metabolic status is observed in myostatin knockout mice (suppression of 
hyperglycaemia) and in mice with a loss of function mutation(s) to the myostatin gene (less insulin 
resistance) (McPherron and Lee 2002, Wilkes, Lloyd et al. 2009).  
 
Myostatin and its effects on pregnancy outcomes are not well understood. In humans, an infant boy 
with homozygous mutation of G to A transition in the first intron-exon of the myostatin gene was 
carried to term and born to a woman who was a heterozygous carrier of a myostatin gene mutation. 
Knockout Mstn
-/- 
mice are known to be fertile and viable (McPherron, Lawler et al. 1997); however 
cattle with double muscling are known to have difficulties in maintaining pregnancies, calving, and 
overall fertility (Bellinge, Liberles et al. 2005, Lee 2007).  
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Figure 1: Myostatin mutants.  
(a) Young boy with myostatin mutation as a neonate (b) seven months of age, (c) whippet 
homozygous myostatin mutant (d) wild type whippet, (e) wild type mouse (f) homozygous 
myostatin mutant (g) Belgian Blue bull with double muscling. (a-b)Reproduced with permission 
from (NEJM), Copyright Massachusetts Medical Society, (c-d) Reproduced with permission from 
Shelton and Engvall 2007 (e-g) Reproduced with permission from McPherron, Lawler et al a. 1997 
and McPherron and Lee 1997 (Copyright (1997) National Academy of Sciences, U.S.A.). 
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The placenta is a specialised and transient organ responsible for the maintenance of the fetus in 
utero (Gude, Roberts et al. 2004). A healthy in utero environment largely provided by a well-
developed and functioning placenta is essential for the well-being of the mother, the developing 
fetus and good health in later life (Gluckman, Hanson et al. 2008). Throughout gestation the 
placenta needs to continually grow and differentiate to increase its functional capacity in order to 
meet the needs of the fetus during its growth (Myatt 2006). Understanding the processes involved in 
the maintenance of placental development will be important in addressing and/or identifying 
inadequate development of the fetus. 
 
Myostatin and the role it plays in placental development and function is largely unknown, as is the 
expression of this protein in the various complications that can arise during pregnancy. From the 
limited literature of myostatin and placenta, it is known that myostatin expression (protein) 
decreases with gestational age and that myostatin can alter glucose uptake (Mitchell, Osepchook et 
al. 2006). Furthermore, maternal nutrition affects the expression of myostatin in the placenta (Peiris 
and Mitchell 2012). Women with pre-eclampsia have also been identified to have elevated 
myostatin levels in serum and higher expression in placentae compared to uncomplicated 
pregnancies (Guo, Tian et al. 2012). The aim of this thesis therefore is to expand the limited 
knowledge of myostatin in the placenta and evaluate its potential functions within placentae.   
 Myostatin  1.2 
Myostatin, was initially discovered in 1997 (McPherron, Lawler et al. 1997). Through targeted 
investigations of myostatin gene disruptions in mice (myostatin knockouts) the ability for myostatin 
to negatively regulate muscle development was identified. A “doubling” of muscle tissue was seen 
in the myostatin knockouts (Figure 1e-f) (McPherron, Lawler et al. 1997) and this 2-3 fold increase 
in muscle was observed to be due to a combination of hyperplasia (increase in number) and 
hypertrophy (increase in size) of muscle fibers (McPherron, Lawler et al. 1997).  
 
Disrupting the myostatin gene and therefore inhibiting the function of the myostatin protein not 
only increases muscle but also decreases adipose tissues (McPherron, Lawler et al. 1997). An 
improved metabolic status is observed in myostatin knockout mice (suppression of hyperglycaemia) 
and in mice with a loss of function mutation(s) to the myostatin gene (less insulin resistance) 
(McPherron and Lee 2002, Wilkes, Lloyd et al. 2009). Transgenic mice carrying a dominant 
negative activin IIB receptor expressed either in adipocytes or skeletal muscle were evaluated and 
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specific inhibition of myostatin signalling in muscle have been identified to be most effective in 
improving glucose metabolism and insulin sensitivity (Guo, Jou et al. 2009).  
 
Mutations to the myostatin gene resulting in the absence of functional myostatin protein occur in 
several different species. The impressive double muscled phenotype (Figure 1g) in the cattle 
industry was selectively bred over centuries without specific knowledge of the genetic aberrations 
behind their existence (Kambadur, Sharma et al. 1997, McPherron and Lee 1997). To date, seven 
different mutations of the myostatin gene have been identified in these cattle, including premature 
stop codons, frame-shift mutations, and point mutations at conserved amino acids (Kambadur, 
Sharma et al. 1997, McPherron and Lee 1997, Rodgers and Garikipati 2008). A two base pair 
deletion in the third exon of the canine myostatin gene was identified in whippet dogs, a breed of 
racing dogs (Figure 1c-d). Speed testing of these dogs found heterozygous offspring to be faster 
than wild type animals (Mosher, Quignon et al. 2007, Shelton and Engvall 2007). In humans, an 
infant boy with a G to A transition in the first intron-exon region was carried to term and born to a 
woman who was a heterozygous carrier of a myostatin gene mutation. The boy was identified to be 
homozygous for this mutation which resulted in the introduction of a stop codon and the truncation 
of the myostatin protein and inactivation of its function. The characteristic increase to muscle mass 
seen when myostatin is not functional, was observed in the boy as a neonate, at 7 months and at 4.5 
years of age (Figure 1a-b). He was also observed to be extraordinarily strong (Schuelke, Wagner et 
al. 2004).  
 
In situ hybridisation and northern blotting identified myostatin to be highly expressed in muscle. 
However, expression of myostatin was also observed in a number of other tissues (McPherron, 
Lawler et al. 1997). Myostatin expression is known to be present in adipose, brain, cardiac, 
mammary, uterine, endometrial and placental tissues (McPherron, Lawler et al. 1997, Sharma, 
Kambadur et al. 1999, Roberts and Goetz 2001, Roberts and Goetz 2003, Mitchell, Osepchook et al. 
2006, Shyu, Lu et al. 2006, Arai and Nishiyama 2007, Kubota, Sato et al. 2007, Manickam, Pena et 
al. 2008, Rodgers and Garikipati 2008, Stoikos, Harrison et al. 2008, Heineke, Auger-Messier et al. 
2010). 
  
The human myostatin gene comprises of three exons, intervened by two conserved introns and a 3’ 
untranslated region. It is mapped to chromosome region 2q32.2 in humans (Gonzalez-Cadavid, 
Taylor et al. 1998). Similar organisation in vertebrates of the myostatin gene has been observed by 
the comparison of the myostatin gene, with birds and mammals having introns of a similar (~2kb) 
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size as in humans (Rodgers and Garikipati 2008). The amino acid sequence of myostatin is also 
highly conserved among species (Figure 2). The later sequence forming the active myostatin dimer 
(c-terminal chain) is more highly conserved among the species compared to the pro-peptide regions 
(as indicated by the greater proportion of exact matches in Figure 2).  
 
 Myostatin biosynthesis  1.3 
Myostatin is a distinct member of the Transforming Growth Factor beta (TGF-β) superfamily 
(Figure 3) and as such  retains many of the classic features of this family (McPherron, Lawler et al. 
1997, Lee 2004). Myostatin is initially synthesised as a~52kDa precursor protein with an N-
terminal secretory sequence (signal peptide), N- terminal pro-peptide domain, dibasic proteolytic 
processing site (RSRR: Arg-Ser-Arg-Arg - Figure 2, highlighted in grey) and a C-terminal domain 
(Figure 4). The C-terminal domain (mature protein chain) also contains nine cysteine residues 
(Figure 2 - in red) that are required for the formation of a “cystine knot” and dimerisation to form 
the active myostatin protein (McPherron, Lawler et al. 1997, Lee 2004).  
 
Two proteolytic cleavages of the ~52kDa precursor protein are required to form active myostatin 
(Figure 4). The first proteolytic cleavage removes the N-terminal signaling sequence required for 
protein secretion (Figure 4a). The second proteolytic cleavage, most likely performed by paired 
dibasic amino acids (PACE, also known as Furin)  occurs at the proteolytic processing site (RSRR; 
Arg-Ser-Arg-Arg) releasing the ~42kDa N-terminal pro-peptide (latency associated peptide; LAP) 
and a ~12kDa C–terminal fragment which is the mature myostatin protein (Figure 4b) (Lee 2004) . 
Dimerisation of the ~12kDa mature myostatin protein creates the ~24kDa myostatin dimer, known 
to be the active form of myostatin (Figure 4c) (Lee 2004). The pro-peptide, the N-terminal fragment 
plays two important roles: it facilitates the proper folding of the C-terminal domain to form a 
cystine knot and controls the activity of the myostatin dimer (Hill, Davies et al. 2002). 
 
Two monomeric pro-peptides bind non-covalently to the myostatin dimer forming a latent complex 
preventing the dimer from binding to its receptor ACTRIIB (Figure 4d) (Thies, Chen et al. 2001, 
Hill, Davies et al. 2002, Lee 2004). The majority of myostatin (~70%) found in the circulating 
blood is in this latent complex form (Hill, Davies et al. 2002, Lee 2008). Four metalloproteinases of 
the BMP-1/Tolloid family are involved in the release of the myostatin dimer from its latent complex 
via the proteolytic cleavage at Asp-76 of the myostatin pro-peptide (Figure 4e) (Hill, Davies et al. 
2002, Lee 2008). 
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Figure 2: CLUSTAL Omega multiple sequence alignment.  
(*) indicate an exact match, (:) strong similarity, (.) weak similarity in the amino acid sequences 
between species.    
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Figure 3: Myostatin a distinctive member of the TGF-β superfamily modified from (Lee 2004)  
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Figure 4: Biosynthesis of myostatin  
 
  
 9 
 
 Myostatin signaling  1.4 
As with other members of the TGF-β superfamily, myostatin signals through a heterotetrameric 
receptor complex (Figure 5). Binding of the myostatin dimer to the Activin type II receptor (Activin 
receptor IIB; ACTRIIB) initiates the Smad mediated signaling pathway. This leads to the 
transphosphorylation of the type I receptor (ALK4/ALK5) and the stimulation of downstream 
serine/threonine kinases associated with the type I receptor. The activation results in the 
phosphorylation of intracellular transcription factors Smad 2 and Smad 3 (R-Smads) which 
oligomerize with the Co-Smad, Smad 4 (Miyazawa, Shinozaki et al. 2002, Zhu, Topouzis et al. 
2004, Forbes, Jackman et al. 2006). The Smad 2, 3 and 4 oligomer translocates to the nucleus, 
where in association with other transcription factors, it regulates the transcription and expression of 
downstream genes necessary for myostatin action (Zhu, Topouzis et al. 2004).  
 
The myostatin signaling pathway is regulated by a number of proteins. Smad 7 binds to activated 
receptors and prevents the conscription and activation of R-Smads. Smad 7 can also competitively 
bind to activated R-Smads and prevent the formation of the oligomer complex required for 
translocation into the nucleus. Smurf 1 (Smad Ubiquitin Regulatory Factor 1) in combination with 
Smad 7 enhances the inhibition of myostatin transcription (Suzuki, Yagi et al. 2004, Zhu, Topouzis 
et al. 2004). Through a negative feedback loop, myostatin regulates the transcription and expression 
of both Smad 7 and c-ski, thus regulating its own signaling (Suzuki, Yagi et al. 2004). The nuclear 
protein c-ski is another inhibitor of the myostatin signaling pathway. It disturbs R-Smad/Co-Smad 
complex formation by recruiting N-CoR (nuclear co-repressor) and histone deacetylases to the 
Smad complexes causing the interference of transcriptional co-activator p300/CBP binding 
(Akiyoshi, Inoue et al. 1999, Suzuki, Yagi et al. 2004, Kobayashi, Goto et al. 2007). 
1.4.1 Regulation of myostatin  
One of the most potent antagonists of myostatin activity is Follistatin like-3 (FSTL-3; follistatin 
related gene; FLRG) (Hill, Davies et al. 2002). FLST-3 is a structural homologue of follistatin that 
has been shown to bind with a high affinity  to the active myostatin dimer (C-terminal dimer), thus 
inhibiting the biological activity of myostatin (Hill, Davies et al. 2002). The binding of FSTL-3 to 
myostatin can also occur after myostatin binds to its receptor and has initiated signalling (Hill, 
Davies et al. 2002). Myostatin signaling through the Smad mediated pathway triggers a negative 
feedback loop involving FSTL-3 (Hill, Davies et al. 2002). The Smad complex formed binds the 
Smad binding element of the FSTL-3 promoter resulting in the transcription and expression of 
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FSTL-3 and the consequent negative regulation of myostatin (Hill, Davies et al. 2002, Patel and 
Amthor 2005). 
 
 
 
 
Figure 5: Myostatin signaling   
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 Clinical potential  1.5 
A consistently ageing population, debilitating muscular disorders (e.g. muscular dystrophy), and 
muscle loss through severe illness (e.g. cancer, HIV) drives the research into therapeutic 
interventions utilizing myostatin or the inhibition of myostatin activity (Sharma, Langley et al. 
2001, Lee, Reed et al. 2005, Bradley, Yaworsky et al. 2008, Rodino-Klapac, Haidet et al. 2009, 
Springer, Adams et al. 2010). The inhibition of the myostatin pathway, through the use of 
myostatin-blocking antibodies, soluble myostatin receptors, small interfering RNA, regulating 
proteins such as the pro-peptide or follistatin, and small chemical inhibitors, have shown promise in 
some preclinical studies (Lee, Reed et al. 2005, Rodino-Klapac, Haidet et al. 2009). Phase I and II 
trials have already been completed on two compounds MYO-029 (recombinant human antibody 
against myostatin used as a treatment of muscular dystrophy) and ACE-011 (fusion protein 
consisting of the extracellular domain of the ACTRIIB and Fc portion of human IgG1, studied in 
postmenopausal women) (Wagner, Fleckenstein et al. 2008, Ruckle, Jacobs et al. 2009). In these 
studies both inhibitors were found to be safe for human administration but had limited effect on 
muscle, bone and fat biomarkers. Studies are currently underway (clinicaltrials.gov) testing the 
effectiveness and safety of compounds which inhibit myostatin in cancer patients (NCT01524224; 
myostatin is increased in cancer cachexia (Costelli, Muscaritoli et al. 2008, Aversa, Bonetto et al. 
2012) and muscular dystrophy (NCT01519349). 
 
Homozygous myostatin null mice (Mstn
-/-
) exhibit doubling of muscle tissue mass compared to wild 
type mice (McPherron, Lawler et al. 1997). Myostatin has also been shown to regulate adipose 
deposition and glucose metabolism (Lin, Arnold et al. 2002, Dilger, Spurlock et al. 2010). The 
absence of myostatin activity partially reduces hyperglycemia and adipogenesis in mouse models of 
obesity and type 2 diabetes (McPherron and Lee 2002). Humans with type 2 diabetes were 
identified to have significantly higher skeletal muscle myostatin mRNA expression (Palsgaard, 
Brøns et al. 2009, Brandt, Nielsen et al. 2012) and interestingly an up-regulation in the myostatin 
gene was seen in the first-degree relatives (people with at least 50% of their genes in common) of 
people with type 2 diabetes (Palsgaard, Brøns et al. 2009).  
 
The prevalence of obesity, maternal obesity and the metabolic consequences of obesity including 
the increased risk of hypertension, type II diabetes, cardiovascular disease, impaired fertility and 
obesity-related cancers are steadily increasing (Dixon 2010, Du, Yan et al. 2010). Myostatin 
expression in plasma and protein expression in muscle are higher in extremely obese women 
compared to lean women (Hittel, Berggren et al. 2009). Decreases in myostatin gene expression in 
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obese humans following exercise and correlations of myostatin single nucleotide polymorphisms 
with obesity have been documented in both male and female populations Single Nucleotide 
Polymorphisms (SNPs) for myostatin are also associated with obesity. Myostatin SNPs rs3791783, 
rs1799883 and rs1805086 are associated with an increased risk and rs3791782 is associated with a 
decreased risk of obesity in Chinese and Indian populations (Bhatt, Nigam et al. 2012, Pan, Ping et 
al. 2012, Yue, He et al. 2012). Moreover, interventions against obesity such as biliopancreatic 
diversion, gastric bypass and aerobic exercise were all found to decrease the expression of 
myostatin in the skeletal muscle of obese humans (Milan, Dalla Nora et al. 2004, Park, Berggren et 
al. 2006, Hittel, Axelson et al. 2010, Ryan, Li et al. 2013). 
 Placenta 1.6 
The placenta is a specialised and temporary organ which throughout gestation acts as a life support 
system for the developing fetus (Myatt 2006, Fowden, Forhead et al. 2008). It maintains intrauterine 
growth by controlling nutrient, oxygen and hormone transfers as well as respiration and waste 
management for the developing fetus (Gude, Roberts et al. 2004). The placenta also acts as an 
immune interface between the mother and fetus (Norwitz, Schust et al. 2001, Gude, Roberts et al. 
2004). The in utero environment plays a critical role in the programming of the fetus and its 
preparation for life outside the womb (Barker 2004, Gluckman, Hanson et al. 2008). During 
gestation and the development of the fetus, an aberrant environment in utero such as intrauterine 
growth restriction, over-nutrition and under-nutrition leads to a higher likelihood of developing 
adult onset disorders including obesity, type II diabetes and hypertension (Barker 2004, Myatt 2006, 
Gluckman, Hanson et al. 2008). Furthermore, inadequate placental development and weak 
implantation have been linked to miscarriage, preeclampsia and growth restriction of the developing 
fetus (Chaddha, Viero et al. 2004). Throughout pregnancy it is critical that the functional capacity 
of the placenta increases to meet the needs of the growing fetus. Continual growth and 
differentiation, increased villous volume and trophoblast surface-area, result in a 40-fold increase in 
placental efficiency (fetal/placenta ratio) from the 6th week in pregnancy to term (Myatt 2006).   
1.6.1 Establishment of the human placenta 
The implantation and development of the placenta is a highly coordinated event involving maternal 
and fetal cell interactions (Chaddha, Viero et al. 2004, Gude, Roberts et al. 2004). Proper 
implantation and establishment of the placenta are crucial for the success of pregnancy, 56% of 
pregnancies do not continue past 20 weeks of gestation and of these terminated pregnancies, 75% 
are thought to be due to inadequate implantation (Bernirschke and Kaufmann 1999).   
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 Implantation  1.6.1.1
Prior to implantation, the fertilised ovum (zygote) travels through the fallopian tube continually 
dividing on its journey, reaching the uterus at six to seven days post-conception as a blastocyst (a 
“flattened vesicle” composed of 107 to 256 cells) (Bernirschke and Kaufmann 1999). The process 
of implantation in the human has three stages (Norwitz, Schust et al. 2001). First is apposition 
where microvilli of the blastocyst interdigitates with pinopodes of the uterine epithelium. Secondly, 
a more permanent adhesive process follows where increased interactions occur between the 
blastocyst and the uterine epithelium. The third and crucial stage for the development of the 
placenta is invasion (Bernirschke and Kaufmann 1999, Norwitz, Schust et al. 2001). 
 
After the initial attachment of the blastocyst, the trophoblast layer proliferates rapidly (Bernirschke 
and Kaufmann 1999). Upon proliferation the trophoblast differentiates into an inner layer of 
cytotrophoblast and an outer layer multi-nucleated syncytiotrophoblast (formed through the fusion 
of cytotrophoblast), creating the trophoblastic shell (Bernirschke and Kaufmann 1999, Chaddha, 
Viero et al. 2004). Cytotrophoblast cells penetrate through the syncytiotrophoblast creating 
anchoring columns making contact with the maternal decidua (Kaufmann, Black et al. 2003, 
Chaddha, Viero et al. 2004). Cytotrophoblast within the cell column differentiates into extravillous 
trophoblast (EVT; Figure 6), with the potential to invade (Kaufmann, Black et al. 2003, Gude, 
Roberts et al. 2004). EVT invade the endometrium extending to the inner third of the myometrium 
(Kaufmann, Black et al. 2003, Gude, Roberts et al. 2004).  
 
Cytokines and growth factors expressed by the maternal decidua and by cytotrophoblast regulate 
the invasiveness of the EVT. For example, cytokines such as interluekin 6 (IL-6) and IL1β 
expressed in cytotrophoblast assist in the proliferation of cytotrophoblast cells and help regulate 
both the implantation and the development of the placenta (Norwitz, Schust et al. 2001, Bowen, 
Chamley et al. 2002). Furthermore growth factors such as Activin A can stimulate invasion by 
increasing the expression of matrix metalloproteinase 2 (MMP2), whereas TGF-β1 and TGF-β2 
found in the cytotrophoblast, up-regulate the endogenous tissue inhibitors of MMPs (TIMPs 1 and 
2) (Bowen, Chamley et al. 2002, Jones, Stoikos et al. 2006).  
 Hypoxia environment  1.6.1.2
The initial weeks of pregnancy and placental development occur in a low oxygen environment 
protecting the developing fetus from oxygen-mediated injury (<10 weeks) (Kaufmann, Black et al. 
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2003, Chaddha, Viero et al. 2004, Gude, Roberts et al. 2004). Extravillous trophoblast invading the 
maternal spiral arteries (endovascular trophoblast) proliferate and clump together to prevent the 
flow of blood. The blood flow blocked for the initial weeks of pregnancy are released after 10 
weeks of gestation (Kaufmann, Black et al. 2003, Chaddha, Viero et al. 2004, Gude, Roberts et al. 
2004). The blood released from the dilated arteries that have been invaded, flows into the 
intervillous space of the placenta to be in direct contact with the trophoblast cells facilitating 
exchange between the maternal and fetal circulations (Kaufmann, Black et al. 2003, Chaddha, Viero 
et al. 2004, Gude, Roberts et al. 2004). 
 Villous formation  1.6.1.3
The human placenta is hemochorial. In this type of placentation the trophoblast invade the maternal 
vessels releasing blood into the intervillous space bathing the placental villi (Bernirschke and 
Kaufmann 2000). A low intra-placental pressure prevents the compression of fetal vessels (Osol and 
Mandala 2009). In the first trimester, the human placenta is described as being hemodichorial where 
two layers of trophoblast separate the maternal and fetal circulations. At term, the human placenta is 
described as hemomonochorial where only one layer of trophoblast separates the maternal and fetal 
circulations (Bernirschke and Kaufmann 2000).  
 
Placental villi are formed in three stages. Primary villi are created by evaginations of 
syncytiotrophoblast (Bernirschke and Kaufmann 2000, Chaddha, Viero et al. 2004, Gude, Roberts 
et al. 2004). These villi comprise of an inner core of cytotrophoblast and an outer layer of 
syncytiotrophoblast. Secondary villi are created by the growth of the fetal mesenchyme within the 
cytotrophoblast. Therefore secondary villi have an inner core of connective tissue, a middle layer of 
cytotrophoblast and an outer layer of syncytiotrophoblast. In tertiary villi fetal capillaries develop 
within the villous mesenchyme (Bernirschke and Kaufmann 2000, Chaddha, Viero et al. 2004, 
Gude, Roberts et al. 2004). Interdigitating tree-like branching of the villous takes place increasing 
the surface area for exchange between maternal and fetal circulations (Bernirschke and Kaufmann 
2000, Chaddha, Viero et al. 2004). In villous hemochorial placenta, the fetal blood within the tips of 
villous branches flows towards and away from the maternal blood – also known as multivillous 
exchanger (Bernirschke and Kaufmann 2000). This type of organisation is known to be an efficient 
method for transfer between maternal and fetal circulations (Figure 7) (Bernirschke and Kaufmann 
2000). 
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Figure 6: Trophoblast and placentation  
(a) Placental invasion (b) trophoblast differntiation  
(b) Reproduced from (Gude, Roberts et al. 2004) with permission  
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1.6.2  Functions of the human placenta 
For the duration of fetal development, the placenta maintains gaseous exchange, nutrient transfer, 
and waste management, temporarily taking over the functions of the fetal lungs, gastrointestinal 
tract, and kidneys (Gude, Roberts et al. 2004, Myatt 2006). The placenta also functions to protect 
the fetus from the mother’s immune system (Harding and Bocking 2001, Norwitz, Schust et al. 
2001, Gude, Roberts et al. 2004).  
 Gaseous exchange 1.6.2.1
Respiratory gases are small molecules that can easily cross the maternal-fetal blood barrier (Gude, 
Roberts et al. 2004). The rate limiting factor of gaseous exchange is the blood flow rate that can be 
different in different areas of the placenta. The low partial pressure of oxygen (PO2) found in the 
fetal blood is said to be due to this limiting step in addition to the consumption of oxygen by the 
placenta to maintain its own functions (Harding and Bocking 2001, Donnelly and Campling 2011). 
The low PO2 in fetal blood does not however, correspond with low oxygen saturation or content in 
the fetal blood. Fetal hemoglobin is found at a higher concentration in fetal blood (~40% increase). 
Fetal haemoglobin also has a higher binding affinity for oxygen (Gude, Roberts et al. 2004). This 
allows for a 50% greater saturation of oxygen in the fetal blood at a lower PO2 (Donnelly and 
Campling 2011). A relatively low partial pressure of carbon dioxide and a lower pH in the fetal 
arterial circulation also play a role in assisting the uptake of oxygen. The carbon dioxide found in 
the fetal blood combines with water (60%) to form carbonic acid that dissociates to form protons 
and bicarbonate ions. The protons and bicarbonate ions diffuse according to the concentration 
gradient from the fetal to maternal circulation. This process lowers the pH in the intervillous space 
and mediates the dissociation of oxygen from the maternal haemoglobin (Harding and Bocking 
2001, Donnelly and Campling 2011). The movement of the protons from the fetal to maternal 
circulations also increases the pH in the fetal circulation, thus facilitating the uptake of oxygen by 
fetal haemoglobin. Part of the remaining carbon dioxide (30%) combines with haemoglobin, and 
the balance 10% remains in circulation (Donnelly and Campling 2011).  
 Nutrient transport 1.6.2.2
During the 1
st
 trimester until the blood supply is established, nutrition is obtained by the 
phagocytosis of maternal glycoproteins secreted by the maternal endometrial glands (Burton, 
Watson et al. 2002, Gude, Roberts et al. 2004). Upon connection with the maternal circulation, 
nutrient transfer (of carbohydrates, amino acids, lipids and minerals) between the fetal and maternal 
circulation can begin (Gude, Roberts et al. 2004, Donnelly and Campling 2011). Placental transport 
is regulated by a number of factors including blood flow and placental metabolism. 
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Figure 7: The placenta  
(a) Multivillous exchanger: blood flow of fetal capillaries towards and away from maternal blood 
modified from (Bernirschke and Kaufmann 2000). (b) Overview of placental structure modified 
from (Gude, Roberts et al. 2004). 
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Figure 8: Glucose and fatty acid transport 
(a) Glucose transporters in the placenta. GLUT1 (clear) ; GLUT3 black; : GLUT4 grey (b) Fatty 
acid transport across the placenta 
(a) Reproduced with permission from (Illsley 2000), (b) reproduced with permission from (Lager 
and Powell 2012). 
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Glucose and amino acid transport across the placenta is dependent on the membrane bound 
receptors/transport proteins (Jones, Powell et al. 2007). Changes to the expression of these 
receptor/transporters have been identified in pregnancies complicated with diabetes, IUGR and 
preeclampsia (Illsley 2000, Myatt 2006)
 
. 
Glucose 
Glucose is a key source of energy required for the development of the fetus and is also the main 
form of carbohydrate transported across the placenta (Bell and Ehrhardt 2002, Mitchell, Osepchook 
et al. 2006).The majority of the glucose that is required by the fetus has to be acquired from the 
maternal circulation (Harding and Bocking 2001). The fetus has a high demand for glucose, 
especially in the third trimester of its development (Baumann, Deborde et al. 2002). This increased 
demand may be met in a number of ways: (1) the structural changes in the placenta increasing the 
surface area for exchange to occur (2) greater differences in the concentration gradient promoting 
more glucose to move toward the fetal circulation that is lower in glucose concentration at term, (3) 
increased delivery of glucose to the fetus from the placenta and (4) increased density of transporters 
(Hay 1995, Harding and Bocking 2001, Myatt 2006). Glucose is transported across the placenta by 
means of facilitated diffusion along a concentration gradient by glucose transporters (GLUTs) 
(Jansson, Myatt et al. 2009). 
GLUTs-1, 3, 4, 8, and 12 have all been localised within the placenta (Knipp, Audus et al. 1999, 
Gude, Roberts et al. 2004, Leonce, Brockton et al. 2006, Jansson, Myatt et al. 2009). GLUT-1 has 
been identified in the microvillous membrane (MVM) and basal membranes (BM) of 
syncytiotrophoblast as well as in placental endothelial cells (Knipp, Audus et al. 1999, Illsley 2000). 
GLUT-3 was also found in endothelial cells lining the fetal capillaries. GLUT-4 is known to be 
present in the placental intervillous stromal cells (Illsley 2000). GLUT-4 is sensitive to insulin and 
is thought to be important in transporting glucose in response to insulin in the fetal circulation 
(Illsley 2000, Jansson, Myatt et al. 2009). Differences have been observed in the expression of 
GLUTs between the 1st trimester and term placenta as seen by the changes in abundance and the 
type of cell in which the GLUT is identified. An example of this is the immunohistochemical 
detection of GLUT-12 which although identified in 1
st
 trimester syncytiotrophoblast is almost
absent at term (Baumann, Deborde et al. 2002, Gude, Roberts et al. 2004). GLUT-1 is considered to 
be important throughout pregnancy whereas GLUTs 3, 4, and 12 are thought to be more important 
in early pregnancy (Knipp, Audus et al. 1999, Gude, Roberts et al. 2004, Leonce, Brockton et al. 
2006).
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GLUT-1 is the main transporter for glucose in human placentae (Figure 9) (Illsley 2000, Gude, 
Roberts et al. 2004, Leonce, Brockton et al. 2006). The initial uptake of glucose occurs at the MVM 
of syncytiotrophoblast. The movement of glucose out of the syncytiotrophoblast to the fetal 
capillary is facilitated by GLUT-1 transporters present in the BM and in endothelial cells (Illsley 
2000). The rate limiting step in glucose transport is thought to be the lower localisation of GLUT-1 
transporters in the BM of syncytiotrophoblast compared to the MVM (Jones, Powell et al. 2007). 
GLUT-3 may also assist in the transport of glucose (Illsley 2000). The expression of GLUT-3 in the 
arterial vasculature and its ability to bind at a higher affinity (a lower Km in comparison to GLUT-1) 
allows GLUT-3 to scavenge the glucose in fetal blood already low in glucose, thus widening the 
concentration gradient between the maternal and fetal circulations (Knipp, Audus et al. 1999, Illsley 
2000). The placenta is a metabolic organ that requires glucose to maintain its functions and draws 
glucose from both maternal and fetal circulations. Without the utilisation of glucose by the placenta, 
the concentration of glucose in the fetal circulation would be much higher, resulting in a loss of the 
concentration gradient required for transport of glucose (Hay 1995, Bell and Ehrhardt 2002).  
 
Amino acids  
Amino acids (AA) are vital for the development of the fetus as they are essential for the synthesis of 
proteins (Harding and Bocking 2001, Gude, Roberts et al. 2004, Jansson, Myatt et al. 2009). Non-
essential amino acids can also be used as energy substrates (Jansson, Myatt et al. 2009). The 
concentration of AAs in the fetal circulation is much higher than that found in the maternal 
circulation (Jones, Powell et al. 2007). This implicates the need for active movement of AAs against 
the concentration gradient inward to the placenta and the movement along the concentration 
gradient outward to the fetus (Jansson, Myatt et al. 2009). The point of exchange between maternal 
and fetal circulations for amino acids is the trophoblast (Gude, Roberts et al. 2004).  
 
The transporters present on the MVM of syncytiotrophoblast mediate the uptake from the maternal 
circulation (Knipp, Audus et al. 1999, Jansson, Myatt et al. 2009, Lee and Kaufman 2011). 
Transporters present on the BM mediate the efflux of AA to the fetus. A number of different 
transporter systems (15-20) have been identified in the placenta (Jones, Powell et al. 2007, 
Donnelly and Campling 2011). The transporters are differentially localised on the MVM and BM of 
syncytiotrophoblast (Knipp, Audus et al. 1999, Battaglia and Regnault 2001, Donnelly and 
Campling 2011). Transporters can be classified by their dependency on sodium (Na dependent or 
independent) and substrate specificity (neutral, zwitterionic, basic) (Bell and Ehrhardt 2002, 
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Donnelly and Campling 2011). The transporters have some overlapping substrate specificity with 
multiple transporters able to transport one amino acid.  
 
The placenta also uses AA as a source of fuel (Regnault, de Vrijer et al. 2002). Serine, leucine, 
isoleucine, valine and in particular glutamate are utilised by the placenta (Cetin 2001, Regnault, de 
Vrijer et al. 2002). The fetal liver generates glutamate from glutamine; the placental uptake of 
glutamate is much higher from the fetal circulation (Cetin 2001, Bell and Ehrhardt 2002, Grillo, 
Lanza et al. 2008). There is also a small amount of glutamine production from glutamate within the 
placenta. The metabolism and production of AAs within the placenta can influence the amount and 
composition of AAs delivered to the fetus (Bell and Ehrhardt 2002, Grillo, Lanza et al. 2008).  
 
Fatty acids   
Plasma levels of free fatty acids (FFA) increase in pregnancy. FFAs (e.g. triglycerides rich - Very 
Low Density Lipoprotein or Albumin bound FFA) are the main form of lipid to cross the placenta. 
The transport of FFA is mediated by a maternal to fetal concentration gradient and can occur 
through diffusion (Donnelly and Campling 2011).  
 
Essential fatty acids and long chain polyunsaturated fatty acids are integrated with triglycerides 
(TG) in lipoproteins that cannot be transported as a whole across syncytiotrophoblast (Gude, 
Roberts et al. 2004). The transport of TG is mediated by interactions of lipoproteins with 
lipoprotein receptors inducing endocytosis and also by lipases (e.g. Lipoprotein lipase; LPL)  
present at the MVM of syncytiotrophoblast that hydrolyze TGs to FFA which then are able to cross 
by diffusion  (Gude, Roberts et al. 2004, Jones, Powell et al. 2007, Donnelly and Campling 2011). 
Plasma membrane fatty acid binding proteins (FABPpm), fatty acid translocase (FAT/CD36) and a 
family of fatty acid transport proteins (FATP; Figure 8) also assist in the transport of fatty acids 
across the placenta (Knipp, Audus et al. 1999, Jones, Powell et al. 2007). FABPpm has been 
identified to exist in the MVM. Furthermore, FAT/CD36 and FATP were identified in both the 
MVM and BM. FFA within the syncytial cytoplasm can bind FABPs and be transported to different 
locations for esterification, β-oxidation or transport across the BM (by diffusion or assisted by 
FATPs) (Jones, Powell et al. 2007, Jansson, Myatt et al. 2009, Lager and Powell 2012).  
1.6.3 Placenta and immune regulation  
The fetus is a semi-allograft that is tolerated by the maternal immune system throughout pregnancy 
(Norwitz, Schust et al. 2001, Bowen, Chamley et al. 2002). The implantation site is populated by a 
number of maternal leukocytes 70% of which are uterine natural killer cells (uNK) (Trowsdale and 
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Betz 2006). The initial point of contact between the mother and fetus is the placenta and therefore 
the first point of attack by the maternal immune system (Norwitz, Schust et al. 2001). More 
specifically, trophoblasts that are in contact with both fetal and maternal circulations form the layer 
that separates the two systems. As such, trophoblasts have to employ methods to evade detection 
(Norwitz, Schust et al. 2001, Szekeres-Bartho 2002, Gude, Roberts et al. 2004).  
 
The most important method by which the trophoblast evades detection is the lack of classical major 
histocompatibility complex (MHC) alloantigens (Norwitz, Schust et al. 2001, Szekeres-Bartho 
2002, Gude, Roberts et al. 2004). Trophoblast completely lack MHC class II molecules and are not 
induced by infection (Trowsdale and Betz 2006). Trophoblast express human leukocyte antigen 
HLA-C and nonclassical MHC class I alloantigens HLA-E and HLA-G (Norwitz, Schust et al. 
2001, Szekeres-Bartho 2002, Trowsdale and Betz 2006). The expression of HLA-G is seen mainly 
in EVT. HLA-G is thought to inhibit the killing of trophoblasts by NK cells and T cells in maternal 
deciduas (Szekeres-Bartho 2002). Syncytiotrophoblast also produce indoleamine 2, 3- dioxygenase 
(IDO) that depletes tryptophan. Tryptophan is an amino acid crucial for the proliferation of T cells 
as seen by the decreased proliferation of T cells when tryptophan concentration is decreased 
(Trowsdale and Betz 2006, Zhu 2010).  
 
The ability for trophoblast to limit the effectiveness of the immune system is essential in preventing 
the recognition and destruction of the fetus. An example of the maternal immune system 
recognizing the fetal semi-allograft is in Rh disease, where recognition of fetal red blood cells 
(Rh+) by the maternal (Rh-) immune system result in the production of antibodies that can cross the 
placenta and lead to the destruction of the fetal red blood cells and cause severe anaemia 
(Trowsdale and Betz 2006, Lee and Kaufman 2011, Zipursky and Paul 2011). 
 
Cytokines are important in the establishment, development and maintenance of pregnancy. The 
switch from an environment rich in T-helper 1 (Th1) cytokines (e.g. IFN-γ and TNF-α) to an 
environment rich in T-helper 2 (Th2) cytokines (e.g. IL-4) also may support the evasion of the 
maternal immune system (Wegmann, Lin et al. 1993, Bowen, Chamley et al. 2002, Challis, 
Lockwood et al. 2009, Sykes, MacIntyre et al. 2012).  
 
Tumour necrosis factor-α (TNF-α) is a pro-inflammatory cytokine, which changes expression 
across gestation (Haider and Knofler 2009). The expression of TNFα has been identified in 
trophoblast, syncytiotrophoblast and extravillous trophoblast (EVT) (Monzon-Bordonaba, Vadillo-
23 
Ortega et al. 2002, Haider and Knofler 2009). TNF-α is thought to be involved in the apoptosis of 
trophoblast cells and the negative regulation of syncytialisation (by negatively affecting human 
chorionic gonadotropin expression), and EVT invasion (Monzon-Bordonaba, Vadillo-Ortega et al. 
2002, Haider and Knofler 2009). IFN-γ is expressed in human trophoblast cells early in pregnancy 
of humans (Banerjee, Smallwood et al. 2005). A potential role in the regulation of EVT invasion 
has also been proposed for IFN-γ, as treatment with IFN-γ resulted in increased apoptosis of EVT 
and decreased secretions of MMPs (required for invasion) (Lash, Otun et al. 2006). The presence of 
IL-4 at the materno-fetal interface was identified through immunohistochemical studies, whereby 
cytotrophoblast, endothelial cells and decidual macrophages were positively stained (de, Vince et 
al. 1997). In mice, IL-4 knockouts were found to have a mild PE phenotype with increased levels of 
pro-inflammatory cytokines, mild hypertension, proteinuria and endothelial dysfunction (Chatterjee, 
Kopriva et al. 2013).  
In pregnancies complicated with conditions such as PE and GDM elevated Th1 cytokines (e.g. 
TNF-α) have been identified (Coughlan, Oliva et al. 2001, Holcberg, Huleihel et al. 2001, Founds, 
Powers et al. 2008, Mullins, Prior et al. 2012, Gomes, Torloni et al. 2013). 
1.6.4 Complicated pregnancies 
Complications during pregnancy have adverse consequences for the mother and baby in the 
immediate and long term. High risk pregnancies include those complicated by preeclampsia (PE) 
(Karumanchi, Maynard et al. 2005), intrauterine growth restriction (IUGR) (Li, Zeki et al. 2012, Li 
Z, McNally L et al. 2011), preterm birth (PTB) (Li, Zeki et al. 2012, Li Z, McNally L et al. 2011) 
and gestational diabetes mellitus (GDM) (AIHW 2010) (Table 1).  
Table 1: Pregnancy complications 
Pregnancy complication Pregnancies affected (%) 
Preeclampsia (PE) 3-5% of women worldwide  
Gestational Diabetes Mellitus (GDM) 5-15% of pregnancies in Australia , 
Preterm birth (PTB) 7-8% of pregnancies in Australia  
Intrauterine Growth Restriction (IUGR) 1-4% of births in Australia  
PE and IUGR are major obstetric health problems, leading to poor maternal, fetal and neonatal 
outcomes. The multi-factorial nature of these pregnancy-complications presents great difficulties 
for early detection, treatment and management. PE is diagnosed in the latter half of pregnancy and 
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is characterised by gestational onset of hypertension and proteinuria. Once clinically overt, the only 
treatment for PE is to deliver the baby and placenta (Karumanchi, Maynard et al. 2005). IUGR 
according to RANZCOG/ACHS (2012) guidelines is defined as fetal growth less than the 5th 
centile for gestational age and can be symmetric (growth of the head affected) or asymmetric 
(abdomen affected) (Roberts and Post 2008, Scifres and Nelson 2009). 
 
Gestational diabetes mellitus (GDM) is characterised by maternal glucose intolerance leading to 
hyperglycaemia, β-cell dysfunction and insulin resistance (AIHW 2010). GDM is associated with 
an increased risk of adverse outcomes for mother and infant, including a higher risk of induced 
labour, Caesarean section delivery, preterm birth, hypertension, preeclampsia, stillbirth, 
macrosomia and infant respiratory distress syndrome (AIHW 2010, Fraser and Lawlor 2014). The 
associated long term adverse outcomes associated with GDM for the mother include a higher risk of 
developing metabolic disorders, diabetes and cardiovascular disease, and for infants, a higher risk of 
obesity and type 2 diabetes (Lappas, Hiden et al. 2011, Malcolm 2012, Fraser and Lawlor 2014, 
Harreiter, Dovjak et al. 2014).  
 
The pathogenesis of complicated pregnancies e.g. PE, IUGR, GDM are complex and multifactorial. 
Changes to the development of the placenta may play a role in the progression of these pregnancies. 
The incomplete invasion and transformation of spiral arteries in PE (Kaufmann, Black et al. 2003), 
decreased utero-placental blood flow in asymmetric IUGR (Huppertz 2011) and the reduced 
exchange surfaces in the villi of placentae with PE-IUGR (Mayhew, Wijesekara et al. 2004) and in 
GDM alterations to insulin signalling (Colomiere, Permezel et al. 2009) are examples of the adverse 
changes that could affect the maintenance of a normal pregnancy.  
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 Myostatin in the placenta 1.7 
Myostatin in the human placenta was identified by Mitchell et al in 2006 (Mitchell, Osepchook et 
al. 2006). Myostatin protein expression in placentae is negatively correlated with gestational age as 
myostatin protein expression was higher in preterm compared to term placentae (Mitchell, 
Osepchook et al. 2006). Myostatin was recently used as a component of culture medium in the 
culture of human embryonic stem cells (HES) and was found to maintain the undifferentiated 
growth of these HES cells (Hannan, Jamshidi et al. 2009). However the effect of myostatin on 
placental cell growth and function are unknown. 
 
The potential for myostatin to modulate glucose uptake of the placenta was identified by Mitchell et 
al in 2006. A significant increase in glucose uptake (via the analysis of deoxyglucose) in human 
placental explants treated with 1µg/ml of myostatin was observed (Mitchell, Osepchook et al. 
2006). Conversely, glucose uptake experiments in a human placental choriocarcinoma cell line 
(BeWo cells) observed myostatin treatment to decrease glucose uptake in a dose-dependent manner 
(Antony, Bass et al. 2007). In this study, the effects of myostatin treatment (4nM) over a 72 hour 
time period on glucose transporters GLUT 1, GLUT 3 and GLUT 4 was also investigated. However 
no change was observed in the protein expression of these transporters. 
 
The nutritional state of the mother can also affect the expression of myostatin as seen in a trans-
generational model of under-nutrition in Wistar rats (Peiris, Ponnampalam et al. 2010). The 
gestational under-nutrition of Wistar rat grand-dams resulted in increased placental expression of 
myostatin compared to controls. The fetal weight of the trans-generationally under-nourished 
offspring was not found to be different from controls, although the placental weight of the trans-
generationally under-nourished dietary group was lower. Thus, these smaller placentae were 
potentially working more efficiently to maintain fetal size possibly aided by the high levels of 
myostatin and indicating a potential role for myostatin in regulating the nutrient supply to the 
offspring (Peiris, Ponnampalam et al. 2010).  
 
In pregnancies complicated with PE and GDM changes to myostatin serum concentrations were 
recently described. Higher myostatin concentrations were observed in the serum of women with PE; 
however no difference was seen in the serum of women with GDM (Guo, Jou et al. 2009, Hu, Tian 
et al. 2012). Information on the placental expression of myostatin is available only for pregnancies 
complicated with PE. No expression data is available for GDM or other pregnancy complications 
(excluding PE). Higher myostatin protein and mRNA expression was identified in placentae of 
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women with PE compared to controls in the study by Guo et al  (Guo, Tian et al. 2012). 
Concentrations of a potent endogenous antagonist of myostatin activity, follistatin like-3 (FSTL-3) 
is also known to be significantly altered in PE and GDM. Significantly lower serum concentrations 
and placental expression have been identified for FSTL-3 in patients with GDM compared to 
control participants (Thadhani, Powe et al. 2010, Hu, Tian et al. 2012, Founds, Ren et al. 2014). 
Serum concentration and placental expression of FSTL-3 in pregnancies complicated with PE 
expression are known to be significantly higher compared to control women (Pryor-Koishi, 
Nishizawa et al. 2007, Guo, Tian et al. 2012). FSTL-3 therefore maybe active in these complicated 
pregnancies to regulate myostatin activity.  
Hypothesis and Aims 1.8 
Information on the role of myostatin in placental development and function, as well as the 
expression of this protein in the various complications that can arise during pregnancy is limited. 
The aim of this thesis therefore is to expand the current knowledge of myostatin in the placenta and 
evaluate its potential functions within placentae.  
1.8.1 Overall Hypothesis: 
Myostatin is important for the development of the placenta and will be differentially expressed in 
placental tissues of complicated pregnancies in comparison to uncomplicated pregnancies. 
1.8.2 Chapter Specific hypotheses and aims 
Chapter 3: Myostatin is present in cells of the placenta and would alter their function. 
 Determine the localisation of myostatin in first and third trimester placentae Specific Aim: 1
 Evaluate the localisation and function of myostatin in isolated cells Specific Aim: 2
 Determine the potential role of myostatin in cytokine production Specific Aim: 3
Chapter 4: Myostatin is differentially expressed in pregnancies complicated with 
preeclampsia and intrauterine growth restriction 
 Evaluate differences in plasma myostatin concentrations of pre-symptomatic Specific Aim: 1
women who later developed IUGR or PE  
 Evaluate the expression of myostatin protein in placentae of pregnancies Specific Aim: 2
complicated with IUGR, PE and PE-IUGR. 
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Chapter 5: Myostatin is differentially expressed in pregnancies complicated with 
gestational diabetes 
 Evaluate differences in plasma myostatin concentrations of pre-symptomatic Specific Aim: 1
women who later developed GDM 
 Evaluate the expression of myostatin protein in placentae of pregnancies Specific Aim: 2
complicated with GDM 
 
Chapter 6: Development of a mass spectrometry method will allow for more specific and 
highly sensitive detection of myostatin 
 Investigate and develop a method for the use of mass spectrometry as a Specific Aim: 1
method of myostatin protein detection   
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 Methods  Chapter 2.
 Ethical clearance and placental collection  2.1 
2.1.1 Human Muscle  
Paraffin embedded human muscle tissue sections used in this study were  gifted from The 
University of Queensland pathology and were collected prior to the initiation of Transplantation and 
Anatomy Act (1979) and Human Tissues Act (1982) and therefore required no patient consent.  
2.1.2 Placental tissues 
Collection of first trimester and third placental tissues was approved by the Human Research Ethics 
Committees of the Royal Brisbane and Women’s Hospital, and the University of Queensland. First 
trimester placental tissues were collected from women undergoing terminations of pregnancy for 
psychosocial reasons. These first trimester placental tissues were collected from pregnancies at 10 
weeks gestation. Third trimester tissues were collected from women delivering at term (37–40 
weeks’ gestation) by elective Caesarean section in compliance with national research 
guidelines. Women gave written informed consent for the use of placental tissue for research 
purposes. 
 Collection procedure first trimester tissues  2.1.2.1
Contents of first trimester placental tissue collection containers were moved to a large culture dish 
and chorionic villous tissues selected and placed in another dish. Tissues were washed with PBS, 
fixed for use in immunohistochemistry in neutral buffer formalin (10 %), and immediately snap 
frozen in liquid nitrogen and stored at -80
o
C until required.  
 Collection procedure third trimester tissues  2.1.2.2
Within 15 min of delivery placental cotyledons were obtained from various locations of the 
placenta; the basal plate and chorionic surface were removed from the cotyledon, and villous tissue 
was obtained from the middle cross-section. Tissues were blunt dissected to remove visible 
connective tissue and calcium deposits. Tissues were washed with PBS, fixed for use in 
immunohistochemistry in neutral buffer formalin (10 %), and immediately snap frozen in liquid 
nitrogen and stored at -80
o
C until required.  
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Complicated human tissues 2.2 
2.2.1 Applications made for collection of placentae from complicated pregnancies 
An application to the ethics board of the Royal Brisbane Women’s Hospital (RBWH)  and the 
University of Queensland was made for the collection of human placentae in pregnancies 
complicated with preeclampsia, gestational diabetes mellitus, preterm birth and intrauterine growth 
restriction (Appendix I: application documents). Due to the extended delays incurred from the 
approval process the enrolment and collection of placentae from women with complicated 
pregnancies at RBWH was not possible. Maternal blood and placental tissues for complicates 
pregnancies were acquired through collaboration made with researchers at the University of 
Melbourne Dr Harry Georgiou, Dr Martha Lappas, Dr Tu'uhevaha Kaitu'u-lino, Dr Stephan Tong.  
2.2.2 Collaborator ethics 
 Maternal blood  2.2.2.1
Maternal plasma used for the study of myostatin in complicated pregnancies was provided by 
collaborations made with the University of Melbourne researcher Dr Harry Georgiou.  
Maternal blood was collected from pregnant women attending their first ante-natal visit (12-14 
weeks gestation) at the Mercy Hospital for Women (MHW), Victoria Australia. Informed, written 
consent was obtained from all participants (Mercy Health Research Ethics Committee (MHRC), 
R08/31).  
Pregnancies complicated with PE or IUGR:  
After birthing, women with PE or IUGR, as well as matched controls, were retrospectively selected 
for the study. IUGR complicated pregnancies were not complicated with PE or GDM and PE 
pregnancies were not complicated with IUGR or GDM.  
Pregnancies complicated with GDM:  
After birthing, women with pregnancies complicated with GDM (n =18) and with normal glucose 
tolerance (NGT, n = 23), were retrospectively selected for the study. GDM complicated pregnancies 
were not complicated with PE or IUGR. 
Collection procedure for maternal blood  
After ultrasound confirmed a viable fetus and the gestational age was established, 10mL of venous 
blood was collected into an EDTA vacuum tube. The blood was centrifuged at 1000x g for 5 
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minutes, the plasma aliquoted into 1 mL microfuge tubes and immediately stored at -80
o
C until 
required. 
 Placental tissues  PTB, PE or IUGR  2.2.2.2
PE, IUGR and PE-IUGR placental tissues used for the study of myostatin were provided by 
collaborations made with the University of Melbourne researchers, Dr Martha Lappas, Dr 
Tu'uhevaha Kaitu'u-lino, Dr Stephan Tong.  
 
MHRC approved the study. Written informed consent was obtained from all participating women. 
Placenta was collected prior to labor onset at caesarean section and from singleton gestations. 
Placenta was obtained from normotensive PTB pregnancies and those complicated with PE. PE was 
defined according to Somanz criteria (2008), as hypertension arising after 20 weeks gestation with 
one of the following: significant proteinuria – dipstick proteinuria subsequently confirmed by spot 
urine protein/creatinine ratio ≥ 30mg/mmol. Serum or plasma creatinine > 90 μmol/L. Babies were 
classified as having IUGR when birth weight was below the fifth percentile for gestational age as 
per RANZCOG/ACHS 
2
. All PE, IUGR and PE-IUGR cases were matched to those of similar 
gestation age (PTB). Indications for preterm delivery (in the absence of PE) were prolonged 
prelabor rupture of the fetal membranes, placenta previa, or antepartum hemorrhage. All placentae 
collected from preterm pregnancies were swabbed for microbiological culture investigations and 
histopathological examination, and patients with chorioamnionitis were excluded from the analyses. 
 
 Placental tissues GDM  2.2.2.3
GDM placental tissues for the study of myostatin were provided by collaborations made Dr Martha 
Lappas. Women with GDM were diagnosed according to the criteria of the Australasian Diabetes in 
Pregnancy Society (ADIPS) by either a fasting venous plasma glucose concentrations of 
⩾5.5 mmol/l glucose, and/or ⩾8.0 mmol/l glucose 2 h after a 75 g oral glucose load at 
approximately 28 weeks gestation. Placenta was collected from women who were scheduled for an 
elective Caesarean section (with singleton pregnancies) at term (≥37 weeks gestation). Indications 
for Caesarean section were breech presentation and/or previous Caesarean section. Women with 
chorioamnionitis, preeclampsia, pre-existing diabetes, asthma, multiple pregnancies, and fetal 
chromosomal abnormality were excluded. Placentae of women with normal glucose tolerance 
(NGT) were collected as controls. Placentae of women with GDM were separated to those managed 
by diet alone or insulin. Women were controlled by diet if their fasting glucose readings were 
maintained < 5.5 mmol/l over a 2 week period post diagnosis. Women with fasting glucose readings 
> 5.5 mmol/l were placed on insulin for optimal glucose control. Women were also stratified 
 31 
 
according to their pre-pregnancy body mass index (BMI). Lean women were categorised as having 
a BMI≤24.9 kg/m2, overweight patients with a BMI≥25 and ≤29.9, and obese patients with a 
BMI≥30 kg/m2.  
 
Collection procedure for placental tissues  
Within 15 min of delivery placental cotyledons were obtained from various locations of the 
placenta; the basal plate and chorionic surface were removed from the cotyledon, and villous tissue 
was obtained from the middle cross-section. Tissues were blunt dissected to remove visible 
connective tissue and calcium deposits. Tissues were washed with phosphate buffered saline (PBS), 
immediately snap frozen in liquid nitrogen and stored at -80
o
C until required.  
 Experimental procedures – Protein expression  2.3 
2.3.1 Immunohistochemistry  
Table 2: Antibodies used for immunohistochemistry and immunocytochemistry  
Primary 
Antibodies 
Species Dilution Source 
Myostatin I Goat 1/50 (SC-34781) Santa Cruz Biotechnology, USA) 
Myostatin II Rabbit 1.6μg/ml (HPA021681) Sigma Aldrich, Australia 
HLA-G Mouse 4μg/ml (SC21799) Santa Cruz Biotechnology, USA 
Cytokeratin 7 Rabbit 1.6μg/ml (HPA007272) Sigma Aldrich, Australia 
Vimentin Rabbit 1.6μg/ml (HPA001762) Sigma Aldrich, Australia 
B-actin  Mouse  1/10000 (A5441) Sigma Aldrich, Australia 
Rabbit IgG Rabbit 1.6μg/ml (A0545) Sigma Aldrich, Australia 
Mouse IgG Mouse 4μg/ml (18765) Sigma Aldrich, Australia 
Secondary 
antibodies 
Against 
species 
Dilution Source 
Universal HRP Rabbit - Medical Biocare Mach I universal HRP polymer 
(Millennium Science Pty Ltd) 
HRP Mouse 4μg/ml (SC2314) Santa Cruz Biotechnology, USA 
HRP Goat 1/50 (SC2020) Santa Cruz Biotechnology, USA 
 
Tissue preparation: Third trimester placentae (n=3 biological samples) were fixed in neutral buffer 
formalin (10 %) prior to embedding in paraffin for immunohistochemistry. Embedded sections were 
cut to 5μm thickness onto superfrost plus slides and kept at room temperature overnight. Sections 
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were then de-paraffinised and rehydrated through immersion in a series of xylene and graded 
alcohol baths. Antigen retrieval was achieved by the incubation in citrate buffer (10mM), pH6 at 
120
o
C for 30 seconds and 90
o
C for 10 minutes. 3% hydrogen peroxide was used to block
endogenous peroxidase activity. Medical Biocare Mach I universal HRP polymer kit blocking 
reagent (Millennium Science Pty Ltd) was used for the blocking and the preparations of primary 
antibodies.  
Immunohistochemistry: Consecutive first and third trimester placental sections were incubated 
overnight with primary antibodies) for the detection of myostatin, HLA-G, Cytokeratin 7 and 
Vimentin (details listed in Table 1)  were incubated for 18 hours at 4
o
C and secondary antibodies
(Table 1) incubated for two hours. 3,3-Diaminobenzidine (DAB) was used as the chromogen (30-40 
second development time) and sections were counterstained with Mayer's haematoxylin (40-50 
seconds). Sections were mounted and coverslips applied using Leica CV Mount (Leica 
Microsystems Pty Ltd). The sections were viewed using an Aperio ScanScope XT Digital Scanner 
(Aperio Technologies Inc., Vista, CA). Images were obtained at 8, 20 and 40 times magnification.  
Postive Controls: Human muscle tissue was used for the positive detection of myostatin 
(HPA021681; Sigma Aldrich, Australia) in the same manner as described above. Identification of 
trophoblast was through the positive staining for HLA-G and Cytokeratin 7 and negative staining 
for Vimentin.  
Negative controls: Primary antibodies were omitted and secondary antibody interactions alone were 
tested for the antibodies listed in Table 1. Isotype control experiments were performed for 
antibodies listed (Table 1) with identical concentrations and methods used.  
2.3.2 Immunocytochemistry 
Following 48 hours of culture, EVT were fixed in 4% Paraformaldehyde (PFA) for 20 minutes at 
room temperature and washed in PBS (3 times). Cells were incubated in H2O2 for 12 minutes, 
washed in PBS (3 times) and incubated in 7% Donkey serum for 30 minutes. Primary antibodies 
(Table 1) were incubated overnight (18 hours). Following washing with PBS, secondary antibodies 
(Table 1) were incubated for 2 hours. DAB was used as the chromogen (30-40 second development 
time) and sections were counterstained with Mayer's haematoxylin (40-50 seconds). Sections were 
mounted and coverslips applied using Leica CV Mount (Leica Microsystems Pty Ltd). Staining was 
viewed using a Nikon Eclipse 80i microscope with a Nikon D5-Ri1 camera (Nikon, Tokyo, Japan) 
and NIS-Elements imaging software (Nikon). 
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2.3.3 Western blot analyes 
 Protein extraction 2.3.3.1
Placental tissue and cells were lysed by bead disruption (TissueLyser II- QIAGEN Pty Ltd, 
Chadstone VIC Australia) in Radioimmunoprecipitation assay buffer (RIPA buffer; 20 mM, pH 
7.4–7.6, Tris, 1% Triton base, 10% deoxycholic acid, 500 mM EDTA, 10% sodium dodecyl 
sulphate (Sigma-Aldrich, Castle Hill, NSW, Australia) and a protease inhibitor tablet (Roche 
Applied Science, Castle Hill, NSW, Australia). Extracted samples were centrifuged at 15,000 g at 
4°C for 15 min. The supernatant was stored at −80°C, and total protein concentration was 
determined against bovine serum albumin (BSA) serially diluted standards using a bicinchoninic 
assay (Sigma-Aldrich, Castle Hill, NSW, Australia). 
 Bicinchoninic (BCA) assay 2.3.3.2
The total protein concentrations of the extracted samples were determined through the use of the 
BCA assay. A stock solution of BSA (4mg/ml) was serially diluted in 1:4 (RIPA: 1M NaOH) 
resulting in the standards with the concentrations 2000, 1000, 500, 250, 125, 61.5, 31.25, 0μg/ml. 
25µl of each the standards were loaded in duplicate onto a 96-well plate (Figure 16). Samples were 
diluted 1: 4 ( 10ul : 40 ul NaOH) and loaded in duplicate. 200μl of BCA Reagent was then added to 
each well. Following a 30 minutes incubation on a orbital shaker (room temperature) the 
concentrations were measured at an absorbance wavelength of 562nm on SpectraStar Nano plate 
reader (Molecular Devices Corporation). Softmax Pro V software (Molecular Devices Corporation) 
was used for the analysis of protein concentrations against the linear BSA standard curve (r
2
 >0.95).  
Final concentrations (μg/μl) were determined in excel using the standard curve generated.  
 Western blot  2.3.3.3
Total protein extracted from placental tissue and cells were incubated for 10 min at 70°C in 20× 
reducing agent (NuPAGE® Sample Reducing Agent, Life Technologies Australia Pty Ltd, 
Mulgrave, VIC Australia) and 4× loading buffer (NuPAGE® LDS sample buffer, Life 
Technologies Australia Pty Ltd, Mulgrave, VIC Australia). Electrophoresis was performed on the 
reduced proteins loaded and separated in NuPAGE® Novex® 4–12% Bis-Tris Gels for 55min at 
200 V. After electrophoresis, the separated proteins were transferred to a polyvinyl difluoride 
(PVDF) membrane using the Trans-Blot Turbo system with pre-packed transfer packs and the 7-
min protocol (Bio-Rad Laboratories Pty., Ltd, Australia). Membranes were blocked for 1 hour in 
blocking solution (1g non-fat milk powder and 1g of Bovine serum albumin powder in 100 ml of 
Tris Buffered Saline with 0.001% Tween 20, Sigma Aldrich, Castle Hill, NSW, Australia). 
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Membranes were incubated overnight at 4°C in myostatin primary antibody, at 1:1,000 dilution 
(goat polyclonal growth differentiating factor-8 (F-13), Sc-34781; Santa Cruz Biotechnology, Santa 
Cruz, CA) and secondary antibody (donkey anti-goat IgG-HRP sc-2020), at 1:10,000 dilution for 2 
hours. Bio-Rad Clarity™ western ECL substrate (Bio-Rad Laboratories Pty., Ltd. Australia) was 
used to visualize the proteins on Agfa medical X-ray blue film and developed using a Konica 
Minolta SRX-101A processor (Konica Minolta medical and graphic INC, Japan). The film was 
imaged on GS 800 calibrated densitometer and using Quantity One software (Bio-Rad Laboratories 
Pty., Ltd. Australia). Re-probe with β-actin as loading control.  
2.3.4 ELISA  
 Myostatin  2.3.4.1
Myostatin ELISA was performed according to the manufacturer’s instructions (Immundiagnostik, 
Germany). Samples were read using a microtiter plate reader at 450 nm against 620 nm as a 
reference. A 4-parameter-algorithm was used to calculate the standard curve from which the 
concentration of myostatin was determined. The coefficient of variance between replicates was 
consistently below 10%. The detection limit of the kit is 0.273 ng/mL and the linear range 0 to 65 
ng/mL. Controls tested (included in the kits) were within acceptable limits (C1 at 2-13ng/ml and C2 
at 15-29ng/m l).  
  Bio-Plex  2.3.4.2
Cytokines were assessed by the Bio-Plex Pro Human Cytokine 8-plex Assay. Experiments were 
performed according to manufacturers’ instructions. Briefly, antibody–conjugated magnetic beads 
were added to individual wells of a 96-well flat bottom plate. After washing on the Bio-Rad Pro II 
plate washer, 50μl of pre-diluted standards and culture media (all samples were run in duplicate) 
were added to the wells and the plate was shaken at 400 rpm for 30 minutes at room temperature. A 
pre-diluted detection antibody was then added for 30 minutes followed by the pre-diluted 
streptavidin-conjugated PE. The Bio-Rad Bio-Plex 200 instrument was used to analyse the plate. 
Standard curves using 5 parameter logistic regression were generated for each cytokine. 
Concentrations of each cytokine were determined using the Bio-Plex Manager v6.0 software (Bio-
Rad).The coefficient of variance between replicates was consistently below 10%. The detection for 
IL-8 ranged from 1.88 to16,089 pg/mL, INF-γ  from 1.63 to 26,678pg/mL and IL-4 from 0.29 to 
4683 pg/mL, TNF-α ranged from 4.30 to 21,146 pg/mL 
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 Experimental procedures - Gene expression  2.4 
2.4.1 PCR 
Total RNA was extracted from HTR-8/SVneo cells, primary isolated EVT and whole third trimester 
placental tissue using the RNeasy Extraction kit (Qiagen) as per manufacturers’ instructions.  
Genomic DNA was removed by On-column Dnase1 treatment.  Following extraction, total RNA 
was quantified via NanoDrop ND-1000 spectrophotometer (Thermo Scientific, DE, USA). The 
RNA was reverse transcribed following manufacturer’s instructions by the QuantiTect Reverse 
transcription kit (Qiagen VIC, Australia) using 1μg of RNA for use in PCR. Primers unique for the 
target gene were designed with primerBLAST. PCR was used to validate the expression of 
ACTRIIB (forward primer, 5’- AGA TCT TCA GCA CAC CTG GC - 3’; reverse primer, 5’ - AGG 
GAG CCC TGG TCA TGG AA - 3’) and myostatin (previously published [9] forward primer, 5’- 
TGG TCA TGA TCT TGC TGT AAC CTT - 3’; reverse primer, 5’- TGT CTG TTA CCT TGA 
CCT CTA AAA- 3’) genes. Each experiment was performed in duplicate using a no reverse 
transcriptase, no cDNA and H2O controls. PCR products of the target genes were visualised by 
DNA electrophoresis using the MultiNA microchip electrophoresis system (Shimadzu Biotech). 
Single bands were identified according to size, against a 25bp DNA ladder (Life Technologies 
Australia Pty Ltd). 
 
Table 3: List of Primers 
Gene  Forward Primer Reverse Primer  
MSTN  5’-TGG TCA TGA TCT TGC TGT AAC 
CTT-3’ 
5’-TGT CTG TTA CCT TGA CCT 
CTA AAA-3’ 
TBP 5’-GGG CAC CAC TCC ACT GTA TC-
3’ 
5’-CTG TTC TTC ACT CTT GGC 
TCC T-3’ 
ACTRIIB 5’-AGA TCT TCA GCA CAC CTG GC-
3’ 
5’-AGG GAG CCC TTG TCA TGG 
AA-3’ 
 
 Experimental procedures - Cell and explant culture 2.5 
2.5.1 EVT isolation  
EVT isolations were performed according to Tarrade et al 2001 [27]. Briefly, first trimester tissues 
were enzymatically digested in HBSS containing 0.125% trypsin (Life Technologies Australia Pty 
Ltd, VIC Australia) and 50 Kunitz/ml DNase (Sigma Aldrich, NSW, Australia) for 35 minutes at 
36 
37
o
C without agitation. Supernatant was taken after tissue sedimentation and filtered (100 μm
pores). Trypsin digestion was stopped with 5% fetal calf serum (FCS) (Life Technologies Australia 
Pty Ltd, VIC Australia). Cells were centrifuged at 300 x g for 10 minutes and plated with 
DMEM/F12 with 10% FCS, Antibiotic-Antimycotic, 100 U/ml penicillin, and 100 μg/ml 
streptomycin (Life Technologies Australia Pty Ltd, VIC Australia) onto Corning
®
 Costar
®
 24 well
cell culture plates (Sigma Aldrich, NSW, Australia) with autoclaved 10mm coverslips (Thermo 
Fisher Scientific Australia Pty Ltd, VIC, Australia) and cell culture flasks (Sigma Aldrich, NSW, 
Australia). Plates and flasks were washed after 3 hours to eliminate debris and incubated again in 
the medium.  
2.5.2 Cell culture –Incucyte proliferation 
HTR-8/SVneo cells were seeded at a low density of 10 x 10
3
 cells per well and cultured in RPMI-
1640 (HyClone, USA), 100 U/ml penicillin, and 100 μg/ml streptomycin (HyClone) under serum-
free conditions. HTR-8/SVneo cells were kindly donated by Dr Charles H. Graham (Queen's 
University, Ontario, Canada) (Graham, Hawley et al. 1993, Irving, Lysiak et al. 1995, Salomon, 
Kobayashi et al. 2013). Myostatin concentrations (0.005, 0.01, 0.05, 0.5 and1μg/ml) were based on 
a previous publication by Anthony et al (Antony, Bass et al. 2007) investigating the effect of 
myostatin on glucose uptake of a choriocarcinoma cell line (BeWo). Recombinant myostatin 
(Fitzgerald Industries, USA) reconstituted in aqueous buffer (UltraPure 
TM
 DNase/RNase free 
distilled water Life Technologies Australia Pty Ltd, VIC Australia) was applied to wells for 
proliferation experiments (in triplicate). Cells were visualized using a real-time cell imaging system 
(IncuCyte™ live-cell ESSEN BioScience Inc, Michigan, USA) (Salomon, Ryan et al. 2013) and 
were imaged every 1-2 hours to monitor treatment-induced effects on cell proliferation and 
migration. Time course and dose response effects were established in the absence and presence of 
myostatin for up to 48 hours. Cell proliferation was determined using a standard confluence 
algorithm (IncuCyte™) as previously published (Salomon, Ryan et al. 2013).  
2.5.3 Cell culture –Incucyte migration 
EVT and HTR-8/SVneo cells were cultured under serum-free conditions in 96-well culture plates 
(Corning Life Science, MA, USA) coated with 50 μg/ml collagen type I (Life Technologies 
Australia Pty Ltd, VIC Australia) for 18-24 hours at a seeding density of 5 x10
5
 cells per well to
reach confluence prior to wound creation. A scratch was made on confluent monolayers using a 96-
pin WoundMaker™ (BioScience Inc, Michigan, USA). HTR-8/SVneo cells were treated with 
0.005, 0.01, 0.05, 0.5 and1μg/ml of recombinant myostatin (Fitzgerald Industries USA) 
reconstituted in aqueous buffer (UltraPure 
TM
 DNase/RNase free distilled water, Life Technologies
 37 
 
Australia Pty Ltd, VIC Australia) and EVT at treatments of 10, 1, 0.5, 0.01, 0.05, 0.005, 
0.001μg/ml. Experiments were performed in triplicate with at least 3 technical replicates. Cells were 
incubated in the IncuCyte™ (Salomon, Ryan et al. 2013) and wound images automatically acquired 
and registered by the IncuCyte™ software system. CellPlayer™ 96-Well migration Assay software 
was used to fully automate data collection and analyzed using the IncuCyte™ 96-Well Cell 
migration Software Application Module.  Data are presented as the Relative Wound Density (Eizen, 
v1.0 algorithm).  The rate of wound closure was compared using the half-maximal stimulatory time 
(ST50) and area under the time course curve (AUC) as was previously described (Salomon, Ryan et 
al. 2013). 
2.5.4 First trimester explant culture  
The first trimester placental tissues were collected from pregnancies at 10 weeks gestation from 
women undergoing terminations of pregnancy. First trimester placental tissues were rinsed in PBS 
supplemented with Gibco Antibiotic–Antimycotic (Amphotericin B, Streptomycin, Penicillin) and 
Gentamicin. Approximately 20 mg (wet weight) of placental villous tissue was selected and plated 
in triplicate onto 12-well culture plates (Corning). Placental explant cultures were based on previous 
publications 
21,35,36
. Explants were cultured under serum-free conditions in DMEM/F12 with 1% 
Antibiotic–Antimycotic (Gibco) at 37 oC under conditions of 5% CO2-balanced N2 to obtain 1% and 
3% oxygen (pO2 ~6.75 and ~20.25 mmHg,) in an automated PROOX 110-scaled hypoxia chamber 
(BioSpherics, USA) and in a humidified atmosphere of  ~21% oxygen. Cultures were treated for 24 
hours with 1μg/ml of recombinant myostatin (Fitzgerald Industries, USA) reconstituted in aqueous 
buffer 
21
. Control tissues were maintained without myostatin treatment under identical conditions 
for the duration of the experiment. Culture media and tissues from placental explants were collected 
and stored at -80
o
C until required for cytokine analyses. Lactate dehydrogenase (LDH) assay 
measured LDH in supernatants from control and myostatin treated villous explant cultures using a 
commercially available kit Pierce LDH cytotoxicity assay kit (Thermo scientific). Following the 
manufacturer’s protocol, explant media was incubated with the reaction mixture for 30mins at room 
temperature in a 96-well plate and terminated with stop solution provided by the kit. Absorbance as 
measured at 490 nm on the SpectraStar Nano plate reader (Molecular Devices Corporation).  
 Mass spectrometry  2.6 
Mass spectrometry method and development are detailed in chapter 6: Method Development for the 
Detection of Human Myostatin by High-Resolution and Targeted Mass Spectrometry. Published in 
Journal of Proteome Research (2014)  
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 Localisation of myostatin and potential function of myostatin Chapter 3.
in human placentae 
Hypothesis: Myostatin is present in cells of the placenta and would alter 
their function. 
 Rationale 3.1 
In human placentae, myostatin expression is negatively correlated with gestational age, with 
myostatin protein significantly higher in preterm tissues. Furthermore, a role for myostatin 
has previously been established in the modulation of glucose uptake by placental explant and 
placental cell line culture. Still to be evaluated however are the cells in the placenta to which 
myostatin is localised and the possible effect of myostatin on these cells. Interaction between 
myostatin and cytokine production are known to exist outside of the placenta. The role of 
myostatin on the production of cytokines from placental tissues is yet to be evaluated. 
Chapter 3 of this thesis aimed to identify the localisation of myostatin in human placenta and 
determine the possible role of this protein on the function of placental cells and tissue. 
 Specific aims and publications generated  3.2 
 Determine the localisation of myostatin in first and third trimester Specific Aim: 1
placentae  
 Evaluate the localisation and function of myostatin in isolated cells Specific Aim: 2
Findings from specific aims 1 and 2 have been incorporated into two first author manuscripts 
 Publiction 1. The expression and potential functions of placental myostatin - 
Published in the journal Placenta  
 Publiction 2. Myostatin is localized in extravillous trophoblast and up-regulates 
migration - Published in the Journal of Clinical Endocrinology and 
Metabolism  
 Determine the potential role of myostatin on cytokine production Specific Aim: 3
Findings from specific aim 3 were incorporated to the manuscript accepted for publication in 
Reproductive Sciences (chapter 4). Please refer to chapter 4 for discussion of these findings.   
 Publiction 3. Myostatin expression in intrauterine growth restriction and preeclampsia 
complicated pregnancies, and alterations to cytokine production of first 
trimester placental explants following myostatin treatment.  
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Myostatin (growth differentiation factor-8; GDF-8) is a potent negative regulator of muscle development
affecting both proliferation and differentiation. Myostatin has been reported to enhance the release of
cytokines, including TNF-a (a pro-inﬂammatory cytokine involved in implantation). In the human
placenta, myostatin production is negatively correlated with gestational age and has been implicated in
the control of glucose uptake. Preliminary data indicate its expression is primarily localized to cyto-
trophoblast and syncytiotrophoblast. The role of myostatin in the placenta, however, remains to be fully
elucidated. We speculate that myostatin is key regulator that contributes to placentation and the
regulation of placental function throughout pregnancy.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Implantation and placentation are highly coordinated events
involvingmaternal and fetal cell interactions [1,2]. A key role for the
placenta is the transfer of nutrients [3] and recent ﬁndings suggest
a role for myostatin in the regulation of glucose uptake in human
placentae [4]. Higher risks of pregnancy disorders, miscarriages and
adult onset disorders are associated with inadequate placental
development and high or low in utero nutritional environments
respectively [2,3,5e7]. Understanding the processes involved in
placentation is requisite to identifying and addressing inadequate
development of the fetus. The following article will provide a basic
introduction to myostatin and present the research focusing on
myostatin in a clinical setting and review current investigations on
placental myostatin.
Myostatin (GDF-8) is a distinct member of the transforming
growth factor-b (TGF-b) superfamily and was ﬁrst identiﬁed by
McPherron and Lee in 1997 [8]. Myostatin is best known as
a negative regulator of muscle development [8]. Mutations dis-
rupting the myostatin gene result in signiﬁcant increases in muscle
development (“double muscling”) [8]. The increase in muscle is due
to a combination of hypertrophy and hyperplasia of muscle ﬁbers
[8,9].
A number of species exist with mutations in the myostatin gene
[10e13] however, information regarding the effect of theseearch, Building 71/918, Royal
029, Australia. Tel.: þ61 7
Mitchell).
All rights reserved.mutations on reproductive performance is limited. In humans,
a young boy was identiﬁed with a homozygous G to A transition in
the ﬁrst intron-exon region of his myostatin gene, his mother was
also identiﬁed to be a heterozygous carrier of the same variant [11].
As a result of this mutation both greater muscle development and
strength was evident in this young boy [11]. In cattle breeds with
double muscling, difﬁculties have been noted in calving, carrying to
term and fertility [14]; however homozygous myostatin null mice
(Mstn/) are known to be viable and fertile. The inﬂuence of
a maternal myostatin null environment on offspring muscle
development has also been documented [15]. Highermuscleweight
was observed in offspring of femaleMstn/mice crossed with wild
typemales compared to offspring of wild type females crossedwith
Mstn/ males [15]. No effect of nursing was identiﬁed on animal
growth, as identiﬁed through animal fostering experiments in
which onemyostatin genotypewas fostered to another (i.e.Mstn/
offspring toMstnþ/þ fostermother) [15]. It is possible therefore, that
the increased muscle weight in the offspring is caused by
maternalefetal interactions prior to birth, possibly mediated by
myostatin (or the lack thereof) and facilitated by the placenta. The
effects of mutations in the myostatin gene on placental develop-
ment are unknown and worthy of further research.
Myostatin is highly expressed in skeletal muscle but is also
expressed in adipose, cardiac (cardiomyocytes and Purkinje ﬁbers),
mammary, uterine (smooth muscle), endometrial and placental
tissue [4,12,16e27]. Whereas myostatin expression has been
documented in the human placenta [4], an understanding of
myostatin’s role during pregnancy has yet to be fully elucidated.
Myostatin in non-gestational tissues (e.g. muscle and adipose)
affects proliferation, differentiation and cytokine production
[8,28e37] and may have similar roles in the placenta.
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Myostatin shares many of the key features of the TGF-b super-
family including: a dibasic proteolytic processing site; N-terminal
signal sequence for secretion; and a C-terminal domain [8,18].
Myostatin also contains nine cysteine residues that form a “cystine
knot” in the C-terminal end of the myostatin precursor protein
known to be conserved in the TGF-b superfamily [8,18].
Myostatin is initially synthesized as a w52 kDa precursor
protein with an N-terminal secretory signal, a pro-peptide domain,
and a C-terminal RSRR (Arg-Ser-Arg-Arg) proteolytic processing
site [8,18]. Two proteolytic cleavages of the w52 kDa precursor
protein are required to form active myostatin (Fig. 1).
The ﬁrst proteolytic cleavage removes the N-terminal signaling
sequence required for protein secretion (Fig.1a) [38,39]. The second
proteolytic cleavage (cleaved by Paired Dibasic Amino acid-Cleaving
enzyme; PACE, also known as Furin) occurs at the proteolytic pro-
cessing site releasing thew42 kDa N-terminal pro-peptide (latency
associated peptide; LAP) and aw12 kDa Ceterminal fragment that
is thematuremyostatin protein (Fig.1b) [38,39]. Dimerization of the
w12 kDa mature myostatin protein creates thew28 kDa myostatin
dimer, known to be the active form of myostatin (Fig. 1c) [18,38,40].
Like other members of the TGF-b superfamily, myostatin signals
through a heterotetrameric receptor complex. The myostatin dimer
binds to the Activin type II receptor (Activin receptor IIB; ACTRIIB)
and initiates the Smad mediated signaling pathway [9,40].Fig. 1. Myostatin Biosynthesis. Initially synthesized as a precursor protein (w52 kDa) myost
signaling sequence. (b) The second cleavage taking place at the RSRR site releases the LAP (w
active myostatin dimer (w24Kda). (d) LAP can non-covalently bind the myostatin dimer
metalloproteinase’s can act to cleave the latent complex releasing the active myostatin dimLAP, the N-terminal fragment plays two important roles: it
facilitates the proper folding of the C-terminal domain to form
a cystine knot and controls the activity of the myostatin dimer.
Two monomeric (LAP) pro-peptides bind non-covalently to the
myostatin dimer forming a latent complex (w75 kDa) and thus
preventing the dimer from binding to its receptor ACTRIIB
(Fig. 1d) [9,38,41e44]. The majority of myostatin (w70%) found in
circulating blood is in this latent complex form [43,45]. Four
metalloproteinases of the bone morphogenetic protein (BMP)-1/
Tolloid family have been identiﬁed to be involved in the release of
the myostatin dimer from its latent complex via the proteolytic
cleavage at Asp-76 of the myostatin pro-peptide (Fig. 1e)
[9,43,46].
A number of proteins regulate myostatin action, the most
potent of which is Follistatin-like-3 (FSTL-3; follistatin related
gene; FLRG) [45]. FLST-3 is a structural homolog of follistatin that
binds with a high afﬁnity (in vivo) to mature myostatin
(C-terminal dimer), inhibiting the biological activity of myostatin
[46]. The binding of FSTL-3 to myostatin can also occur after
myostatin binds to its receptor and has initiated signaling [45].
Myostatin signaling through the Smad-mediated pathway
triggers a negative feedback loop involving FSTL-3 [45]. The
Smad complex formed binds the Smad binding element of the
FSTL-3 promoter resulting in the transcription and expression of
FSTL-3 and thus the consequent negative regulation of myostatin
[45,46].atin undergoes two proteolytic cleavages. (a) The ﬁrst cleavage releases the N terminal
42 kDa) and active peptide (w12 kDa). (c) The active peptide is dimerized to form the
forming a latent complex and thus sequestering myostatin action. (e) BMP-1/Tolloid
er.
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Disruption of the myostatin gene not only increases muscle
development but also reduces fat mass and creates an improved
metabolic state [8,35,47e50]. Research into myostatin has been
driven by the beneﬁcial effects of disturbing myostatin action and
the need for treatments of many muscular degenerative disorders
and metabolic disorders [9,35,47e54]. Myostatin-blocking anti-
bodies, soluble myostatin receptors, small interfering RNA, regu-
lating proteins such as LAP or follistatin, and small chemical
inhibitors have shown promise in preclinical studies as methods of
interrupting myostatin function [9,51,52]. Two compounds, MYO-
029 (recombinant human antibody against myostatin) and ACE-
011 (fusion protein consisting of the extracellular domain of the
ACTRIIA and Fc portion of human IgG1) have been entered into
clinical trials in which they were identiﬁed to be safe for human
administration [54,55]. Limited improvements to muscle develop-
ment were observedwith the use ofMYO-029, but ACE-011 in phaseFig. 2. IHC 1st trimester placentae. a) Myostatin is expressed in cytotrophoblast, syncytiot
staining of trophoblast cells as identiﬁed by cytokeratin 7. c) Staining of cells of mesenchymI trials was found to increase markers of bone formation [54,55].
Currently, clinical trials in postmenopausal women are underway
using ACE-031 (a fusion protein of ACTRIIB and IgG) as a decoy
receptor for myostatin and therefore limiting myostatins action and
preliminary results show increased leanmusclemass and decreased
biomarkers of adiposity in the women taking part in the study [56].
Obesity is associated with impaired fertility and type II diabetes
[57].Maternal obesity duringpregnancyandweight gain throughout
gestation is associated with complications in pregnancy including
preeclampsia and gestational diabetes mellitus (GDM) [58].
Higher expression of myostatin has been documented in obesity
and type II diabetes [59e61]. Extremely obese women were found
to have higher myostatin protein (dimer) concentrations in plasma
and expression in muscle compared to their lean counterparts [59].
Increased gene expression of myostatin in the muscle of type II
diabetics and their ﬁrst degree relatives (people with at least 50% of
their genes in common with the type II diabetic) has also been
identiﬁed [60,61].rophoblast, endothelial and stromal cells of the 10 week human placentae. b) Positive
al origin by vimentin.
H.N. Peiris, M.D. Mitchell / Placenta 33 (2012) 902e907 905Signiﬁcant increases in serum levels of myostatin have been
reported in womenwith pregnancies complicated by preeclampsia
[62]. Myostatin protein and mRNA expression in the placentae of
these pregnancies was also signiﬁcantly increased compared to
control women [62]. In addition, higher expression of FSTL-3
a potent inhibitor of myostatin action was also observed in preg-
nancies complicated by preeclampsia [63]. Hypoxia is a known
contributor to pathological placental development, and is associ-
ated with preeclampsia [64]. Myostatin and FSTL-3 expression are
increased by hypoxia [65,66]. Up-regulation of myostatin expres-
sion was evident in the skeletal muscle of mice exposed to hypoxic
conditions and in patients with chronic hypoxemia [65] and theFig. 3. IHC term human placentae. a) Myostatin is expressed in cytotrophoblast, syncytiotrop
of trophoblast cells as identiﬁed by cytokeratin 7. c) Staining of cells of mesenchymal origiincreased secretion of FSTL-3 by primary human trophoblast
cultures under hypoxic conditions [66].
In pregnancies complicated with GDM no signiﬁcant differences
in myostatin production have been found, however serum levels of
FSTL-3 were identiﬁed to be signiﬁcantly lower [67,68]. It is possible
that in these pregnancies FSTL-3 may act to control the expression
and function of myostatin. Myostatin expression in the placentae of
pregnancies complicated with GDM is yet to be documented. These
ﬁndings, the importance of glucose transfer for fetal development,
the role of myostatin in placental glucose uptake, the interactions of
myostatin and hypoxia all provide further support for the study of
placental myostatin in complicated pregnancies.hoblast, endothelial and stromal cells of the term human placentae. b) Positive staining
n by vimentin.
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The expression of myostatin in the placenta has been docu-
mented in human, mouse and rat [4,17,23]. A negative correlation
between placental myostatin and gestational age was by observed
Mitchell et al. [4], as in term placentae a lower expression of both
myostatin mRNA and protein was identiﬁed compared to early
gestation and preterm placental tissue (respectively) [4]. A similar
pattern was also seen in murine placentae where lower myostatin
protein expression (precursor and dimer) was observed later in
gestation (unpublished data).
Glucose is a key energy source required for fetal development
and is the main form of carbohydrate transported across the
placenta [4,69]. Increased uptake of deoxyglucose has been
observed in human placental explants treated with myostatin
(1 mg/ml), [4]. This presents a potential role for myostatin in
placental glucose uptake [4]. In support of this observation, myo-
statin increases glucose uptake in a dose dependent manner in
C2C12 myotubles and L6 myocytes [70]. In this study up-regulation
of glucose uptake was observed with co-stimulation with insulin,
whereas treatment with myostatin inhibitory proteins (follistatin
and themyostatin pro-peptide) resulted in the inhibition of glucose
uptake by C2C12 myotubes [70].
In contradiction, Antony et al. (2007) reported a decrease in
glucose uptake of the human choriocarcinoma cell line (BeWo cells)
after treatment with myostatin [16]. The inconsistency of ﬁndings
could be due to the use of cell lines by Anthony et al. and the use of
primary tissue by Mitchell et al. [4,16]. Discrepancies have been
identiﬁed in the gene expression, methylation patterns and
expression of HLA molecules in primary isolated trophoblast and
cell lines [71e74]. Therefore future investigations focusing more on
primary isolated cells rather than placental cell lines may be
beneﬁcial in studying myostatin mediated placental glucose
uptake.
The nutritional state of the mother is also known to affect the
expression of myostatin as described by Peiris et al. (2010). In that
study the gestational under-nutrition of wistar rat grand-dams
resulted in the increased placental expression of myostatin
compared to controls [17]. The offspring fetal weight was not found
to be different from controls, although the placental weight of this
dietary group was lower. Thus, these smaller placentae were
potentially working more efﬁciently to maintain fetal size possibly
aided by the high levels of myostatin suggesting a potential role for
myostatin in regulating the nutrient supply to the offspring [17].
Other thanmyostatin’s potential role in nutrient uptake it is also
possible that myostatin is acting to alter the establishment of the
placenta and may do so through its interactions with cytokines. A
number of cytokines such as tumor necrosis factor-a (TNF-a),
interleukin 6 (IL-6) and IL1b assist in the proliferation of cyto-
trophoblast cells and help regulate both the implantation and the
development of the placenta [75,76]. Reduced levels of TNF-a have
been observed in the plasma of mice without functional myostatin.
In this study following treatment with recombinant myostatin an
increase in TNF-a concentrations was seen in the plasma of these
mice [35]. The treatment of C2C12 myotubes with recombinant
myostatin also resulted in increased expressions of IL-6 mRNA and
protein [34]. Further, myostatin mRNA and protein expression is
altered by cytokine treatment as found by the treatment of C2C12
myotubes with TNFa [34,36].
The ability of myostatin to affect cell growth has been utilized in
the culture of human embryonic stem (HES) cells in which the
addition of myostatin into the culture media maintains the undif-
ferentiated growth of these cells [77]. Proliferation, differentiation
and invasion of trophoblastic cells are essential for the accurate
development and function of the placenta [8,75]. These cells arealso essential in forming the exchange surface between the
maternal and fetal circulations. The roles of myostatin in the
establishment of the placenta, (implantation, proliferation and
syncytialisation) and placental functions are yet to be established.
However, preliminary results of immunohistochemistry performed
on 10 week placental villous (Fig. 2a) and term (Fig. 3a) placental
sections found strong staining of myostatin to be localized in
cytotrophoblast and syncytiotrophoblast. Staining for myostatin
was also seen in endothelial and stromal cells. Trophoblast was
positively veriﬁed by staining for cytokeratin 7 (Figs. 2b and 3b) and
negatively by vimentin (Figs. 2c and 3c) [78].
5. Conclusion
We postulate myostatin to be a key regulator of placental
formation, development and function. Further research on the
regulation and functions of placental myostatin could not only
advance our understanding of placental development but also
create new avenues for therapeutic intervention and diagnostic
tools for complications of pregnancy.
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Figure 9: IHC of consecutive first trimester placental sections.  
(A) Myostatin is localized to cytotrophoblast (1), syncytiotrophoblast (2), stromal (3) and 
endothelial cells (4) of first trimester human placentae. (B) Cytokeratin 7 identifying 
trophoblast cells. (C) Vimentin staining cells of mesenchymal origin by vimentin. Controls 
for secondary antibody interactions and rabbit IgG isotype control of first trimester placental 
sections are seen in figures (D) and (E). Sections were imaged with Aperio ScanScope XT 
Digital Scanner at 20 times magnification (100μm scale bar).  
Myostatin is localized in extravillous trophoblast and
up-regulates migration
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Context: Myostatin is a highly conserved secretory protein that negatively regulates muscle de-
velopment by affecting both proliferation and differentiation ofmuscle cells. In human placentae
theexpressionofmyostatin is negatively correlatedwithgestational ageand inplacental explants,
myostatin acts to facilitate glucose uptake. Myostatin expression is known to be higher in the
placentaeofpregnancies complicatedbypreeclampsia. Properplacental development is crucial for
a healthy and successful pregnancy. Alterations to the function of placental cells following treat-
ment with myostatin have not previously been published.
Objective: This study investigated the localization ofmyostatin in extravillous trophoblast (EVT) of
human placentae. Furthermore, the effect of myostatin treatment on the proliferative and mi-
grative capabilities of these placental cells was investigated.
Results: Myostatin is localized in EVT, as identified by immunohistochemistry of third trimester
placentae and immunocytochemistry of first trimester EVT isolations positively staining for myo-
statin andHLA-G. Treatmentof anEVT cell line (HTR-8/SVneo) andprimary isolatedEVTwith varied
concentrations of myostatin resulted in a significant increase in proliferation (HTR-8/SVneo;
p0.0001) and migration (HTR-8/SVneo and primary isolated EVT; p0.05), with proliferation
being dose dependent and migration being dose independent.
Conclusions:Myostatin localization was positively identified in EVT. Myostatin positively affected
proliferation (HTR-8/SVneo) andmigrationof EVT (HTR-8/SVneoandprimary isolated EVT). For the
first timetheeffectofmyostatin treatmentonplacental cells isdescribed.The resultsprovideabase
fromwhich further in vitro investigationsonmyostatin’s ability tomodulateplacental cell function
can be made.
Myostatin is a distinct member of the transforminggrowth factor- superfamily (1).As a secretedpro-
tein in human circulation (2–4) myostatin is thought to
function in both an autocrine and a paracrine manner (1,
4, 5). Myostatin is synthesized initially as a52 kDa pre-
cursor protein that is proteolytically cleaved twice to re-
lease a 42 kDa N-terminal propeptide and a 12 kDa
mature myostatin protein. A homodimer of the 12 kDa
mature protein is the active form. Most myostatin found
in circulating blood is a 72 kDa latent complex (6–9)
composed of the active dimer bound noncovalently to two
monomeric propeptides (7, 8). Thepost-translational pro-
cessing of myostatin to create and release its active form is
described elsewhere (6, 7).
Myostatin is best knownas anegative regulator ofmus-
cle development (1) that inhibits both proliferation and
differentiation. Inhibition of myoblast cell cycle progres-
sion (10) and inhibition of differentiation aremediated by
myogenic regulatory factors which are key to differenti-
ation (11, 12). Myostatin is also associated in the regula-
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tion of glucose metabolism and fat deposition (1, 7, 13).
Alterations to myostatin expression occur in obesity, type
2 diabetes and pregnancies complicated with preeclamp-
sia (2, 3, 14, 15). Plasma and muscle of extremely obese
women showed higher expressions of themyostatin dimer
compared to their lean counterparts (2). In the muscle of
type II persons with diabetes and their first degree rela-
tives, higher myostatin gene expression was observed (14,
15). Furthermore, myostatin protein, mRNA (placentae)
and maternal serum concentrations were higher in preg-
nancies complicated by preeclampsia (3).
In human placentae,myostatin expression is negatively
correlated with gestational age, with myostatin protein
significantly higher in early and pretermplacentae as com-
pared to term placentae (16). Further, treatment of term
placental explants with 1 g/ml of myostatin increased
glucose uptake (16). Supportingmyostatin’s potential role
inmodulating glucose uptake,Chen et al recently reported
that myostatin treatment led to a dose dependent increase
in glucose uptake in C2C12 myotubles and L6 myocytes
(17).
Findings published by our group described myostatin
localization in cytotrophoblast, syncytiotrophoblast,
stromal and endothelial cells of both first (early) and third
(term) trimester human placentae (6). However, the effect
of myostatin on placental cell function has not been pre-
viously published.The aimof this study,was to investigate
whether myostatin was localized in extravillous tropho-
blast (EVT) of human placentae, as this had not been pre-
viously established. Furthermore, if myostatin was local-
ized to EVT, this study sought to investigate the effect of
myostatin treatment on the proliferative and migrative
capabilities of these cells.
Materials and Methods
Placental tissues-Ethics
Collection of first and third trimester placentaewas approved
by the Human Research Ethics Committees of the Royal Bris-
bane andWomen’s Hospital, and the University of Queensland.
Women gave written informed consent for use of placental tis-
sues for research purposes. First trimester placental tissues were
collected from women undergoing pregnancy terminations for
psychosocial reasons (10 weeks gestation) and third trimester
placental tissues collected from women delivering at term by
elective Caesarean section (37–40 weeks’ gestation) in compli-
ance with national research guidelines. Paraffin embedded hu-
man muscle tissue sections used in this study were gifted from
The University of Queensland pathology and were collected
prior to the initiation of Transplantation and Anatomy Act
(1979) andHumanTissuesAct (1982) and therefore required no
patient consent. All experimental procedures were conducted
within an ISO17025 accredited (NationalAssociation ofTesting
Authorities, Australia) research facility.
Immunohistochemistry
Fixed placental tissue sections were deparaffinised and rehy-
drated through immersion in a series of xylene and graded al-
cohol baths. Antigen retrieval was achieved by incubation in
citrate buffer (10 mM), pH6 at 120°C for 30 seconds and 90°C
for 10 minutes. 3% hydrogen peroxide was used to block en-
dogenous peroxidase activity.Medical BiocareMach I universal
HRP polymer kit blocking reagent (Millennium Science Pty Ltd)
was used for blocking nonspecific antibody binding. Immuno-
histochemistry: Consecutive third trimester placental sections
were incubated for 18 hours at 4°C with primary antibodies for
the detection ofmyostatin (HPA021681 Sigma-Aldrich, Austra-
lia), HLA-G (SC21799 Santa Cruz Biotechnology, USA), Cyto-
keratin 7 (HPA007272 Sigma-Aldrich, Australia) and Vimentin
(HPA001762 Sigma-Aldrich, Australia). The sections were in-
cubated for 2 hours with secondary antibodies (Myostatin, Cy-
tokeratin 7 and Vimentin - Medical Biocare Mach I universal
HRP polymerMillennium Science Pty Ltd andHLA-G - SC2314
Santa Cruz Biotechnology, USA). 3,3-Diaminobenzidine (DAB)
was used as the chromogen and sections were counterstained
with Mayer’s hematoxylin. Sections were mounted and cover-
slips applied using Leica CV Mount (Leica Microsystems Pty
Ltd) and were viewed using an Aperio ScanScope XT Digital
Scanner (Aperio Technologies Inc., Vista, CA). Human muscle
tissue was used for the positive detection of myostatin. Primary
antibodies were omitted and secondary antibody interactions
alone were tested for the antibodies listed above. Isotype control
experiments were performed for antibodies used, rabbit IgG
(A0545 Sigma-Aldrich, Australia) and mouse IgG (18765 Sig-
ma-Aldrich, Australia) with identical concentrations and
methods.
Immunocytochemistry
Following 48 hours of culture, EVTwere fixed in 4%PFA for
20 minutes at room temperature and washed in PBS (3 times).
Cells were incubated in H2O2 for 12 minutes, washed in PBS (3
times) and incubated in 7% Donkey serum for 30 minutes. Pri-
mary antibodies (listed above) were incubated for 18 hours. Fol-
lowing washing with PBS, secondary antibodies (listed above)
were incubated for 2 hours. 3-Diaminobenzidine (DAB) was
used as the chromogen and sections were counterstained with
Mayer’s hematoxylin. Sectionsweremounted and coverslips ap-
pliedusingLeicaCVMount (LeicaMicrosystemsPtyLtd). Stain-
ing was viewed using a Nikon Eclipse 80i microscope with a
Nikon D5-Ri1 camera (Nikon, Japan) and NIS-Elements imag-
ing software (Nikon).
Protein extraction and western blot analysis
Placental tissue and cells were lysed by bead disruption (Tis-
sueLyser II-QIAGENPty Ltd, VICAustralia) inRIPAbuffer (20
mM, pH 7.4–7.6, Tris, 1% Triton base, 10% deoxycholic acid,
500 mM EDTA, 10% sodium dodecyl sulfate - Sigma-Aldrich,
NSW, Australia) and a protease inhibitor tablet (Roche Applied
Science,NSW,Australia). Extracted sampleswere centrifuged at
15,000 g at 4°C for 15 minutes. The supernatant was stored at
–80°C, and total protein concentration was determined using a
Bicinchoninic assay (Sigma-Aldrich, NSW, Australia).
Protein extracted was incubated for 10 minutes at 70°C in
10 reducing agent (NuPAGE® Sample Reducing Agent, Life
Technologies Australia Pty Ltd, VIC Australia) and 4 loading
buffer (NuPAGE® LDS sample buffer, Life Technologies Aus-
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tralia Pty Ltd, VIC Australia). NuPAGE® Novex® 4%–12%
Bis-Tris Gels for 55min at 200 V were used for electrophoresis
separation of proteins. Trans-Blot Turbo system (Bio-Rad Lab-
oratories Pty., Ltd, Australia) was used to transfer to polyvinyl
difluoride (PVDF) membrane. Membranes were blocked for 1
hour with 1:1 nonfat milk powder and Bovine serum albumin
powder in Tris Buffered Saline with 0.001% Tween 20 (Sigma-
Aldrich, NSW, Australia). Myostatin primary antibody (Sc-
34781; Santa Cruz Biotechnology, Santa Cruz, CA) was incu-
bated for 18 hours at a 1:1,000 dilution and secondary antibody
(donkey antigoat IgG-HRP sc-2020), at 1:10,000 dilution for 2
hours the following day. Bio-Rad Clarity™ western ECL sub-
strate (Bio-Rad Laboratories Pty., Ltd. Australia) was used to
visualize the proteins on Agfa medical X-ray blue film and de-
veloped using a Konica Minolta SRX-101A processor (Konica
Minolta medical and graphic INC, Japan). The film was imaged
onGS 800 calibrated densitometer usingQuantityOne software
(Bio-Rad Laboratories Pty., Ltd. Australia).
Expression of ACTRIIB (myostatin receptor) and
myostatin in HTR-8/SVneo cells
Total RNA was extracted from HTR-8/SVneo cells, primary
isolated EVT andwhole third trimester placental tissue using the
RNeasy extraction kit (Qiagen) as per manufacturers’ instruc-
tions. GenomicDNAwas removed byOn-columnDnase1 treat-
ment. Following extraction, totalRNAwasquantified viaNano-
Drop ND-1000 spectrophotometer (Thermo Scientific, DE,
USA). The RNAwas reverse transcribed following manufactur-
er’s instructions by the QuantiTect Reverse transcription kit
(Qiagen VIC, Australia) using 1 g of RNA for use in PCR.
Primers unique for the target gene were designed with prim-
erBLAST. PCR was used to validate the expression of ACTRIIB
(forward primer, 5- AGA TCT TCA GCA CAC CTG GC - 3;
reverse primer, 5 - AGG GAG CCC TGG TCA TGG AA - 3)
and myostatin (previously published (9) forward primer, 5-
TGG TCA TGATCT TGC TGTAACCTT - 3; reverse primer,
5- TGT CTG TTA CCT TGA CCT CTA AAA- 3) genes. Each
experiment was performed in duplicate using a no reverse tran-
scriptase, no cDNA and H2O controls. PCR products of the
target genes were visualized by DNA electrophoresis using the
MultiNAmicrochip electrophoresis system (Shimadzu Biotech).
Single bands were identified according to size, against a 25bp
DNA ladder (Life Technologies Australia Pty Ltd).
Effect of myostatin on proliferation
HTR-8/SVneo cells were seeded at a low density of 10 103
cells per well and cultured in RPMI-1640 (HyClone, USA), 100
U/ml penicillin, and 100 g/ml streptomycin (HyClone) under
serum-free conditions. HTR-8/SVneo cells were kindly donated
by Dr Charles H. Graham (Queen’s University, Ontario, Can-
ada) (18–20). Myostatin concentrations (0.005, 0.01, 0.05, 0.5
and1g/ml) were based on a previous publication by Anthony et
al (21) investigating the effect of myostatin on glucose uptake of
a choriocarcinoma cell line (BeWo). Recombinant myostatin
(Fitzgerald Industries, USA) reconstituted in aqueous buffer (Ul-
traPure TM DNase/RNase free distilled water Life Technologies
Australia Pty Ltd, VIC Australia) was applied to wells for pro-
liferation experiments (in triplicate). Cells were visualized using
a real-time cell imaging system (IncuCyte™ live-cell ESSEN Bio-
Science Inc, Michigan, USA) (22) and were imaged every 1–2
hours to monitor treatment-induced effects on cell proliferation
and migration. Time course and dose response effects were es-
tablished in the absence and presence of myostatin for up to 48
hours. Cell proliferation was determined using a standard con-
fluence algorithm (IncuCyte™) as previously published (22).
Effect of myostatin on migration
EVT isolation. Performed according to Tarrade et al 2001 (27).
Briefly, first trimester tissues were enzymatically digested in
HBSS containing 0.125% trypsin (Life Technologies Australia
Pty Ltd, VIC Australia) and 50 Kunitz/ml DNase (Sigma-Al-
drich,NSW,Australia) for35minutes at37°Cwithout agitation.
Supernatant was taken after tissue sedimentation and filtered
(100 m pores). Trypsin digestion was stopped with 5% fetal
calf serum (FCS) (Life Technologies Australia Pty Ltd, VIC Aus-
tralia). Cells were centrifuged at 300 x g for 10 minutes and
plated with DMEM/F12 with 10% FCS, Antibiotic-Antimy-
cotic, 100 U/ml penicillin, and 100 g/ml streptomycin (Life
Technologies Australia Pty Ltd, VIC Australia) onto Corning®
Costar® 24 well cell culture plates (Sigma-Aldrich, NSW, Aus-
tralia) with autoclaved 10 mm coverslips (Thermo Fisher Scien-
tific Australia Pty Ltd, VIC, Australia) and cell culture flasks
(Sigma-Aldrich,NSW,Australia). Plates and flaskswerewashed
after 3 hours to eliminate debris and incubated again in the
medium.
EVTcellandHTR-8/SVneocellmigration.Prior toexperiments,
EVT and HTR-8/SVneo cells were cultured under serum-free
conditions in 96-well culture plates (Corning Life Science, MA,
USA) coated with 50 g/ml collagen type I (Life Technologies
Australia Pty Ltd, VIC Australia) for 18–24 hours at a seeding
density of 5  105 cells per well to reach confluence prior to
wound creation. A scratch was made on confluent monolayers
using a 96-pin WoundMaker™ (BioScience Inc, Michigan,
USA). HTR-8/SVneo cells were treated with 0.005, 0.01, 0.05,
0.5 and1g/ml of recombinant myostatin (Fitzgerald Industries
USA) reconstituted in aqueous buffer (UltraPure TM DNase/
RNase free distilled water, Life Technologies Australia Pty Ltd,
VIC Australia) and EVT at treatments of 10, 1, 0.5, 0.01, 0.05,
0.005, 0.001 g/ml. Experiments were performed in triplicate
with at least 3 technical replicates. Cells were incubated in the
IncuCyte™ (22) and wound images automatically acquired and
registered by the IncuCyte™ software system. CellPlayer™ 96-
Well migration Assay software was used to fully automate data
collection and analyzed using the IncuCyte™ 96-Well Cell mi-
gration Software ApplicationModule. Data are presented as the
Relative Wound Density (Eizen, v1.0 algorithm). The rate of
wound closure was compared using the half-maximal stimula-
tory time (ST50) and area under the time course curve (AUC) as
was previously described (22).
Results
Localization of myostatin to EVT
Localization ofmyostatin in EVT (Figure 1a-b and Fig-
ure 2a) was confirmed by the positive staining of cells for
the major histocompatibility antigen (MHC I class), hu-
man leukocyte antigen-G ( HLA-G) (23) and Cytoker-
atin 7 staining as well as negative Vimentin staining (24)
(HLA-G/CK7/-VIM). Negative controls (isotype and
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secondary only incubations) did not show any staining,
therefore assuring the specificity of the localization. Hu-
man muscle tissue was the positive control for myostatin
and stained for the myostatin.
Myostatin and ACTRIIB gene and protein
expression in HTR-8/SVneo cells, EVT and placental
tissues
PCR and DNA electrophoresis confirmed that EVT,
HRT-8/SVneo cell and third trimester placental tissues
were positive for the expression of myostatin and its re-
ceptor ACTRIIB (Figure 3A-C). Negative controls had no
amplifications of gene products. Western blot analysis
(Figure 3D) of representative first and third trimester
whole placental tissues,HTR-8/SVneo cells, primary EVT
protein and recombinant myostatin (positive control)
identifiedmyostatinprotein expression in all samples in its
varied forms. Under reduced conditions, bands indicative
of the 52 kDa precursor were identified in all samples
except the recombinantmyostatin. The homodimer of the
precursor (100kDa)was detected inHTR-8/SVneo cells
and primary EVT. The active 24 kDa dimer (faint band)
was seen in first and third trimester placental tissues and
HTR-8/SVneo cells and the 12 kDa monomer was ob-
served in the recombinant protein, first and third trimester
placental tissue. Collectively these results confirm the pro-
tein and mRNA expression of myostatin in tissues and
cells used in this study and also confirm the presence of the
ACTRIIB (myostatin receptor) in the cells utilized for the
study of the effect myostatin treatment has on prolifera-
tion and migration.
Effect of myostatin on proliferation
Myostatin treatment significantly increased HTR-8/
SVneo cell proliferation in a time- and dose-dependent
manner (P  .0001, n  12) (Figure 4A). Figure 4B are
phase contrast images at 40 hours incubation of control
and 1 g/ml myostatin treated HTR-8/SVneo cells. The
area under curves analysis showed that the effect of myo-
statinwas greaterwith1g/ml.Treatmentwithmyostatin
increased HTR-8/SVneo cell proliferation 1.7  0.062
fold compared with control (Figure 4C). The effect of
myostatin on HTR-8/SVneo cell proliferation was con-
centration dependent with a half-maximal effective con-
centration (EC50) of 0.66  0.1 g/ml (Figure 4D).
Effect of myostatin on migration
Myostatin treatment significantly increased the migra-
tive capacity ofHTR-8/SVneo cells (Figure 5A-C) and pri-
mary isolated EVT (Figure 5D-F). The time taken for
wound closure (area under the time course curve; AUC)
was significantly reduced (faster) with all myostatin treat-
ments onHTR-8/SVneo cells (Figure 5A and B) compared
to control. No significant differences were found between
the myostatin treatment groups (ANOVA, P  .8401).
Migration of isolated EVT significantly increased at myo-
statin treatments of 0.005, 0.01, 0.05, and 10 g/ml com-
pared to the control (Figure 5D and E). No significant
Figure 1. Localization of myostatin in third trimester placentae (A,B) Localization of myostatin in extravillous trophoblast of third trimester
placentae. C, HLA-G positive EVT. D, Cytokeratin 7 positive trophoblast cells. E, Negative staining of EVT for Vimentin. (F and G) Negative staining
for isotype controls for the rabbit and mouse antibodies used in ICC and secondary antibody interactions (H and I). Human muscle tissue positive
for myostatin (J). Sections were imaged with Aperio ScanScope XT Digital Scanner at 40 times magnification (100 m scale bar).
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differences were observed at 0.001, 0.5 and 1 g/ml myo-
statin treatment compared to control (Figure 5D and E)
although these concentrations were effective on HTR-8/
SVneo cells. Differences between the myostatin treatment
groups are detailed in Table 1 (Statistical significance was
defined as P  .05).
Statistical analyses
Data are represented as mean  SEM, with n  3–6
Comparisons between two group means were performed
by unpaired Student’s t test. Multiple groups were com-
pared using the analysis of variance (ANOVA) post hoc
analyses were used for pair-wise comparisons (Bonferroni
correction test). Statistical significancewas defined as P
.05.
Discussion
Trophoblasts are essential for the establishment, develop-
ment and growth of the human placenta. An appropriate
blood supply is critical in maintaining placentation and is
required to support both the demands of the developing
placenta and the fetus (25, 26). EVT are cells critical to the
establishment of placental perfusion (24, 25). EVT pro-
liferate and migrate out of cell columns (penetrating be-
yond the syncytiotrophoblast) to invade the maternal de-
cidua and up to the inner third of the myometrium. EVT
(interstitial trophoblast) “transform” spiral arteries by
surrounding and destroying the smooth muscle and sub-
sequently replacing the endothelium (endovascular tro-
phoblast) of the arteries (24, 25). Insufficient or excessive
invasions are associated with complications of pregnancy
such as preeclampsia (insufficient invasion) and placenta
accreta (excessive invasion) (25, 26).
In this study we identified that myostatin is localized in
EVT of third trimester placentae and isolated EVT (first
trimester placentae). Localization of EVT was confirmed
by the positive staining of cells for the  HLA-G (23),
positive CK7 and negative VIM (24). The ability of the
antibody to detect myostatin was confirmed by western
Figure 2. Localization of myostatin in primary isolated EVT (A) EVT isolated from first trimester placental villous tissues positive for myostatin. B,
HLA-G positive EVT. C, Cytokeratin 7 positive trophoblast cells. D, Negative staining of EVT for Vimentin. (E and F) Negative staining for isotype
controls for the rabbit and mouse antibodies used in ICC and secondary antibody interactions (G and H). Staining was viewed using a Nikon
Eclipse 80i microscope with a Nikon D5-Ri1 camera (Nikon, Japan) and NIS-Elements imaging software (Nikon) and presented at 10 times
magnification (and 40x magnification for myostatin in A) (100 m scale bar).
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blot of the recombinant myostatin protein and positive
staining of muscle tissues where myostatin was initially
identified (1) (Figures 1, 2 and 3B). Localizations of myo-
statin’s receptor Activin receptor IIB (ACTRIIB) aswell as
myostatin’s inhibitor follistatin like-3 (FSTL-3) have pre-
viously been identified in human cytotrophoblast, syncy-
tiotrophoblast, endothelial cells and placental blood ves-
sels (27–29). mRNA expression of myostatin and
ACTRIIB were confirmed by PCR in all tissues and cells
utilized in this study. Collectively, these results confirmed
the presence of myostatin in EVT and led us to investigate
the possible effects myostatin treatment could have on the
proliferation and migration of EVT.
Myostatin is a secretory protein known to act both in
a autocrine and paracrine manner (1, 4, 5). The active
dimer form of myostatin is created through the dimeriza-
Figure 3. HTR-8/SVneo cells and placental tissue expression of myostatin (A) (1) Activin receptor IIB (ACTRIIB) gene expression in whole third
trimester human placental tissue (2). Using ACTRIIB primers, No cDNA control (3). Myostatin (MSTN) gene expression in third trimester human
placental tissue (4). Using MSTN primers No cDNA control. B, (1) ACTRIIB and (2) MSTN gene expression in HTR-8/SVneo cells. Negative controls
using ACTRIIB primers (3) No cDNA control and (4) no reverse transcriptase. Negative controls using MSTN primers (5) No cDNA control and (6) no
reverse transcriptase. C) (3) MSTN and (6) ACTRIIB gene expression in primary EVT. Negative controls using MSTN primers (1) no reverse
transcriptase and (2) No cDNA control. Negative controls using ACTRIIB primers (4) no reverse transcriptase and (5) No cDNA control. D, Western
blot under reduced conditions of myostatin protein expression detected by antibody used for IHC and ICC in representative (1) first and (2) third
trimester placental tissues, (3) HTR-8/SVneo cells and (4) primary EVT protein and (5) recombinant myostatin as a positive control. Bands indicative
of the precursor (52 kDa) were identified in samples 1–4 and myostatin monomer (12 kDa) in samples 1, 2, and 5. A faint band (indicated by the
arrowheads) was present for the active dimer (24 kDa) in samples 1, 2, and 3. Also seen was the homodimer of the precursor (100 kDa) in HTR-
8/SVneo cells and primary EVT samples.
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tion of the mature form. Peptides of the mature form and
the protein itself were confirmed by mass spectrometry
(30) (Supplemental Figure 1) and western blot. Experi-
ments were conducted under serum-free conditions, as a
recent report suggested that myostatin’s ability to affect
proliferation and differentiation may be confounded by
the presence of serum in cultures (31). The effect of myo-
statin on proliferation and migration was initially evalu-
ated in HTR-8/SVneo cells. HTR-8/SVneo cells were es-
tablished by the transfection of first trimester trophoblast
with a plasmid containing the simian virus 40 large T
antigen. These cells have an extended lifespan and are a
widely used model of EVT (18, 32). Following investiga-
tions on HTR-8/SVneo cells, the effect of myostatin on
migration was further investigated on primary EVT iso-
lated from first trimester placentae.
Majority of the literature on myostatin describes myo-
statin as a negative regulator of cell proliferation and dif-
ferentiation (10, 11). Based on this literature, we had hy-
pothesized that myostatin would negatively affect EVT
proliferation and migration. Our findings were contrary
to this hypothesis, as recombinant myostatin treatments
resulted in increased proliferation (HTR-8/SVneo cells)
and migration (shorter time for wound closure; HTR-8/
SVneo and primary EVT).
A dose-dependent effect was found on the proliferation
of HTR-8/SVneo cells with a half-maximal effective con-
centration (EC50) of 0.66  0.1 g/ml (Figure 4). The
highest concentration of myostatin 1 g/ml (16, 21) was
the most effective in increasing the proliferative ability of
the HTR-8/SVneo cells (P  .0001). Recent publications
have described similar stimulatory effects of myostatin
treatment on proliferation and differentiation (31, 33–
35). For example, fibroblasts isolated from anterior cru-
ciate ligaments (human), fibroblasts isolated from the
hindlimb/forelimb of mice and C2C12 myoblasts in-
creased in proliferation following myostatin treatment
(33–35). Furthermore, following an initial period of pro-
liferation being suppressed, trout myosatellite cells were
also stimulated to differentiate following myostatin treat-
ment (31).
MigrationofHTR-8/SVneo cells andprimaryEVTwas
also significantly increased with myostatin treatment.
However, a dose-dependent increase inmigrationwas not
Figure 4. HTR-8/SVneo cell proliferation assay Myostatin significantly increased HTR-8/SVneo proliferation in a time- and dose-dependent
manner compared to control. A, HTR-8/SVneo cell proliferation exposed for 40 hours to myostatin treatments 1, 0.5, 0.05, 0.01, 0.005 g/ml. (B)
HTR-8/SVneo cell proliferation images (IncuCyte™) of control and 1ug/ml myostatin treatment at 40 hours. C, The Area Under Curves analyses
showed that the effect of myostatin treatment resulted in significantly increased proliferation of HTR-8/SVneo cell compared to control *P  .03,
and *** P  .0001). Significant increases in cell proliferation were also evident in the 1 g/ml myostatin treatment compared to 0.005, 0.01, and
0.05 g/ml myostatin treatments (†P  .05), values are presented as mean  SEM. D, Half-maximal effective concentration of myostatin (EC50;
0.66  0.1 g/ml) on HTR-8/SVneo proliferation.
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seen (Figure 5). Migration into the wound by HTR-8/
SVneo cells was increased at all concentrations of myo-
statin, whereas, primary isolated EVT migration was
greater at myostatin concentrations of 0.005, 0.01, 0.05
and 10 g/ml compared to control (Table 1). The varied
responsiveness of the HTR-8/SVneo and primary isolated
EVT to myostatin treatment may occur due to differences
known to exist between these cells (eg, altered gene ex-
pressions, methylation patterns and expression of HLA
molecules) (36). In this study we have shown that AC-
TRIIB mRNA is expressed in all the tissues and cells used.
However further quantitative mRNA as well as protein
expression should be investigated as changes to proteins
such as ACTRIIB may also play a role in the differential
response seen between the cell line and primary isolated
EVT.
Abnormalities in the migrativenvasive capacities of
EVTand the inadequate transformationofmaternal spiral
arteries are factors associated in pathological processes of
preeclampsia.Myostatin is higher in the placentae of preg-
nancies complicated with preeclampsia (3), as is FSTL-3
(3, 37, 38). FSTL-3 inhibits myostatin activity by binding
tomyostatin and preventing receptor binding (9). In preg-
nancies complicated with preeclampsia, myostatin func-
tion and activity could therefore be inhibited by FSTL-3 or
by other regulatory proteins including the myostatin pro-
peptide (cleaved alongside the mature myostatin from the
precursor) (9).
Investigations of the effect of myostatin treatment on
placental cell functions are limited and in particular stud-
ies onmyostatin’s effects onproliferationandmigrationof
placental cell populations are nonexistent. Hence, the re-
sults of this study are the first to be published on the effect
of the active myostatin form on proliferation and migra-
Figure 5. HTR-8/SVneo cell and isolated EVT migration assay (A) Time course of wound closure for HTR8/SVneo expressed as relative wound
density (%). Data are presented as mean  SEM. B, Area under the time course curve analysis showed that in the presence of myostatin wound
closure occurred at a faster rate (2.2 fold) as HTR-8/SVneo cells migration into wounds significantly increased (* P  .05) in comparison to
control. However, no significant differences were found between the myostatin treatment groups (1, 0.5, 0.05, 0.01, 0.005 g/ml; ANOVA, P 
.8401). C, Representative scratch wound mask images (IncuCyte™) of migration into wound of wells treated with 1 g/ml myostatin. White
center indicates wound (0 hours), gray section shows migrating cells (12 hours) and complete migration of cells can be seen at 24 hours. D, Time
course of wound closure for EVT expressed as relative wound density (%). Data are presented as mean  SEM. E, Area under the time course
curve analysis showed that in the presence of myostatin wound closure occurred at a faster rate as EVT migration into wounds significantly
increased in treatment groups 10, 0.05, 0.01, 0.005 g/ml in comparison to control. Comparisons of between groups are presented in Table 1
(ANOVA, * P  .05). F, Representative scratch wound mask images (IncuCyte™) of migration into wound of wells treated with 10 g/ml
myostatin. White center indicates wound (0 hours), gray section shows migrating cells (12 hours) and complete migration of cells can be seen at
24 hours.
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tion of placental cells. Future studies should take into con-
sideration the complexity of myostatin regulation (7, 9,
39) and environmental conditions such as hypoxia (40)
that may affect myostatin activity.
Conclusion
In this paper we describe the localization of myostatin in
third trimester placentae and first trimester primary iso-
lated EVT cells. Following treatment withmyostatin both
proliferation and migration were increased in HTR-8/
SVneo cells and migration increased in isolated EVT.
These results are the first to be published on the effect of
myostatin on placental cell function. The results provide a
base from which further in vitro investigations on myo-
statin’s ability to modulate placental cell function can be
made. In conjunction with our current results, the higher
levels of myostatin protein in placentae from early in ges-
tation (and a decrease in expression in term placentae)
suggestmyostatinmay be active early in gestation to assist
in the establishment and development of the human pla-
centa (6, 16). Future studies will need to take into consid-
eration the complexity of myostatin regulation and the
possible inhibitors of myostatin activity present in a bio-
logical setting (eg, preeclampsia). We hypothesize that
myostatin will be an important regulator of placental cell
function and that further investigations will improve our
understanding of placental development and function.
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 Placental myostatin expression in pregnancies complicated Chapter 4.
with preeclampsia and intrauterine growth restriction 
Hypothesis:  Myostatin is differentially expressed in pregnancies 
complicated with preeclampsia and intrauterine growth restriction 
 Rationale 4.1 
A single publication is available on the expression of myostatin in PE. Guo et al evaluated the 
concentration of myostatin in the maternal serum of women with overt PE and the expression 
of myostatin in their placental tissues. Higher concentration of myostatin in serum and 
expression in placental tissues were identified in women with PE compared to term delivered 
controls. Chapter 4 aimed to expand the current literature of myostatin expression in placental 
tissue of women with PE and extend these findings to the placental tissues of women with 
IUGR, and PE with IUGR. The expression of myostatin in pre-symptomatic women who 
later developed PE or IUGR was also evaluated to determine if changes to myostatin 
expression could be detected earlier in pregnancy.  
 Specific aims and publications generated  4.2 
 Evaluate differences in plasma myostatin concentrations of pre-Specific Aim: 1
symptomatic women who later developed IUGR or PE  
 Evaluate the expression of myostatin protein in placentae of Specific Aim: 2
pregnancies complicated with IUGR, PE and PE-IUGR. 
This chapter consists of a first author manuscript prepared by the PhD accepted for 
publication in Reproductive Sciences 2015. 
 Publiction 1. Myostatin expression in intrauterine growth restriction and preeclampsia 
complicated pregnancies, and alterations to cytokine production of first 
trimester placental explants following myostatin treatment.  
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Abstract  
Preeclampsia (PE) and intrauterine growth restriction (IUGR) are major obstetric health 
problems. Higher levels of Th1 (pro-inflammatory) cytokines have been observed in 
pregnancies complicated with PE and IUGR; this is in contrast to the predominant Th2 (anti-
inflammatory) cytokine environment found in uncomplicated pregnancies. Myostatin is best 
known as a negative regulator of muscle development and reportedly has a role in fat 
deposition, glucose metabolism and cytokine modulation (outside of the placenta). Myostatin 
concentrations in plasma and protein expression in placental tissue are significantly higher in 
women with PE. Myostatin expression in IUGR and PE-IUGR and the effect of this protein 
on the cytokine production from the placenta is unknown. In the current study significant 
differences were identified in the expression of myostatin in pregnancies complicated with 
IUGR, PE and PE with IUGR. Furthermore, cytokine production by first trimester placental 
tissues was altered following myostatin treatment.  
Keywords: Myostatin, GDF-8, Placenta, Preeclampsia, Intrauterine growth restriction 
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Introduction  
Preeclampsia (PE) and intrauterine growth restriction (IUGR) are major obstetric health 
problems, leading to poor maternal, fetal and neonatal outcomes. The multi-factorial nature 
of these pregnancy-complications presents great difficulties for early detection, treatment and 
management. PE affects 3-5% of pregnant women worldwide
1
. It is diagnosed in the latter 
half of pregnancy and is characterised by gestational onset of hypertension and proteinuria. 
Once clinically overt, the only treatment for PE is to deliver the baby and placenta
1
. IUGR 
according to RANZCOG 
2
 guidelines is defined as fetal growth less than the 5th centile for 
gestational age and can be symmetric (growth of the head affected) or asymmetric (abdomen 
affected) 
2-4
. 
 
The expression of myostatin in pregnancy complications  has been previously investigated in 
pregnancies complicated with PE 
5
 and GDM 
6
, (gestational diabetes mellitus). No 
information is currently available on the expression of myostatin in pregnancies complicated 
with IUGR. In the paper by Guo et al  investigating myostatin expression in PE, higher 
concentrations of myostatin in plasma and the expression of myostatin  in placental tissue 
were reported 
5
.  A report by Hu et al 
6
 and a recent publication by our group 
7
 found no 
significant difference in the concentrations of myostatin in maternal plasma in pregnancies 
complicated with GDM. Hu et al did not report on myostatin expression in placentae of 
pregnancies complicated with GDM. Our recent publication reported significant differences 
in the expression of myostatin in placentae of GDM pregnancies 
7
.  
 
Myostatin is best known as a negative regulator of muscle development. A loss of myostatin 
function results in a significant increase of musculature
8
. Comprehensive reviews on the 
biosynthesis, signalling and function of myostatin have been published
9,10
. Myostatin is 
synthesized initially as a ~52kDa precursor protein that is proteolytically cleaved twice to 
release a ~42kDa N-terminal pro-peptide and a ~12kDa mature myostatin protein. A 
homodimer of the 12kDa mature protein is the active form (~24kDa). The majority of 
myostatin found in circulating blood is a latent complex
9,11-13
 composed of the active dimer 
bound non-covalently to two monomeric pro-peptides 
9,12
.  
 
Myostatin is a distinct member of the Transforming Growth Factor-β (TGF-β) superfamily 8, 
known to function in the development of the placenta 
14
. In the human placenta, myostatin 
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protein and mRNA expression decrease with gestational age 
15
. Exposure to myostatin 
treatment alters glucose uptake of placental explants and placental cells 
15,16
. In a rat model of 
under-nutrition, placental tissue expression of myostatin was affected by the nutritional status 
of the grandmother 
17
. Myostatin is localised in cytotrophoblast, syncytiotrophoblast and 
extravillous trophoblast cells of the human placentae 
13,18
. Treatment of extravillous 
trophoblast cells with various concentrations of myostatin increased both the proliferation 
and migration of these cells 
18
. Together these finding suggest a role for myostatin in the 
development and function of the placenta.  
 
A well-developed placenta is vital for a healthy pregnancy and fetus. The placenta acts as a 
temporary life support system, controlling a number of processes including  nutrient, oxygen 
and hormone transfers, waste management, and as a immune interface between mother and 
fetus
19
. The functional capacity of the placenta must also increase to meet the needs of the 
growing fetus and placenta. Preeclampsia and asymmetric IUGR, are associated with 
abnormalities of placental development, structure and function 
20
, such as incomplete 
invasion and transformation of spiral arteries 
21
 in PE and decreased utero-placental blood 
flow in IUGR 
22
. Further, reduced exchange surfaces in the villi of placentae with PE-IUGR 
have been identified 
23
.  
 
Cytokines are also important in the establishment, development and maintenance of 
pregnancy. As a semi allograft, the placenta needs to evade the maternal immune system. 
One way in which the maternal immune system is altered to aid pregnancy is thought to be an 
environment rich in T-helper (Th) 2 cytokines. Th2 cytokines are broadly anti-inflammatory 
(e.g. IL-4) although IL-6 which has pro-inflammatory actions, also belongs to this group. Th1 
cytokines produce a number of pro-inflammatory cytokines (e.g. TNF-α) 24,25. In complicated 
pregnancies (e.g. GDM, IUGR and PE) the necessary skew towards Th2 environment is 
altered and as elevated levels of Th1 cytokines (e.g. higher expressions of IL-2, IL-8, IFN-γ 
and TNF-α ) have been observed25-33.  
 
The effect of myostatin on the production of placental cytokines is unknown, although 
alterations to cytokine production following manipulations to myostatin have been identified 
outside of the placenta. In male homozygous mice with a loss-of-function allele of myostatin 
(Mstn
Ln/Ln
), plasma levels of TNF-α were significantly lower compared to heterozygous 
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(Mstn
+/Ln
) males. Following treatment with recombinant myostatin these Mstn
Ln/Ln
 mice were 
observed to have an increase in plasma concentrations of TNF-α 34. In mice with chronic 
kidney disease, treatment with an anti-myostatin peptibody (blocking myostatin), resulted in 
a decrease in pro-inflammatory cytokines (TNF-α, IFN-γ and IL-6) 35. Alterations in 
cytokines can also mediate changes in the expression of myostatin, as seen in C2C12 
myotubes treated with TNF-α significantly increasing both myostatin protein and mRNA 
expression 
35,36
. Moreover the use of TNF-α blocking agents pentoxifylline and Remicade 
decreased myostatin expression in gastrocnemius (pentoxifylline: protein) and heart muscle 
(Remicade; mRNA) 
37,38
.  
 
The current study evaluated myostatin expression in plasma of pre-symptomatic women 
(collected in early second trimester) who later developed PE or IUGR. This study was done 
to establish whether myostatin expression was different earlier in pregnancies of women who 
later developed IUGR or PE. The expression of myostatin in the placentae of pregnancies 
complicated with IUGR, PE and PE- IUGR was compared to expression in age matched 
placentae (preterm birth; PTB). This study also examined the effect of in vitro myostatin 
treatment on the production of placental cytokines; cytokine modulation may be one 
mechanism of how myostatin could affect placental establishment, development and 
pregnancy maintenance.  
 
Materials and Methods 
Maternal blood collection from pre-symptomatic women:   
Maternal blood was collected from pregnant women attending their first ante-natal visit (12-
14 weeks gestation) at the Mercy Hospital for Women (MHW), Victoria Australia following 
approval by Mercy Health Research Ethics Committee (MHRC; R08/31). Informed, written 
consent was obtained from all participants. After ultrasound confirmed a viable fetus and the 
gestational age was established, 10mL of venous blood was collected into an EDTA vacuum 
tube for research purposes. The blood was centrifuged at 1000x g for 5 minutes and the 
plasma aliquoted into 1 mL microfuge tubes and immediately stored at -80
o
C until required 
for analysis. After birthing, women with PE or IUGR, as well as matched controls, were 
retrospectively selected for the study. IUGR complicated pregnancies were not complicated 
with PE or GDM and PE pregnancies were not complicated with IUGR or GDM. Clinical 
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characteristics of the women (pre-symptomatic) that provided blood for the study of 
myostatin plasma concentrations are shown in Table 1.    
 
Placental tissue collection from complicated pregnancies:   
The Mercy Health Research Ethics Committee (MHRC)approved this study. Written 
informed consent was obtained from all participating women. Placentae were collected prior 
to labor onset at caesarean section and from singleton gestations. Placentae were obtained 
from normotensive PTB pregnancies and those complicated with PE. PE was defined 
according to Somanz criteria 
39
, as hypertension arising after 20 weeks gestation with one of 
the following: significant proteinuria – dipstick proteinuria subsequently confirmed by spot 
urine protein/creatinine ratio ≥ 30mg/mmol. Serum or plasma creatinine > 90 μmol/L. Babies 
were classified as having IUGR when birth weight was below the fifth percentile for 
gestational age as per RANZCOG/ACHS 
2
.  All PE, IUGR and PE-IUGR cases were 
matched to those of similar gestation age (PTB). Indications for preterm delivery (in the 
absence of PE) were prolonged prelabor rupture of the fetal membranes, placenta previa, or 
antepartum hemorrhage. All placentae collected from preterm pregnancies were swabbed for 
microbiological culture investigations and histopathological examination, and patients with 
chorioamnionitis were excluded from the analyses. Clinical characteristics of the women that 
provided placentae for the study of myostatin expression in placentae are shown in Table 2.   
 
 
First trimester placental tissue collection and explant culture:  
Collection was approved by the Human Research Ethics Committees of the Royal Brisbane 
and Women’s Hospital, and the University of Queensland. Women gave written informed 
consent for use of placental tissue for research purposes. First trimester placental tissues were 
collected from pregnancies at 10 weeks gestation from women undergoing terminations of 
pregnancy for psychosocial reasons. Placental explant culture: First trimester placental 
tissues were rinsed in Phosphate-Buffered Saline (GIBCO® PBS, Life Technologies 
Australia Pty Ltd, VIC, Australia) supplemented with 1% Antibiotic–Antimycotic (Gibco® 
Antibiotic-Antimycotic containing penicillin, streptomycin, and Fungizone® Antimycotic, 
Life Technologies Australia Pty Ltd) and Gentamicin (Gibco® Gentamicin, Life 
Technologies Australia Pty Ltd., VIC, Australia). Approximately 20 mg (wet weight) of 
placental villous tissue was selected and plated in triplicate onto 12-well culture plates ( 
Corning® Costar® cell culture plates, Sigma-Aldrich, NSW, Australia). Placental explant 
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cultures were based on previous publications 
15,40,41
. Explants were cultured under serum-free 
conditions in DMEM/F12 (Gibco® Life Technologies Australia Pty Ltd, VIC, Australia) 
with 1% Antibiotic–Antimycotic (Gibco® Life Technologies Australia Pty Ltd, VIC, 
Australia)  at 37
 o
C under conditions of 5% CO2-balanced N2 to obtain 1% and 3% oxygen 
(pO2 ~6.75 and ~20.25 mmHg,) in an automated PROOX 110-scaled hypoxia chamber 
(BioSpherics, USA) and in a humidified atmosphere of  ~21% oxygen. Cultures were treated 
for 24 hours with 1μg/ml of recombinant myostatin (Fitzgerald Industries, USA) 
reconstituted in aqueous buffer 
15
. Control tissues were maintained without myostatin 
treatment under identical conditions for the duration of the experiment. Culture media and 
tissues from placental explants were collected and stored at -80
o
C until required for  cytokine 
analyses.  
 
Myostatin ELISA:  
Myostatin ELISA was performed according to the manufacturer’s instructions 
(Immundiagnostik, Germany). Samples were read using a microtiter plate reader at 450 nm 
against 620 nm as a reference. A 4-parameter-algorithm was used to calculate the standard 
curve from which the concentration of myostatin was determined. The coefficient of variance 
between replicates was consistently below 10%. The detection limit of the kit is 0.273 ng/mL 
and the linear range 0 to 65 ng/mL. Controls tested (included in the kits) were within 
acceptable limits and coefficient of variance was below 10% for each control tested (C1 at 2-
13ng/ml and C2 at 15-29ng/ml).  
 
Cytokine ELISA:  
Cytokines were assessed by the Bio-Plex Pro Human Cytokine 8-plex Assay (Bio-Rad 
Laboratories Pty., Ltd., NSW, Australia). Experiments were performed according to 
manufacturers’ instructions. Briefly, antibody–conjugated magnetic beads were added to 
individual wells of a 96-well flat bottom plate. After washing on the Bio-Rad Pro II plate 
washer, 50μl of pre-diluted standards and culture media (all samples were run in duplicate) 
were added to the wells and the plate was shaken at 400 rpm for 30 minutes at room 
temperature. A pre-diluted detection antibody was then added for 30 minutes followed by the 
pre-diluted streptavidin-conjugated PE. The Bio-Rad Bio-Plex 200 instrument was used to 
analyse the plate. Standard curves using 5 parameter logistic regression were generated for 
each cytokine. Concentrations of each cytokine were determined using the Bio-Plex Manager 
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v6.0 software (Bio-Rad).The coefficient of variance between replicates was consistently 
below 10%. The detection for IL-8 ranged from 1.88 to16,089 pg/mL, INF-γ  from 1.63 to 
26,678pg/mL, TNF-α ranged from 4.30 to 21,146 pg/mL and IL-4 from 0.29 to 4683 pg/mL.  
 
Protein extraction:  
Placental tissue and ovine skeletal muscle tissue (positive control for myostatin) were lysed 
by bead disruption (TissueLyser II- QIAGEN Pty Ltd, Australia) in RIPA buffer for protein 
(20 mM, pH 7.4–7.6, Tris, 1% Triton base, 10% deoxycholic acid, 500 mM EDTA, 10% 
sodium dodecyl sulphate) and a protease inhibitor tablet (Sigma-Aldrich, Australia and Roche 
Applied Science, Australia). Samples were centrifuged at 15,000x g at 4°C for 15 min. The 
supernatant was stored at −80°C, and the total protein concentration was determined against 
BSA serially diluted standards using a bicinchoninic assay (Sigma-Aldrich, Australia).  
 
Western blot analysis:  
Extracted protein from human placental tissue and ovine skeletal muscle tissue were 
incubated for 10 min at 70°C in 10× reducing agent (NuPAGE Sample Reducing Agent, Life 
Technologies Australia Pty Ltd VIC, Australia) and 4× loading buffer (NuPAGE LDS sample 
buffer, Life Technologies Australia Pty Ltd, VIC, Australia). Electrophoresis was performed 
on the reduced proteins loaded and separated in NuPAGE Novex 4–12% Bis-Tris Gels for 55 
min at 200 V. After electrophoresis, the separated proteins were transferred to a polyvinyl 
difluoride (PVDF) membrane using the Trans-Blot Turbo system with pre-packed transfer 
packs and the 7-min protocol (Bio-Rad Laboratories Pty, Ltd, Australia). Membranes were 
blocked for 1 hour in blocking solution (1g non-fat milk powder and 1g of bovine serum 
albumin powder in 100 ml of Tris Buffered Saline with 0.001% Tween 20, (Sigma Aldrich, 
NSW, Australia). Membranes were incubated overnight at 4°C in myostatin primary antibody 
(Sc-34781- Santa Cruz Biotechnology , Inc, USA), at 1:1,000 and secondary antibody at 
1:10,000 dilution (Sc-2020 Santa Cruz Biotechnology , Inc, USA) for 2 hours. Bio-Rad 
Clarity western ECL substrate (Bio-Rad Laboratories Pty. Ltd. Australia) was used to 
visualize the proteins on Agfa medical X-ray blue film and developed using a Konica Minolta 
SRX-101A processor (Konica Minolta medical and graphic INC, Japan). Membranes were 
later stripped with 0.2 M NaOH for 5 min and reprobed for β-actin as the loading control. 
Relative optical densities of the bands were determined using a GS 800 calibrated 
densitometer and analyzed using Quantity One software (Bio-Rad Laboratories Pty, Ltd, 
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NSW, Australia). The relative optical densities were normalized to sheep skeletal muscle 
(positive control) expression of myostatin as previously described
15,17
. 
 
 
Statistical analyses:  
All datasets were tested for normal distribution using the Kolmogorov-Smirnov test 
(GraphPad Prism 4 software (San Diego, CA).  Kruskal–Wallis one-way analysis of variance 
test was used for comparison of data between multiple groups. For comparison between two 
groups, the Mann–Whitney U-test was used and significance was defined as p<0.05. Data are 
presented as the mean ± S.E.M. 
 
Results 
Myostatin concentration in plasma of pre-symptomatic women:  
Myostatin concentrations in the plasma from women who later developed a complication of 
pregnancy (pre-symptomatic) were processed by ELISA (Figure 1). No differences were 
observed in the women for maternal age, BMI, gestational age and all pregnancies were 
singleton. Myostatin concentrations were significantly elevated in women who later 
developed PE compared to control and to women who later developed IUGR (p<0.05). No 
significant difference was found between women who later developed IUGR women 
compared to control. 
 
Myostatin protein expression in complicated placental tissues:  
Significantly higher myostatin dimer was observed in the IUGR, PE and PE-IUGR placentae 
compared to PTB (the gestational age matched placental group). Precursor expression in PE 
and PE-IUGR was lower than precursor of PTB placentae. Precursor expression in the IUGR 
group was higher than PTB and had the highest expression overall. Compared to dimer 
expression, precursor expressions were significantly higher in the PTB and IUGR placentae. 
However, no significant differences were seen in PE and PE-IUGR (Figure 2B). A 
representative image of Western blot is given in Figure 2A 
 
Cytokine ELISA:  
First trimester placental explants were maintained in 1% (hypoxic) 3% (physiologically 
relevant) and 21% oxygen (standard culture conditions) ± myostatin (1μg/ml) and media 
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analysed by the Bio-Plex human cytokine assay and normalised for wet weight of tissue 
collected. Following treatment with myostatin, a decrease in pro-inflammatory cytokines IL-8 
IFN-γ and TNF-α was seen. The concentration of IL-4 was significantly increased (Figure 
3E). The level of oxygen also affected the production of these cytokines. In the presence of 
myostatin, cytokine concentrations in placental explants were lower at higher oxygen levels.  
Lactate dehydrogenase release, as an index of tissue viability was analysed as described 
previously 
42,43
. Villous explants did not show any negative effect due to myostatin treatment 
in cultured tissues. Experimental treatment significantly did not affect LDH activity in the 
incubation medium with levels ~90% percent of controls after 24h in culture (data not 
shown). This indicated that the concentrations used in this study did not affect cell viability.  
 
Discussion  
Pre-symptomatic plasma concentrations of myostatin   
The plasma of pre-symptomatic women who later developed PE, IUGR or had a normal 
pregnancy was collected at 12 to 14 weeks of gestation. The concentrations of myostatin in 
the plasma at this  earlier time-point (than assessed by Guo et al 
5
) was  evaluated to 
determine whether myostatin expression was different earlier in pregnancies of women who 
later developed IUGR or PE. In the study by Guo et al, measurements of myostatin 
concentrations in the serum of women with PE were made at approximately 35 weeks of 
gestation 
5
. In these women with PE, significantly higher serum myostatin concentrations 
were identified compared to gestational age matched control women 
5
. Similarly in the 
current study of the pre-symptomatic women, significantly higher plasma concentrations of 
myostatin were observed in women who later developed PE compared to women who later 
developed IUGR or women with normal pregnancies.  
 
This finding of an earlier significant rise in myostatin plasma concentration in women who 
later developed PE is interesting. However, further studies in a larger cohort with more 
variables taken into account are required to assess the consistency of this finding. Variables 
that need to be included are the severity of PE and pregnancies with PE-IUGR. More frequent 
blood sampling should also be undertaken, as this may reveal when the higher myostatin 
concentrations in serum can be detected. If with these more complex investigations, 
myostatin concentrations in the serum are consistently higher earlier in pregnancy of PE 
women, it is possible that myostatin could be developed as a part of a biomarker panel along 
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with other potential biomarkers for the earlier detection of PE. A recent publication by 
Founds et al identified FSTL-3 (a potent antagonist of myostatin) as another potential 
biomarker. FSTL-3 concentrations were identified to be significantly higher in second and 
third trimester of pregnancy in women who later developed PE 
44
. The higher FSTL-3 levels 
in mid-gestation were also associated with an increased odds ratio of PE and therefore 
concluded to warrant further study as a biomarker of PE 
44
. 
 
Differential expression of myostatin in IUGR, PE and PE-IUGR 
The expression of myostatin protein in placentae of PE, IUGR and PE-IUGR were compared 
to gestational age matched placentae (PTB) in the current study. Appropriate controls in the 
study of PE and IUGR are difficult to define as pregnancies are often preterm. Guo et al in 
their study of myostatin in the placentae of PE complicated pregnancies used a term delivered 
placental population for their comparisons. In the current study the gestational age matched 
group (PTB) was chosen as the best possible choice for comparisons to be made. One major 
reason being that myostatin is known to be negatively correlated with gestational age 
15
 and 
therefore a term population may not be suitable as the higher expression of myostatin seen in 
the complicated tissues maybe due to the decrease in expression known to occur later in 
gestation. 
 
The expression of myostatin in pregnancies complicated with IUGR and PE-IUGR have not 
been previously established. Here, we identified higher expression of the active dimer form 
of the myostatin protein in placentae of women whose pregnancies were complicated with 
PE, IUGR and PE-IUGR compared to gestational age matched placentae (PTB). The 
expression of the myostatin precursor, the initially synthesised form of myostatin required for 
the formation of the dimer and the pro-peptide, was significantly higher in placentae of IUGR 
complicated pregnancies and lower in placentae of pregnancies complicated with PE as well 
as those complicated with PE-IUGR. Together these findings indicated that the active form of 
myostatin is significantly affected by abnormal pregnancy conditions. Furthermore, the 
expression of the myostatin precursor and dimer are differentially affected in complicated 
pregnancies.  
 
Proteolytic processing of the myostatin precursor is required for the release of the pro-peptide 
and mature myostatin proteins (homodimer of the mature protein is the active form). The 
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myostatin pro-peptide is an antagonist of myostatin as it can bind to the active dimer and 
prevent receptor binding. Expression of the myostatin pro-peptide is unknown in PE IUGR, 
and PE-IUGR complicated pregnancies. Evaluating the expression of enzymes regulating the 
processing of myostatin needed to release the pro-peptide and mature forms of myostatin may 
provide essential information on whether the expressional differences observed in this study 
are due, to a defect in the processing of the precursor, or, to alterations in expression. 
Furthermore, evaluation of the myostatin signalling pathway (e.g. myostatin receptor, 
transcription factors etc.) and antagonists of myostatin activity (e.g. FSTL-3 and the 
myostatin pro-peptide) will provide insight to the possible role of myostatin in complicated 
pregnancies.  
 
Potential functional role of myostatin in placentae  
The function of myostatin in complicated pregnancies (, PE, IUGR, GDM) is still unclear and 
little is known of the effect of myostatin on normal placental function. Myostatin is known to 
alter glucose uptake of placental explants and cells in a conflicting manner. Myostatin 
treatment of placental explants was observed to increase glucose uptake 
15
, whereas 
myostatin treatment decreased glucose uptake of placental cells (BeWo; a choriocarcinoma 
cell line)
16
. Myostatin is localised in cytotrophoblast, syncytiotrophoblast and extravillous 
trophoblast cells (EVT) of term and first trimester placentae
13,18
.  In a recent publication we 
described the increase in both proliferation and migration of EVT, following treatment with 
myostatin
13,18
. 
 
Another possible way in which myostatin could mediate its effect on the placenta is by the 
modulation of cytokine productions. IFN-γ is a Th1 cytokine, shown to be expressed in 
human trophoblast cells, early in pregnancy (human) 
45
. A potential role in the regulation of 
EVT invasion has also been proposed for IFN-γ, as treatment with IFN-γ resulted in 
increased apoptosis of EVT and decreased secretions of matrix metallopeptidases (required 
for invasion) 
46
. TNF-α, another pro-inflammatory Th1 cytokine, has been identified in 
syncytiotrophoblast and extravillous trophoblast (EVT) 
47,48
 and  investigation in the placenta 
has found TNF-α to negatively affect placentation by its involvement in the apoptosis of 
trophoblast cells and the negative regulation of syncytialisation (by negatively affecting hCG 
expression) 
47,48
.  IL-8  although a Th1 chemokine is said to promote EVT invasion 
49
. The 
production of this cytokine is also known to increase with gestational age 
50
. The presence of 
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IL-4 at the materno-fetal interface was identified through IHC studies, whereby 
cytotrophoblast, endothelial cells and decidual macrophages were positively stained
51
. In 
mice, IL-4 knockouts were found to have a mild PE phenotype with increased levels of pro-
inflammatory cytokines, mild hypertension, proteinuria and endothelial dysfunction 
52
.The 
move from a Th1 to a Th2 predominant environment in pregnancies is important for the 
maintenance of a healthy pregnancy. In pregnancies complicated with IUGR, PE, PE-IUGR 
higher expression of IFN-γ 29,30, IL-8 31, as well as IL-2 53, IL-6 31, and TNF-α 31-33, have been 
identified in maternal serum and placental tissue. However, reports are also available 
showing no change 
31,53,54
. Alterations to the expressions of Th2 cytokines in these 
pregnancies are reported to be decreased (IL-10) 
54
, unchanged 
54
 or increased 
53
. Therefore in 
these pregnancies the switch from a Th1 rich to a Th2 rich environment may be disrupted. 
A relationship between myostatin and cytokine production has been established outside of 
placental tissue 
34-38
. However, the effect of myostatin on placental production had not  been 
previously described. In the current study a clear response was seen with myostatin treatment 
on the production of cytokines in first trimester explants (10 weeks gestation). With 
myostatin treatment, significantly lower productions of  Th1 (pro-inflammatory) cytokines 
TNF-α, IFN-γ and IL-8 and higher productions of  IL-4 Th2 (anti-inflammatory) cytokines 
were identified in the media of first trimester placental explants cultured in the presence of 
myostatin under 1%, 3% and 21% oxygen. In pregnancy, the development of the placenta 
occurs under hypoxic conditions (2-3% oxygen from 8-10 weeks) 
55,56
: as such 3% oxygen  
was considered the physiologically relevant oxygen group. 21% oxygen was tested as many 
experiments are still performed under this “normal” atmospheric condition, and 1% 
considered the adverse hypoxic condition. Even under the hypoxic conditions the cytokine 
concentrations in the media of the explants treated with myostatin followed the pattern 
thought to be supportive of pregnancy (higher Th2). Potentially, one function of myostatin 
may be as a mediator to assist in the switch from a Th1 to a Th2 cytokine rich environment 
by affecting cytokine production. Furthermore, this effect on cytokines may have 
downstream effects on the establishment of the placenta due to responses of placental cells to 
cytokines.   
 
Conclusions  
In summary, our findings show that alterations to myostatin concentration in plasma can be 
detected early in pregnancies complicated with PE IUGR, and PE-IUGR, with higher 
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expression of myostatin in pre-symptomatic PE plasma. However, further studies in a larger 
more comprehensive cohort are needed to investigate the potential of myostatin as a 
biomarker of PE. In the current observational study we also found the expression of 
myostatin protein to be significantly altered in the placentae of pregnancies complicated with 
PE IUGR, and PE-IUGR compared to PTB. Future investigations should also incorporate 
evaluations of the enzymes involved in the processing of myostatin, myostatin antagonists, 
and the activation of the myostatin signalling pathway. The findings of the explant cultures 
suggest myostatin may help in the move from a Th1 cytokine environment to a Th2 required 
for a successful pregnancy. This together with the increased proliferation and migration of 
EVT described previously present a potential positive role for myostatin in pregnancy. The 
higher expression of myostatin in complicated pregnancies therefore may occur to support the 
pregnancy rather than disrupt. Future studies should investigate the role of myostatin (e.g. 
cytokine production, invasive, proliferative and differentiate capacities) on isolated cells and 
placental tissues of complicated pregnancies to gain a better understanding of the role of 
myostatin under high risk pregnancy conditions.  
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Tables 
Table 1:  Clinical characteristics of pre-symptomatic women for the study of myostatin 
plasma concentrations 
  Normal  PE IUGR 
  n=21 n=11 n= 10 
Maternal age (years) 32.4 ± 5.6 33.6 ± 3.8 30.1 ± 2.0 
Maternal BMI at sampling  (kg/m2) 26.9 ± 5.5 29.0 ± 6.5 24.2 ± 4.3 
Gestational age at sampling (weeks) 14.4 ±  1.6 14.1 ±  2.4 12.7 ±  2.014 
Gestational age at birth (weeks) 40.1 ±  1.2 37.7 ±  2.7* 38.59 ±  1* 
Fetal birth weight (Kg) 3422 ± 262  2948 ± 670  2599 ± 170 
§
  
Fasting plasma glucose (mmol/l) 4.3  ±  0.3 4.6 ± 0.4   4.3  ±  0.3 
1 h plasma glucose (mmol/l) 7.0  ±  1.3 7.8  ±  0.8 6.6  ±  1.2 
2 h plasma glucose (mmol/l) 6.0  ±  1.2 5.6 ±  1.3 5.7  ±  1 
Values presented as mean ± SD.   
 *
 p< 0.05, 
 ‡
 p < 0.005, 
§
 p< 0.0001 vs. Normal    
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Table 2: Clinical characteristics: placental expression of myostatin  1 
 
PTB IUGR PE PE IUGR 
 
(n= 12) (n= 16) (n= 15) (n= 10) 
Maternal Age (y) 31.0 ± 6.1 31.8 ± 5.9 30.6 ± 6.2 27.6 ± 3.8 
Maternal BMI at 12 weeks (kg/m2) 28.7 ± 4.7 31.2 ± 9.2 33.7 ± 6.7 34.8 ± 9.2 
Maternal BMI at delivery (kg/m2) 25.7 ±  5.2 27.9 ±  11 31.8 ± 7.1 31.1 ± 8.6 
Gestation (weeks) 31.6  ±  3.4 30.7  ±  2.9 30.3  ± 2.6 29.8  ±  3.3 
Fetal birth weight  (g) 1946 ± 663 1063 ± 426* 1398 ± 444 960.4 ± 563* 
Women were did not have gestational diabetes and were below the criteria for diagnosis by the  Australasian Diabetes in Pregnancy 
Society (ADIPS)either fasting venous plasma glucose concentrations of 5.5 mmol/l glucose, and/or 8.0 mmol/l glucose 2 h after a 75 g 
oral glucose load at approximately 28 weeks gestation.  
Values represent mean ± SD.  
*P < 0.005, compared to PTB (one way ANOVA).  
 2 
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Figure Legends   
Figure 1: Myostatin concentrations in the plasma of pre-symptomatic women taken in early second 
trimester (12-14 weeks gestation; p = 0.08). Myostatin concentrations were significantly elevated in 
women who later developed PE (n= 11, Black bar) compared to control (n = 21, white bar; p= 0.03) 
and women who later developed IUGR (n= 10 grey bar; p = 0.04). No significant differences were 
found in women who later developed IUGR compared to control (p =0.95). Data presented as mean 
± SEM. Statistical analyses performed were Mann–Whitney U-test and significance defined as 
p<0.05.  
 
Figure 2: (A) Representative Western blot of pregnancy complication in the order of IUGR, PTB, 
PE, PE-IUGR and positive control (SM) ovine skeletal muscle. (B) Western blot analysis. Precursor 
expressions (black bar; a) were significantly altered in all groups compared to PTB precursor, 
higher in IUGR and lower in PE and PE-IUGR. Significantly higher myostatin dimer (grey bar; b) 
expression compared to PTB was also observed in all groups (IUGR, PE and PE-IUGR). Compared 
to precursor expression of the IUGR group (c) significantly lower myostatin precursor expression 
was seen in the PE and PE-IUGR groups. Significantly lower dimer compared to precursor 
expression seen in the IUGR (****, p<0.0001) and PTB (*, p<0.05) placentae. Comparison of data 
between multiple groups, the Kruskal–Wallis test was used. For comparison between the two 
groups, the Mann–Whitney U-test was used and significance was defined as p<0.05. Data was 
presented as the mean ± S.E.M.  
 
Figure 3: First trimester placental explants were maintained in 1% (hypoxic) 3% (physiologically 
relevant) and 21 % oxygen (standard culture conditions) ± myostatin (1μg/ml) for 48 hours and 
media analysed by the Bio-Plex human cytokine assay. Following treatment with myostatin (black 
bar) a significant increase in the concentration (pg/ml) of Th2 cytokine (C) IL-4 was observed,  Th1 
(pro-inflammatory) cytokines (B) IL-8 (B) IFN-γ and (C) TNF-α concentrations (pg/ml) however 
were significantly decreased compared to control (white bar). The level of oxygen also affected the 
production of these cytokines as following myostatin treatment lower oxygen levels (21% compared 
to 1%) resulted in elevated cytokine concentrations of IFN-γ, IL-4, and IL-8 (21% 3%.1%). 
Oxygen tension alone (without myostatin treatment) also resulted in a similar pattern in IL-8 
concentrations. Data presented as mean ±  SEM. Statistical analyses performed were Students t-test 
and significance defined as p<0.05. Detailed analyses are presented in the table below graphs (E). 
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 Placental myostatin expression in pregnancies complicated  with Chapter 5.
gestational diabetes    
Hypothesis:  Myostatin is differentially expressed in pregnancies complicated 
with gestational diabetes 
 Rationale 5.1 
Myostatin in the serum of women with overt gestational diabetes mellitus (GDM) was not found to 
be significantly different. However, the expression of FSTL-3 an endogenous inhibitor of myostatin 
is significantly altered in the placentae of women with GDM. Myostatin is also known to be higher 
in the muscle of obese women and persons with type 2 diabetes. In placental tissues it is also 
significantly altered in another complication of pregnancy (PE). The expression of myostatin in the 
placental tissues of pregnancies complicated with GDM is not available in the current literature. 
Also unavailable is the expression of myostatin in placentae of women who were obese during 
pregnancy.   
 Specific aims and publications generated  5.2 
 Evaluate differences in plasma myostatin concentrations of pre-symptomatic Specific Aim: 1
women who later developed GDM 
 Evaluate the expression of myostatin protein in the placental tissues of lean Specific Aim: 2
and obese normal glucose tolerant (NGT) women and the expression of 
myostatin in women with GDM who were treated with diet or insulin. 
This chapter consists of a first author manuscript prepared by the PhD candidate accepted for 
publication in the journal Placenta entitled:  
 Publiction 1. Myostatin in the placentae of pregnancies complicated with gestational 
diabetes mellitus  
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Introduction: Gestational diabetes mellitus (GDM) is characterised by maternal glucose intolerance and
insulin resistance during pregnancy. Myostatin, initially identiﬁed as a negative regulator of muscle
development may also function in the regulation of placental development and glucose uptake. Myo-
statin expression in placentae of GDM complicated pregnancies is unknown. However, higher myostatin
levels occur in placentae of pregnancies complicated with preeclampsia. We hypothesise that myostatin
will be differentially expressed in GDM complicated pregnancies.
Methods: Myostatin concentrations (ELISA) were evaluated in plasma of presymptomatic women who
later developed GDM and compared to plasma of normal glucose tolerant (NGT) women. Furthermore,
myostatin protein expression (Western blot) was studied in placentae of pregnant women with GDM
(treated with diet or insulin) compared to placentae of NGT women.
Results: No signiﬁcant difference in myostatin concentration was seen in plasma of pre-symptomatic
GDM women compared to NGT women. In placenta signiﬁcant differences in myostatin protein ex-
pressions (higher precursor; p < 0.05and lower dimer: p < 0.005) were observed in GDM complicated
compared to NGT pregnancies. Furthermore, placentae of GDM women treated with insulin compared to
diet have higher dimer (p < 0.005) and lower precursor (p < 0.05). Compared to lean women, placentae
of obese NGT women were lower in myostatin dimer expression (p < 0.05).
Discussion: Myostatin expression in placental tissue is altered under stress conditions (e.g. obesity and
abnormal glucose metabolism) found in pregnancies complicated with GDM. We hypothesise that
myostatin is active in these placentae and could affect glucose homoeostasis and/or cytokine production
thereby altering the function of the placenta.
© 2014 Published by Elsevier Ltd.1. Introduction
Gestational diabetes mellitus (GDM) is characterised by
maternal glucose intolerance leading to hyperglycaemia, b-cell
dysfunction and insulin resistance [1]. GDM affects ~5% of all
pregnancies globally [1e3]. GDM is associated with an increased
short and long term risk of adverse outcomes formother and infant,
including a higher risk of induced labour, Caesarean sectionearch, Building 71/918, Royal
QLD, Australia. Tel.: þ61 7
Mitchell).
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lacenta.2014.11.006delivery, preterm birth, hypertension, preeclampsia stillbirth,
macrosomia and infant respiratory distress syndrome, developing
metabolic disorders, diabetes and cardiovascular disease [1,4e7].
Myostatin is a member of the Transforming Growth Factor-Beta
(TGF-b) super family and members of this family function in the
development of the placenta [8,9]. Comprehensive reviews are
available on myostatin biosynthesis, signalling and function
[8,10,11]. Myostatin is initially synthesised as a ~52 kDa precursor
protein. Two proteolytic cleavages of the precursor release a
~42 kDa N-terminal pro-peptide and a ~12 kDa mature myostatin
protein. The active form of myostatin is a homodimer of the mature
protein. Myostatin circulating in blood is found mainly in a latent
complex [10,12e14] composed of the active dimer bound non-
covalently to two monomeric pro-peptides [10,13,15]. As antae of pregnancies complicated with gestational diabetes mellitus,
H.N. Peiris et al. / Placenta xxx (2014) 1e62secreted protein in the human circulation [16], myostatin is thought
to function in both an autocrine and paracrine manner [8,17].
Myostatin is best known as a negative regulator of muscle
development [8]. Increased muscle, decreased adipose tissues and
an improved metabolic status were observed in myostatin
knockout mice (suppression of hyperglycaemia) and in mice with a
loss of function mutation(s) to the myostatin gene (less insulin
resistance) [8,18,19]. Speciﬁc inhibition of myostatin in muscle has
been identiﬁed to be most effective in improving glucose meta-
bolism and insulin sensitivity [20].
Expression of myostatin in the human placenta has been iden-
tiﬁed to be negatively correlated with gestational age, as lower
protein levels in term compared to preterm human placentae [21].
Myostatin is localised to cytotrophoblast, syncytiotrophoblast and
extravillous trophoblast cells of ﬁrst trimester and term human
placentae [14,22]. Following myostatin treatment alterations to
glucose uptake of placental explants and BeWo cell (placental cell
line) [21,23], and increased proliferations of primary isolated
extravillous trophoblast cells [22] have been observed.
In complicated pregnancies, myostatin is known to be higher
(mRNA and protein) in placentae of pregnancies complicated with
preeclampsia [24]. A study by Hu et al. of serum myostatin con-
centrations of women with overt GDM found no signiﬁcant dif-
ference [25]. However, no reports are available on the expression of
myostatin in placentae of GDM.We hypothesise that myostatinwill
be differentially expressed in GDM complicated pregnancies. The
current observational study evaluated myostatin expression in
plasma of pre-symptomatic women who later developed GDM, to
ascertain whether a difference in myostatin concentration can be
seen earlier in pregnancy. Moreover, myostatin protein expression
was evaluated in placentae of women with GDM and/or obesity, as
myostatin expression in placentae GDM complicated pregnancies is
currently unknown.
2. Methods
2.1. Ethics and collections (plasma and placentae)
Maternal blood was collected from pregnant women attending
their ﬁrst ante-natal visit (8e17 weeks gestation) at the Mercy
Hospital for Women (MHW), Victoria Australia. Informed, written
consent was obtained from participants (Mercy Health Ethics
Committee, R08/31). After ultrasound conﬁrmed a viable fetus and
gestational age was established, 10 mL of venous blood was
collected into an EDTA vacuum tube. The blood was centrifuged at
1000 g for 5 min, the plasma aliquoted into 1 mL microfuge tubes
and immediately stored at 80 C until required. After birthing,
women with GDM (n ¼ 18) and normal glucose tolerance (NGT,
n ¼ 23), were retrospectively selected for the study. GDM compli-
cated pregnancies were not complicated with polycystic ovarian
syndrome (PCOS), PE or IUGR. An a priori power analysis wasTable 1
Clinical characteristics: myostatin in pre-symptomatic plasma.
NGT (n ¼ 23) GDM (n ¼ 18)
Maternal age (years) 31.98 ± 5.6 32.55 ± 4.6
Maternal BMI at sampling (kg/m2) 26.7 ± 5.4 29.96 ± 6.9
Gestational age at sampling (weeks) 14.67 ± 1.8 13.19 ± 2.5
Gestational age at birth (weeks) 40.1 ± 1.2z 39.15 ± 0.8
Fetal birth weight (kg) 3.4 ± 0.3 3.3 ± 0.3
Fasting plasma glucose (mmol/l) 4.33 ± 0.4x 5.17 ± 0.7
1 h plasma glucose (mmol/l) 6.91 ± 1.5x 10.88 ± 1.5
2 h plasma glucose (mmol/l) 5.97 ± 1.2x 10.46 ± 1.2
Values presented as mean ± SD.
zp ¼ 0.0080, xp < 0.0001 vs. GDM (one way ANOVA).
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tailed student t-test, alpha error of 0.05 and power 0.3. The sample
size required identiﬁed was n ¼ 18 per group. Clinical and de-
mographic details of participants are given in Table 1 (Mean ± SD).
Mercy Health approved this study andwritten informed consent
was obtained from participating women. Women with GDM were
diagnosed according the Australasian Diabetes in Pregnancy Soci-
ety (ADIPS) criteria by either fasting venous plasma glucose con-
centrations of5.5mmol/l glucose, and/or8.0 mmol/l glucose 2 h
after a 75 g oral glucose load at approximately 28 weeks gestation.
Placenta was collected from women scheduled for an elective
Caesarean section (with singleton pregnancies) at term (37 weeks
gestation). Indications for Caesarean section were breech presen-
tation and/or previous Caesarean section. Women with cho-
rioamnionitis, preeclampsia, pre-existing diabetes, asthma, multi-
fetal pregnancy, PCOS and fetal chromosomal abnormality were
excluded. Placentae of women with NGT were collected as controls
(n¼ 22 patients). Placentae of womenwith GDMwere separated to
those managed by diet alone (n ¼ 14 patients) or insulin (n ¼ 20
patients). Women were controlled by diet if their fasting glucose
readings were maintained <5.5 mmol/l over a 2 week period post
diagnosis. Women with fasting glucose readings >5.5 mmol/l were
placed on insulin for optimal glucose control. Women were also
stratiﬁed according to their pre-pregnancy BMI. Lean women were
categorised as having a BMI 24.9 kg/m2, overweight patients with
a BMI  25 and 29.9, and obese patients with a BMI  30 kg/m2.
Clinical and demographic details of participants are given in
Table 2.
Within 15 min of delivery placental cotyledons were obtained
fromvarious locations of the placenta; the basal plate and chorionic
surface were removed from the cotyledon, and villous tissue was
obtained from the middle cross-section. Tissues were blunt
dissected to remove visible connective tissue and calcium deposits.
Tissues were washed with PBS, immediately snap frozen in liquid
nitrogen and stored at 80 C until required.
2.2. ELISA
Myostatin ELISA was performed following the manufacturer's
instructions (Immundiagnostik, Germany). A microtiter plate
reader at 450 nm against 620 nm as a reference was used to read
samples. A 4-parameter-algorithm was used to calculate the stan-
dard curve from which the concentration of myostatin was deter-
mined. The coefﬁcient of variance between replicates was
consistently below 10%. The detection limit of the kit is 0.273 ng/mL
with a linear range 0e65 ng/mL. Controls tested (included in the
kits) were within acceptable limits (C1 at 2e13 ng/mL and C2 at
15e29 ng/mL).
2.3. Western blot
Placental and ovine tissue (positive control) were extracted and
Western blot performed (80 mg) according to previously described
methods [27]. Membraneswere blocked for 1 h in blocking solution
(1 g non-fat milk powder and 1 g of Bovine serum albumin powder
in 100 mL of Tris Buffered Saline with 0.001% Tween 20, Sigma
Aldrich, Australia). Membranes were incubated overnight at 4 C in
myostatin primary antibody (Sc-34781 e Santa Cruz Biotech-
nology), at 200 ng/mL and secondary antibody at 20 ng/mL (Sc-
2020 Santa Cruz Biotechnology) for 2 h. Bio-Rad Clarity western
ECL substrate (Bio-Rad Laboratories Pty., Ltd., Australia) was used to
visualise the proteins on Agfa medical X-ray blue ﬁlm and devel-
oped using a Konica Minolta SRX-101A processor (Konica Minolta
medical and graphic INC, Japan). The ﬁlm was imaged on GS 800
calibrated densitometer, using Quantity One software (Bio-Radentae of pregnancies complicated with gestational diabetes mellitus,
Table 2
Clinical characteristics: placental expression of myostatin.
NGT (n ¼ 22) GDM DIET (n ¼ 14) GDM INSULIN (n ¼ 20)
Lean (n ¼ 11) Obese (n ¼ 11) Lean (n ¼ 8) Obese (n ¼ 6) Lean (n ¼ 11) Obese (n ¼ 9)
Maternal age (years) 32.7 ± 4.4 32.9 ± 4.7 32.6 ± 4.4 31.0 ± 5.5 31.3 ± 5.1 30.7 ± 6.4 33.4 ± 4.6 34.1 ± 4.2 32.4 ± 5.2
Maternal BMI at 12 wks (kg/m2) 31.9 ± 11.6 21.7 ± 1.3 42.2 ± 7.0z 27.6 ± 7.0 22.4 ± 1.8 34.5 ± 5.0x 27.7 ± 6.5 22.7 ± 1.5 33.7 ± 4.8z
Maternal BMI at delivery (kg/m2) 36.8 ± 10.4 27.7 ± 2.1 46.0 ± 6.0z 29.9 ± 5.9 26.1 ± 3.0 36.2 ± 3.6x 31.5 ± 6.3 27.1 ± 2.4 36.9 ± 5.2z
Gestational age at birth (weeks) 39.1 ± 1.1 39.3 ± 1.4 38.9 ± 0.6 38.7 ± 0.7 38.5 ± 0.8 39.0 ± 0.4 38.5 ± 0.7 38.9 ± 0.4 38.0 ± 0.7
Fetal birth weight (kg) 3.6 ± 0.5¥ 3.4 ± 0.4 3.8 ± 0.6 3.4 ± 0.3 3.4 ± 0.4 3.4 ± 0.4 3.2 ± 0.6 3.2 ± 0.4 3.3 ± 0.8
Placental weight (kg) 0.69 ± 0.2 0.57 ± 0.1 0.72 ± 0.2 0.60 ± 0.1 0.66 ± 0.1 0.57 ± 0.1 0.60 ± 0.1 0.56 ± 0.1 0.61 ± 0.1
Fasting plasma glucose (mmol/l) 4.7 ± 0.3þ 4.6 ± 0.3 4.8 ± 0.3 5.1 ± 0.7 5.1 ± 0.7 5.3 ± 0.7 5.6 ± 0.9 5.1 ± 0.8 6.3 ± 0.7
1 h plasma glucose (mmol/l) 7.7 ± 1.5y* 6.9 ± 1.0 8.4 ± 1.8 11.1 ± 1.2 11.2 ± 1.6 11.2 ± 0.4 11.5 ± 2.5 10.4 ± 2.4 12.8 ± 2.0
2 h plasma glucose (mmol/l) 5.5 ± 1.3y# 5.7 ± 1.4 5.3 ± 1.2 9.6 ± 1.4 9.7 ± 1.8 9.5 ± 1.1 9.6 ± 1.8 9.1 ± 1.2 10.2 ± 2.3
Values represent mean ± SD.
zp < 0.0001, xp < 0.005 OBESE vs. LEAN (one way ANOVA).
#p < 0.0001, *p < 0.005 vs. GDM DIET (one way ANOVA).
yp < 0.0001, þp < 0.005, ¥p < 0.05 vs. GDM INSULIN (one way ANOVA).
H.N. Peiris et al. / Placenta xxx (2014) 1e6 3Laboratories Pty., Ltd., Australia). Analyses were performed as
described in Refs. [21,27].2.4. Statistical analyses
All datasets were tested for normal distribution using the Kol-
mogoroveSmirnov test (GraphPad Prism 4 software (San Diego,
CA)). KruskaleWallis one-way analysis of variance test was used for
comparison of data between multiple groups. For comparison be-
tween two groups, the ManneWhitney U-test was used and sig-
niﬁcance was deﬁned as p < 0.05. Clinical data is presented as
mean ± SD and myostatin data presented as the mean ± S.E.M.3. Results
3.1. Plasma
All pregnancies were singleton. No signiﬁcant differences were
observed in maternal age, fetal weight and BMI at delivery. Par-
ticipants were overweight with a BMI greater than 25 kg/m2.
Gestational age, fasting, one-hour and two-hour plasma glucose
concentrations at OGTT were signiﬁcantly different in GDM
compared to NGT participants (Table 1). Myostatin concentrationsFig. 1. Plasma myostatin in pre-symptomatic women with GDM. Myostatin concen-
trations in the plasma of pre-symptomatic women taken in early second trimester
(13e14 weeks gestation; p ¼ 0.2). Myostatin concentrations were not signiﬁcantly
different in women who later developed GDM (n ¼ 18, grey bar) compared to NGT
(n ¼ 23, black bar; p ¼ 0.6). Data presented as mean ± SEM. Statistical analyses per-
formed were ManneWhitney U-test and signiﬁcance deﬁned as p < 0.05.
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oped GDM compared to NGT (Fig. 1).
3.2. Placentae
Higher fetal weight was seen infants born of the women in the
NGT group compared GDM groups (diet and insulin treated). Fast-
ing, one-hour and two-hour plasma glucose concentrations at
OGTTwere signiﬁcantly higher in GDMparticipants comparedwith
NGT subjects. BMI at 12 weeks and at delivery was signiﬁcantly
higher in obese compared to lean subjects of NGT, GDM diet and
GDM insulin groups. No signiﬁcant differences in BMI (12 weeks or
delivery), placental weight, maternal age or gestational ages were
seen between the groups (Table 2).
3.3. NGT population
Lower myostatin dimer protein expression (p < 0.05) was
observed in placentae of obese compared to lean NGT women. No
difference was seen in precursor protein expression. All compari-
sons made are listed in Fig. 2d.
3.4. GDM compared to NGT
Placentae of women with GDM (diet and insulin treated) had
higher myostatin precursor (p < 0.05) and lower dimer expression
(p < 0.005) compared to placentae of NGT women (Fig. 2A). A
similar pattern was seen when comparisons of myostatin expres-
sion in placentae from lean and obese NGT women and women
with GDM (treated with insulin or diet) were made, apart from no
difference being seen in comparisons of myostatin precursor
expression in placentae from lean NGT women and lean insulin
treated women showed (Fig. 2B).
3.5. GDM treated with diet or insulin
Placentae of GDM women treated with insulin had lower pre-
cursor (p < 0.05) and higher dimer protein expression (p < 0.005)
compared to placentae of GDM women treated with diet (Fig. 2a).
No differences in myostatin expression (precursor or dimer) were
evident in placentae of obese compared to lean women with GDM
treated with diet or insulin (Fig. 2b).
4. Discussion
Muscle is the major site for myostatin secretion and accounts for
a large proportion of glucose disposal [28]. Under abnormalntae of pregnancies complicated with gestational diabetes mellitus,
Fig. 2. Expression of myostatin protein in placentae of pregnancies complicated with GDM. Myostatin protein expression by Western blot in placentae of pregnancies complicated
by GDM. (a) GDM placentae (n ¼ 34) expression of myostatin precursor (black bar) and dimer (grey bar) compared to control (n ¼ 22). Signiﬁcant comparisons are designated with
(a) e NGT precursor designated, (b) e NGT dimer, (c) e GDM diet precursor, (d) e GDM diet dimer. (b) GDM placentae categorised by treatment and obesity (n-values available in
2d). Black bars represent lean-precursor, grey bars represent lean-dimer, checked bars represent obese-precursor and striped bars represent obese-dimer. Signiﬁcant comparisons
with (a) e lean NGT precursor designated, (b) e lean NGT dimer, (c) e obese NGT precursor, (d) e obese NGT dimer, (e) e lean GDM diet treated dimer. (c) Representative Western
blot of pregnancies complicated with GDM and positive control (SM) ovine skeletal muscle. (d) Table of comparisons for myostatin expression in placentae of GDM complicated
pregnancies compared to NGT. Signiﬁcance was deﬁned as p < 0.05 and data was presented as the mean ± S.E.M.
H.N. Peiris et al. / Placenta xxx (2014) 1e64conditions such as obesity and diabetes, signiﬁcant alterations to
muscle occur, including alterations to the insulin signalling
pathway and the ability to metabolise glucose [29,30]. Alterations
to myostatin are also noted in obese women (increased secretions
of myostatin from cultures of muscle myotubes) and patients with
type 2 diabetes (higher plasma concentrations and myostatin
mRNA expression in muscle) [16,31].
Hu et al. 2012, evaluating overt GDM women at delivery, found
no signiﬁcant difference in maternal serum concentrations of
myostatin [25]. In the current study, no signiﬁcant difference in
myostatin concentrations were found in plasma collected from
women who later developed (pre-symptomatic) GDM women
compared to plasma of women with NGT pregnancies. One limi-
tation that may inﬂuence both studies is body weight. Both GDM
and NGT women in the current study were overweight and in the
study by Hu et al. womenwere lean. Incorporating a wider range of
women (lean to extremely obese), collection of cord blood and a
larger cohort could provide essential information and allow for
better discernment of maternal and placental myostatin concen-
trations of GDM and NGT pregnancies.
Tissue speciﬁc differences in myostatin expression have previ-
ously been identiﬁed in type 2 diabetes, where although plasmaPlease cite this article in press as: Peiris HN, et al., Myostatin in the plac
Placenta (2014), http://dx.doi.org/10.1016/j.placenta.2014.11.006levels of myostatin did not differ, muscle tissue myostatin mRNA
was higher compared to control [32]. Hu et al. in their study only
presented information on serum myostatin of women with GDM
they did not report on the expression of myostatin in placental
tissues. In our study, signiﬁcant differences were found for the
myostatin expression in placentae of GDM compared to NGT
women.
Placentae of the GDM groups (diet and insulin treated) had
higher myostatin precursor and lower dimer protein expressions
compared to placentae of NGT women. Interestingly, in the
placentae of GDM women treated with insulin, signiﬁcantly lower
myostatin precursor and higher dimer protein levels were seen
compared to placentae of diet treated GDM women. Although still
higher in precursor and lower in dimer compared to expression in
placentae of NGT women, the variation in myostatin expression in
the placentae of the insulin treated GDM women (compared to
diet) may indicate a change in expression towards one closer to that
of NGT placentae. Thus insulin treatment in these GDM women
may support the processing of myostatin precursor into the active
dimer form (through a yet unknown mechanism). Furthermore,
alterations to myostatin expression in GDM complicated pregnan-
cies may occur due to the disturbances to insulin signalling and/orentae of pregnancies complicated with gestational diabetes mellitus,
H.N. Peiris et al. / Placenta xxx (2014) 1e6 5glucose metabolism found in these women and their placentae
[29,33].
In GDM, the insulin signalling pathway is altered in the
placentae, adipose tissue and skeletal muscle including alterations
to phosphatidylinositol-3-kinase (PI3-K) [29,33]. Insulin interacts
with the insulin receptor, and by recruitment of PI3-K [29]. Higher
expression of PI3-K has been identiﬁed in placental tissue of obese
womenwith GDM treated with diet compared to NGT women [33].
Inwomenwith GDM, lower placental PI3-K levels were observed in
insulin treated compared to diet treated women [33]. The effect of
myostatin on insulin signalling and/or conversely, the effects of
insulin on myostatin are not fully known. Myostatin may inhibit
insulin signalling (PI3/Akt pathway) through the inhibition of the
Akt phosphorylation [34]. However, C2C12 cells co-stimulated with
insulin and myostatin, increased glucose uptake more than the
increase in glucose uptake seen with myostatin treatment alone
[35]. Mitchell et al. also found increased glucose uptake of placental
explants following myostatin treatment [21]. On the contrary a
placental cell line (BeWo) found myostatin treatment decreased
glucose uptake [23]. Furthermore, the inhibition of myostatin (e.g.
adeno-associated virus-8-myostatin inhibition of myostatin)
outside of the placenta can increase glucose uptake [28]. Due to
these contradictory ﬁndings additional investigations are required
to fully elucidate the role of myostatin in the regulation of glucose
homoeostasis and interactions between myostatin and insulin.
Another way in which myostatin expression and function may
be altered is though interaction with cytokines. Cytokine concen-
trations in maternal plasma are known to be altered GDM and
following glucose stimulation explants from GDM placentae are
known to increase the release of TNF-a [36,37]. The effect of
myostatin on placental cytokines and in GDM is yet to be deter-
mined. However, myostatin treatment of mice lacking functional
myostatin increased concentrations of TNF-a [19], and in C2C12
myotubes treatment with TNF-a increased myostatin expression
[38]. Insulin treatment can decrease inﬂammatory mediators [39].
Insulin treatment of the GDM pregnancies could therefore improve
glucose homoeostasis as well as decrease inﬂammatory cytokines
(e.g. TNF-a), which in turn could result in the changes in myostatin
expression observed (towards a return to NGT myostatin
expression).
Differences were also evident in placentae of lean compared to
obese NGT women, as a signiﬁcantly lower expression of myostatin
dimer was observed in placentae of obese NGT women. Lower
expression of myostatin protein in obese placentae contrasts with
higher myostatin protein expressions observed in obese muscle
[16]. In GDM women no difference was seen in obese compared to
lean populations and this could be due to the alterations in the
insulin signalling pathway and glucose metabolism previously
described.
In placentae of NGT women no signiﬁcant difference was seen
between the expressions of myostatin precursor or dimer proteins.
However, higher precursor expressions were evident compared to
myostatin dimer inwomenwith GDM (diet and insulin). Proteolytic
processing of the myostatin precursor is required for release of the
pro-peptide and mature proteins (homodimer of the mature is the
active form). The myostatin pro-peptide is an antagonist of myo-
statin as it can bind the active dimer and prevent receptor binding.
Expression of the myostatin pro-peptide is unknown in GDM
complicated pregnancies. However, expression of other myostatin
antagonists follistatin and follistatin-like 3 (FSTL-3; a structural
homologue of follistatin) are known to be lower in serum and
placentae of GDM pregnancies [12,25,40e42]. Further in-
vestigations are required beyond the current observational study.
Evaluating the expression of enzymes regulating the processing of
myostatin, members of the myostatin signalling pathway (e.g.Please cite this article in press as: Peiris HN, et al., Myostatin in the place
Placenta (2014), http://dx.doi.org/10.1016/j.placenta.2014.11.006myostatin receptor) and antagonists of myostatin activity (e.g.
FSTL-3 and the myostatin pro-peptide) will provide insight to the
possible role of myostatin in complicated pregnancies.
5. Conclusions
Findings of the current observational study show that myostatin
protein expression (precursor and dimer) is signiﬁcantly different
in placentae of GDM pregnancies and NGT pregnancies. Further-
more, insulin treatment of GDM pregnancies increases the active
form of myostatin and trends towards an expression similar to NGT
placentae (although still signiﬁcantly different). Further in-
vestigations are required particularly evaluating the expression of
myostatin antagonists, activation of the myostatin signalling
pathway and interactions between myostatin and placental cyto-
kines as well as the effect of myostatin on insulin and glucose
homoeostasis. However, the current study shows that under the
stress of obesity and abnormal glucose metabolism found in GDM,
myostatin expression is signiﬁcantly altered. We hypothesise that
myostatin is active in GDM placentae and could inﬂuence placental
function through the regulation of glucose homoeostasis and/or
cytokine production.
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 Method development of myostatin detection by mass spectrometry Chapter 6.
Hypothesis:  Development of a mass spectrometry method will allow for more 
specific and highly sensitive detection of myostatin 
 Rationale 6.1 
The current gold standard methods of myostatin protein detection (Western blot and ELISA) are 
heavily dependent on the specificity of antibodies, and, at best, the results from these methods are 
semi-quantitative. In contrast to the single signal generated for a protein form by Western blot, mass 
spectrometry allows the identification of several unique peptides per quantified protein and 
therefore each protein targeted can have several independent measures made. Moreover, a specific 
region of the target protein can be identified. Furthermore, the ability for the myostatin pro-peptide 
to bind and inhibit the function of the myostatin dimer (active form) adds to the need to identify the 
forms of the myostatin protein. Chapter 6 aimed to develop and assess the use of a targeted 
approach to discriminate between the different myostatin protein forms through the analysis of 
individual peptides by tandem mass spectrometry.  
 Specific aims and publications generated  6.2 
 Develop a method for the specific and sensitive detection of myostatin by Specific Aim: 1
mass spectrometry  
This chapter consists of a first author manuscript Published in the Journal of Proteome Research 
entitled:  
 Publiction 1. Method Development for the Detection of Human Myostatin by High-
Resolution and Targeted Mass Spectrometry 
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ABSTRACT: Myostatin, a highly conserved secretory protein, negatively
regulates muscle development, aﬀecting both the proliferation and dif-
ferentiation of muscle cells. Proteolytic processing of the myostatin pre-
cursor protein generates a myostatin pro-peptide and mature protein.
Dimerization of the mature myostatin protein creates the active form of
myostatin. Myostatin dimer activity can be inhibited by noncovalent bind-
ing of two monomeric myostatin pro-peptides. This ability for myostatin
to self-regulate as well as the altered expression of myostatin in states of
abnormal health (e.g., muscle wasting) support the need for speciﬁc
detection of myostatin forms. Current protein detection methods (e.g.,
Western blot) rely greatly on antibodies and are semiquantitative at best.
Tandem mass spectometry (as in this study) provides a highly speciﬁc
method of detection, enabling the characterization of myostatin protein
forms through the analysis of discrete peptides fragments. Utilizing the scheduled high-resolution multiple reaction monitoring
paradigm (sMRMHR; AB SCIEX 5600 TripleTOF) we identiﬁed the lower limit of quantitation (LLOQ) of both mature
(DFGLDCDEHSTESR) and pro-peptide regions (ELIDQYDVQR) as 0.19 nmol/L. Furthermore, scheduled multiple reaction
monitoring (sMRM; AB SCIEX QTRAP 5500) identiﬁed a LLOQ for a peptide of the pro-peptide region (LETAPNISK) as
0.16 nmol/L and a peptide of the mature region (EQIIYGK) as 0.25 nmol/L.
KEYWORDS: Myostatin, GDF-8, mass spectrometry
■ INTRODUCTION
Myostatin is a distinct member of the transforming growth
factor super family-β (TGF-β). It is best known as a negative
regulator of muscle development. The role of myostatin on
muscle development was elucidated by the use of a myostatin
knockout mouse, which resulted in a doubling of muscle
tissue.1 The doubling eﬀect was identiﬁed as being due to a
combination of hyperplasia and hypertrophy of muscle tissue.1,2
Naturally occurring mutations to the myostatin gene have been
identiﬁed in a number of species, including in humans. A male
infant born with extraordinary musculature was identiﬁed as
having a homozygous G to A transition in the ﬁrst intron−exon
region of his myostatin gene. At 4.5 years, he continued to
have increased muscle development and was also exceptionally
strong.3 Reduced fat mass and an improved metabolic state
are observed when the myostatin gene is disrupted.1,2,4−10
Disrupting the myostatin gene in models of obesity, diabetes
(agouti lethal yellow; Ay, lepob/ob mice), and atherosclerosis
(lipoprotein receptor-null mice; Ldlr) had favorable physical
and metabolic eﬀects, including lower accumulations of adipose
tissue; improved glucose metabolism;6−8 decreased athero-
genesis; lower plasma level of triglyceride, cholesterol, and free
fatty acids; decreased insulin resistance; decreased accumu-
lation of fat in the liver; and an increased hepatic oxidation of
fatty acids.7
Myostatin is initially synthesized as a ∼52 kDa precursor
protein (that contains an N-terminal secretory signal, a pro-
peptide domain, a C-terminal RSRR (Arg-Ser-Arg-Arg), and a
proteolytic processing site).1,11 The ﬁrst proteolytic cleavage
removes the N-terminal signaling sequence required for protein
secretion.12,13 The second proteolytic cleavage (by paired dibasic
amino acid-cleaving enzyme, PACE, also known as Furin) occurs
at the proteolytic processing site, releasing the ∼42 kDa
N-terminal pro-peptide (latency associated peptide, LAP) and a
∼12 kDa C-terminal fragment that is the mature myostatin
protein.12,13 Dimerization of the ∼12 kDa mature myostatin
protein is required to create the active form of myostatin, i.e.,
the ∼28 kDa myostatin dimer.11,12,14
The binding of the active myostatin dimer to activin type IIB
receptor (activin receptor IIB, ACTRIIB) initiates the Smad-
mediated signaling pathway.2,14 The noncovalent binding of
two monomeric (LAP) pro-peptides to the active myostatin
dimer forms a large latent complex (∼75 kDa), preventing the
active dimer from binding to its receptor, ACTRIIB, and thus is
self-regulating.2,12,15−17 The majority of myostatin circulating
in blood (∼70%) is found in this latent complex form.16,18
To dissociate the myostatin dimer from this complex, four
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metalloproteinases of the bone morphogenetic protein (BMP)-
1/Tolloid family are involved via the proteolytic cleavage at
Asp-76 of the myostatin pro-peptide.2,4,16
A number of studies have investigated the use of the pro-
peptide as a “pharmacological” method for inhibiting myostatin
activity. Treatment with the myostatin pro-peptide,19 the pro-
peptide stabilized by fusion to a IgG-FC,20 and adeno-associated
virus-mediated pro-peptide treatments21 have resulted in im-
provements to muscle development19,20 and bone repair19 as well
as a decrease in atherosclerosis and hepatosteatosis in mice.21
Alterations to myostatin expression are evident in a number
of abnormal health states, as upregulated myostatin in serum
and/or muscle has been observed with muscle wasting (sar-
copenia, cachexia), obesity, diabetes, and in pre-eclampsia
(a pregnancy complication).22−28 Understanding the variations
in the expression levels of the diﬀerent forms of myostatin will
be important in discerning the state of the disease of interest
and also in targeting antagonistic and agonistic treatments.
The current gold standard proteomic methods for detecting
myostatin are Western blot (protein extractions) or ELISA (for
serum studies). Our previous work using Western blot analyses
identiﬁed variations in the expression of myostatin precursor
and dimer levels with changes in diet and gender.29 We propose
the use of a targeted approach to discriminate between the dif-
ferent myostatin protein forms through the analysis of indi-
vidual peptides by tandem mass spectrometry.
Scheduled high-resolution multiple reaction monitoring
(sMRMHR) experiments allow the combined acquisition of
selective peptide precursor masses with the corresponding full
product ion spectra at high accuracy (less than 2 ppm) in the
same run. An inclusion list for targeted peptides at known re-
tention times provides quantitative data for a set of character-
istic peptides and MS/MS signatures at high resolution for
conﬁrmation of detected peptides. These peptides can then be
searched through the ProteinPilot database search engine for
further conﬁrmation. For high-throughput applications, con-
ﬁrmed peptide MS/MS transitions and retention times were
optimized on a triple quadrupole linear ion trap spectrometer
(AB SCIEX 5500 QTRAP). The ion trap used in enhanced
product ion (EPI) scanning mode provides full MS/MS scans,
across the range m/z 100−1000, on a short time scale (90 ms),
enabling the unambiguous assignment of integrated peaks (15
data points across each chromatographic peak). This workﬂow
is thus ideally suited for the quantitation of low-abundance
proteins that would otherwise be diﬃcult to detect.
■ MATERIALS AND METHODS
Mass Spectrometry
The following is a description of the sample preparation and
instrument settings used in the identiﬁcation of myostatin. Re-
agents used in the preparation of samples for mass spec-
trometry analysis are listed in Table 1.
Method 1: Establishing Peptide Library for Use in Inclusion
List
Step 1: Reduction and Alkylation. Reconstituted pro-
form of myostatin (1 μg/mL; Sigma-Aldrich, Castle Hill, NSW,
Australia), mature myostatin (1 μg/mL; Fitzgerald Industries
International, USA), and BSA (0.66 μg/mL; as control for
digestion) were diluted in 100 μL of 50 mM ammonium bicar-
bonate (ABC) solution, which was followed by adding 10 μL of
20 mM dithiothreitol (DTT) in 100 mM ABC and incubating
for 1 h at 60 °C. Subsequently, 10 μL of 1 M iodoacetamide
(IAA) in 100 mM ABC was added to the mixer and incubated
again for 1 h at 37 °C in the dark.
Step 2: Trypsin Digestion. Samples were digested with
Trypsin Gold (0.5 μg/μL; 2 μL) (to peptide form) incubated
for 18 h at 37 °C. Samples were then evaporated to dryness in a
vacuum centrifuge at 30 °C for 2 h. Digested samples were
reconstituted in 100 μL 0.1% formic acid in water (reagent A),
an equal volume of 0.1% triﬂuoroacetic acid (TFA) in water
was added to each sample, and the resulting solution was
desalted.
Step 3: Desalting Method. Postdigestion, the reconsti-
tuted sample (method 1) and ﬁltrate (method 2) containing
the digested peptides was passed through the microcolumn for
desalting using a modiﬁed version of the stage tip protocol.30
Brieﬂy, a 3 mm piece of an Empore C18 (Octadecyl) SPE
extraction disk was excised and placed in a gel loader tip, and
5 μL POROS R3 slurry (25 mg/mL) was added on top to form
a microcolumn. Twenty microliters of reagent B (0.1% formic
acid in acetonitrile) was passed through the column followed by
20 μL of 0.1% TFA. Reconstituted samples (peptides in formic
acid/TFA) were pressed through the microcolumn, following
which columns were rinsed with 20 μL of 0.1% TFA. Bound
peptides were then eluted (three times) with reagent B (0.1%
formic acid in acetonitrile). Samples were dried at 30 °C in a
vacuum centrifuge for 45 min. Samples were reconstituted in
50 μL reagent A, mixed by vortex (10 s), and centrifuged for
2 min at 5000g, and 40 μL was subjected to LC−MS/MS.
Step 4: Mass Spectrometry Identiﬁcation of Peptide
Library. Desalted samples were analyzed by LC−MS/MS on a
5600 TripleTOF mass spectrometer (AB SCIEX) connected to
an Eksigent 1D plus nanoﬂow UPLC system equipped with a
Nanoﬂex chipLC (Eksigent). The chipLC was conﬁgured as a
trap/column system. The trap was 200 μm i.d. and 6 mm long
and was ﬁlled with 3 μm 120 Å C18 chromXP reversed-phase
support. The column was 200 μm i.d. and 15 cm long and was
ﬁlled with the same material. HPLC solvents were reagents A
and B as described in Table 1. A 35 min linear gradient from
5 to 35% B at a ﬂow rate of 500 nL/min was used to separate
Table 1. Reagents Used in the Preparation of Sample for
Mass Spectrometric Analysis
reagent catalog no. supplier
trypsin gold mass spectrometry
grade
V5280 Promega
ammonium bicarbonate salt
(ABC) (>99%)
A6141-500g
MS reaction buﬀer R0154 Sigma-Aldrich
formic acid (∼98%) 56302-10 × 1 ML-
F Fluka
iodoacetamide (IAA) I1149 Sigma-Aldrich
ultrapure dithiothreitol (DTT) 15508-013 Sigma-Aldrich
bovine serum albumin (BSA) Sigma-Aldrich
empore c18 (octadecyl) spe
extraction disk
66883-U Sigma-Aldrich
acetonitrile 34998-2.5L Sigma-Aldrich
triﬂuoroacetic acid reagent plus
(99%)
T6508 Sigma-Aldrich
HPLC water 95304-2.5L Sigma-Aldrich
2-propanol 19516-25mL Sigma-Aldrich
methanol 34860-2.5L-R Sigma-Aldrich
chromasolv for HPLC (>99.9%) Sigma-Aldrich
poros oligo r3 bulk media
reverse-phase packing
1133226 Applied Biosystems
protein extraction reagent 78501 ThermoFisher
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the peptides in the samples. The mass spectrometer was equip-
ped with a nanospray III electrospray interface in which a 105 mm
stainless steel emitter (ThermoFisher THIES528) was installed.
For standard data-dependent analysis experiments, the mass
spectrometer was operated in a manner where a 250 ms survey
scan (TOF−MS) was collected, from which the top 25 ions
were selected for automated MS/MS in subsequent experi-
ments, where each MS/MS event consisted of a 100 ms scan.
The selection criteria for parent ions included intensity, where
ions had to be greater than 150 counts/s with a charge state
greater than 2. Once an ion had been fragmented by MS/MS,
its mass and isotopes were excluded for a period of 6 s. Ions
were isolated using a quadrupole resolution of 0.7 Da and
fragmented in the collision cell using collision energy ramped
from 15 to 45 eV within the 100 ms accumulation time. In the
instances where there were less than 25 parent ions that met
the selection criteria, those ions that did were subjected to
longer accumulation times to maintain a constant total cycle
time of 1250 ms.
Step 5: Data Analysis of Peptide Library. All mass
spectra were analyzed using the MASCOT and ProteinPilot
search engines against the SwissProt database in FASTA format
(http://www.ebi.ac.uk/uniprot/download-center), with the
species set as human, specifying trypsin as the enzyme, one
missed cleavage, and cysteines as carbamidomethyl and
oxidized methionine as the variable modiﬁcations. Myostatin
peptides observed are listed in Table 2.
Method 2: Targeted and Determination of Lower Limit of
Detection for Myostatin
Step 1: Reduction and Alkylation. Reconstituted myo-
statin at concentrations of 5 μg/mL and BSA at 0.66 μg/mL
(used as a digestion control) were prepared for reduction and
alkylation, as in step 1 of method 1 (peptide library), on PALL
Nanosep 10K membranes.31,32
Step 2: Trypsin Digestion. Samples were digested on the
Nanosep membranes with 1 μg of Trypsin Gold (Promega
Corporation, Sydney, Australia) for 18 h at 37 °C (as described
in the previous section). Postdigestion, 100 μL of reagent A
(0.1% formic acid in water) was added to the samples. Samples
were then processed at 15 000g for 5 min to pass the tryptic
peptides through a PALL Nanosep 10K membrane followed by
an equal volume of 0.1% triﬂuoroacetic acid (0.1% TFA).
Step 3: Desalting Method. Desalting was performed as
described in Method 1.
Step 4: Mass Spectrometry, Scheduled High-Reso-
lution Multiple Reaction Monitoring (sMRMHR).Myostatin
data ﬁles were processed in Peak View software with XIC man-
ager, which can perform extracted ion chromatogram calcu-
lations. Mass data for identiﬁed myostatin peptides (Table 2)
from ProteinPilot−MASCOT analyses was entered into XIC
manager, and XIC was performed to identify retention times
for each speciﬁed myostatin peptide. An acquisition method for
scheduled high-resolution multiple reaction monitoring
(sMRMHR) was developed using deﬁned masses and retention
times (Table 2).
For standard data-dependent analysis experiments, the mass
spectrometer was operated in a manner where an MS1 scan
(250 ms TOF−MS survey scan) was followed by a product ion
scan (MS2). Accumulation time was set to 100 ms, the period
duration was 100.009 min, and 2264 cycles were performed,
with each cycle time being 2.6504 s. The IDA experiment was
set to identify ions with a mass greater than m/z 300 and
smaller than m/z 1250 with a charge state between 2 to 5. A
high triggering threshold was set at 2 000 000 cps, and the
maximum number of candidate ions per cycle was set to 25.
This was done to avoid triggering nonscheduled candidates and
to trigger only on masses and retention times speciﬁed on the
inclusion list (Table 2). Collision energy was set using rolling
collision energy with a collision spread of 6 V. To generate a
standard curve and to determine the limit of detection, the
volume of the sample injected (5, 0.5, and 0.05 μg/mL) was
increased from 1 to 10 μL in a stepwise manner.
Step 5: Data Analysis for the Limit of Detection.
Samples of recombinant myostatin were processed using
method 2, as deﬁned above for sMRMHR. To determine the
accuracy of the developed method, all mass spectra were ana-
lyzed using the MASCOT and ProteinPilot search engines
against the SwissProt database, with the species set as human,
specifying trypsin as the enzyme, one missed cleavage, and cys-
teines as carbamidomethyl and oxidized methionine as the
variable modiﬁcations. All mass spectra for the speciﬁed pep-
tides were analyzed by MultiQuant software to generate a
standard curve used to determine the limit of detection.
Step 6: Targeted Analysis for Myostatin by MRM. The
targeted analysis of the proform and mature myostatin forms
was achieved by monitoring speciﬁc precursor/product ion
pairs corresponding to their respective proteolytic peptides at
distinct retention times (scheduled MRM transitions, Table 2).
LC−MS/MS analysis was performed on a triple quadrupole
linear ion trap mass spectrometer (AB SCIEX 5500 QTRAP)
equipped with an electrospray ionization (ESI) source interface
operating in positive ion mode. The ion source parameters
were as follows: interface temperature, 150 °C; curtain gas,
25 psi; collision gas, high; ion spray voltage, 5500 V; ion source
gas, GS1 20 psi and GS2 6 psi; entrance potential (EP), 10 V;
cell exit potential (CXP), 9 V; peptides collision energies
(Table 2). Chromatography separation was achieved on a
microLC 200 system (Eksigent), composed of a CTC-PAL
autosampler cooled to 10 °C to preserve samples and a binary
pump operating at a ﬂow rate of 20 μL/min using a C18 HALO
2.7 μm 90 Å 50 × 0.5 mm i.d. column from Eksigent,
maintained at 45 °C. The injection volume was 5 μL. Mobile
phase A consisted of water, mobile phase B acetonitrile, and
both contained 0.1% formic acid (v/v). Elution of the peptides
followed the gradient 5% B (0−1 min), increasing to 20% B
(1−12 min) and up to 80% B (17−22 min) and then main-
taining at 80% (17−22 min) before re-equilibrating to 5% B
(27−30 min). Data was acquired in the multiple reaction moni-
toring (MRM) mode, monitoring the precursor (Q1) and
product ions (Q3) of myostatin peptides at expected retention
times (detection window 120 s). Data processing was carried
out using Analyst software (AB SCIEX, version 1.6). The
lowest limit of quantitation (LLOQ) was determined as the
lowest detected concentration with coeﬃcient of variation less
than 10%. The instrument lower limit of detection (LLOD)
was based on a signal-to-noise value greater than 3.
Recovery of Myostatin with Gluﬁb Internal Standard
Recombinant myostatin (25 μg; Fitzgerald Industries Interna-
tional, USA) was digested, desalted, and dried as described
above. Dried samples were reconstituted in 250 μL of reagent A
(0.1% formic acid in water). Reconstituted myostatin (210 μL)
was diluted with an equal volume of reagent A (total volume
420 μL). Eight 50 μL aliquots (of equal concentration) were
used in two lots: four aliquots for desalting by the stage tip
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(SPE) method previously described and four unprocessed
(NSPE). Following desalting and reconstitution in 50 μL of
reagent A, [Glu1]-ﬁbrinopeptide B human (F3261, Sigma-
Aldrich, St. Louis, MO) at a concentration of 2.5 pmol/μL was
added to all samples. Samples were analyzed on the QTRAP
5500 (AB SCIEX). Additional MRM transitions for [Glu1]-
ﬁnbrinopeptide B, used as an internal standard for determining
extraction recovery, were as follows: m/z 785.8 > 480.3 and
785.8 > 333.2, using a collision energy CE of 39 V. MultiQuant
software was used to determine recovery of peptides EQIIYGK
and GSAGPC[CAM]C[CAM]TPTK. Using the peak area
(myostatin peptide peak area/Gluﬁb peak area), the average
recovery was calculated. Recovery = 100 × NSPE (peak area)/
SPE (peak area).
Western Blot
Recombinant myostatin protein (Fitzgerald Industries Interna-
tional, USA) was reconstituted to 50 μg/mL concentration.
Concentrations of 10, 8, 4, 2, 1, and 0.5 μg were loaded with 1×
Laemmli sample buﬀer on 4−20% TGX gel at 250 V for 25 min
in Tris/Glycine/SDS buﬀer (Bio-Rad Laboratories Pty., Ltd.,
Australia). The molecular weight standard was Precision Plus
protein dual color standards (Bio-Rad Laboratories Pty., Ltd.,
Table 2. Inclusion List for MRM and Myostatin Peptide Proﬁlea
(A)a
peptide sequence mass (Da) retention time (min)
1 R.GSAGPCCTPTK.M + 2 Carbamidomethyl (C)_1 568.242 13.4
2 R.GSAGPCCTPTK.M + 2 Carbamidomethyl (C)_2 379.167 13.4
3 K.YPHTHLVHQANPR.G_1 523.938 13.6
4 K.YPHTHLVHQANPR.G_2 393.208 13.6
5 K.YPHTHLVHQANPR.G_3 785.405 13.6
6 K.IPAMVVDR.C + Oxidation (M)_1 458.748 19.1
7 R.LETAPNISK.D_1 486.767 19.3
8 R.LETAPNISK.D_2 324.850 19.3
9 K.EQIIYGK.I 425.735 20.2
10 K.LRLETAPNISK.D 621.357 22.9
11 R.DFGLDCDEHSTESR.C + Carbamidomethyl (C)_1 556.551 23.4
12 R.DFGLDCDEHSTESR.C + Carbamidomethyl (C)_2 834.333 23.4
13 K.IQILSK.L 351.201 23.7
14 K.LDMNPGTGIWQSIDVK.T 591.962 24.1
15 K.IPAMVVDR.C_2 450.751 25.0
16 K.EGLCNACTWR.Q + 2 Carbamidomethyl (C)_1 633.766 25.3
17 K.EGLCNACTWR.Q + 2 Carbamidomethyl (C)_2 422.850 25.3
18 R.ELIDQYDVQR.D_1 639.814 26.4
19 R.ELIDQYDVQR.D_2 426.882 26.4
20 K.QPESNLGIEIK.A _1 614.328 28.4
21 K.QPESNLGIEIK.A _2 409.891 28.4
22 K.ANYCSGECEFVFLQK.Y + 2 Carbamidomethyl (C)_1 617.937 35.6
23 K.ANYCSGECEFVFLQK.Y + 2 Carbamidomethyl (C)_2 926.407 35.6
24 K.TVLQNWLK.Q_1 501.288 35.8
25 K.TVLQNWLK.Q_2 334.531 35.8
26 K.MSPINMLYFNGK.E + 2 Oxidation (M) 723.838 30.9
27 K.VTDTPK.R 330.682 25.9
(B)a
signal peptide 1−26 pro-peptide 26−266 mature protein 267−375
10 20 30 40 50
MQKLQLCVYI YLFMLIVAGP VDLNENSEQK ENVEKEGLCN ACTWRQNTKS
60 70 80 90 100
SRIEAIKIQI LSKLRLETAP NISKDVIRQL LPKAPPLREL IDQYDVQRDD
110 120 130 140 150
SSDGSLEDDD YHATTETIIT MPTESDFLMQ VDGKPKCCFF KFSSKIQYNK
160 170 180 190 200
VVKAQLWIYL RPVETPTTVF VQILRLIKPM KDGTRYTGIR SLKLDMNPGT
210 220 230 240 250
GIWQSIDVKT VLQNWLKQPE SNLGIEIKAL DENGHDLAVT FPGPGEDGLN
260 270 280 290 300
PFLEVKVTDT PKRSRRDFGL DCDEHSTESR CCRYPLTVDF EAFGWDWIIA
310 320 330 340 350
PKRYKANYCS GECEFVFLQK YPHTHLVHQA NPRGSAGPCC TPTKMSPINM
360 370 375
LYFNGKEQII YGKIPAMVVD RCGCS
a(A) Myostatin peptide library used for the development of sMRMHR method (in order of retention time). (B) Myostatin peptide proﬁle.
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Australia). After electrophoresis, the separated proteins were
transferred to a poly(vinylidene diﬂuoride) (PVDF) membrane
using the Trans-Blot Turbo system with prepacked transfer
packs and the 7 min protocol (Bio-Rad Laboratories Pty., Ltd.,
Australia). Membranes were blocked for 1 h in blocking solu-
tion (1 g of Bovine serum albumin powder in 100 mL of Tris
buﬀered saline with 0.001% Tween 20; Sigma-Aldrich, Castle
Hill, NSW, Australia). Membranes were incubated overnight
at 4 °C in myostatin [goat polyclonal growth diﬀerentiating
factor-8 (F-13), Sc-34781; Santa Cruz Biotechnology, Santa
Cruz, CA] primary antibody at 1:1000 dilution. Bio-Rad Clarity
Western ECL substrate (Bio-Rad Laboratories Pty., Ltd.
Australia) was used to visualize the proteins on AGFA medical
X-ray blue ﬁlm, and ﬁlm was developed using a Konica Minolta
SRX-101A processor (Konica Minolta Medical and Graphic
INC, Japan). Film was imaged on GS-800 calibrated densitom-
eter and using Quantity One software (Bio-Rad Laboratories
Pty., Ltd. Australia).
■ RESULTS
Peptide Library
A myostatin peptide library was generated by the use of method
1 for the preparation of myostatin protein for mass spectrom-
etry (TripleTOF 5600 system, AB SCIEX) and subsequent
analysis of data through MASCOT and ProteinPilot. Twenty-
seven peptides were identiﬁed for myostatin (Table 2A), and
this library was then utilized to develop a sMRMHR method for
the targeted detection of myostatin. Peptides identiﬁed with the
Figure 1. (A) Standard curve of myostatin peptides identiﬁed by TripleTOF 5600 (AB SCIEX) scheduled MRMHR. (B) Extracted ion
chromatogram (XIC) and product ion scan of myostatin peptides by scheduled MRM on the QTRAP 5500 (AB SCIEX).
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most sensitive detection on the AB SCIEX QTRAP 5500 are
listed in Table 2B.
Myostatin Detection by sMRMHR and sMRM
Samples were processed using method 2 and detected by the
above-deﬁned sMRMHR method. Peptides were identiﬁed from
the pro-peptide and mature regions of the myostatin protein
(Figure 1A). The lower limit of quantitation for peptides (LLOQ,
deﬁned as S/N ≥ 10) using the sMRMHR method performed on a
TripleTOF 5600 system (AB SCIEX) is described in Table 3.
Using this targeted sMRMHR (AB SCIEX 5600 TripleTOF), we
identiﬁed the peptide LLOQ of both mature (DFGLDCDEH-
STESR) and pro-peptide regions (ELIDQYDVQR) as 0.19 nmol/
L. The analysis of myostatin by the sMRM method performed on
the AB SCIEX QTRAP 5500 (Figure 1B) identiﬁed LLOQ of a
peptide of the pro-peptide region (LETAPNISK) as 0.16 nmol/L
and a peptide of the mature region (EQIIYGK) as 0.25 nmol/L .
Recovery of Sample Using Modiﬁed Stage Tip Protocol
The recovery of peptides EQIIYGK and GSAGPCCAMC-
CAMTPTK using the modiﬁed stage tip protocol are shown in
Figure 2 and Table 4. Approximately 77% of EQIIYGK pep-
tides and 70% GSAGPCCAMCCAMTPTK peptides were re-
covered with this method (Table 4).
Western Blot Results
Western blot analysis of recombinant myostatin (under con-
ditions speciﬁed in methods and with myostatin antibody
Sc-34781) observed strong bands at 10, 8, and 4 μg of loaded
protein, and a faint band was seen at 2 μg (83.33 nmol/L) of
loaded protein; however, no bands were visible at 1 and 0.5 μg
of loaded protein (Figure 3).
■ DISCUSSION
The current gold standard methods of myostatin protein
detection (Western blot and ELISA) are heavily dependent on
the speciﬁcity of antibodies, and, at best, the results from these
methods are semiquantitative. In contrast to the single signal
generated for a protein form by Western blot, mass spec-
trometry allows the identiﬁcation of several unique peptides per
quantiﬁed protein and therefore each protein targeted can have
several independent measures made.33,34 Moreover, a speciﬁc
region of the target protein can be identiﬁed.
Myostatin is associated with muscle wasting, as an up-
regulation of myostatin protein expression has been observed in
the serum and/or muscle of men infected with HIV and those
deﬁned to have AIDS,24 cancer (cachexia),22,23 in older popula-
tions of men and women compared with younger subjects
(sarcopenia),25 and in abnormal metabolic states, such as obesity
and diabetes.26,27 Upregulated myostatin in the placentae and
serum of women with preeclampsia (a pregnancy complication that
aﬀects 3−5% of women worldwide35) has also been documented.28
The majority of the experimental and clinical work that have
been presented, especially those that used Western blot, are
focused on the expression of the active myostatin dimer
form.9,22−25,36 The total expression proﬁles of the various myo-
statin forms (precursor, pro-peptide, and mature protein) are
often not presented. Identifying the diﬀerent forms of myo-
statin will allow for a better understanding of the potential
availability (precursor) or activity (pro-peptide) of myostatin.
In support of the need to discriminate between the diﬀerent
Table 3. (A) Peptide List Utilized in MultiQuant Analysis
and Limit of Quantitation and (B) Optimized Scheduled
MRM Pairs and Parameters for Myostatin
(A)
peptide sequence
mass
(Da)
RT
(min)
lower limit of
quantitation
(nmol/L)
Mature Myostatin Protein Region
R.DFGLDCDEHSTESR.C +
Carbamidomethyl (C)
556.551 23.54 0.19
K.IPAMVVDR.C +
Oxidation (M)
458.748 19.17 0.38
R.GSAGPCCTPTK.M +
2 Carbamidomethyl (C)
568.242 13.48 0.96
Pro-peptide Myostatin Protein Region
K.EGLCNACTWR.Q +
2 Carbamidomethyl (C)
633.766 25.32 0.96
R.LETAPNISK.D 486.767 19.13 0.48
R.ELIDQYDVQR.D 639.814 24.85 0.19
(B)
MS/MS parameters
targeted peptide
sequence Q1 Q3 CE
RT
(min)
lower limit of
quantitation
(nmol/L)
Mature Myostatin Protein Region
GSAGPCCTPTK +
6 (C) + 7 (C)
568.2 345.2 29 2.0 0.33
EQIIYGK 425.7 480.3 24 4.7 0.25
Pro-peptide Myostatin Protein Region
LETAPNISK 486.8 629.4 26 4.8 0.16
IQILSK 351.2 588.4 21 6.2 0.53
Figure 2. Recovery of sample using modiﬁed stage tip protocol.
Table 4. Peptides Analyzed for the Recovery of Digested
Myostatin by Modiﬁed Stage Tip Protocol
REC (%) SD % CV
EQIIYGK.y4 77.46 9.44 12.18
EQIIYGK.y5 77.05 9.64 12.51
GSAGPC[CAM]C[CAM]TPTK.+2y7 69.92 2.79 3.99
GSAGPC[CAM]C[CAM]TPTK.+2y8 71.10 2.94 4.14
Figure 3. Detection of recombinant myostatin (0.5−10 μg) by
Western blot. Myostatin protein is no longer identiﬁable at 1 μg of
loaded protein.
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forms of the myostatin protein is our previous work (by Western
blot) that identiﬁed marked diﬀerences in the expression of the
myostatin precursor and dimer forms due to diet or gender.29
Furthermore, the ability for the myostatin pro-peptide to bind
and inhibit the function of the myostatin dimer (active form)
adds to the need to identify the forms of the myostatin pro-
tein.2,4,16 Understanding the expressions of the diﬀerent forms of
myostatin will provide a better idea of the role that this protein
has in contributing to disease pathways as well as in targeting
antagonistic and agonistic treatments for myostatin action.
Here, we have presented highly discriminative methods for
the identiﬁcation of myostatin peptides on two sensitive mass
spectrometry platforms: the AB SCIEX TripleTOF 5600 and
AB SCIEX QTRAP 5500. Additionally, the preparation method
on the 10 kDa exclusion membrane and the modiﬁed stage tip
method allowed for a straightforward preparation and a 70−
80% recovery of the processed samples.
The AB SCIEX 5600 TripleTOF mass spectrometer identi-
ﬁed the LLOQ as 0.19 nmol/L for peptides DFGLDCDEH-
STESR (of the mature protein region) and ELIDQYDVQR (of
the pro-peptide protein region) (Table 3 and Figure 1A). Fur-
thermore, the detection of myostatin on the AB SCIEX QTRAP
5500 identiﬁed LLOQ for peptide of the mature region as
0.25 nmol/L (EQIIYGK) and peptide of the pro-peptide region
(LEPATNISK) as 0.16 nmol/L.
The sensitivity for the detection of myostatin by the standard
protein analysis methods is less sensitive and discriminative
than the methods that we have here described. A commercially
available ELISA kit commonly used for the detection of myo-
statin in human plasma and serum37 is reported to have a detec-
tion limit of 0.273 ng/mL. Moreover, the analysis of recom-
binant myostatin dilutions by Western blot with the speciﬁed
antibody (Figure 3) was observed only to detect levels at 2 μg
of loaded protein or higher (∼83.33 nmol/L; 400-fold less sen-
sitive). The current study is an initial step in the development
of a method for the identiﬁcation of myostatin by mass spec-
trometry. The next step is to expand the utility of this method
to identify myostatin within biological samples.
■ CONCLUSIONS
Myostatin is a protein associated with a number of abnormal
health conditions that can inhibit its own function (myostatin
dimer bound to its pro-peptide is prevented from binding to
the receptor and therefore its activity is inhibited). The experi-
mental design outlined in this article can be utilized to detect
various forms of myostatin through the speciﬁc idenﬁcation of
myostatin peptides. The use of this approach could, therefore,
improve the sensitivity and characterization of myostatin in in
vitro experimentation and, with further development, the study
of clinical samples in the future.
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 Discussion  Chapter 7.
  Rationale  7.1 
Myostatin is known best as a negative regulator of muscle development affecting proliferation and 
differentiation of muscle cells, as identified by gene knockout experiments in mice (McPherron, 
Lawler et al. 1997). A role for myostatin in modulating fat accumulation and glucose metabolism 
has also been reported utilising two genetic mouse models of obesity combined with the loss of 
myostatin gene function (McPherron, Lawler et al. 1997, McPherron and Lee 2002). Alterations to 
myostatin expression (protein/mRNA) are known to occur in abnormal states of health including in 
obesity, diabetes and in muscle wasting (e.g cancer cachexia and sarcopenia) (Yarasheski, Bhasin et 
al. 2002, Costelli, Muscaritoli et al. 2008, Hittel, Berggren et al. 2009, Palsgaard, Brøns et al. 2009, 
Brandt, Nielsen et al. 2012, Wang, Liao et al. 2012). Interactions between myostatin and cytokine 
production have also been established by the culture of muscle cells in the presence of TNF-α and 
the resultant higher myostatin expression (Bonetto, Penna et al. 2011).  
 
Myostatin is a distinct member of the TGF-β superfamily. Members of the TGF-β superfamily are 
known to function in the development and maintenance of the human placenta (Caniggia, Grisaru-
Gravnosky et al. 1999, Keelan, Marvin et al. 1999, Keelan, Zhou et al. 2000, Lyall, Simpson et al. 
2001, Staff 2011). Furthermore higher concentrations of Activin A and Inhibin (also members of 
this family) have been identified in PE (Bersinger, Smárason et al. 2003). 
 
Myostatin in the human placenta was first identified in 2006 (Mitchell, Osepchook et al. 2006). 
Higher myostatin protein expression were observed in preterm placental tissues compared to term 
placental tissues indicating that myostatin expression is negatively correlated with gestational age. 
The potential for myostatin to regulate glucose uptake was identified through placental tissue 
explants culture and in placental cell line culture (Mitchell, Osepchook et al. 2006, Antony, Bass et 
al. 2007) in which treatment with myostatin increased glucose uptake of placental explants but 
decreased glucose uptake of the myostatin treated placental cell line (BeWo). A recent publication 
by Chen et al. investigated the effect of myostatin treatment on glucose uptake of C2C12 myotubes 
and their finding supported that of the placental explant studies, as an increase in glucose uptake 
was seen following treatment with myostatin (Chen, Ye et al. 2010). 
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Maternal nutrition and maternal health during pregnancy can alter the expression of myostatin in the 
placenta (Peiris, Ponnampalam et al. 2010, Guo, Tian et al. 2012). In a rat model of maternal under-
nutrition, placental expression of myostatin was significantly increased in the placentae of trans-
generationally undernourished rats (Peiris, Ponnampalam et al. 2010). In women with PE, a 
pregnancy disorder identified by maternal hypertension and proteinuria and known to have 
abnormal placental development and function, significantly higher myostatin concentrations in 
maternal serum and active myostatin protein in placental tissue were noted (Guo, Tian et al. 2012).   
 
It is clear from the limited literature available, that myostatin can alter the function of the placenta 
and that the expression of myostatin in placental tissues can be altered by changes in maternal 
health during the course of pregnancy. The work presented in this thesis investigated myostatin 
further and identified new potential roles for myostatin in the human placenta. The aims of this 
thesis were   
 to determine the localisation of myostatin in the human placenta and potential functions of 
myostatin in human placentae, in particular to evaluate  
o the potential effect of myostatin treatment on placental cell function and   
o the potential effect of myostatin on cytokine production from placental explants,  
 to evaluate the expression of myostatin in pregnancies complicated with  
o PE, IUGR and PE-IUGR as well as GDM  
 to develop a new discriminative method for identifying myostatin through the analysis of 
individual peptides by tandem mass spectrometry. 
 Overall findings  7.2 
The work presented in this thesis was performed to test the overall hypothesis that myostatin is 
important for the development of the placenta and will be differentially expressed in placental 
tissues of complicated pregnancies. 
7.2.1 Localisation of myostatin in the human placenta and potential functions of myostatin 
in human placentae  
The initial experimentation undertaken was to identify the cells of the first and third trimester 
human placenta to which myostatin was localised and possibly was acting in and/or on. The 
localization of ACTRIIB (myostatin receptor) and follistatin like-3 (a potent antagonist of myostatin 
function; FSTL-3) have been previously established in cytotrophoblast, syncytiotrophoblast, 
endothelial cells and placental blood vessels (Schneider-Kolsky, Manuelpillai et al. 2002, Ciarmela, 
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Florio et al. 2003, Florio, Luisi et al. 2004). Immunohistochemistry experiments presented in the 
publications of Chapter 3 observed localisation of myostatin in trophoblast cells (cytotrophoblast 
and syncytiotrophoblast) of first and third trimester tissues. However, the strongest staining for 
myostatin was seen in extravillous trophoblast (EVT) of third trimester placental tissue. First 
trimester tissues were then enzymatically digested as described by Tarrade et al to isolate EVT 
(Tarrade, Lai Kuen et al. 2001). Immunocytochemistry of isolated first trimester EVT confirmed 
that myostatin was localised to EVT. Positive identification of myostatin localisation to trophoblast 
cells was through CK7 positive, VIM negative staining and further positive staining for HLA-G for 
the identification of EVT (Bernirschke and Kaufmann 1999, Bernirschke and Kaufmann 2000).   
 
EVT cells are critical for the establishment of placental perfusion (Gude, Roberts et al. 2004). EVT 
proliferate and migrate out of cell columns (penetrating beyond the syncytiotrophoblast) to invade 
the maternal decidua and up to the inner third of the myometrium. EVT (interstitial trophoblast) 
“transform” spiral arteries by surrounding and destroying the smooth muscle and subsequently 
replacing the endothelium (endovascular trophoblast) of the arteries (Bernirschke and Kaufmann 
2000, Kaufmann, Black et al. 2003, Gude, Roberts et al. 2004).  
 Effect of myostatin treatment on placental cell function  7.2.1.1
The effect of myostatin treatment on the function of EVT was investigated on HTR8/Svneo cells 
(proliferation and migration) and on the first trimester isolated EVT (migration). HTR-8/SVneo 
cells were chosen as they are a widely used model of EVT (Graham, Hawley et al. 1993, Biondi, 
Ferretti et al. 2006, Huber, Saleh et al. 2006, Horita, Kuroda et al. 2007). HTR8/Svneo were 
established by the transfection of first trimester trophoblast cells with a plasmid containing the 
simian virus 40 large T antigen, resulting in trophoblast cells with an extended lifespan (Graham, 
Hawley et al. 1993). Treatment with myostatin at various concentrations (0.005, 0.01, 0.05, 0.5 and 
1μg/ml) resulted in a dose-depended increase in the proliferation of HTR8/Svneo cells.  
 
Treatment with myostatin also increased the migration of both the HTR8/Svneo cell line and 
isolated EVT. Differences were however seen between the isolated and cell line (HTR8/Svneo) 
EVT in their responsiveness to myostatin. In the EVT cell line migration assay all concentrations of 
myostatin treatment (0.005, 0.01, 0.05, 0.5 and 1μg/ml) increased migration. Migration assays of 
isolated EVT increased migration only at concentrations of 0.005, 0.01, 0.05 and 10μg/ml 
(treatments: 0.001, 0.005, 0.01, 0.05, 0.5, 1 and 10μg/ml). These differences may be attributed to 
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differences found between cell line and primary isolated cells, for example the altered gene 
expressions and methylation patterns reported in these cells (Novakovic, Gordon et al. 2011).  
 
The ability of myostatin to positively regulate proliferation of EVT in the placenta is contrary to its 
role in muscle. The majority of literature presents myostatin as an inhibitor of  proliferation and 
differentiation of muscle cells and thus a negative regulator of muscle development (Thomas, 
Langley et al. 2000, Rios, Carneiro et al. 2002). The ability of myostatin to increase proliferation 
and migration of EVT suggests that in the placenta myostatin may act to support placental 
establishment. 
 
Contrasting functions have been noted for proteins in the placenta compared to functions in other 
organs and tissues. An example of this can be seen in the interactions of glucocorticoids and 
corticotropin-releasing hormone (CRH) in the placenta compared to the hypothalamus. CRH is a 
component of the hypothalamic-pituatary-adrenal (HPA) axis that stimulates the release of 
corticotropin (ACTH) (Majzoub 2006). Glucocorticoids in the hypothalamus suppress CRH gene 
expression. In the placenta glucocorticoids stimulated the gene expression of CRH (Robinson, 
Emanuel et al. 1988). As in  placenta, glucocorticoids in the amygdala (region of the brain) also 
increase CRH gene expression, again acting contrary to expectations (Makino, Gold et al. 1994).  
 
Increased proliferation in cultures of C2C12 mouse myoblasts, fibroblasts isolated from anterior 
cruciate ligaments (human) and fibroblasts isolated from the hindlimb / forelimb of mice, and the 
differentiation of trout myosatellite cells were recently described following treatment with 
myostatin (Mendias, Bakhurin et al. 2008, Fulzele, Arounleut et al. 2010, Garikipati and Rodgers 
2012, Rodgers, Wiedeback et al. 2014). These stimulatory effect of myostatin treatment resulting in 
increased proliferation and differentiation are therefore supportive of the findings presented in the 
current study showing  increased proliferation (and migration) of placental cells crucial for 
placental establishment. 
 Effect of myostatin treatment on cytokine production from placental tissues  7.2.1.2
The fetus is a semi-allograft and as such should be rejected by the mother. It is therefore crucial that 
in pregnancy a balance of immune tolerance, suppression and activity exists to maintain the 
pregnancy (protect fetus from the mother) and protect both mother and fetus from infections 
(Challis, Lockwood et al. 2009, Sykes, MacIntyre et al. 2012). One way in which the maternal 
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immune system is altered to aid pregnancy is thought to be by developing an environment rich in T-
helper (Th) 2 cytokines. Th2 cytokines are broadly anti-inflammatory (e.g. IL-4) although IL-6 
which has pro-inflammatory actions also belongs to this group. Th1 cytokines produce a number of 
pro-inflammatory cytokines (e.g. TNF-α) (Bowen, Chamley et al. 2002, Sykes, MacIntyre et al. 
2012). The predominance of Th2 cytokines and down-regulation of Th1 cytokines in pregnancy was 
first proposed by Wegmann et al (Wegmann, Lin et al. 1993). This skew toward a Th2 environment 
is hypothesised to aid pregnancy. In complicated pregnancies (e.g. PE and GDM) and in pregnancy 
loss, elevated levels of Th1 cytokines are known to occur (Challis, Lockwood et al. 2009, Szarka, 
Rigo et al. 2010, Tosun, Celik et al. 2010, Mullins, Prior et al. 2012, Raghupathy, Al-Azemi et al. 
2012, Sykes, MacIntyre et al. 2012, Gomes, Torloni et al. 2013).  
 
The effect of myostatin on the production of placental cytokines is unknown, although alterations to 
cytokine production following manipulations to myostatin have been identified outside of the 
placenta. In male homozygous mice with a loss-of-function allele of myostatin (Mstn
Ln/Ln
), plasma 
levels of TNF-α were significantly lower compared to heterozygous (Mstn+/Ln) males. Following 
treatment with recombinant myostatin, these Mstn
Ln/Ln
 mice were observed to have an increase in 
plasma concentrations of TNF-α (Wilkes, Lloyd et al. 2009). In mice with chronic kidney disease, 
treatment with an anti-myostatin peptibody (blocking myostatin), resulted in a decrease in pro-
inflammatory cytokines (TNF-α, IFN-γ and IL-6) (Zhang, Rajan et al. 2011). Alterations in 
cytokines can also mediate changes in the expression of myostatin, as seen in C2C12 myotubes 
treated with TNF-α significantly increasing both myostatin protein and mRNA expression (Bonetto, 
Penna et al. 2011, Zhang, Rajan et al. 2011). Moreover the use of TNF-α blocking agents 
pentoxifylline and Remicade decreased myostatin expression in gastrocnemius (pentoxifylline: 
protein) and heart muscle (Remicade; mRNA) (Costelli, Muscaritoli et al. 2008, Ermolova, 
Martinez et al. 2014).  
 
In the current study, first trimester tissue explant cultures were treated with 1μg/ml of myostatin. 
This concentration was consistent with the concentration used in previously published work by 
Mitchell et al investigating glucose uptake (Mitchell, Osepchook et al. 2006). Cultures were 
maintained at three oxygen tensions of 1% oxygen, 3% oxygen and 21% oxygen over a 24hour 
culture period. The oxygen tensions were primarily chosen for the benefit of placental tissues in the 
explant cultures: 1% oxygen to mimic a hypoxic environment the tissues may see under abnormal 
conditions, 3% oxygen a physiologically relevant environment of first trimester tissues and 21% 
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oxygen as standard culture conditions still used in studies of the placenta and studies utilising 
myostatin treatment outside of the placenta. Changes in cytokine concentrations in the media of 
these cultures were measured using the BioPlex platform which allows the simultaneous detection 
of cytokines in a single sample.  
 
Interestingly in the myostatin treated explant culture media compared to untreated culture media, 
significantly higher  concentrations of  Th2 cytokine IL-4 and lower concentrations of Th1 
cytokines IFN-γ and TNF-α as well as chemokine IL-8 were observed. This “pattern” is similar to 
that hypothesised to be required for a successful pregnancy. In this study (chapter 4) reduced 
producitons of IFN-γ,  IL-8 and TNF-α  were observed. However, in  pregnancies complicated with 
PE, IUGR and GDM significantly higher IFN-γ,  IL-8 and TNF-α  have been documented to occur 
in serum and placental tissues (Coughlan, Oliva et al. 2001, Szarka, Rigo et al. 2010, Tosun, Celik 
et al. 2010, Raghupathy, Al-Azemi et al. 2012, Gomes, Torloni et al. 2013). IFN-γ is also known to 
negatively affect EVT by promoting apoptosis and decreasing secretions of matrix 
metallopeptidases (Lash, Otun et al. 2006). IL-4 is thought to support pregnancy and in IL-4 
knockout mouse models a mild PE phenotype was seen with increased pro-inflammatory cytokines, 
mild hypertension, proteinuria and endothelial dysfunction (Chatterjee, Kopriva et al. 2013).  
 
The oxygen tensions at which the tissues were maintained also affected the production of cytokines 
in the media following myostatin treatment. The highest production of cytokines present in the 
media of the explants irrespective of being a Th1 or Th2 cytokine was identified at the hypoxic 
oxygen tension of 1% O2 (Chapter 4, Figure 3). The increase in oxygen tension therefore saw a 
decrease in cytokine production, i.e. cytokine production decreased at 3% O2 and decreased even 
further at 21% O2. The 21% O2 therefore had the lowest Th1 cytokines concentration (5 to 6-fold 
decrease in IFN-γ, TNF-α and IL-8). At 1% O2, the highest concentration of Th2 cytokine IL-4 was 
observed (approximately 14-fold).  
 
In Chronic Obstructive Pulmonary Disease (COPD) and in mice exposed to a hypoxic environment,  
higher myostatin concentrations in serum and in muscle have been identified (Hayot, Rodriguez et 
al. 2011). COPD is associated with chronic hypoxemia and can lead to skeletal muscle dysfunction 
and atrophy. Higher serum concentrations of myostatin have also been observed in COPD and were 
inversely correlated with the amount of muscle tissue (higher myostatin, less muscle) in male 
patients (Ju and Chen 2012). In the same study,  higher TNF-α levels of COPD patients also 
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correlated with higher serum myostatin concentrations in these patients (Ju and Chen 2012). 
Moreover, muscle tissues of COPD patients were identified as having a higher expression of 
myostatin protein, possibly indicating a role for this protein in the  skeletal muscle dysfunction and 
atrophy known to occur in COPD (Hayot, Rodriguez et al. 2011). Chronic exposure of rats to a 
hypoxic environment also showed an increase in myostatin gene expression. The use of CoCl2 (a 
mimic of hypoxia) resulted in a higher protein expression of myostatin. The atrophic effect of CoCl2 
treatment was diminished when investigated in muscle cells of knockout myostatin mice (MSTN
-/-
) 
and  once given recombinant myostatin in combination with CoCl2 the atrophic effect was restored 
(Hayot, Rodriguez et al. 2011). Furthermore, blocking myostatin activity through the use of a 
soluble activin type IIB receptor/Fc fusion protein was found to prevent muscle loss known to occur 
with the exposure of mice to an hypoxic environment (Pistilli, Bogdanovich et al. 2010). Therefore 
it is possible to say that myostatin production is affected by hypoxia. 
 
In the current study, under hypoxic conditions and myostatin treatment, the pattern that would 
support pregnancy was still maintained. An effect of hypoxia was still evident in these cultures, 
although lower than at the more physiologically relevant oxygen tension of 3% O2, as the 
production of Th1 cytokines remained significantly lower than the untreated group. Moreover at 1% 
O2 the IL-4 levels were the highest indicating possibly that in pregnancy myostatin supports the 
move toward a Th2 cytokine environment. Taken together with the results of the previous section 
(increased proliferation and migration of EVT), this potential role of myostatin to affect the 
production of cytokines (in a pattern reminiscent of the skew towards a Th2 environment) suggests 
that myostatin potentially acts in a manner supportive of the pregnancy.  
7.2.2 Myostatin in complicated pregnancies   
To date, only two publications regarding the expression of myostatin in pregnancy complications 
are available; Guo et al  investigating myostatin expression in PE and Hu et al  investigating 
myostatin expression in GDM (Guo, Tian et al. 2012, Hu, Tian et al. 2012). In these publications  
Guo et al reported that the expression of myostatin protein in placental tissue and serum 
concentrations of myostatin were higher in women with PE (Guo, Tian et al. 2012). No information 
on the expression of myostatin in placental tissues of women with GDM was reported in the article 
by Hu et al and no difference in serum concentrations of myostatin were observed in the studies 
performed and described in this publication  (Hu, Tian et al. 2012).  
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Information on the expression of myostatin in the placentae of women with pregnancies 
complicated with GDM, IUGR or PE with IUGR (PE-IUGR) was not known. In this study 
therefore, the expression of the active myostatin dimer and precursor protein was evaluated in the 
placental tissues of women with these pregnancy complications. Plasma concentrations of myostatin 
in women who later developed a complication of pregnancy of PE, IUGR or GDM (women were 
retrospectively assigned to a pregnancy complication) were also evaluated as a part of the study.  
 PE, IUGR, PE-IUGR complicated pregnancies  7.2.2.1
The plasma of pre-symptomatic women who later developed PE, IUGR or had a normal pregnancy 
was collected at 12 to 14 weeks of gestation. The concentrations of myostatin in the plasma at this  
earlier time-point (than assessed by Guo et al ) was  evaluated to determine whether myostatin 
expression was different earlier in pregnancies of women who later developed IUGR or PE. In the 
study by Guo et al, measurements of myostatin concentrations in the serum of women with PE were 
made at approximately 35 weeks of gestation (Guo, Tian et al. 2012). In these women with PE 
significantly higher serum myostatin concentrations were identified compared to gestational age 
matched control women in the study (Guo, Tian et al. 2012). Similarly in the current study of the 
pre-symptomatic women, significantly higher plasma concentrations of myostatin were observed in 
women who later developed PE compared to women who later developed IUGR or women with 
normal pregnancies.  
 
This finding of an earlier significant rise in myostatin plasma concentration in women who later 
developed PE is interesting. However, further studies in a larger cohort with more variables taken 
into account are required to assess the consistency of this finding. Variables that need to be included 
are the severity of PE and pregnancies with PE-IUGR. More frequent blood sampling and sampling 
across the trimesters should also be undertaken, as this may reveal when the higher myostatin 
concentrations in serum can be detected. If with these more complex investigations, myostatin 
concentrations in the serum are consistently higher earlier in pregnancy of PE women, it is possible 
that myostatin could be developed as a part of a biomarker panel along with other potential 
biomarkers for the earlier detection of PE. A recent publication by Founds et al identified FSTL-3 
(a potent antagonist of myostatin) as another potential biomarker. FSTL-3 concentrations was 
identified to be significantly higher in second and third trimester of pregnancy in women who later 
developed PE (Founds, Ren et al. 2014). The higher FSTL-3 levels in mid-gestation were also 
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associated with an increased odds ratio of PE and therefore concluded to warrant further study as a 
biomarker of PE (Founds, Ren et al. 2014). 
 
Placental expressions of the active myostatin dimer and myostatin precursor proteins were 
evaluated in the placentae of women with IUGR, PE and PE-IUGR compared to the gestational age 
matched placentae (PTB). PTB group deliveries included in this study were due to prolonged 
prelabor rupture of the fetal membranes, placenta previa, or antepartum haemorrhage, and any 
patients with chorioamnionitis were excluded. The choice of appropriate controls for the study of 
PE and IUGR is difficult as pregnancies are often completed and babies delivered preterm. A 
limitation outlined in the study by Guo et al was the lack of a gestational age matched group for 
comparisons to be made against for their investigation of myostatin expression in PE complicated 
pregnancies (Guo, Tian et al. 2012). A gestational age matched control group (PTB) is particularly 
important in the comparisons of myostatin in placenta, as myostatin expression is known to 
decrease with gestational age (Mitchell, Osepchook et al. 2006), and therefore the higher levels 
found by Guo et al  in PE pregnancies compared to term controls may not be accurate and may be 
due to the decrease in myostatin expression known to occur later in gestation.  
 
 
The findings of myostatin protein expression in the current work was consistent with that of Guo et 
al. Higher active myostatin was identified in placentae of women with PE complicated pregnancies. 
Placentae of women with pregnancies complicated with IUGR and in PE-IUGR followed a similar 
trend with higher expression of the active myostatin observed. Precursor expression was also 
significantly altered in these pregnancies with IUGR complicated pregnancies having higher 
myostatin precursor levels and PE and PE-IUGR significantly lower. These findings show that 
myostatin expression in the placentae of pregnancies complicated with PE, IUGR and PE-IUGR is 
affected and that the different forms of myostatin (precursor and dimer) are differentially expressed 
in these placentae. 
 
FSTL-3 is known to be elevated in placentae and serum of pregnancies complicated with PE and 
IUGR (Okamoto, Endo et al. 2006, Pryor-Koishi, Nishizawa et al. 2007). The significant increase in 
FSTL-3 in placentae of PE complicated pregnancies was identified to originate in 
syncytiotrophoblast (Pryor-Koishi, Nishizawa et al. 2007). Primary human trophoblast cell cultures 
under hypoxic conditions also showed an increased secretion of FSTL-3 into the culture media 
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(Biron-Shental, Schaiff et al. 2008). It is possible therefore that FSTL-3 (as well as other regulators) 
is functioning in complicated pregnancies to modulate the activity of myostatin in the placenta.   
 
Abnormal oxygenation is a known contributor to improper placental development, and is associated 
with both PE and IUGR (McCarthy, Cotter et al. 2007, Eastabrook, Brown et al. 2011). PE and 
asymmetric IUGR, and PE-IUGR are associated with abnormalities of placental development, 
structure and function, such as incomplete invasion and transformation of spiral arteries (PE) 
(Kaufmann, Black et al. 2003), decreased utero-placental blood flow (IUGR) (Huppertz 2011) and 
reduced exchange surfaces in the villi of placentae (PE-IUGR) (Mayhew, Wijesekara et al. 2004). 
The proliferation and migration of EVT are key to the establishment of the placenta and the 
appropriate remodelling of the maternal spiral arteries which will allow blood to flow to the 
intervillous space at the correct volume and velocity and therefore the correct oxygenation 
(Huppertz, Weiss et al. 2014). The role of myostatin in these complicated pregnancies is yet to be 
determined. However the work from the previous sections of this thesis (increased proliferation and 
migration of EVT and the maintenance of a “Th2 rich” environment) suggests that myostatin may 
support pregnancy. In PE it is possible that myostatin is acting in a similar manner to support the 
pregnancy by altering the cytokine environment.  
 GDM complicated pregnancies 7.2.2.2
In humans, with type 2 diabetes and in hyperinsulinemic first-degree relatives of people with type 2 
diabetes, a significantly higher expression of myostatin mRNA was identified in skeletal muscle 
(Palsgaard, Brøns et al. 2009, Brandt, Nielsen et al. 2012). Higher myostatin protein expressions 
were also identified in the muscle of extremely obese women compared to lean women (Hittel, 
Berggren et al. 2009). Western blot of plasma from these extremely obese women also showed a 
higher concentration of myostatin compared to lean women. Following interventions against obesity 
(e.g. biliopancreatic diversion, gastric bypass and aerobic exercise) decreases to the expression of 
myostatin in skeletal muscle of the obese humans was noted (Milan, Dalla Nora et al. 2004, Park, 
Berggren et al. 2006, Hittel, Axelson et al. 2010). The single publication available on the myostatin 
expression in women with GDM found no difference in serum concentrations of myostatin and did 
not report any information of the expression of myostatin in placentae of the women with GDM 
(Hu, Tian et al. 2012).  
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Plasma of pre-symptomatic women that went on to have GDM or a normal pregnancy was studied 
in this thesis. No significant differences in myostatin concentrations were observed in the plasma of 
pre-symptomatic GDM compared to the women with normal pregnancy. This does not mean 
however that placental myostatin expression is not different. Tissue specific differences in 
myostatin expression have been identified in type 2 diabetes, where although plasma levels showed 
no difference, muscle mRNA of myostatin was significantly altered (Brandt, Nielsen et al. 2012). 
Therefore alterations in myostatin expression in the placentae of the population studied by Hu et al 
may have existed. In the current study, significant differences were detected in myostatin protein 
expression in the placentae of women with GDM compared to expressions in placentae of woment 
wiith normal glucose tolerance (NGT). 
 
Higher myostatin precursor and lower active dimer protein expressions were seen in placentae of 
women with GDM compared to women with NGT in pregnancy. Within the population of women 
with GDM, alterations to the expression of myostatin were found relative to the treatment received. 
Women were either treated with diet or insulin (if fasting glucose read above 5.5mmol/l over a 2 
week period post diagnosis). In the insulin treated population of women with GDM, significantly 
higher myostatin dimer (active) and lower precursor expressions were observed compared to 
placentae of diet treated women. Although still higher in precursor and lower in dimer protein 
expression compared to that of NGT placentae, the variation in myostatin expression of insulin 
treated GDM placentae (compared to diet) may indicate a move towards an expression closer to that 
of NGT placentae. Thus insulin treatment in these GDM women (through a yet unknown 
mechanism) may support the processing of the myostatin precursor into the active dimer form.  
 
Within the NGT population, significantly decreased active myostatin expression in the placentae of 
obese NGT women was observed compared to their lean counterparts. In the placentae of women 
with GDM, differences between lean and obese expression of myostatin in placentae were not 
significantly different. The effect of obesity on myostatin expression in placentae of GDM 
pregnancies may be hidden or overpowered by other abnormal changes in these pregnancies and 
placentae such as alterations to insulin signalling.  
 
Significant alterations to the insulin signalling pathway occur in the placentae of obese and GDM 
pregnancies. Alterations to phosphatidylinositol-3-kinase (PI3-K) in the placenta, adipose tissue and 
skeletal muscle have been identified in women with GDM. PI3-K is a downstream effector of the 
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insulin signalling pathway recruited by insulin receptor substrates following the binding of insulin 
to its receptor (Colomiere, Permezel et al. 2009, Colomiere, Permezel et al. 2010). Moreover, 
differences in PI3-K were observed in placentae of women with GDM relative to the treatment 
received (Colomiere, Permezel et al. 2009, Hiden and Desoye 2010). In obese women with GDM 
treated with diet, significantly more PI3-K has been identified compared to NGT placentae 
(Colomiere, Permezel et al. 2009). Insulin treatment of GDM women also altered PI3-K expression, 
as lower levels were seen compared to diet treated GDM placental PI3-K expression (Colomiere, 
Permezel et al. 2009).  
 
The effect of myostatin on insulin signalling and/or conversely, the effect of insulin on myostatin 
production and function are not fully known. Myostatin is thought to inhibit insulin signalling 
(PI3/Akt pathway) through the inhibition of the Akt phosphorylation (Watts, Ghozlan et al. 2014). 
However, co-stimulation of C2C12 cells with insulin and myostatin, increased glucose uptake 
compared to myostatin treatment alone (Chen, Ye et al. 2010). Myostatin and its relation to insulin 
signalling in placenta are unknown. Findings on glucose uptake in placental explants and cells 
following myostatin treatment are currently contradictory, as both increased (in placental explants) 
and decreased (placental BeWo cell line) glucose uptake have been observed (Mitchell, Osepchook 
et al. 2006, Antony, Bass et al. 2007). Literature outside of the placenta also supports an increase in 
glucose uptake with either the treatment with myostatin (C2C12 treated with myostatin) (Chen, Ye 
et al. 2010), or the inhibition of myostatin (e.g. adeno-associated virus-8-myostatin inhibition of 
myostatin) (Cleasby, Jarmin et al. 2014). Moreover, in muscle tissue cultures of myostatin knockout 
mice (the absence of myostatin) glucose uptake was increased (Zhang, McFarlane et al. 2011). 
Further investigations are therefore required as currently the role of myostatin in the regulation of 
glucose homeostasis in placenta is inconclusive and the effect of myostatin on insulin signalling in 
the placenta unknown. 
 
Alterations in cytokine concentrations in maternal plasma are known to occur in GDM. 
Furthermore, placental explant experiments of GDM tissues found an increased production of TNF-
α following glucose stimulation (Coughlan, Oliva et al. 2001, Gomes, Torloni et al. 2013). The 
effect of myostatin on placental cytokine production and in GDM is yet to be determined. However 
as described in the previous section, myostatin may help maintain the pregnancy by decreasing Th1 
cytokines concentrations such as TNF-α. Interactions of the cytokines with insulin may also alter 
myostatin expression in placentae of GDM pregnancies. Insulin treatment is known to decrease 
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inflammatory mediators (Jeschke, Klein et al. 2004). Therefore, insulin treatment of GDM 
pregnancies could improve glucose homeostasis as well as decrease inflammatory cytokine 
production (e.g. TNF-α), which in turn could result in changes to the myostatin expression observed 
in the placentae of GDM women treated with insulin (towards a return to NGT myostatin 
expression).  
7.2.3 Better method of myostatin protein detection   
The final chapter of this thesis aimed to develop a better method of detecting myostatin. The need 
for this research is two-fold. Firstly, current gold standard methods of myostatin protein detection 
(Western blot and ELISA) are heavily dependent on the specificity of antibodies, and, at best, the 
results from these methods are semi-quantitative. Secondly, myostatin as a protein is generated as a 
precursor which is cleaved to release the mature and a pro-peptide protein (Lee 2004). The mature 
form of myostatin once dimerised is the active protein. The pro-peptide facilitates the proper 
folding of the C-terminal domain to form a cystine knot and also can control the activity of the 
myostatin dimer (Hill, Davies et al. 2002, Lee 2004). Two monomeric pro-peptides bind non-
covalently to the myostatin dimer forming a latent complex preventing the dimer from binding to its 
receptor ACTRIIB. The majority of myostatin (~70%) found in the circulating blood is in this latent 
complex form (Hill, Davies et al. 2002, Lee 2004).  
 
A majority of the experimental and clinical work presented especially those that used Western blot 
are focussed on the expression of the active myostatin dimer form.(Gonzalez-Cadavid, Taylor et al. 
1998, Yarasheski, Bhasin et al. 2002, Costelli, Muscaritoli et al. 2008, Guo, Jou et al. 2009, 
Springer, Adams et al. 2010, Hu, Tian et al. 2012) The total expression profiles of the various 
myostatin forms (precursor, pro-peptide and mature protein) are often not presented. Identifying the 
different forms of myostatin will allow for a better understanding of the potential availability 
(precursor) or activity (pro-peptide) of myostatin. In support for the need to discriminate between 
the different forms of the myostatin protein is our previous work (by Western blot) that identified 
marked differences in the expression of the myostatin precursor and dimer forms due to diet or sex 
(Oldham, Osepchook et al. 2009, Peiris, Ponnampalam et al. 2010).  
 
Understanding the expressions of the different myostatin protein forms will provide a better idea of 
the role myostatin has in affecting disease pathways. Moreover, it will assist in targeting 
antagonistic and agonistic treatments for myostatin action. Therefore, the development of a targeted 
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mass spectrometry approach which would allow the specific identification of each protein through 
detection of several unique peptides per quantified protein (contrasting the single signal generated 
for a protein form by Western blot) was carried out as part of the research documented in this PhD 
thesis  (Bantscheff, Lemeer et al. 2012, Aebersold, Burlingame et al. 2013).  
 
Utilising two mass spectrometry platforms the AB SCIEX Triple TOF® 5600 and AB SCIEX 
QTRAP® 5500, a highly discriminative method for the identification of myostatin was developed. 
Peptides within the mature and pro-peptide protein were identified and the lower limit of 
quantitation (LLOQ) determined. The LLOQ of 0.19 nmol/L was defined for peptides 
DFGLDCDEHSTESR (of the mature protein region) and ELIDQYDVQR (of the pro-peptide 
protein region) on the AB SCIEX 5600 triple TOF mass spectrometer. The LLOQ myostatin on the 
AB SCIEX QTRAP
®
 5500 instrument was identified for a peptide of the mature region as 
0.25nmol/L (EQIIYGK) and a peptide of the pro-peptide region (LEPATNISK) as 0.16nmol/L. The 
sensitivity for the detection of myostatin by the mass spectrometry method far exceeds that of 
currently available techniques (as detailed in the Journal of Proteome Research article).  
 
The mass spectrometry method developed in this thesis is an initial step in the development of a 
specific method for the identification of myostatin by mass spectrometry. The next step is to expand 
the utility of this method to identify myostatin within biological samples. 
 Future Directions 7.3 
A recent letter to the editor by Rogers et al 2014  questioned the validity of using myostatin from 
prokaryotic sources (Rodgers 2014). Rogers et al argued that eukaryotic sources of myostatin allow 
for concentrations to be applied at physiological, rather than supraphysiological concentrations as 
required by prokaryotic sources (Rodgers 2014). This letter was in response to a publication by 
Bonala et al 2014 (Bonala, Lokireddy et al. 2014) which showed that myostatin treatment at 5μg/ml 
of myotubes induced the degradation of insulin receptor substrate 1 via the up-regulation of a 
ubiquitin E3 ligase (Cblb; Casitas B-lineage lymphoma b) (Bonala, Lokireddy et al. 2014). 
Kambadur et al in response to Rogers et al rebutted that myostatin produced in E.coli (prokaryotic 
source) have been shown to have the same biological function as that of myostatin produced in a 
CHO cell line (Chinese hamster ovary cells- i.e. eukaryotic source) (Kambadur 2014). An earlier 
publication by this group reported similar effects of decreased proliferation of C2C12 mouse 
myotubes following treatement with both prokaryotic (5 μg/mL) and eukaryotic (10 ng/mL) sources 
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of myostatin, concentrations required however were supraphysiological for prokaryotic sources 
(McFarlane, Hui et al. 2011). These publications have polarised the myostatin research field. 
 
The current study as in others in the field (McFarlane, Hui et al. 2011, Bonala, Lokireddy et al. 
2014) used a recombinant myostatin protein made in E. coli (prokaryotic source). This recombinant 
protein has been previously published as affecting glucose uptake of placental explants and 
placental cells (Mitchell, Osepchook et al. 2006, Antony, Bass et al. 2007) and is known to bind 
with high affinity to a fusion molecule containing an human activin receptor IIB extracellular 
domain followed by the human IgG1 Fc domain ( ACTRIIB-FC) (Koncarevic, Kajimura et al. 
2012). The fusion molecule ACTRIIB-FC is used as a soluble receptor to bind and inhibit myostatin 
as well as other members of the TGF-β superfamily (Koncarevic, Kajimura et al. 2012). The 
myostatin concentrations used in the current study ranged from physiological (0.001μg/ml or 0.005 
μg/ml) to supraphysiological (10μg/ml) concentrations. Effects were observed at many of the 
concentrations used. In future studies the use of eukaryotic and prokaryotic sources for myostatin 
should be considered along with a wider range of myostatin concentrations.  
 
Future studies should be performed derived from the work presented in this thesis to further expand 
the understanding of myostatin in the placenta. Proteolytic processing of the myostatin precursor is 
required for the release of the pro-peptide and mature myostatin proteins (homodimer of the mature 
protein is the active form). The myostatin pro-peptide is an antagonist of myostatin as it can bind to 
the active dimer and prevent receptor binding. Expression of the myostatin pro-peptide is unknown 
in complicated pregnancies (e.g. GDM, PE, IUGR, and PE-IUGR). Evaluating the expression of the 
enzymes regulating the processing of myostatin (needed to release the pro-peptide and mature 
forms of myostatin) may provide essential information on whether the expressional differences 
observed in this thesis are due, to a defect in the processing of the precursor, or, to alterations in 
expression.  
 
Furthermore, evaluation of the myostatin signalling pathway (e.g. myostatin receptor,  transcription 
factors etc.) and antagonists of myostatin activity (e.g. FSTL-3 and the myostatin pro-peptide) will 
provide insight to the possible role of myostatin in complicated pregnancies. A range of oxygen 
tensions, treatment with inhibitors/regulators of myostatin activity (FSTL-3, pro-peptide), and 
cytokine stimulatory treatment should be included and evaluated in primary cell and primary tissue 
culture experiments. Placental tissues used for primary culture and isolation experiments need to 
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include first trimester tissues and term/preterm complicated pregnancy tissues. This would allow for 
a better understanding of the possible role of myostatin in complicated pregnancy and expand 
current work identifying differences in the expression of myostatin.  
 
Towards this work an ethics application was submitted and approved for collection of placental 
tissue from complicated pregnancies between the University of Queensland and the Royal Brisbane 
Women’s Hospital (Appendix I). The process of attaining the ethics and legal access to tissues took 
an extended period of time that was unpredictable (close to 1.5 years). Due to this delay, enrolment 
and collection of placental tissues for use in primary culture from complications of pregnancy was 
not possible, in the duration of this PhD. However as essential documentation is now completed, 
future studies can be planned for in vitro experimentation with placental tissues of pregnancies 
complicated with PE, IUGR, PE-IUGR, PTB and GDM.  
 
Three grant applications were submitted to two national funding bodies (Appendix  II). Funding 
was awarded by the Diabetes Australia Research Trust (Appendix IIa) and supported the work 
performed in this thesis.  
 Conclusions  7.4 
In summary, myostatin is localised to cells of the placenta needed for placental establishment 
(EVT) and for the maintenance of immune regulation and nutrient transport (syncytiotrophoblast 
and cytotrophoblast). Following myostatin treatment in culture of an EVT cell line and isolated 
EVT (the cell type staining most strongly for myostatin) an increased proliferation and migration of 
EVT was observed. This suggests that myostatin may be active in placental development and 
function, possibly acting to support the pregnancy (Figure 10A). Further supporting this was the 
effect of myostatin on cytokine production toward a Th2 rich environment (down-regulated 
concentrations of Th1 cytokines and up-regulated concentrations of IL4 a Th2 cytokine) from 
media of first trimester placental explant cultures. Under hypoxic oxygen tensions the effect of 
myostatin treatment on cytokine production was still present, although diminished (Figure 10B). 
Together with the above findings the higher expression of myostatin in placentae of pregnancies 
complicated with PE, IUGR and PE- IUGR may indicate that myostatin is attempting to support the 
pregnancy in an abnormal environment. Findings of differences in myostatin expression in 
pregnancies complicated with GDM and in placentae of NGT obese women indicate that under 
stress conditions such as obesity or abnormal insulin signalling (found in GDM), myostatin 
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expression is altered and possibly mediated to some degree by interactions between insulin and 
myostatin (Figure 10C). Finally, a new method for the identification of myostatin protein needed in 
the field is currently well under way (Figure 10D). This method will allow for sensitive detection 
and quantitation of the myostatin protein forms in in vitro study, and with further development, 
possibly in a clinical setting. Understanding the expressions of the different myostatin protein forms 
will provide a better idea of the role myostatin has in contributing to disease pathways. Moreover, it 
will assist in targeting antagonistic and agonistic treatments for myostatin action. The findings 
presented in this thesis have advanced the current knowledge of myostatin in the human placenta; 
future investigations are warranted and needed to fully understand the role of myostatin in the 
human placenta in uncomplicated and complicated pregnancies. 
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Figure 10: Thesis summary  
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Approval of this project from the RBWH HREC is valid from 21.12.2012 to 21.12.2015 
subject to the following conditions being met: 
 The Coordinating Principal Investigator will immediately report anything that might warrant 
review of ethical approval of the project. 
 The Coordinating Principal Investigator will notify the RBWH HREC of any event that 
requires a modification to the protocol or other project documents and submit any required 
amendments in accordance with the instructions provided by the HREC.  These 
instructions can be found at http://www.health.qld.gov.au/rbwh/research/hrec.asp. 
 The Coordinating Principal Investigator will submit any necessary reports related to the 
safety of research participants in accordance with the RBWH HREC policy and procedures.  
These instructions can be found at http://www.health.qld.gov.au/rbwh/research/hrec.asp. 
 In accordance with Section 3.3.22 (b) of the National Statement the Coordinating Principal 
Investigator will report to the RBWH HREC annually in the specified format, the first report 
being due on 21.12.2013 and a final report is to be submitted on completion of the study.  
These instructions can be found at 
http://www.health.qld.gov.au/ohmr/html/regu/reporting_templates.asp.  
 The Coordinating Principal Investigator will notify the RBWH HREC if the project is 
discontinued before the expected completion date, with reasons provided. 
 The Coordinating Principal Investigator will notify the RBWH HREC of any plan to extend 
the duration of the project past the approval period listed above and will submit any 
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associated required documentation.  Instructions for obtaining an extension of approval can 
be found at http://www.health.qld.gov.au/rbwh/research/hrec.asp. 
 The Coordinating Principal Investigator will notify the RBWH HREC of his or her inability 
to continue as Coordinating Principal Investigator including the name of and contact 
information for a replacement. 
 A copy of this ethical approval letter together with completed Site Specific Assessment 
(SSA) and any other requirements must be submitted by the Coordinating Principal 
Investigator to the Research Governance Office at the Royal Brisbane & Women’s Hospital 
in a timely manner to enable the institution to authorise the commencement of the project at 
its site. 
 Should you have any queries about the RBWH HREC’s consideration of your project 
please contact the HREC Coordinator on 07 3646 5490.  The RBWH HREC’s Terms of 
Reference, Standard Operating Procedures, membership and standard forms are available 
from http://www.health.qld.gov.au/rbwh/research/hrec.asp. 
 
The RBWH HREC wishes you every success in your research. 
Yours sincerely, 
 
Dr Conor Brophy 
Chairperson RBWH Human Research Ethics Committee 
Metro North Hospital and Health Service 
21.12.2012 
 
 
 
 
This HREC is constituted and operates in accordance with the National Health and Medical 
Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research 
(2007). The processes used by this HREC to review research proposals have been certified by 
the National Health and Medical Research Council. 
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Participant Information Sheet/Consent Form 
Non-Interventional Study - Adult providing own consent 
 
The University of Queensland Centre for Clinical Research 
 
 
Part 1 What does my participation involve? 
 
1 Introduction 
 
You are invited to take part in this research project: Mechanisms of placental growth and function 
related to uncomplicated and complicated pregnancies. This is because we want to look at the 
differences between healthy pregnancies and pregnancies with complications.   Complications in 
pregnancy are common.  This includes diabetes (gestational diabetes; 5-15% of Australian pregnancies), 
high blood pressure (preeclampsia; 3-5% of women worldwide), small babies (intrauterine growth 
restriction; 1-4% of births in Australia) and early delivery (preterm birth; 7-8% in Australia) occurs in 
many pregnancies. In some of these complications, the placenta might be the problem.  The placenta is an 
organ that allows blood to flow from mother to baby. We aim to understand how complications in 
pregnancy can affect the placenta.  
 
This Participant Information Sheet/Consent Form tells you about the research project. It explains the tests 
and research involved. Knowing what is involved will help you decide if you want to take part in the 
research. 
 
Please read this information carefully. Ask questions about anything that you don’t understand or want to 
know more about. Before deciding whether or not to take part, you may want to talk about it with a 
relative, friend or local doctor. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. You will 
receive the best possible care whether or not you take part. 
 
If you decide you want to take part in the research project, you will be asked to sign the consent form. By 
signing it, you are telling us that you: 
• Understand what you have read 
• Consent to take part in the research project 
• Consent to the tests and research that are described 
• Consent to the use of your personal and health information as described. 
Title Mechanisms of placental growth and function related to 
normal and complicated pregnancies 
Protocol Number HREC/12/QRBW/391 
Coordinating Principal Investigator/ 
Principal Investigator 
Researchers involved  
Professor Murray D. Mitchell and 
Professor Gregory E. Rice, A/Prof Leonie Callaway 
Dr Jenny Ryan, Dr Carlos Salomon or Dr Hsiu-Wen Chan 
Location  Royal Brisbane and Women’s Hospital, Herston 
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You will be given a copy of this Participant Information and Consent Form to keep. 
 
2 What is the purpose of this research? 
 
This study will investigate differences in placentae from normal and complicated pregnancies. The 
placenta grows in the mother’s womb to provide oxygen and nutrients for the baby.  A well-developed 
placenta is important for a health pregnancy.  To understand this process, we want to carefully examine 
the placenta, the cells (building blocks) that make up the placenta and what changes its growth and 
development. Knowing the differences between a placenta from a complicated pregnancy and a healthy 
pregnancy will help us to understand what causes problems in pregnancy.  This may lead to better tests 
and treatments for complicated pregnancies.  
 
3 What does participation in this research involve? 
 
To do this research, we need to collect placenta from both healthy and complicated pregnancies.   After 
the baby is born, the cord between the baby and the placenta is clipped and cut (to separate the baby from 
the mother), and then the placenta is delivered.  After looking at the placenta to check for obvious 
problems, the placenta is generally thrown out.  This occurs unless you have made a special request to 
keep your placenta. We ask your permission instead to collect your placenta after your baby has been 
born to conduct this research project. We also request to collect some information about your pregnancy 
from your clinical notes.  
 
3.1  Why have I been chosen? 
You have been chosen because you are pregnant and are having a baby at the Royal Brisbane and 
Women’s Hospital.  As part of this research, we will need to collect information about your pregnancy.  
We will need to know if you have had a normal healthy pregnancy, or if you have had complications 
during your pregnancy (e.g. diabetes, high blood pressure, small babies or early birth).  If you agree to 
donate the placenta (the placental unit, including the attached fetal membranes and umbilical cord), our 
clinical research midwife/nurse or the doctor looking after you at delivery will collect the placenta after 
the baby is born and no longer attached.  After checking the placenta carefully, it will then be taken to our 
research laboratories.  
 
3.2  What are the possible disadvantages and risks of taking part? 
Because we are using discarded tissues obtained after birth, there is no risk to you or your baby. The 
placenta will be collected after it is no longer connected to your baby. 
 
3.3  What are the possible benefits of taking part? 
There is no clinical benefit to you or your baby. You will not receive any extra information on the health 
of you or your baby. The information we get from this study may help develop tests for early detection of 
and methods to treat pregnancy complications.   
 
4 What do I have to do? 
In you decide to donate your placenta; there will be no impact to your lifestyle in any way. We are only 
requesting your placenta after the birth of your baby. Unless you request otherwise, your placenta would 
normally be discarded after the cord to the baby has been tied and cut. We ask your permission instead to 
collect your placenta after your baby has been born to conduct research.  
 
In addition we also request access to you medical history such as your age, baby age (how many weeks) 
height, weight and smoking status. This information will assist us in interpreting the data and will allow 
us to group similar women together. The information will be accessed only by the clinical research nurse 
or medical staff (refer to section 8 for more details).  
 
 
5 Other relevant information about the research project 
 
We expect to collect 350 placentae over the next three years. 250 of these will be from women with 
healthy pregnancies, and the 250 from women with complicated pregnancies.     
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6 Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take part, you do not have to. If 
you decide to take part and later change your mind, you are free to withdraw from the project up until 
your placenta is collected by the researchers involved. 
  
 
If you do decide to take part, you will be given this Participant Information and Consent Form to sign and 
you will be given a copy to keep. 
 
Your decision whether to take part or not to take part or to take part and then withdraw will not affect 
your routine treatment, your relationship with those treating you or your relationship with University of 
Queensland Centre for Clinical Research. 
 
7 What will happen to my test samples? 
 
The placenta samples will be assigned a study number after collection to protect your privacy.  
There are a number of different laboratory tests we will do on the donated placenta we receive. Samples 
will be given a study number so your information is kept private and will be stored for a maximum of 7 
years in a secure researcher’s laboratory (CCTV, triple swipe card, access restricted)at the UQ Centre for 
Clinical Research (UQCCR).  
  
The study will determine the differences between placenta from complicated and healthy pregnancies. We 
will do this by investigating the following:  
1. Placental factors such as hormones, proteins, genes etc. that control the way the placenta is 
formed and functions to determine differences between complicated and healthy pregnancies.  
2. The function of different cell types that make up the placenta to determine differences between 
complicated and healthy pregnancies.  
. 
Any results that we get from your donated placenta will be grouped with other similar donated placenta. 
Only the grouped results will be shown in publications in journals or at national and international 
conferences. There will be no way to individually identify scientific results or clinical information.   
 
This study has been approved by Research Ethics Committee of the Royal Brisbane and Women’s 
Hospital. All information relating to the study will be securely stored and will only be accessible by the 
researchers. There are no apparent commercial implications of this study.  
 
Any future use of data and tissue will only be used in projects that relate to pregnancy/ pregnancy 
complications in order to improve outcomes for mother and baby. All tissues including all extracted 
samples will be destroyed after 7 years.   
Any future projects using this material however would be subject to review by a Human Research Ethics 
Committee.  
 
Part 2 How is the research project being conducted? 
 
8 What will happen to information about me 
 
By signing the consent form you consent to the study doctor and relevant research staff collecting and 
using personal information about you for the research project. Any information obtained in connection 
with this research project that can identify you will remain confidential. We will protect your information 
by giving all your information a study number.  
Your information will be used for the purpose of this research project and may be used in future research 
project that relate to pregnancy research in order to improve healthy outcomes for pregnancy 
complications. The information will only be disclosed with your permission, except as required by law. 
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Information about you will be obtained from your health records by the medical clinicians for the purpose 
of this research. By signing the consent form, you agree to the research team accessing health records if 
they are relevant to your participation in this research project. 
 
It is anticipated that the results of this research project will be published and/or presented in a variety of 
forums. In any publication and/or presentation, information will be provided in such a way that you 
cannot be identified because your placental sample will not be traceable back to you.  
 
9 Who is organising and funding the research? 
 
This research project is being conducted by Professors Murray Mitchell and Professor Gregory Rice’s 
research team in the University of Queensland Centre for Clinical Research. It is funded by the University 
of Queensland. 
 
10 Who has reviewed the research project? 
   
All research in Australia involving humans is reviewed by an independent group of people called a 
Human Research Ethics Committee (HREC).  The ethical aspects of this research project have been 
approved by the HREC of Royal Brisbane and Women’s Hospital and the Medical Research Ethics 
Committee at the University of Queensland.  
 
This project will be carried out according to the National Statement on Ethical Conduct in Human 
Research (2007). This statement has been developed to protect the interests of people who agree to 
participate in human research studies. 
 
11 Further information and who to contact 
 
Please feel free to ask any questions you may have with those discussing the research project with you, or 
you may contact the investigators for this study: Dr Jenny Ryan, Dr Carlos Salomon or Dr Hsiu-Wen 
Chan Ph 0733465418 email j.ryan2@uq.edu.au/ c.salomongallo@uq.edu.au / h.chan4@uq.edu.au 
 
   Clinical contact person 
 
 
Reviewing HREC approving this research and HREC Executive Officer details 
 
“This study has been reviewed and approved by the Royal Brisbane & Women’s Hospital 
Human Research Ethics Committee (EC00172). Should you wish to discuss the study in 
relation to your rights as a participant, or should you wish to make an independent 
complaint, you may contact the Coordinator or Chairperson, Human Research Ethics 
Committee, Royal Brisbane & Women’s Hospital, Herston, Qld, 4029 or telephone (07) 
3646 5490, email: RBWH-Ethics@health.qld.gov.au”  
 
Name Associate Professor Leonie Callaway 
Position Head, Royal Brisbane Clinical School, Staff Specialist RBWH 
Telephone 36468111 
Email l.callaway@uq.edu.au 
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Consent Form - Adult providing own consent 
 
 
 
 
Declaration by Participant 
 
I have read the Participant Information Sheet or someone has read it to me in a language that I understand.  
 
I understand the purposes, procedures and risks of the research described in the project. 
 
I have had an opportunity to ask questions and I am satisfied with the answers I have received. 
 
I freely agree to participate in this research project as described and understand that I am free to withdraw at 
any time during the project without affecting my future health care. 
 
I understand that I will be given a signed copy of this document to keep. 
 
 
I give permission for my doctors or other health professionals to release information to UQCCR concerning 
my condition and treatment for the purposes of this project. I understand that such information will remain 
confidential.  
 
 
 
 Name of Participant (please print)     
 
 Signature   Date   
 
 
 
 
Declaration by Doctor/Research Nurse/Senior Researcher
† 
 
I have given a verbal explanation of the research project, its procedures and risks and I believe that the 
participant has understood that explanation. 
 
 Name of 
Doctor/Researchurse/Senior 
Researcher / 
Senior Researcher
†
 (please print) 
 
  
 Signature   Date   
 
† A senior member of the research team must provide the explanation of, and information concerning, the research project.  
 
Note: All parties signing the consent section must date their own signature 
Title Mechanisms of placental growth and function related to 
normal and complicated pregnancies 
Protocol Number HREC/12/QRBW/391 
Coordinating Principal Investigator/ 
Principal Investigator 
Researchers involved  
Professor Murray D. Mitchell,  
Professor Gregory E. Rice, A/Prof Leonie Callaway 
Dr Jenny Ryan, Dr Carlos Salomon or Dr Hsiu-Wen Chan 
Location  Royal Brisbane and Women’s Hospital, Herston 
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Mechanisms of placental growth and function related to uncomplicated and complicated 
pregnancies 
Principal investigators: Prof Murray Mitchell, Prof Gregory Rice, Associate Professor Leonie 
Callaway 
 
Background  
Complications in pregnancy including gestational diabetes mellitus  (GDM; 5-15% of Australian 
pregnancies)(1), preeclampsia (PE; 3-5% of women worldwide)(2), intrauterine growth restriction 
(IUGR; 1-4% of births in Australia) (3), and preterm birth (PTB; 7-8% in Australia) (3) are major 
obstetric health problems. These disorders of pregnancy lead to poor maternal, fetal and neonatal 
outcomes. The etiologies of complications in pregnancies are complex as it can be multi-factorial.  
One key factor for a healthy pregnancy and fetus is a well-developed placenta. The placenta acts as a 
temporary life support system, controlling nutrient, oxygen and hormone transfers and respiration and 
waste management for the developing fetus during its time in utero (4). The placenta also acts as an 
immune interface between the mother and fetus (4).  
Throughout pregnancy, it is critical that the functional capacity of the placenta increases to meet the 
needs of the growing fetus. The building blocks of the placenta are trophoblast cells that mediate the 
development of the placenta from initial implantation and invasion as well as playing a major role in 
the remodelling the maternal uterine blood vessels in order to increase the blood flow required by the 
developing placenta (4).  
Abnormalities in placental development and function may explain why placental pathologies and 
pregnancy complications occur. IUGR and PE are two pregnancy complications associated with poor 
placental development (5). The incomplete invasion of spiral arteries (small arteries in the 
endometrium) results in  continued high vascular resistance and poor perfusion of the placenta (5).  
Alterations in epigenetics, protein expression and inflammatory mediators are also associated with 
complications in pregnancy. Epigenetics is the study of heritable modifications (e.g. DNA 
methylation, histone modification, miRNA regulation) in gene expression in the absence of changes in 
the DNA sequence. It is becoming apparent that epigenetic processes regulate labour events. For 
example, small RNA molecules known as microRNAs that promote gene silencing have been shown 
to be differentially expressed in placenta tissue from PE compared to normotensive pregnancies (6). 
Furthermore, promoters of specific genes (SERPINA1, TIMP3) are hypomethylated (decreased DNA 
methylation) in placenta tissue from PE patients compared to control patients (7, 8).   
Alterations in protein expression have been identified in pregnancies complicated with GDM, IUGR 
and PE. Examples of altered proteins are follistatin like-3 (FSTL-3), myostatin, and members of the 
transforming growth factor beta superfamily. Altered FSTL-3 has been identified in pregnancies 
complicated with GDM (9), IUGR(10) and PE (11). Altered myostatin protein was also recently 
reported in pregnancies complicated with PE (11). Myostatin is associated with glucose uptake in the 
placenta (12) and FSTL-3 is a potent inhibitor of myostatin activity (13). The expression and function 
of myostatin has been identified to be regulated by factors affecting placental development, in 
particular tumour necrosis factor alpha (an inflammatory mediator) (14) and hypoxia (15).  
Idiopathic PTB and premature rupture of fetal membranes (which usually results in preterm labor) 
account for 50% of cases of preterm delivery and it is this cohort in which bacterial infection may be 
an etiological factor.  Bacterial infection of the placenta induces hypermethylation of genes involved 
in fetal growth and alters protein expression of inflammatory mediators (16, 17).  Given that maternal 
infection is a key risk factor for preterm birth, it is possible that activation of inflammatory events 
prior to term may be a cause of preterm delivery (18-37). 
Proposal 
The development of pregnancy complications is complex. A vital organ for both a healthy mother and 
infant is a well-developed placenta. We aim to evaluate the differential release of substances 
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(proteins, exosomes, microRNA) and gene expression in placentae of complicated and uncomplicated 
pregnancies. Pregnant women with both uncomplicated and complicated pregnancies will be 
recruited.   
Hypotheses: 
Cells and tissue explants isolated from the placental unit (i.e. the placenta and the attached membranes 
and umbilical cord) of complicated pregnancies display  
1. differentially expressed genes and release of gene products   
2. altered epigenetic profiles; and  
3. altered cellular phenotype  
when compared to placentae from uncomplicated pregnancies  
The aims of this study are: 
1. To identify substances and released products from placentae that contribute to pregnancy 
pathologies 
2. To understand mechanisms of pathological pregnancy development 
3. Compare epigenetic profiles of placentae from complicated and uncomplicated pregnancies 
Project Significance  
This study will provide important information on differences in the expression, production, and 
function of substances and released products from complicated and uncomplicated pregnancies. The 
information gathered has a longer term potential of being developed into methods of detection and 
treatment for pregnancy complications.  
Study Design:  
Eligibility and recruitment  
Pregnant women between 18 and 45 years of age with either uncomplicated or complicated 
pregnancies will be eligible for recruitment. A letter of invitation to the research project will be 
provided midwives and doctors to be given to potential participants. An experienced clinical academic 
midwife/research nurse funded by the office of health and medical research will approach and explain 
the research project to eligible pregnant women attending the maternity outpatient clinic at the Royal 
Brisbane and Women's hospital interested in participating. Consent will be sought after signed written 
consent has been given for the clinical procedure. Researchers will liaise with the clinical research 
nurse for collection of the donated placentae  
The opportunity to participate will be open to all women who are capable of understanding the 
consent form. Women with a mental illness, intellectual disability or cognitive impairment will be 
assessed on a case by case basis for their ability to understand and give consent. The ability to consent 
will be decided by the treating physician who gives the patient the letter of invitation.  
Women of non-English background will only be excluded if their level of understanding is not 
sufficient to understand the patient participation information necessary to obtain informed consent. 
Women over 45 or under 18 will also be excluded.  
Description of groups  
 Control group:  Uncomplicated pregnancies 
Expected number of participants in this group:100 
Age range: 18 - 45 
The control group will consist of placentae from women without pregnancy complications. Placentae 
from this group will be best matched for gestational age with placentae from women in the 
experimental group, with the exception of preterm deliveries where the control group will be term 
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pregnancies. Placentae will be collected from women at the time of delivery (caesarean section or 
vaginal). These placental tissues will be used as a healthy control group 
Experimental group:  Complicated pregnancies  
Expected number of participants in this group: 250 
Age range: 18 – 45 
The experimental group will consist of pregnancies that were complicated including GDM, (PE), 
IUGR, and PTB. Placentae will be collected from women at the time of delivery (caesarean section or 
vaginal). 
 GDM 
Number of placentae to be collected =50.  
GDM after one or more of the following glucose levels are elevated; fasting glucose ≥ 
5.1mmol/L, 1hr glucose ≥ 10.0mmol/L, 2hr glucose ≥ 8.5mmol/L (per ADIPS 
criteria(38)) 
 
 PE 
Early onset < 32 weeks gestation. Number of placentae to be collected =50.  
Late onset >32 weeks gestation Number of placentae to be collected =50.  
Hypertension arising after 20 weeks gestation with one of the following: significant 
proteinuria – dipstick proteinuria subsequently confirmed by spot urine protein/creatinine 
ratio ≥ 30mg/mmol. Serum or plasma creatinine > 90 μmol/L. (per SOMANZ criteria 
(39)) 
 
 IUGR  
Number of placentae to be collected =50. 
Identification of babies less than the 5th centile delivered after 40 weeks of gestation. (per 
RANZCOG/ACHS (40)(ref) 
 
 PTB 
Number of placentae to be collected =50.  
Deliveries occurring before 34 completed weeks gestation (per Queensland maternity and 
neonatal clinical guidelines (41)) 
 
Clinical information relevant to the pregnancy and complications of pregnancy (such as gestational 
age, BMI, and smoking status) will be accessed only by the clinical research nurse or other clinicians 
involved in the study. The information will be stored in a re-identifiable form during the course of the 
study only. Each participant will be given a study number. This will be the information used to label 
all samples and data collected. The identification data will be kept separately in a 21CRF11 compliant 
document management system (21CRF11 compliance refers to data storage system where data 
collected, retrieved or accessed is recorded and traceable in accordance to international electronic data 
management requirements) maintained by the University of Queensland Centre for Clinical Research 
Placental tissue collection 
The placental unit (placenta, placental membranes, umbilical cord and umbilical cord blood) will be 
collected after the birth of babies by both vaginal and caesarean section deliveries of uncomplicated 
and complicated pregnancies. The collection of these tissues will not interfere with the delivery of the 
baby or complicate the care of the participant in any way.  Tissue samples of the placental unit will be 
utilised for experimental analyses and no tissues will be banked in the long term.  
Through the utilization of explant and placental derived cell culture (e.g. trophoblast, endothelial, 
human umbilical vein endothelial cells and mesenchymal stem cells) of tissues from the placental unit 
(including fetal membranes, chorionic villi and umbilical cord) for short periods of time (maximum of 
4 weeks), we will evaluate the production and release of substances that may contribute to 
pathological pregnancies.  
 Protocol : Mechanisms of placental growth and function related to uncomplicated and complicated pregnancies 
Version 2, Date: 17/12/2012    Page 4 of 8  
Methods  
 Placental cell culture 
Placental tissue will be enzymatically digested for the isolation of placental derived cell culture 
(e.g. trophoblast, endothelial, human umbilical vein endothelial cells and mesenchymal stem 
cells) 
 Endothelial and stem/progenitor cell derivation 
- FACS selection 
- Growth on matrigel 
- Mark with reporters 
 Characterisation: 
- Immunophenotype (haemopoietic, endothelial, mesenchymal markers) 
- Growth kinetics, telomere length, telomerase, hTERT 
- Purity, transducibility and tranfectability 
- Trilineage and extralineage (neural, muscle, endothelial) differentiation assays 
- Angiogenic arrays 
 Comparative biology: 
- By culture conditions 
- By inflammatory response 
- By oxygen level 
- Incucyte wound and growth assays  
 
 Placental explant culture 
Placental tissue will separated and cut into small pieces to culture in explant conditions (e.g. 
chorionic villi ~2mg of tissue will be left to grow on tissue culture plastic) 
 
 Placental sections  
Small section of placental tissue will be fixed in 10% formalin, paraffin imbedded and cut into 5 
micron sections in preparation for immunohistochemistry and immunofluorescence  
 
 Placental umbilical cord blood  
Substances released and products made by the placenta will be measured in the cord blood of the 
placenta. 
 
Examples of experimental analyses 
A range of proteomic and genomic experimental analyses will be performed to quantify the release 
and production of substances from placental tissues, isolated cells and cultures. Examples are listed 
below.  
 Genotype, gene expression and epigenetic analysis  
- Bisulfite sequencing to analyse DNA methylation differences 
- ChiP (chromatin immunoprecipation) assays for the analysis of histone modifications 
- Next generation sequencing  of genetic material to examine epigenetic regulation and gene 
expression 
- Quantitative real-time PCR analysis of placental gene expression   
- Microarray of global human gene expression  
 Proteins  
- Elisa  
- Western blotting for the expression of whole, nuclear and cytosolic proteins  
- Mass spectrometry for the analysis of proteins and peptides 
- Immunofluorescence 
- Immunohistochemistry   
- Flow cytometry (FACS) 
-  
Statistical Analysis 
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Descriptive statistics will be performed. The differences between the groups will be examined using 
Student’s t-test, and ANOVA as appropriate. Ana priori power analysis was performed, using an 
effect size of 0.75 in a two tailed student t-test (Difference between two independent means (two 
groups), with an alpha error of 0.05 and a range for power (0.95). The sample size required for the 
control and experimental groups was identified to be n=48.  
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RESPONSIBLE INVESTIGATOR 
Title 
Professor  
First Name* 
Murray  
Surname* 
Mitchell
 
Address* 
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University of Queensland Centre for Clinical ResearchDifferential expression of placental myostatin in gestational diabetes
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Average days/month devoted to all other projects* 
10 days per month
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To facilitate the allocation of applications for review please select 3 areas that would fall within your 
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Health Care Delivery Research Beta Cell Function
 
Immunology Retinopathy
 
Nephropathy Neuropathy & Diabetic Foot
 
Cardiovascular Paediatric
 
Insulin Delivery / Glucose Sensing Nutrition
 
Obesity / Body Composition
 
Other (If Not Listed) 
Placental Science  
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Title 
Ms  
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Thompson
 
Address* 
The University of Queensland, Cumbrae Stewaert (Building 72) 
 
Suburb* 
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Country 
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Telephone No. (evening) 
 
Mobile No. 
 
Email Address* 
director.management@research.uq.edu.au
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PROJECT INFORMATION 
Project Title* 
Differential expression of placental myostatin in gestational diabetes
 
Project Aim (Give a short description of the main aim of the project)* 
The current study aims to establish the differential expression of myostatin and evaluate the molecules involved in the 
regulation of myostatin, such as FSTL3, and members of the myostatin signalling pathway (Activin type II receptor, SMAD 
transcription factors) in relation to the placentae of women with gestational diabetes versus healthy controls.
 
Expected duration of the project* 
12 months 
 
Classification (Please tick appropriate box/s in below categories)* 
Basic Science Clinical Science
 
Educational Research Health Care Delivery Research
 
Psychological Research Epidemiology
 
Complications
 
Simple Description (Please tick appropriate box/s in below categories)* 
Type 1 Type 2
Gestational Other
 
Population* 
Paediatric Adult
 
Ethic Clearance Required? (Successful applicants will be required to provide proof of ethics approval)* 
 
Section Completed
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OTHER GRANT OR FUNDING CURRENTLY HELD* 
Give details of grants or other support currently received from, or approved by, other bodies for this or 
related work. Indicate title, granting body, duration and amount of support for each year. 
Funding requested from DART 2012 is the first funding asked for this project.
 
Section Completed
 
PREVIOUS GRANTS FROM DIABETES AUSTRALIA RESEARCH TRUST (DART)* 
Please provide details of outcomes (e.g. publications, other research fund attracted) from prior research 
funded by DART 
No previous funding from DART
 
Section Completed
 
RELATIONSHIP OF THE STUDY TO THE PROBLEMS OF HUMAN DIABETES* 
Describe in non-technical terms the significance of the study for human diabetes 
Gestational diabetes mellitus (GDM) affects 5-15% of pregnancies in Australia. Higher risks of adverse outcomes are 
associated with GDM including preterm birth and preeclampsia. Myostatin is a negative regulator which prevents muscle 
growth. It is also known to regulate blood glucose levels, glucose metabolism and homeostasis. The expression of 
myostatin is in obese women, people with type II diabetes and the lean first degree relatives of people with type II 
diabetes  is higher. We recently identified myostatin in the placenta and found it acted to alter the uptake of glucose by 
the placenta. Glucose is the key nutrient which is transported from the mothers blood to the fetus across the placenta to 
maintain growth. GDM is characterised by glucose intolerance and increased levels of maternal blood glucose 
(hyperglycaemia). We hypothesise that there different levels of myostatin will be seen in placenta from women with 
gestational diabetes compared to uncomplicated pregnancies. We aim to establish the differential expression of 
myostatin in GDM placenta and evaluate the expression of molecules involved in its regulation.  
Section Completed
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DETAILS OF THE PROPOSED PROJECT* 
Include: 
i) An introductory summary of your previous work in this field, and of the relevant work of others, 
which leads to the proposed project; 
ii) Detail the specific aims and potential significance of the project (you may need to use serveral 
paragraphs for this section). If hypothesis are to be tested, they should be clearly stated 
iii) A research plan, giving details of experimental design and methods to be used; 
iv) Up to 12 references 
 
 
Please put the details of the Proposed Project in the blue area below, you may copy and paste any 
additional information. Use additional pages as necessary, but do not exceed 4 pages for General and 
Behavioural Grants and 9 pages for Millennium and Viertel Awards (including references). Please tick 
below checkbox once you’ve included the details of the proposed project to complete the section. 
Differential expression of placental myostatin in gestational diabetes.  
 
Background:  
Glucose is a key source of energy required for the development of the fetus and is also the main 
form of carbohydrate transported across the placenta. The majority of the glucose that is 
required by the fetus has to be acquired from the maternal circulation (1). Gestational diabetes 
mellitus (GDM) is characterised by maternal glucose intolerance leading to hyperglycaemia, β-
cell dysfunction and insulin resistance (2). GDM affects 5-15% of pregnancies in Australia (2). 
GDM is associated with an increased risk of adverse outcomes for both mother and infant, 
including a higher risk of induced labour, caesarean section, preterm birth, hypertension, 
preeclampsia stillbirth, macrosomia and infant respiratory distress syndrome (2).  
 
Myostatin/Growth differentiation factor-8 (GDF-8) is a member of the Transforming growth 
factor (TGF)-β super family. It was initially identified as a negative regulator of muscle growth 
(3). It has also been shown to regulate fat deposition and blood glucose levels, glucose 
metabolism and homeostasis (4, 5).  Elevated myostatin levels have recently been identified in 
obese women, type II diabetics and lean first degree relatives of people  with type II diabeties 
(6). We have recently demonstrated that myostatin is expressed in human placenta and that it 
facilitates glucose uptake in placental explants (7). However, the exact role of myostatin in the 
placenta remains to be elucidated.  
 
The absence of myostatin activity has been shown to partially reduce hyperglycemia and 
adipogenesis in mouse models of obesity and type II diabetes (8). In addition, inhibition of 
myostatin activity can improve insulin sensitivity and increase glucose uptake in muscle and fat 
tissues by the up-regulation of glucose transporters (5). Myostatin has also been reported to 
enhance adipogenic insulin sensitivity and glucose metabolism (9). Collectively these studies 
suggest that myostatin plays an important role in glucose homeostasis.  
 
First trimester serum levels of a potent inhibitor of myostatin -follistatin-like 3 (FSTL-3)- were 
significantly lower in women who went on to develop gestational diabetes mellitus (GDM) (10). 
FSTL-3 may act to control the expression and function of myostatin in the placentae of these 
complicated pregnancies. There has only been one published on placental expression of FSTL3 
and myostatin in GDM placentae (11) and problems with the interpretation of these limited data 
leaves many questions yet to be answered.   
The current study aims to establish the differential expression of myostatin and evaluate the 
molecules involved in the regulation of myostatin, such as FSTL3, and members of the 
myostatin signalling pathway (Activin type II receptor, SMAD transcription factors) in relation 
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to the placentae of women with gestational diabetes versus healthy controls. 
 
Hypothesis: 
We hypothesise that there is differential expression of myostatin in placentae from women with 
gestational diabetes compared to uncomplicated pregnancies.   
 
Preliminary data  
Preliminary results from immunohistochemistry and western blot have identified myostatin to be 
present in the human placenta. Immunohistochemistry of placental sections identified myostatin 
to be localised in the cytotrophoblast and syncytiotrophoblast. As verified by positive 
(cytokeratin 7; Figure 1b) and negative staining (vimentin; Figure 1c) of trophoblast.  Western 
blot analysis of placental myostatin (7) identified protein expression to be lower in term 
placentae compared to preterm placentae (Figure 2) 
 
 A)             B)    C) 
  
Figure 1: Preliminary IHC term human placentae. A) Myostatin B) Cytokeratin 7 C) Vimentin   
 
 
 
Figure 2: Western blot placental myostatin  
 
Aim: Identify the differential expression of myostatin and other molecules involved in the 
regulation of myostatin, such as FSTL3, SMAD transcription factors and Activin type II 
receptor in relation to the placentae of women with gestational diabetes versus healthy controls. 
Specific aims  
1. Determine the protein and gene expression of myostatin and its regulatory proteins in 
both GDM and normal placentae. 
2. Determine the localisation of myostatin and its preferred receptor ActRIIB in both GDM 
and normal placentae. 
3. Determine the production of myostatin from isolated primary trophoblast and villous 
explants of GDM placentae. 
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Experimental design  
Placentae from term deliveries (>37 weeks) of women with gestational diabetes (n=20) and 
appropriate age and BMI matched controls (n=20) will be collected. Exclusion criteria will 
include maternal BMI >35, hypertensive disorders of pregnancy, intrauterine growth restriction, 
multiple gestation, delivery prior to 37 weeks. Placental tissues will be processed for the 
collection of protein, mRNA and formalin fixed- paraffin imbedded sections. Placentae will also 
be processed for the isolation of primary trophoblast cells and, explant production to assess the 
production of myostatin, and inflammatory mediators of GDM placenta  
 
1. The differential protein and gene expression analysis of myostatin and its regulatory proteins 
will be determined in both GDM and normal placentae. 
 
Western blotting: Proteins  will be extracted by homogenisation of placenta tissue in 
Radioimmunoprecipitation assay buffer (RIPA) with an enzyme inhibitor tablet (12). Whole, 
nuclear and cytosolic proteins will be collected and resolved using Novex® NuPAGE® SDS-
polyacrylamide gel electrophoresis and transfer system. Probing for myostatin will be performed 
for myostatin (HPA021681 MSTN antibody), FSTL3, SMAD transcription factors and ActRIIB. 
 
Real-time PCR: RNA will be extracted from placental tissues using the RNeasy Mini Kit 
(Qiagen). RNA will be converted to cDNA using the QuantiTect Reverse Transcription Kit 
(Qiagen). Real-time PCR (SYBR Green) will be performed using the Applied Biosystems 
StepOnePlus instrument at UQCCR. Primers will be designed to amplify myostatin, FSTL3, 
SMAD transcription factors and activin type II receptor. 
 
2. The localisation of myostatin and its preferred receptor ActRIIB in both GDM and normal 
placentae. 
 
Immunohistochemistry: Placental sections will be fixed in 10% formalin, paraffin imbedded and 
cut into 5 micron sections. Following deparaffinisation and heat induced epitope retrieval 
sections will be incubated in HPA021681 antibody for the detection of myostatin and 
counterstained with haematoxylin.  Consecutive sections of will also be stained for the presence 
of cytokeratin-7 (trophoblast), vimentin (mesenchymal origin), and ActRIIB.  
 
3. The production of myostatin from isolated primary trophoblast and  villous explants will be 
determined  
 
Cell culture: Human trophoblast cells will be isolated from first trimester placentae using well-
established protocols in our laboratory. Briefly, chorionic villi will be dissected from whole 
placenta and digested with trypsin and DNase I. Cells will be separated by density using a 
Percoll gradient and centrifugation and trophoblasts will be collected and plated at a density of 3 
x10
5
 cells/cm
2 
in DMEM/F-12 media supplemented with fetal bovine serum, gentamicin, 
penicillin and streptomycin. Cell cultures will be maintained at 37◦C hypoxic 3-8% O2 
(normoxic for the placenta) for 24 and 48hours. Supernatant and cells will be collected for 
further analysis of myostatin production. 
 
Explant culture: Placental explants will be established by finely cutting the chorionic villi. The 
cut placental tissues weighing approximately 30-50mg will be distributed in 6-well plates and 
maintained in DMEM/F-12 media supplemented with fetal bovine serum, gentamicin, penicillin 
and streptomycin. Explant cultures will be maintained at 37◦C hypoxic 3-8% O2  for 24 and 
48hours. Both tissues and supernatant will be collected for further analysis of myostatin 
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production. 
 
Elisa: Supernatant collected from primary trophoblast culture and primary villous explants will 
be analysed for the secretion of myostatin and inflammatory mediators through the use of 
commercially-available ELISA kits performed according to manufacturer’s specifications. 
Myostatin by Immundiagnostik and inflammatory mediators (eg TNF-α, IL1-β etc) by BioRad .   
 
 
1. Gude NM, Roberts CT, Kalionis B, King RG. Growth and function of the normal human 
placenta. Thromb Res. 2004;114(5-6):397-407. Epub 2004/10/28. 
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Diabetes series no 14 Cat no CVD 52 Canberra:. 2010. 
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new TGF-β superfamily member. Nature. 1997;387(6628):83-90. 
4. Kim HS, Liang L, Dean RG, Hausman DB, Hartzell DL, Baile CA. Inhibition of 
preadipocyte differentiation by Myostatin treatment in 3T3-L1 cultures. Biochemical and 
Biophysical Research Communications. 2001;281(4):902-6. 
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6. Palsgaard J, Brøns C, Friedrichsen M, Dominguez H, Jensen M, Storgaard H, et al. Gene 
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7. Mitchell MD, Osepchook CC, Leung KC, McMahon CD, Bass JJ. Myostatin is a human 
placental product that regulates glucose uptake. Journal of Clinical Endocrinology and 
Metabolism. 2006;91(4):1434-7. 
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mice. Journal of Clinical Investigation. 2002;109(5):595-601. 
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National Academy of Sciences of the United States of America. 2006;103(42):15675-80. 
10. Thadhani R, Powe CE, Tjoa ML, Khankin E, Ye J, Ecker J, et al. First-trimester 
follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus. 
Diabetes Care. 2010;33(3):664-9. Epub 2009/12/17. 
11. Hu D, Tian T, Guo J, Wang H, Chen D, Dong M. Decreased maternal and placental 
concentrations of follistatin-like 3 in gestational diabetes. Clinica Chimica Acta. 2012;413(5-
6):533-6. 
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Independent of the above, provide details of 3 articles published in books and refereed journals over the 
past five years with significant relevance to this project. Give full titles Do Not include abstracts or work 
in preparation. Do NOT attach copies of publications. 
 
1. 
Mitchell, M.D., McMahon, C. Osepchook, C.C., Leung, K. and Bass, J. J.  Myostatin is a human placental product that 
regulates glucose uptake.  Journal of Clinical Endocrinology and Metabolism 91:1434-1437, 2006 
 
2. 
Antony, N., Bass, J.J., McMahon, C.D. and Mitchell, M.D. Myostatin regulates glucose uptake in BeWo cells. 
American Journal of Physiology [Endocrinology and Metabolism] 293:  E 1296- E 1302, 2007
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biopsies from people with type 2 diabetes and relatives: Differential regulation of insulin signaling pathways. PLoS ONE. 
2009;4(8).
 
 
PROPOSED BUDGET REQUESTED ($)* 
i) Personnel (indicate base salary and additional leave loading, payroll and 
other costs as required by employing body) 
$ 0
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Project significance  
Complications during pregnancy have adverse consequences for the mother and baby in the 
immediate and long term, thereby adding to the burden of the Australian healthcare system. High 
risk pregnancies include those complicated by gestational diabetes mellitus (GDM) (1), preterm 
birth (PTB) (2, 3), intrauterine growth restriction (IUGR) (2, 3) and preeclampsia (PE) (4) (Table 
1). The pathogenesis of high-risk pregnancies is complex and multifactorial. One factor essential for 
a healthy pregnancy is a well-developed placenta.  Abnormal placental development (i.e. poor 
trophoblast proliferation and invasion), and abnormal placental function (i.e. poor glucose 
metabolism) can lead to poor pregnancy outcomes (5). Myostatin is a highly conserved secretory 
protein that regulates muscle development and metabolism. In the placenta, myostatin is localised in 
trophoblast, endothelial, and 
stromal cells, which are crucial 
for placental development and 
function. Myostatin also plays a 
key role in placental glucose 
uptake (6, 7). Importantly, 
myostatin levels were identified 
to be significantly increased in 
placentae and serum from 
pregnancies complicated with PE 
compared to uncomplicated 
pregnancies (8). 
 
We propose that myostatin plays an important role in the pathogenesis of high-risk pregnancies. We 
aim to determine myostatin expression and its effects on placental function(s) in placentae from 
high-risk pregnancies, specifically GDM, PTB, IUGR and PE. This work will, for the first time, 
detail myostatin expression and its actions to alter placental functions in high-risk pregnancies 
compared to unaffected healthy pregnancies. It will provide new knowledge in the area of placental 
function and may provide novel therapeutic targets and innovative approaches to the diagnosis of 
high-risk pregnancy disease. 
 
Hypothesis: 
Myostatin is differentially expressed in high-risk pregnancies and alters placental function in 
high-risk pregnancies 
 
 
Specific Aims: 
Aim: 1. To determine myostatin SNPs, mRNA expression and protein concentration in placentae 
of normal pregnancy and high-risk pregnancies (GDM, PTB, IUGR and PE). 
Aim: 2. To determine and evaluate gene expression and protein concentration for myostatin and 
other associated regulatory molecules in primary placental cell populations from normal 
and high-risk pregnancies.  
Aim: 3. To establish the effect(s) of varying myostatin concentrations and actions on placental 
cell function(s) from normal and high-risk pregnancies.  
 
Background 
Myostatin, also known as Growth Differentiating Factor 8 (GDF-8), is a member of the 
transforming growth factor beta superfamily (9). Myostatin is highly conserved (10) and expressed 
in a number of tissues including muscle (9), adipose (11), cardiac (12), mammary (13) and in the 
human placenta (6). Myostatin is best known as a negative regulator of muscle development. 
Homozygous myostatin null mice (Mstn
-/-
) exhibit doubling of muscle tissue mass compared to wild 
type mice (9). Myostatin has also been shown to regulate adipose deposition and glucose 
Table 1: Pregnancy complications 
Pregnancy 
complication  
Pregnancies affected (%) 
Gestational Diabetes 
Mellitus (GDM) 
5-15% of pregnancies in Australia (1), 
Preterm birth (PTB) 7-8% of pregnancies in Australia (2, 3) 
Intrauterine Growth 
Restriction (IUGR) 
1-4% of births in Australia (2, 3)  
Preeclampsia (PE) 3-5% of women worldwide (4) 
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metabolism (11, 14). The absence of myostatin activity partially reduces hyperglycemia and 
adipogenesis in mouse models of obesity and type 2 diabetes (15). In humans, people with type 2 
diabetes were identified to have significantly higher skeletal muscle myostatin mRNA expression 
(16, 17) and interestingly an up-regulation in the myostatin gene was seen in the first-degree 
relatives (people with at least 50% of their genes in common) of people with type 2 diabetes (16). 
Myostatin is also elevated in human obesity, as myostatin plasma concentrations and myostatin 
protein levels were identified higher in extremely obese women compared to lean women (18). 
Collectively, these studies suggest that 
myostatin plays an important role in glucose 
homeostasis and has the potential to be a 
diagnostic agent.  
 
Myostatin and its effects on pregnancy, 
placental development and pregnancy 
outcomes are not well understood. Mstn
-/-
mice are fertile and viable, whereas cattle 
with double muscling are known to have 
difficulties in maintaining pregnancies, 
calving, and overall fertility (19, 20).  In 
humans, an infant boy was carried to term 
and born to a woman with a (heterozygous 
carrier of a myostatin gene mutation) G to A transition in the first intron-exon region. The boy was 
identified to be homozygous for this mutation which resulted in the introduction of a stop codon 
and the truncation of the myostatin protein and inactivation of its function. The boy continued to 
have the characteristic increase to muscle mass seen when myostatin is not functional as a neonate, 
7months and at 4.5 years of age and he was also observed to be extraordinarily strong (21).  
 
Studies of myostatin expression and function in high-risk human pregnancies (PE, IUGR, PTB and 
GDM) are limited. No studies of this nature have been performed in Australia. A study conducted in 
women with PE reported significant increases in the concentration of myostatin in serum, placental 
myostatin protein and mRNA expression compared to controls (8). In addition, the concentrations 
of a potent endogenous inhibitor of myostatin activity, follistatin like-3 (FSTL-3), was also 
observed to be higher in PE pregnancies (8, 22). In pregnancies complicated by GDM no significant 
differences in myostatin 
production have been 
observed however, 
FSTL-3 was 
significantly lower in 
serum and placentae of 
patients with GDM (23, 
24). It is possible that in 
pregnancies complicated 
by GDM, FSTL-3 may 
act to control myostatin 
actions.  
 
Myostatin Single 
Nucleotide 
Polymorphisms  
The human myostatin 
gene is comprised of three exons, intervened by two conserved introns and a 3’ untranslated region 
and is mapped to chromosome region 2q32.2 in humans (25). Single Nucleotide Polymorphisms 
Figure 1: Homozygous 
myostatin mutation. (A) 
Morphometric analysis 
of muscle cross-sections 
in a young boy with 
homozygous myostatin 
mutation (left) compared 
to a control (right). (B) 
Arrows indicate muscle 
protrusions in the thigh 
and calf muscles of the 
boy as a neonate and a 7 
month old [17] 
 
Table 2: SNPs identified in the myostatin gene  
SNP Region 
Genotype/ 
Amino 
acid 
Phenotype changes 
Humans    
rs3791783 Intron 2 AA 
Increased BMI, cholesterol, 
triglycerides and low-density lipids 
(23), Fat deposition and obesity (25) 
rs3791782 Exon 3 AG 
Lower cholesterol and low density 
lipid (23) 
rs1799883 
(A55T) 
Exon 1 TT 
Increased adiposity, low lean body 
mass (24) 
rs1805086 
(K153R) 
Exon 2 RR 
Increased adiposity, low lean body 
mass (24) 
Animals    
G2283A Exon 1 GG Increased age of first egg laying (27) 
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(SNPs) in the myostatin gene have been identified in both human and animal populations. 
Myostatin SNPs are found in both coding and non-coding regions of the myostatin gene (Table 2). 
Associations have been made between myostatin SNPs and the risk of obesity (26-28), alterations to 
muscle function (29), reproduction traits (30) and birth-weight (31). Myostatin SNPs rs3791783, 
rs1799883 and rs1805086 are associated with an increased risk and rs3791782 a decreased risk of 
obesity in Chinese and Indian populations (26-28).  
 
The extent to which myostatin polymorphisms play a role in placental development and pregnancy 
is unknown. In particular, our understanding of the role myostatin SNPs have in high-risk 
pregnancy remains to be elucidated. Given the association of myostatin SNPs and the risk of 
obesity, it is possible that further investigation into myostatin polymorphisms may lead to the 
development of a predictor, severity indicator, early diagnostic or therapeutic target for high-risk 
pregnancies. We, therefore, aim to characterise myostatin polymorphisms and myostatin gene 
expression in high-risk pregnancies compared to normal pregnancies.  
 
Myostatin protein 
In addition to the SNP analysis we will determine myostatin protein concentrations (quantify) 
in high-risk pregnancies. Although significant associations have been made between myostatin 
SNPs and phenotype, a major limitation in 
these studies is that myostatin protein 
levels were not analysed. The proteolytic 
processing of the myostatin precursor 
protein generates different molecular 
weight fractions of the myostatin protein 
such as the mature myostatin protein 
12kDa which dimerizes to form the active 
myostatin dimer (28kDa) and the 
propeptide (42kDa) which creates a latent 
complex (75kDa)  with the myostatin dimer 
(Figure 2, boxes A-F). The interactions of 
these different myostatin fractions are 
essential in regulating and maintaining 
myostatin activity. Therefore, to obtain an 
accurate idea of the effect of myostatin 
SNPs or analyse the condition and function 
of myostatin, it is necessary to detect all of 
the various forms of myostatin.  
 
Myostatin biosynthesis and signalling  
Myostatin is initially synthesized as a 
~52kDa precursor protein that contains an N-terminal secretory signal, a pro-peptide domain, and a 
C-terminal RSRR (Arg-Ser-Arg-Arg), and a proteolytic processing site (9, 10). The first proteolytic 
cleavage removes the N-terminal signalling sequence required for protein secretion (Figure 2B) (32, 
33). The second proteolytic cleavage (by Paired Dibasic Amino acid-Cleaving enzyme; PACE, also 
known as Furin) occurs at the proteolytic processing site releasing the ~42kDa N-terminal pro-
peptide (latency associated peptide; LAP) and a ~12kDa C–terminal fragment that is the mature 
myostatin protein (Figure 2C) (32, 33). Dimerization of the ~12kDa mature myostatin protein 
creates the active form of myostatin - the ~28kDa myostatin dimer (Figure 2D) (10, 32, 34).  
 
Binding of the myostatin dimer to Activin type II receptor (Activin receptor IIB; ACTRIIB) 
initiates the trans-phosphorylation of the type I receptor (ALK4/ALK5) and the stimulation of 
downstream serine/threonine kinases associated with the type I receptor (Figure 2H) (34, 35). The 
Figure 2: Myostatin biosynthesis and signalling  
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activation results in the phosphorylation of intracellular transcription factors Smad 2 and Smad 3 
(R-Smads), which oligomerize with the co-Smad-Smad 4 (Figure 2I) (34, 35). The Smad 2, 3 and 4 
oligomer translocates to the nucleus (Figure 2J) and in association with other transcription factors, 
regulates the transcription and expression of downstream genes necessary for myostatin action 
(Figure 2K) (34, 35).  
 
Inhibition of myostatin functional activity 
Antagonists of myostatin activity include the 42kDa propeptide (LAP) and FSTL-3. Two 
monomeric (LAP) pro-peptides bind non-covalently to the myostatin dimer forming a latent 
complex (~ 75kDa) and prevent the dimer from binding to its receptor ACTRIIB (Figure 1E) (32, 
35-37). The majority of myostatin (~70%) found in circulating blood is in this latent complex form 
(37, 38). Four metalloproteinases of the bone morphogenetic protein (BMP)-1/Tolloid family have 
been identified to be involved in the release of the myostatin dimer from its latent complex via the 
proteolytic cleavage at Asp-76 of the myostatin pro-peptide (Figure 1F) (35, 37, 39). LAP also 
facilitates the proper folding of the C-terminal domain by forming a cysteine knot. FSTL-3 is also a 
potent inhibitor of myostatin activity. It is a structural homologue of follistatin that binds with a 
high affinity (in vivo) to myostatin (C-terminal dimer), inhibiting the biological activity of 
myostatin (Figure 2L) (39).   
 
Preclinical studies of FSTL-3 and LAP incorporated into viral vectors, anti-myostatin antibodies, 
soluble myostatin receptors, small interfering RNA and small chemical inhibitors have shown 
promise as methods of interrupting myostatin function (35, 40, 41). Phase I and II trials have 
already been completed on two compounds MYO-029 (recombinant human antibody against 
myostatin used as a treatment of muscular dystrophy) and ACE-011 (fusion protein consisting of 
the extracellular domain of the ACTRIIA and Fc portion of human IgG1, studied in postmenopausal 
women) (42, 43). In these studies both inhibitors were found to be safe for human administration 
but had limited effect on muscle, bone and fat biomarkers. The recruitment of subjects is currently 
underway (clinicaltrials.gov) for trials testing the effectiveness and safety of compounds which 
inhibit myostatin in cancer patients (NCT01524224; myostatin is increased in cancer cachexia (44, 
45)) and muscular dystrophy (NCT01519349).  It is be possible that these inhibitors may be used to 
prevent or treat adverse pregnancy outcomes if myostatin is found 
to be an important factor associated with the pathogenesis of any 
of these high risk pregnancies.  
 
Myostatin and the placenta - preliminary findings  
The expression of myostatin in the placenta has been reported in 
humans, mice and rats (6, 46, 47). We have shown a negative 
correlation between myostatin in the placenta and gestational age 
(6). This was evident as both myostatin mRNA expression and 
myostatin protein levels were lower in term placentae compared 
to early gestation and preterm placental tissue respectively (Figure 
3) (6).   
 
We have also described a possible role for myostatin in placental 
glucose uptake. Glucose is a key energy source required for fetal development and is the main form 
of carbohydrate transported across the placenta (6, 48). We have shown that myostatin (1µg/ml) 
treatment increases uptake of deoxyglucose in human placental explants (6). Supporting these 
findings, another study showed that myostatin increased glucose uptake in a dose dependent manner 
in C2C12 myotubles and L6 myocytes (49). In this study, treatment with the myostatin inhibitory 
protein, follistatin and myostatin pro-peptide (LAP) resulted in the inhibition of glucose uptake by 
C2C12 myotubes (49). 
 
Figure 3: Differences in 
placental myostatin expression 
levels in preterm and term 
placentae detected by western 
blot. (Human muscle tissue 
used as positive control) 
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The nutritional state of the mother and grandmother is also known to affect the expression of 
myostatin as described by Peiris et al. (2010). We have shown that gestational under-nutrition of 
wistar rat grand-dams (UN; F0) resulted in increased myostatin protein levels in the placentae 
supporting the grand-offspring (UNAD; F2) compared to controls (ADAD normal diet) (46). No 
difference was found in the fetal weight of the grand-offspring compared to controls, although the 
placental weight of this group was lower. Thus, these smaller placentae were potentially working 
more efficiently to maintain fetal size possibly aided by the higher levels of myostatin suggesting a 
potential role for myostatin in regulating the nutrient supply to the offspring (46).  
 
Most recently, we reported the 
localization of myostatin in human 
first and third trimester placentae 
through immunohistochemistry 
(IHC) (7). Myostatin was 
identified in trophoblasts, 
endothelial and stromal cells in 
both first and third trimester 
placentae (Figure 4 localization of 
myostatin at both gestations). 
ACTRIIB (myostatin receptor) 
and FSTL-3 are known to be 
localized in cytotrophoblast, 
syncytiotrophoblast, endothelial 
cells (ACTRIIB) and placental blood 
vessels (FSTL-3) (50, 51). This 
therefore provides support for the 
possibility that myostatin is functional 
in these placental sites.  
Myostatin in the placenta may act in a 
similar way as in muscle and adipose 
tissues where the ability of myostatin 
to affect proliferation and 
differentiation has been noted.  
Recently, along these lines myostatin 
has been used in human embryonic 
stem cells to maintain undifferentiated 
growth (9, 35, 52, 53).  
 
We have also identified myostatin expression in placentae from high-risk pregnancies (GDM, PTB, 
IUGR PE and obesity). Preliminary findings indicate that the myostatin dimer protein is increased 
in pregnancies complicated with GDM and PE (Figure 5). Our preliminary findings as well as 
recent myostatin publications on high-risk pregnancies have led us to develop our hypothesis and 
aims. We hypothesise that myostatin is differentially expressed in high-risk pregnancies, and 
alters placental function in high-risk pregnancies.  
 
Research Plan 
Study participants: Pregnant women with both normal and high-risk pregnancies will be recruited. 
High-risk pregnancy groups will be selected according to diagnostic criteria for each disorder (i.e. 
GDM- Australasian Diabetes in Pregnancy Society (ADIPS) criteria (54), PE – Society of Obstetric 
medicine of Australia and New Zealand (SOMANZ) criteria (55), IUGR – (Royal Australian and 
New Zealand College of Obstetricians and Gynaecologists (RANZCOG)/The Australian Council on 
Healthcare Standards (ACHS) (56) and PTB – (per Queensland maternity and neonatal clinical 
Figure 4: (A) Localisation of myostatin in 1
st
 trimester 
cytotrophoblast [1], syncytiotrophoblast [2], stromal [3] and 
endothelial cells [4]. (B) Localisation of myostatin in 3
rd
 
trimester cytotrophoblast [1], intermediate trophoblast [2], 
stromal cells [3] and endothelial cells [4] detected by IHC 
analysis. 
Figure 5:  Myostatin dimer expression in high-risk 
pregnancies. (A) IUGR, PE-IUGR and PE placentae 
compared to PTB (best gestational match control)  (B) 
GDM placentae compared to term placentae (control). 
Western blot- Figure resolution is poor at current size. 
Densitometry performed on Quantity One software. 
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guidelines) (57). The control group will consist of placentae from women with normal pregnancies 
(without the complications listed above) and will be best matched for gestational age with placentae 
from women in the high-risk pregnancy group, with the exception of preterm deliveries where the 
control group will be term pregnancies. Relevant clinical information such as gestational age, 
maternal age, parity, BMI, and smoking status will be incorporated into the analysis of the 
experimental data.  
 
Sample Collection: A tissue bank is already established of placentae from high-risk pregnancies 
through collaborations with researchers and clinicians in Mercy Hospital in Melbourne, Victoria 
The collection of fresh placental tissue from high-risk and normal pregnancies has been approved 
by the Human Research Ethics Committees of the Royal Brisbane and Women’s Hospital, and the 
University of Queensland (HREC/12/QRBW/391). Placental samples will be collected immediately 
after delivery (caesarean section or vaginal). Pieces of placental villous tissue will be removed from 
the placental unit, leaving behind the membranes and decidua.  Placental villous tissue will be 
washed thoroughly with normal saline, snap frozen with liquid nitrogen and stored at -80C until 
required for use in Aim1. For Aim 2 & 3 placenta-derived cells such as trophoblasts will be used. 
Placental villous tissue pieces will be minced and enzymatically digested for the release of 
trophoblast cells using protocols adapted from Fisher et al (58). Finely minced placental explants 
will also be used in Aim 3 to assess deoxyglucose uptake. Primary cell and tissue cultures will be 
conducted at physiologically relevant oxygen tensions (i.e. 8% O2 in third trimester) in contrast to 
other studies that have used superoxic conditions (i.e. 21% O2). This will be done through the use of 
the BioSpherixTM system, which allows us to precisely control oxygen tension and to recapitulate 
in situ oxygen tensions that are clinically and physiologically relevant. 
 
Statistical Analysis 
An a priori power analysis was performed, using an effect size of 0.75 in a two tailed student t-test 
(Difference between two independent means (two groups), with an alpha error of 0.05 and a range 
for power (0.75). The sample size required for the control and experimental groups (PE, IUGR, 
PTB and GDM) was identified to be n=26. Five groups in total with n=26 per group therefore 130 
placental samples in total. The differences between the groups will be examined using ANOVA and 
student’s t-tests as appropriate.  
 
Aim: 1. To determine myostatin SNPs, mRNA expression and protein concentration in placentae 
of normal pregnancy and high-risk pregnancies: GDM, PTB, IUGR and PE. 
Rationale  
A recent publication identified the concentration of myostatin in serumm and myostatin protein 
levels in placental tissues to be significantly elevated in PE women compared to normal controls 
(8). Our preliminary data supports these findings (Figure 5). Compared to the control group 
placentae we observed a fourfold higher myostatin dimer protein in placentae from pregnancies 
complicated with PE and a twofold higher myostatin dimer protein in placentae from pregnancies 
complicated with GDM (Figure 5). We, therefore propose to elucidate the differences in myostatin 
polymophisms (SNPs), mRNA and protien expression in the placentae of women who had a normal 
or high-risk pregnancy. Combined, these data will inform whether myostatin is an important factor 
involved in the pathogenesis of high-risk pregnacies. A major strength of this project is that we 
already have a collaboration established with researchers and clinicians; Dr Martha Lappas, A/Prof 
Stephen Tong and Dr Harry Georgiou at the Mercy hospital in Melbourne, Victoria. Through this 
collaboration, we have already initiated placental tissue collection and have a tissue bank for each 
of the high-risk pregnancy groups and controls (n=12 per group).   
 
Experimental design 
Experimental analyses will be performed on placental samples collected from high-risk pregnancy 
groups GDM, PTB, IUGR and PE (n=26 per group) and compared to placental samples from 
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normal pregnancy best matched for gestational age (n=26). RNA will be extracted from placenta 
tissue using the RNeasy mini kit (Qiagen) and RNA integrity will be assessed using the Bioanalyzer 
(Agilent). 
(i) New and existing myostatin polymorphisms (SNPs) will be investigated in high-risk compared 
to normal placentae, using a custom targeted amplicon-based approach (TruSeq®) the assays 
will cover the full region of both genes and assay 96 samples per run. Samples will be run on 
the MiSeq next generation sequencer which integrates amplification, sequencing and data 
analysis. (AI Brooke Gardiner has extensive expertise in gene expression technology and will 
provide input on the design, processing and data interpretation). 
(ii) The mRNA expression of myostatin and associated genes will be determined by real-time PCR 
(SYBR Green) performed using the Applied Biosystems StepOnePlus instrument. Primers will 
be designed to amplify myostatin, FSTL3, SMAD transcription factors and activin type II 
receptor.   
(iii) The levels of myostatin protein will be determined by semi-quantative methods e.g. western 
blot analysis and 
by a highly 
sensitive method 
(mass 
spectrometry). 
  
Mass Spectrometry 
(MS) Procedure:  
We propose the use of 
MS as a robust 
method of detection 
which will be able to 
discriminate between 
the different myostatin 
protein forms (i.e 
Precursor, LAP, 
Dimer) through the 
analysis of individual 
peptides.  
AI Keith Ashman has 
extensive experience working with MS technique. We have the use of a nano-electrospray 
LC/MS/MS on Triple TOF 5600 system (ADSciex) coupled to an Eksigent nanoflex chip HPLC 
system within our laboratory. Supporting our ability to use MS, the survey scan (Figure 6) shows 
the total ion current of the MS analysis used to obtain the MS/MS scans to determine the transitions 
required to generate the extracted ion chromatogram of targeted myostatin peptides (myostatin 
dimer peptides identified by MASCOT search engine).  
(i) Isoelectric focussing - The protein derived from tissue extracts are highly complex. To address 
this issue, the samples will be separated using a multi-dimensional approach. Firstly, the 
proteins will be proteolytically cleaved with trypsin. The resulting peptide mixture will be 
separated by isoelectric focussing (Agilent off-gel system) and the individual fractions analysed 
by nano-electrospray LC/MS/MS on Triple TOF 5600 system (ABSciex) coupled to an 
Eksigent nanoflex chip HPLC system. The samples will be analysed using information 
dependent acquisition (IDA) and the recently developed SWATH analysis to generate a 
comprehensive spectral library for quantitation.(59) 
(ii) Targeted Proteomics - Taking advantage of the proteomics data generated with the above, we 
will develop a targeted selective reaction monitoring method (SRM) for the various forms of 
Figure 6: Mass Spectrometry Tryptic Profile of Digested Myostatin dimer 
protein analyzed by nano-HPLC/ on a 5500 QTRAP hybrid triple 
quadrupole/linear ion trap mass spectrometer. Peptides identiifed by 
MASCOT  search engine 
 
Peptides identified  
ANYCSGECEFVFLQK 
DFGLDCDEHSTER 
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myostatin. To ensure the method has the required specificity, we will apply Unique Ion 
Signature (UIS) methodology(60). 
 
Expected Outcome 
The data obtained will confirm the level of myostatin gene expression and protein concentrations 
between normal and high-risk pregnancies. Using MiSeq technology existing myostatin SNPs 
and/or new SNPs will be identified in placentae from high-risk pregnancies compared to normal 
pregnancies. These outcomes will provide novel information about placental myostatin and will 
give insight into the role of myostatin polymorphisms in the pathogenesis associated with high-risk 
pregnancies.  
 
Aim: 2. To determine and evaluate gene expression and protein concentration for myostatin and 
other associated regulatory molecules in primary placental cell populations from normal 
and high-risk pregnancies. .  
Rationale 
We propose that the concentrations of myostatin and its regulatory molecules are altered in 
trophoblast cells isolated from placentae of pregnancies complicated with GDM, PTB, IUGR and 
PE. Trophoblast cells are crucial for the development and function of the placenta. They play an 
important role in the process of placental implantation as well as regulating nutrient exchange and 
maintaining an immune interface between the mother and fetus. Our preliminary data demonstrate 
that myostatin is found in first and third trimester trophoblast cells (Figure 5). We will therefore, 
determine whether myostatin and associated regulatory molecules such as FSTL-3 are differentially 
expressed in isolated primary trophoblast cells from normal and high-risk pregnancies.  
 
Experimental design 
(i) Primary trophoblast cells will be isolated from third trimester placentae of normal and high-risk 
pregnacies (sample collection) .  
(ii) Myostatin mRNA expression and mRNA expression for other associated molecules (FSLT-3, 
ACTRIIB, and SMAD transcription factors) will be determined in isolated trophoblast cells 
from normal and high-risk placentae using Sybr Green realtime PCR technique used routinely 
in our laboratory.  
(iii) Levels of myostatin, FSLT-3, ACTRIIB, and SMAD transcription factors protein will be 
determined in these isolated trophoblast cells from normal and high-risk placentae using 
standard techniques (western blotting) and MS. 
 
Expected Outcome 
These findings will determine whether gene expression and protein concentration of myostatin and 
other members of the myostatin pathway are altered in trophoblast cells in high-risk pregnancies 
compared to normal pregnancies.  
 
Aim: 3.  To establish the effect(s) of varying myostatin concentrations and actions on placental 
cell function(s) from normal and high-risk pregnancies. 
Rationale 
We propose myostatin contributes to placental glucose homeostasis and may be a therapeutic target 
in high-risk pregnancies (GDM, PTB, IUGR and PE). We have previously demonstrated that 
myostatin treatment increases glucose uptake in human placental explants (6), suggesting it 
contributes to placental glucose homeostasis. Because myostatin alters functional properties of the 
placenta, we are therefore interested in establishing the direct relationship between myostatin and 
the trophoblast cells. We will investigate the effect(s) of myostatin treatment on the functional 
properties of trophoblast cells isolated from high-risk pregnancies compared to normal pregnancies. 
Simultaneously, we will also investigate these functional properties of trophoblast cells after 
blocking myostatin activity in these cultures.  
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Experimental design 
Primary isolated trophoblast will be cultured in the 
presence or absence of recombinant myostatin as we 
have previously described (6, 61). Loss of myostatin 
function will be achieved using shRNA and endogenous 
inhibitor (FSTL-3). shRNA targeting myostatin (Sigma-
Aldrich) will be transiently transfected into primary 
trophoblast cells. Experiments to assess placental cell 
function are listed below.  
(i) Proliferation - Trophoblast proliferation will be 
monitored in real-time using our IncuCyte
TM
 live-
cell imaging system. 
(ii) Differentiation - Trophoblast syncytialisation will 
be determined using previously published 
techniques: (1) hCG production measured by 
ELISA, and (2) desmoplakin IHC (62).  
(iii) Cell Migration- To determine trophoblast cell migration, a scratch wound assay will be 
performed in which trophoblasts will be grown to confluence and then a scratch will be made 
using a 96-pin WoundMaker
TM
. Migration will be monitored using IncuCyte live-cell imaging 
system. Wound images will be automatically acquired and registered by the IncuCyte
TM
 
software system. The data will then be analysed using an integrated metric: Relative Wound 
density.We have previously demonstrated that myostatin increases migration of trophoblast cell 
lines using the Incucyte in vitro system within our laboratory (Figure 7).   
(iv) Cell Invasion – Invasion assays will be performed using the HTC Transwell System (Corning 
Life Sciences). Briefly, primary trophoblast cells (treated or untreated, as described above) will 
be cultured on an HTC Transwell insert (3.0 μm pore size) precoated with Matrigel (Becton 
Dickinson). The HTC Transwell insert will then be placed into a Receiver Plate containing 
trophoblast medium and incubated for 48 hours. Cells that invade the Matrigel filter and are 
found in the Receiver Plate will be fixed and stained with hematoxylin and eosin and images 
will be captured by microscopy. Values for cell invasion will be expressed as the average 
number of cells per microscope field counted over 4 fields per filter. 
(v) Deoxyglucose uptake-Finely minced placental explants will be cultured in 12-well plate in 
DMEM-medium 199. After 24h, placental explants will be washed three times with PBS to 
remove any residual fetal calf serum. PBS containing 1 µCi [3H] deoxyglucose in the presence 
or absence of 1 µg/ml myostatin will be used to determine glucose uptakes as we have 
previously described (6). Deoxyglucose uptake will be calculated as counts per minute per 
milligram of protein and is will be expressed as a percentage of the control value. 
 
Expected outcome: 
These data will enhance our understanding of the physiological role of myostatin in the placenta by 
determining whether myostatin acts on trophoblast cell function and glucose uptake. The results 
will clarify whether or not myostatin is responsible for altering these functions in trophoblasts from 
high-risk pregnancies. 
 
Project feasibility  
Our laboratory has an established track record collecting and investigating the human placenta. The 
majority of publications on myostatin in the placenta to date are attributed to CI Mitchell. The team 
assembled for this grant are expert at the techniques to be utilised (e.g. next generation sequencing, 
real-time PCR, western blot, mass spectrometry, and primary cell isolation and tissue culture). The 
facilities used for this project all have high-end state-of-the-art equipment run professionally and 
are able to create highly reliable data output. 
Figure 7. Myostatin treatment increases 
cell migration in BeWo cells. Graph 
showing area under curve representation 
of cell migration compared to controls. 
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Associate investigators  
 
AI Ashman 
Associate Professor Ashman is the head of the clinical applications development at The University 
of Queensland Centre for Clinical Research. AI Ashman has extensive international experience in 
quantitative proteomics and has been a leader in world-class analytical laboratories including; 
Director of Mass Spectrometry at the Australian Proteomics Analysis Facility and the Proteomics 
Facility at the Spanish National Centre for Cancer research in Madrid. AI Ashman will provide 
expertise and guidance in the mass spectrometry acquisition and analysis required for Aims 1 and 2.  
 
AI Gardiner 
Dr Brooke Gardiner is the facility manager for the Diamantina Institute’s Centre for Medical 
Genomics at the University of Queensland. She has nearly 10 years experience in microarray and 
gene expression technology. Since 2006, she has played a pivotal role in establishing an array 
processing service for the Institute for Molecular Biosciences and now at the Diamantina Institute. 
This involved coordinating the standardisation of the sequencing instruments and library 
preparation procedures as well as the development and optimisation of novel approaches for library 
generation. She will provide critical feedback and technical assistance with experimental design, 
processing and data interpretation. 
 
AI Kimble 
Associate Professor Rebecca Kimble is the Clinical Director of Obstetric Services at the Royal 
Brisbane and Women’s Hospital. She will oversee the identification and collection of tissues in a 
timely fashion. She will also review the clinical data for subsequent categorisation and all charts for 
confounding factors of events or treatments. Given her role in the Obstetrics and Gynecology 
department, Associated Professor Kimble is the best person to carry out these requirements. 
 
AI Peiris  
Ms Hassendrini Peiris is a researcher at The University of Queensland Centre for Clinical Research 
and has 5 years experience investigating myostatin in both animal and human tissue. She has 
worked with our team for the past 3 years and has substantial experience in placental cell isolations 
as well as expertise in molecular and proteomic techniques. She has contributed to three 
publications on myostatin in the placenta. AI Peiris will coordinate the collection, preparation, 
experimentation and analysis of clinical samples required for all aims.  
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Team Quality and Capability 
Summary of Research Team: CIA Mitchell and CIB Rice are recognized leaders in the field of 
reproductive biology and, in particular, in complications of pregnancy. Each CI brings over 30 
years experience in the field of reproduction. They also have a proven track record in collecting 
appropriate and sufficient clinical samples to successfully complete the project as outlined. CIA and 
CIB occupy offices on the same floor of UQCCR and have contiguous laboratory space. They have 
joint research team meeting and co-supervise all students. The Centre for Clinical Diagnostics 
(CCD) is a part of their joint space and funded through Therapeutics Innovation Australia (QLD) 
via a grant on which they are co-investigators. CI Mitchell and Rice have published over 250 and 
50 papers in prostaglandin research respectively (see CVs). CIA Mitchell has published on 
myostatin since 2005 and has 6 relevant published papers and 8 abstracts in the last decade. AI 
Peiris has worked with CI Mitchell for the last 5 years and has considerable myostatin knowledge 
and experience with the experimental techniques required for this project. AI Peiris has presented 
her work at national and international meetings. Together AI Peiris and CIA Mitchell have 
successfully secured a DART grant for Myostatin and GDM analysis.  
 
AI Gardiner will provide expertise and guidance in MiSeq experiments at the UQ Centre for 
Clinical Genomics. AI Gardiner visits CCR on a weekly basis for MiSeq updates. Recruitment and 
collection of placental samples from women who had high-risk pregnancies will be overseen by AI 
Kimble who is the Clinical Director of Obstetric Services at the RBWH where samples will be 
obtained. CIA Mitchell, CIB Rice and AI Kimble have submitted ethical application for sample 
collection to the RBWH Human Research Ethics Committee. AI Ashman will provide expertise and 
guidance in mass spectrometry and is a part of CIA and CIB’s team and based in the same 
laboratory as AI Peiris. They are both within the CCD at UQCCR.  
 
Productivity of Research Team (in relation to experiments): CIA Mitchell will be responsible for 
overseeing the progress and completion of this project. CIA Mitchell, PSP1 and PSP3 will discuss 
experimental design related to Specific Aims 1, 2, and 3. PSP3 will be responsible for completing 
the experiments with the help of PSP1. PSP1 will support placental collection and isolation. Results 
of these experiments will be analysed by PSP3 and discussed with CIA Mitchell and CIB Rice for 
critical feedback and future direction. AI Gardiner and PSP3 will be responsible for designing the 
approach for SNP analysis in aim 1. AI Gardiner will perform the SNP analysis at the UQ Centre 
for Clinical Genomics on UQCCR owned MiSeq System. The data output will be analysed by 
PSP3, CIA Mitchell and CIB Rice with significant input from AI Gardiner. AI Ashman will be 
responsible for all mass spectrometry experiments and will advise PSP3 and PSP1 on sample 
preparation for mass spectrometry. The data output will be analysed by PSP3, CIA Mitchell, CIB 
Rice and AI Ashman. Manuscript preparation will primarily be the responsibility of PSP3 with CIA 
Mitchell with critical feedback from all other members of this team. 
 
Facilities: This programme of work will be conducted within the CCD at UQCCR.  The UQCCR is 
a state-of-the-art translational research facility located on the RBWH campus.  UQCCR comprises 
eight floors with a total floor space of 11,628m
2
 and boasts 2,841m
2
 of modern well equipped and 
serviced PC2 research laboratories spread across five floors. We have recently installed two next 
generation sequencers (HiSeq and MiSeq) and associated bioinformatics hardware, and have expert 
experienced technical management of the associated facility (The University of Queensland Centre 
for Clinical Genomics).  In a major advance in our proteomic analysis capacity is the three mass 
spectrometers (ABSciex 5500, 5600 and 5800) in CCD; this is underpinned by funding from 
Therapeutic Innovation Australia that also provides for experienced senior technical and academic 
management. These new facilities with cutting edge technologies and expert technical and 
supervisory personnel are the critical facilities through which our analyses will be conducted and 
through which our studies can be completed.  
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CIA TRACK RECORD: Prof. Murray D. Mitchell, MD, D.Phil, D.Sc, FRSNZ,  
Professor Murray D. Mitchell is Director, UQ Centre for Clinical Research. Previously he was 
Research Director and Deputy Director of the Liggins Institute at the University of Auckland and 
Deputy Director of the National Research Centre for Growth and Development in New Zealand. He 
has held positions at the Universities of Oxford, Southwestern Medical School in Dallas, University 
of California, San Diego, University of Utah and was Head of the Department of Pharmacology and 
then Associate Dean of Planning and Deputy Dean the University of Auckland, Faculty of Medical 
and Health Sciences. He has a D.Sc from Liverpool University and a D.Phil from Oxford 
University. 
 
Professor Mitchell has received many distinctions including:1977-1980 Staines Medical Research 
Fellow, Exeter College, Oxford University; 1998 Elected to Fellowship of the Royal Society of 
Chemistry; 1988-1992 Member of NIH Study Section “Human Embryology and Development; 
1991 Presidents Achievement Award, Society for Gynecologic Investigation; 1998-2000 Elected 
NZ President Australasian Society of Clinical and Experimental Pharmacologists and 
Toxicologists; 1999 Elected to Fellowship of the Royal Society of New Zealand (FRSNZ) and in 
2008 the Society awarded him a James Cook Research Fellowship. He is also CChem FRSC 
(Chartered Chemist, Fellow of the Royal Society of Chemistry); FAIC (Fellow of the American 
Institute of Chemistry). 
 
As well as having served on the HED Study Section of NIH he has reviewed for major funding 
bodies in the UK, USA, Canada, Australia and New Zealand. In both 2003 & 2006 he was 
appointed a member of the Medicine and Public Health Peer Review Panel for the Performance- 
Based Research Fund by the Tertiary Education Committee of NZ. This involved a quality review 
of all medical and biomedical researchers in NZ. Notably, in April 1994, he served as invited 
consultant to the Scientific Advisory Committee of the March of Dimes meeting in White Plains, 
New York. "Preterm Labor: what do we know and what should we know?" In 2008, he was an 
invited participant and speaker at March of Dimes/Burroughs Wellcome Fund Symposium on 
“Preventing Prematurity; establishing a network for innovation and discovery”. In 2009, he was an 
invited participant at GAPPS International Conference on Prematurity and Stillbirth. 
 
Professor Mitchell is a specialist in the mechanisms involved in labour and delivery. He and 
Roberto Romero led the team that discovered the only known cause of premature labour: infection 
in the membranes lining the uterus. He has held a Programme Grant from the HRC (New Zealand) 
around prevention and treatment of preterm delivery. Moreover, he was Co PI on a funded Centre 
of Research Excellence in NZ. Previously, he has held major grant funding from NIH (USA) and 
the MRC (UK). In total he has received over $50 million in research funding. He was the first non- 
North American member of the Council of the Society for Gynecologic Investigation, the world’s 
leading OBGyn Research Society, and was elected to a second term on the Council. 
Professor Mitchell has mentored and supervised a total of 110 students. They include PhDs, 
Masters, BSc Honours, MD and Clinical Fellows. Professor Mitchell has published 434 peer 
reviewed papers, over 100 reviews or book chapters and 500 abstracts. He has an h index of 60. 
 
Major achievements in commercial, social and environmental areas: 
His findings of intrauterine infection as the major cause of preterm labour have changed 
management regimes and brought about introductions of new treatments. The introduction of 
Pharmacy and Nursing Schools in the Faculty of Medical and Health Sciences, University of 
Auckland, with active recruitment of Maori students has had significant social (and commercial) 
impact. 
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Demonstration of relationships with end-users: 
Professor Mitchell has been a scientific consultant with Adeza Biomedical, NeuronZ, NZ and 
Dexcel Ltd, NZ. He has also been an invited consultant to the Mangere Health Resources Trust with 
remit to review the pharmacy facilitation system. Moreover he served as a member of the Ceradase 
PTAC sub-committee of PHARMAC with ongoing oversight remit. In 2005 he was co-leader of 
joint initiatives with AgResearch, NZ across all related research programmes. 
 
Key publications 
1. Walker, D.W. and Mitchell, M.D. Prostaglandins in urine of foetal lambs. Nature, 271:161-
162, 1978.  
2. Lucas, A. and Mitchell, M.D. Plasma prostaglandins in pre-term neonates before and after 
treatment for patent ductus arteriosus. Lancet, ii:130-132, 1978.  
3. Mitchell, M.D., Carr, B.R., Mason, J.I. and Simpson, E.R. Prostaglandin biosynthesis in the 
human fetal adrenal: regulation by glucocorticosteroids. Proceedings of the National Academy 
of Sciences, U.S.A., 79:7547- 7551, 1982.  
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women: a novel method for semi-quantitative plasma proteomics. Proteomics: Clinical 
Application in press (Nov 17).  
8. Lim R, Riley C, Barker G, Rice GE, Lappas M. (2012) Human labour is associated with 
decreased cytoplasmic FoxO4. Placenta. 33:52-59 
Awards & Extra NHMRC Academic & Research Appointments (selected) 
1. Member, Technical and Regulatory Standing Committee, IVD Australia 
2. Member, Expert Advisory Panel on Maternal & Perinatal Health & Obstetrics, International 
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Title: Regulation of myostatin production and actions in human placenta: Critical use of 
high resolution mass spectrometry for detection and analysis. 
 
Project significance  
Myostatin is a highly conserved secretory protein that is best known as a negative regulator of 
muscle development, affecting both proliferation and differentiation of muscle cells (1). The 
complexity of actions resulting from the expression of the myostatin gene with post translational 
processing of the myostatin protein (pro-form; precursor) into sub units that include not only an 
active dimer but also moieties such as the propeptide form that can be antagonistic and/or inhibitory 
of myostatin  actions is reminiscent of the proopiomelanocortin gene. Hence, the accurate, 
unequivocal identification of these different forms is vital to our understanding of any subsequent 
actions that might flow from myostatin gene expression. Clearly, this has limitations when 
identification is through immunoblotting techniques that rely upon antibody characteristics and 
cross-reactivity with related substances. Thus, the development and application of mass 
spectrometric methods for identification and quantification of myostatin gene products is vital to 
any understanding of physiological or pathophysiological roles of myostatin. We have developed a 
sensitive and specific mass spectrometry (MS) method for identification of these products that 
is to our knowledge the first such method to be described. With this method we have 
identified the endogenous production of myostatin in placental explant culture media.  
 
Alterations to myostatin expression are evident in a number of abnormal health states including 
muscle wasting (e.g. cachexia), obesity, and diabetes (2-4). Notably up-regulated myostatin in 
serum and placental tissue has been observed in a complication of pregnancy pre-eclampsia (PE). 
Limited information is available however on the effect myostatin has on placental cell function. Our 
preliminary data suggests that myostatin positively affects the proliferation of cells in contrast to the 
negative effect often reported on muscle cell proliferation. Further investigations are therefore 
required to determine the effect of myostatin on placental cell function.  
 
We propose to use stressors associated with PE (e.g. hypoxia, inflammatory mediators) in in 
vitro early pregnancy placental tissue and cell culture models to determine the complete 
protein profile of myostatin in culture by mass spectrometry and to establish the effect of 
myostatin on placental cell function.  
 
Establishing the functional changes stimulated by myostatin (and/or its absence) and the alterations 
to myostatin protein profile under stress conditions will be  crucial to understanding the role 
myostatin plays in contributing to placental development, placental function  and disease pathways,  
as well as in targeting antagonistic and agonistic treatments for myostatin action. 
 
Hypothesis: Myostatin is differentially expressed and alters placental function in early 
pregnancy.  
 
Specific Aims: 
Aim: 1 The identification and analysis of the complete protein profile of myostatin in the 
culture of placental tissue explants and cell population under stress (e.g. hypoxia, inflammatory 
mediators) through the use of high resolution mass spectrometry.  
Aim: 2 To establish the effect(s) of varying myostatin concentrations and actions on 
placental cell function(s) in early pregnancy.  
 
Background 
Myostatin, also known as Growth Differentiating Factor 8 (GDF-8), is a member of the 
transforming growth factor beta superfamily (1). Myostatin is highly conserved (5, 6)  and 
expressed in a number of tissues including human placenta (7). Myostatin is best known as a 
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negative regulator of muscle development. Homozygous myostatin null mice (Mstn
-/-
) exhibit 
doubling of muscle tissue mass compared to wild type mice (1). Myostatin has also been shown to 
regulate adipose deposition and glucose metabolism (8). The absence of myostatin activity partially 
reduces hyperglycemia and adipogenesis in mouse models of obesity and type 2 diabetes (9).  
 
Humans with type 2 diabetes were identified as having significantly higher myostatin mRNA 
expression in skeletal muscle (4). Myostatin is also elevated in human obesity, as myostatin plasma 
concentrations and myostatin protein levels were identified as higher in extremely obese women 
compared to lean women (3). Collectively, these studies suggest that myostatin plays an important 
role in glucose homeostasis and has the potential to be a diagnostic agent.  
 
Myostatin and its effects on pregnancy, 
placental development and pregnancy 
outcomes are not well understood. Mstn
-
/-
mice are fertile and viable, whereas 
cattle with double muscling are known 
to have difficulties in maintaining 
pregnancies, calving, and overall 
fertility (10, 11).  In humans, an infant 
boy was carried to term and born to a 
woman with a (heterozygous carrier of a 
myostatin gene mutation) G to A 
transition in the first intron-exon region. 
The boy was identified as homozygous for this mutation which 
resulted in the introduction of a stop codon and the truncation of 
the myostatin protein and inactivation of its function. The boy 
continued to exhibit the characteristic increase to muscle mass 
seen when myostatin is not functional as a neonate, at 7months 
and at 4.5 years of age and he was also observed to be 
extraordinarily strong (12).  
 
Myostatin and the placenta 
We are the primary source of information on the expression and 
function of myostatin in the human placenta. We have shown a 
negative correlation between myostatin in the placenta and 
gestational age (7). This was evident as both myostatin mRNA 
expression and myostatin protein levels were lower in term placentae compared to early gestation 
and preterm placental tissue respectively (Figure 3) (7).   
 
We have also described a possible role for myostatin in placental glucose uptake. Glucose is a key 
energy source required for fetal development and is the main form of carbohydrate transported 
across the placenta (7). We have shown that myostatin (1µg/ml) treatment increases uptake of 
deoxyglucose in human placental explants (7). Supporting these findings, another study showed that 
myostatin increased glucose uptake in a dose-dependent manner in C2C12 myotubules and L6 
myocytes (13). In this study, treatment with the myostatin inhibitory protein, follistatin and 
myostatin pro-peptide resulted in the inhibition of glucose uptake by C2C12 myotubes (13). 
 
Only a few studies have been performed on myostatin expression and function in high-risk human 
pregnancies. A study conducted in women with pre-eclampsia (PE) reported significant increases in 
the concentration of myostatin in serum, placental myostatin protein and mRNA expression 
compared to controls (14). In addition, the protein and mRNA concentrations of a potent 
endogenous inhibitor of myostatin activity, follistatin like-3 (FSTL-3), was also observed to be 
Figure 1: Homozygous 
myostatin mutation. (A) 
Morphometric analysis of 
muscle cross-sections in a 
young boy with homozygous 
myostatin mutation (left) 
compared to a control (right). 
(B) Arrows indicate muscle 
protrusions in the thigh and 
calf muscles of the boy as a 
neonate and a 7 month old 
[17] 
 
Figure 2: Differences in 
placental myostatin expression 
levels in preterm and term 
placentae detected by western 
blot. (human muscle tissue 
used as positive control) 
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higher in PE pregnancies (14). In pregnancies complicated by gestational diabetes mellitus GDM no 
significant differences in myostatin production have been observed however, FSTL-3 was 
significantly lower in serum and placentae of patients with GDM (15). It is possible that in 
pregnancies complicated by GDM, FSTL-3 may act to regulate myostatin actions.  
 
Myostatin biosynthesis and signalling  
Myostatin is initially synthesized as a ~52kDa precursor protein (Figure 3A) that contains an N-
terminal secretory signal, a pro-peptide domain, and a C-terminal RSRR (Arg-Ser-Arg-Arg), and a 
proteolytic processing site (1, 5, 
6). The first proteolytic cleavage 
removes the N-terminal signalling 
sequence required for protein 
secretion (Figure 3B) (1, 5, 6) . 
The second proteolytic cleavage 
(by Paired Dibasic Amino acid-
Cleaving enzyme or PACE, also 
known as Furin) occurs at the 
proteolytic processing site 
releasing the ~42kDa N-terminal 
pro-peptide and a ~12kDa C–
terminal fragment that is the 
mature myostatin protein (Figure 
3C) (1, 5, 6). Dimerization of the 
~12kDa mature myostatin protein 
creates the active form of 
myostatin - the ~28kDa myostatin 
dimer (Figure 3D) (5).  
Binding of the myostatin dimer to 
Activin type II receptor 
(ACTRIIB; Figure 3G) initiates 
the trans-phosphorylation of the 
type I receptor (ALK4/ALK5) and 
the stimulation of downstream 
serine/threonine kinases 
associated with the type I receptor (Figure 3H) (6). The activation results in the phosphorylation of 
intracellular transcription factors Smad 2 and Smad 3 (R-Smads), which oligomerise with the co-
Smad-Smad 4 (Figure 3I) (6). The Smad 2, 3 and 4 oligomer translocates to the nucleus (Figure 3J) 
and in association with other transcription factors, regulates the transcription and expression of 
downstream genes necessary for myostatin action (Figure 3K) (6).  
 
Inhibition of myostatin functional activity 
A potent antagonist of myostatin activity is the 42kDa pro-peptide generated by the processing of 
the myostatin precursor. Two monomeric pro-peptides bind non-covalently to the myostatin 
dimer forming a latent complex (~ 75kDa) and thereby preventing the dimer from binding to 
its receptor ACTRIIB (Figure 3E) (6, 16, 17). The majority of myostatin (~70%) found in 
circulating blood is in this latent complex form (17, 18). Four metalloproteinases of the bone 
morphogenetic protein (BMP)-1/Tolloid family have been identified as being involved in the 
release of the myostatin dimer from its latent complex via the proteolytic cleavage at Asp-76 of the 
myostatin pro-peptide (Figure 3F) (6, 17, 19). The pro-peptide also facilitates the proper folding of 
the C-terminal domain by forming a cysteine knot. Another potent inhibitor of myostatin activity is 
follistatin like -3 (FSTL-3).  It is a structural homologue of follistatin that binds with a high affinity 
Figure 3: Myostatin biosynthesis and signalling  
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Figure 4: Localisation of myostatin in (A) 1
st
 
trimester cytotrophoblast [1], syncytiotrophoblast [2], 
stromal [3] and endothelial cells [4]. (B) 3
rd
 trimester 
cytotrophoblast [1], intermediate trophoblast [2], 
stromal cells [3] and endothelial cells [4] (C) 3
rd
 
trimester EVT [1]. (D) Localisation of HLA-G a 
marker of EVT in 3
rd
 trimester EVT [1]. 
Figure 5: (A) ACTRIIB 
(1) and myostaitn (3) gene 
expression in third 
trimester human placental 
tissue. (2 and 4) no cDNA 
controls (B)  ACTRIIB 
(1) and myostatin (2) gene 
expression in HTR-
8/SVneo cells. (3-6) No 
cDNA control (3) and no 
reverse transcriptase 
controls 
A B 
(in vivo) to myostatin (C-terminal dimer), inhibiting the biological activity of myostatin (Figure 3L) 
(19).   
 
Preclinical trials and agents for the 
inhibition of myostatin functional 
activity 
Phase I and II trials have already been 
completed on two compounds. These are 
MYO-029, a recombinant human antibody 
against myostatin used as a treatment of 
muscular dystrophy and ACE-011, a 
fusion protein consisting of the 
extracellular domain of the ACTRIIA and 
Fc portion of human IgG1, studied in 
postmenopausal women (20, 21). In these 
studies both inhibitors were found to be 
safe for human administration but had 
limited effect on muscle, bone and fat 
biomarkers.  
 
Currently underway is the recruitment of 
subjects for clinical trials to test agents 
(e.g. anti-myostatin antibodies, follistatin 
based inhibitory agents) which inhibit 
myostatin. These trials include 
the assessment of safety 
(NCT01616277), and inhibition 
of myostatin activity in muscular 
dystrophy (NCT01519349). A 
Phase 2 trial is also currently 
seeking participants to assess the 
use of an anti- myostatin antibody 
in cancer patients 
(NCT01505530), myostatin 
levels have been found to be 
increased in cancer cachexia (22) 
It is be possible that these 
inhibitors could also be used to prevent or treat adverse pregnancy outcomes if myostatin is found 
to be an important factor associated with the pathogenesis of high risk pregnancies such as PE.  
 
Preliminary findings  
Most recently, we reported the localisation of myostatin in cytotrophoblast, syncytiotrophoblast,  
endothelial and stromal cells of first and third trimester human placentae through 
immunohistochemistry (IHC) (Figure 4A- B) (23). In addition to these findings our recent work has 
identified myostatin in extravillous trophoblast (EVT) of third trimester placentae (Figure 4).   
 
PCR analysis of the tissues used for IHC confirmed the gene expression of myostatin and its 
receptor ACTRIIB (Figure 5A). IHC of ACTRIIB has previously been established. ACTRIIB was 
identified in placental cytotrophoblast, syncytiotrophoblast, and endothelial cells (24). These 
findings support the possibility that myostatin is functional in these placental sites. As the staining 
of myostatin in EVT was strongly visible, functional experiments were performed to assess the 
effect of myostatin treatment on HTR-8/SVneo cells, a cell line widely used to model EVT (Figure 
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Figure 6: (A) The Area Under Curves analyses showed that the effect of 
myostatin treatment resulted in in significantly increased HTR-8/SVneo 
cell compared to control *p<0.03, and *** p<0.0001). (B) HTR-8/SVneo 
cell proliferation images (IncuCyte™) of control and  1ug/ml myostatin 
treatment at 40 hours 
Figure 7: (A) Time course of wound closure for HTR8/SVneo expressed 
as relative wound density (%).Data are presented as mean ± SEM. (B) 
Scratch wound mask images (IncuCyte™) of migration into wound. 
Wells treated with 1μg/ml myostatin, white center indicates wound (0 
hours), grey section migrating cells (12 hours) and complete migration of 
cells can be seen at 24 hours.  
6 and 7) (25). Gene expression of myostatin and ACTRIIB was also confirmed in these cells by 
PCR (Figure 5B).  
 
Significant increases in 
HTR-8/SVneo cell 
proliferation and 
migration were 
observed following the 
treatment with 
myostatin (0.005-
1μg/ml). A 
concentration 
dependent increase in 
proliferation was 
evident as the highest 
concentration 
increased proliferation 
~1.7 ± 0.062 fold 
compared to control.  
Migration of HTR-
8/SVneo cells was also 
significantly increased 
(~2.2 fold) with 
treatment, however no 
concentration 
dependent change was 
observed.  The 
majority of the 
literature states that 
myostatin is a negative 
effector of 
proliferation and 
differentiation. We 
initially hypothesised 
that myostatin would 
act in a similar way 
and decrease the 
proliferation of HTR-
8/SVneo cells. Our 
results, however, do 
not support our initial 
hypothesis. This highlights the need to investigate the functional effect of myostatin on 
placental cells.  
  
Rationale 
The current methods for the detection of the myostatin protein expression are western blot and 
ELISA. These methods are well accepted however they are reliant on the specificity of the 
antibodies used and the discrimination of the different protein forms and are at best semi-
quantitative. In contrast tandem mass spectrometry (MS/MS) provides a highly specific method of 
detection, enabling the characterisation of the different myostatin protein forms through the analysis 
of discrete peptides fragments. Mass spectrometry allows the identification of several unique 
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peptides per quantified protein and therefore each protein targeted can have several independent 
measures made (26) moreover a specific region of the target protein can be identified. 
We have developed methods for detecting on 
two of our mass spectrometry instruments the 
Triple TOF 5600 system (ABSciex) and the 
Triple Quad 5500 (ABSciex) LC/MS/MS 
systems. Table 1 describes the optimised 
scheduled-MRM pairs and parameters for 
myostatin on the triple quad 5500 instument.  
The lower limit of quantitation for the peptides 
located in the pro-peptide (acts as an inhibitor of 
myostatin) and mature myostatin protein 
(dimerises to form the active protein) are listed 
in this table and are in the nmol/L range. The 
sensitivity and specificity of myostatin 
detection by mass spectrometry exceeds that 
of the current gold standard immunoblotting 
methods. The limit of detection of myostatin by 
a commercially available ELISA used for the 
detection of myostatin in human plasma and 
serum is 0.273 ng/ml (4) and  the limit of 
detection for western blot analysis of myostatin 
is unknown. Excitingly, we have successfully 
utilised the method developed in the analysis 
of media from placental explants cultured at 
1% O2 (Figure 8). Myostatin peptides located 
in the pro-peptide and mature (dimer) regions of 
the myostatin protein were identified in our 
samples (Figure 8 and Table 1).    
 
We propose to use stressors associated with 
PE (e.g. hypoxia and inflammatory 
mediators) in in vitro early pregnancy 
placental tissue and cell culture models to 
determine the complete protein profile of 
myostatin in culture by mass spectrometry 
and to establish the effect of myostatin on 
placental cell function.  
 
Pre-eclampsia is a complication of pregnancy associated with higher concentrations of myostatin 
and FSTL-3 (in plasma and placentae) (14). Preeclampsia is known as a multifactorial pregnancy 
complication, factors include placental oxygen disruption (e.g. hypoxia) leading to impaired 
Table 1. Optimised scheduled-MRM pairs and parameters for myostatin. 
Myostatin 
Form 
Targeted Peptide Sequence 
Rt 
(min) 
MS/MS Parameters Lower Limit 
of 
Quantitation 
(nmol/L) Q1 Q3 CE 
Pro-peptide GSAGPCCTPTK+6(C)+7(C) 2.0 568.2 345.2 29 0.33 
EQIIYGK 4.7 425.7 480.3 24 0.25 
Mature 
Protein 
(Dimer) 
LETAPNISK   
IQILSK 
4.8 486.8 629.4 26 0.16 
6.2 351.2 588.4 21 0.53 
Figure 8: Extracted ion chromatogram of 
myostatin peptides identified in placental 
explant culture media. Pro-peptide: 0.5 
nmol/L, Mature (dimer) protein: 23.0 
nmol/L 
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trophoblast invasion or trophoblast death (27)  and increased expression of inflammatory cytokines 
(e.g. TNF-α) (28). Interaction and alterations to myostatin expression are known to occur in the 
presence of TNF-α and hypoxia.  Preeclampsia is a disorder identified later in pregnancy, with early 
onset detected < 32 weeks gestation and late onset >32 weeks gestation(29). Changes to placental 
development and function are irreversible at the time of diagnosis and delivery as such the function 
of the tissues and cells cultured from these tissues may be altered.  
 
Myostatin is best known as a negative regulator of muscle development, negatively affecting both 
proliferation and differentiation of muscle cells. Understanding the effect of myostatin on cell 
function of placental cell populations is crucial since our preliminary data (and publications by 
others (30-32)) in other cell populations have shown that the negative regulatory effect of is not 
consistently found (31). Limited information is available on the effect myostatin has on placental 
cell functions.  
 
The activity and function of myostatin can be regulated by a number of proteins including a portion 
of myostatin itself (myostatin pro-peptide) (18), inhibitors such as follistatin like-3 (FSTL-3) (18), 
cytokines such as tumour necrosis factor-α (TNF-α) (33), and environmental conditions such as 
hypoxia (34). Myostatin  is increased under conditions of hypoxia, observed in the skeletal muscle 
of mice exposed to hypoxic conditions and in patients with chronic hypoxemia (34). However, the 
effect of hypoxia on the expression of myostatin in placental cells is however unknown. Interactions 
between TNF-α and myostatin can be seen in the increased expression of myostatin in C2C12 
myotubes treated with TNF-α (35).Furthermore, the levels of TNF-α are known to be reduced in 
mice with non-functional myostatin and the treatment of these mice with recombinant myostatin has 
been found to increase plasma concentrations of TNF-α (33).  Observations such as these confirm 
the complexity of the factors regulating myostatin function. 
 
Figure 9: Experimental design flow chart  
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Research Plan 
Sample Collection: Collection of early pregnancy (first trimester placental tissues) has been 
approved by the Human Research Ethics Committees of the Royal Brisbane and Women’s Hospital 
(HREC/09/QRBW/14), and the University of Queensland. The first trimester placental tissues will 
be collected from pregnancies at 8-12 weeks gestation from women undergoing terminations of 
pregnancy for psychosocial reasons. Tissues will be processed immediately once received. Placental 
villous tissue will be washed thoroughly with normal saline and equal quantities of placental villous 
tissue used in triplicate per experimental condition (Aim 1), finely minced villous tissues will be 
enzymatically digested for the release of trophoblast cells using protocols adapted from Fisher et al 
(36) (Aims 1 and 2). Experiments are designed to be conducted on n=12 biological samples with 3 
technical replicates. Statistical analyses:  The differences between the experimental groups will be 
examined using ANOVA and student’s t-tests as appropriate. 
 
Aim: 1 The identification and analysis of the complete protein profile of myostatin in the 
culture of placental tissue explants and cell population under stress (e.g. hypoxia, 
inflammatory mediators) through the use of high resolution mass spectrometry. 
Experimental design: Cultures will be performed in the presence and absence of myostatin and 
under varied stressors associated with the pathogenesis of preeclampsia, in particular hypoxia and 
inflammatory mediators.  
(i) Various concentrations of myostatin ranging from 0.005μg/ml to 5μg/ml will be used to treat 
early pregnancy primary placental tissue explants, primary isolated placental cells and placental 
cell line cultures.   
Measurements: Changes to protein expression e.g. myostatin regulatory mediators (e.g. 
FSLT-3, ACTRIIB, and SMAD transcription factors), cytokines (e.g. IL-1beta,  IL-
1Ra,  TNFalpha, IL-10, IL-6, IL-4, IFNgamma, IL-8) will be assesed by the current gold 
standard methods of protein analysis (Western and Elisa) following initial analysis with 
mass spectrometry. Gene expression will also be assesed by the use of a Sybr Green real-
time PCR technique used routinely in our laboratory.  
(ii) Cultures will also be performed in the presence and absence of inflammatory mediators (e.g. 
TNF-α, Lipopolysaccharides, IL-1β etc)  
(iii) Early pregnancy primary placental tissue explant, primary isolated placental cell and placental 
cell line cultures will be conducted at physiologically relevant oxygen tensions (i.e. 8% O2 in 
third trimester) in contrast to other studies that have used superoxic conditions (i.e. 21% O2). 
Cells and tissues will also be cultured under hypoxic conditions (i.e. 1% O2). This will be 
accomplished through the use of the BioSpherix
TM 
system, which allows us to precisely control 
oxygen tension and to recapitulate in situ oxygen tensions that are clinically and 
physiologically relevant. 
(iv) Cultures will also be performed combining hypoxia and inflammatory mediators 
Measurements for (ii), (iii) and (iv): The complete protein profile of the various myostatin 
forms will be identified by the use of MS as a high resolution method of detection, able to 
discriminate between the different myostatin protein forms (i.e Precursor, LAP, Dimer) 
through the analysis of individual peptides.  
Mass Spectrometry (MS): AI David Kvaskoff has extensive experience working with MS 
technique. We have the use of a nano-electrospray LC/MS/MS on Triple TOF 5600 system 
(ABSciex) coupled to an Eksigent nanoflex chip HPLC system and  Trilple Quad 5500 
(ABSciex) LC/MS/MS system within our laboratory. We have already developed and 
established a scheduled high-resolution multiple reaction monitoring (sMRM
HR
) methods 
for the identification of myostatin on both these systems. The lower limit of quantitation 
for myostatin by mass spectrometry (nmol/L ) exceeds the abilities of current gold standard 
methods 
.  
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Aim: 2 To establish the effect(s) of varying myostatin concentrations and actions on placental 
cell function(s) from normal and high-risk pregnancies. 
Experimental design: Primary isolated trophoblast and placental cell lines will be cultured in the 
presence or absence of recombinant myostatin as we have previously described (7, 37). Loss of 
myostatin function will be achieved using shRNA and an endogenous inhibitor (FSTL-3). shRNA 
targeting myostatin (Sigma-Aldrich) will be transiently transfected into primary trophoblast cells. 
Experiments to assess placental cell function are listed below. Cultures will also be performed 
under hypoxic condition (i.e. 1% O2). This will be done through the use of the BioSpherixTM 
system, which allows us to precisely control oxygen tension and to recapitulate in situ oxygen 
tensions that are clinically and physiologically relevant. 
(i) Proliferation - Trophoblast proliferation will be monitored in real-time using our IncuCyteTM 
live-cell imaging system (38). - Preliminary data Figure 6   
(ii) Differentiation - Trophoblast syncytialisation will be determined using previously published 
techniques: (1) hCG production measured by ELISA, and (2) desmoplakin IHC (39).  
(iii) Cell migration- To determine trophoblast cell migration, a scratch wound assay will be 
performed in which trophoblasts will be grown to confluence and then a scratch will be made 
using a 96-pin WoundMaker
TM
. Migration will be monitored using the IncuCyte
TM
 live-cell 
imaging system. Wound images will be automatically acquired and registered by the 
IncuCyte
TM
 software system. The data will then be analysed using an integrated metric: 
Relative Wound density.We have previously demonstrated that myostatin increases migration 
of trophoblast cell lines using the IncuCyte
TM
 in vitro system within our laboratory (38).-
Preliminary data Figure 7   
(iv) Cell invasion – To determine trophoblast cell invasion, a scratch wound assay will be 
performed in which trophoblasts will be grown to confluence and then a scratch will be made 
using a 96-pin WoundMaker
TM
. Invasion into a collagen I matrix by cells will be monitored 
using IncuCyte
TM
 live-cell imaging system. Wound images will be automatically acquired and 
registered by the IncuCyte
TM
 software system. The data will then be analysed using an 
integrated metric: Relative Wound density.We have previously demonstrated that myostatin 
increases migration of trophoblast cell lines using the IncuCyte
TM
 in vitro system within our 
laboratory (40). 
 
Project feasibility  
Our laboratory has an established track record collecting and investigating the human placenta. The 
majority of publications on myostatin in the placenta to date are attributed to CI Mitchell. The team 
assembled for this proposed project are experts at the techniques to be utilised (e.g. real-time PCR, 
western blot, mass spectrometry, and primary cell isolation and tissue culture). The facilities used 
for this project all have high-end state-of-the-art equipment run professionally and are able to create 
highly reliable data output. 
 
Expected outcome 
Through the use of MS the findings of these experiments will elucidate the changes to myostatin 
protein forms when cultured under stress as well as the changes elicited by myostatin on other 
members of the myostatin pathway and to factors associated with placental development. Further, 
the changes to placental cell function in the presence/absence of myostatin will enhance our 
understanding of the physiological role of myostatin in the placenta and its role in placental 
development as well as function  
 
Time-Line 
TimeLine Year 1 Year 2 Year 3 
AIM 1      
AIM 2    
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CIA Mitchell 
Time Commitment to this project: CIA will commit 20% of his NHMRC research time to this 
project.    
Other NHMRC Grants: CIA currently holds no other NHMRC grants.   
Time Commitment to non-NHMRC grants: 20% of CIA time is committed to non-NHMRC 
research projects funded by ARC, State and Federal Government and International programs.  20% 
of CIA’s time is committed to research and translational administration within UQCCR. 
Role in this project: CIA will have overall responsibility of the execution and successful 
completion of the project. CIA will supervise the project in accordance with the requirement of our 
NATA accredited research facility. He will be responsible for data analysis, interpretation, 
presentation and manuscript presentation. CIA will supervise research staff. 
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Team Quality and Capability 
Summary of Research Team: CIA Mitchell is a recognized leader in the field of reproductive 
biology and, in particular, in complications of pregnancy.  CI Mitchell brings over 30 years 
experience in the field of reproduction. CI Mitchell also has a well-established track record and 
contribution to the field in: defining the role of inflammatory mediators (eg cytokines and 
eicosanoids) and nuclear regulatory factors in human pregnancy and labour; gestational tissue 
genomics, transcriptomic; proteomic and epigenetic methodologies required to interrogate 
signalling response pathways; the use of ex situ human gestational tissue models. CI Mitchell has 
over 200 publications in the area of placental and reproductive research. CIA Mitchell has 
published on myostatin since 2005 and has 6 relevant published papers and 10 abstracts in the last 
decade. AI Peiris has worked with CI Mitchell for the last 5 years and has considerable myostatin 
knowledge and has substantial experience in placental cell isolations as well as expertise in 
molecular and proteomic techniques required for this project. AI Peiris has presented her work at 
national and international meetings. Together AI Peiris and CIA Mitchell have successfully secured 
a DART grant for Myostatin and GDM analysis. She has contributed to three publications on 
myostatin in the placenta. AI Peiris will coordinate the collection, preparation, experimentation and 
analysis of placental samples required for all aims. AI Kvaskoff has a strong background in mass 
spectrometry and a successful track record in bioanalytical methods. His expertise covers the 
targeted profiling of metabolites in challenging biofluids such as brain, plasma, culture media, and 
he recently presented a quantitative approach to characterise the lipid composition in neurons at the 
24th biennial conference of the Australia and NZ Society for Mass Spectrometry. He is based 
within the Centre for Clinical Diagnostics (CCD) within UQCCR. 
 
Productivity of Research Team (in relation to experiments): CIA Mitchell will be responsible for 
overseeing the progress and completion of this project. CIA Mitchell, AI Peiris and PSP3 discuss 
experimental design related to Specific Aims 1 and 2. PSP3 will be responsible for completing the 
experiments. Results of these experiments will be analysed by AI Peiris and PSP3 and discussed 
with CIA Mitchell for critical feedback and future direction. AI Kvaskoff will be responsible for all 
mass spectrometry experiments and will advise PSP3 on sample preparation for mass spectrometry. 
The data output will be analysed by AI Peiris,  PSP3, CIA Mitchell, and AI Kvaskoff. Manuscript 
preparation will primarily be the responsibility of AI Peiris, PSP3 with CIA Mitchell and critical 
feedback from all other members of this team. 
 
Facilities: This programme of work will be conducted within a NATA accredited research and 
development facility - the Centre for Clinical Diagnostics (CCD) at the University of Queensland 
Centre for Clinical Research (UQCCR). The CCR is a state of the art translational research facility 
located on the Royal Brisbane and Women’s Hospital campus. The experimental research capacity 
is underpinned by a substantial core of equipment including BioPlex 200 bead-based assay system, 
flow cytometery), a suite of real-time PCR machines, a central histology facility, two next 
generation sequencers (HiSeq and MiSeq) and associated bioinformatics hardware, and have expert 
experienced technical management of the associated facility (The University of Queensland Centre 
for Clinical Genomics). Our lipidomic, proteomic, and metabolomic biomarker capacity includes 
three mass spectrometers (ABSciex 5500, 56000 and 5800). Moreover, we have recently installed a 
Nanosight nanoparticle instrument, an IncuCyte
TM
 real time cell imaging system, a laser dissection 
microscope and an automated tissue arrayer in CCD. This is underpinned by funding from 
Therapeutic Innovation Australia that also provides for experienced senior technical and academic 
management.Our clinical research capacity is underpinned by the clinical floor that includes rooms 
specifically developed for trials and outpatient services. These new facilities with cutting edge 
technologies and expert technical and supervisory personnel are the critical facilities through which 
our analyses will be conducted and through which our studies can be completed.  
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CI A TRACK RECORD: Prof Murray David Mitchell, DPhil  DSc  FRSNZ  
Top 5 Publications in the last 5 years  
1.      Rahnama, F.,Thompson, B.,Steiner, M.,Shafiei, F., Lobie, P. and Mitchell, M.D.,   
Epigenetic regulation of e cadherin controls endometrial receptivity.    
Endocrinology 150: 1466-1472, 2009.  
Impact Factor 4.717 Citations 40 
This study was among the first to describe epigenetic regulation of a key reproductive mechanism 
and demonstrate specific effects on functional as well as biochemical end points. As such it has 
been highly cited. 
2.      Keelan, J.A., Khan, S., Yosaatmadja, F., and Mitchell, M.D.,  
Prevention of inflammatory activation of human gestational membranes in an ex vivo model of 
intrauterine infection using a pharmacological NF-kB inhibitor.  
         Journal of Immunology 183: 5270-5278, 2009.   
         Impact Factor 5.520   Citations 11 
This study demonstrated functional, and biophysical end points to inflammatory gene activation in 
human fetal membranes with retained structural architecture (Ussing chambers) and a potential 
therapeutic intervention.    
3.      McEwan, M., Lins, RJ., Munro, S., Vincent, Z., Ponnampalam, A. and  
         Mitchell, M.D.   
         Cytokine regulation during the formation of the fetal-maternal interface: focus  
         on cell- cell adhesion and remodelling of the extra-cellular matrix. 
         Cytokine and Growth Factor Reviews 20/3:241-249, 2009. 
         Impact Factor 8.831  Citations 14 
This study demonstrated the key role of inflammatory mediators such as cytokines in several events 
of the early phases of human implantation. Potentially novel therapeutic targets were mooted. 
4.      Perry, J.K., Lins, R.J., Lobie, P. and Mitchell, M.D 
Regulation of invasive growth: similar epigenetic mechanisms underpin tumour progression 
and implantation in human pregnancy.   
Clinical Science 118: 451-457, 2010. Impact Factor 4.859   Citations 6 
This study described the not only the data supporting epigenetic regulation of critical pathways in 
human implantation but also drew parallels with similar regulation in pathways associated with 
tumour progression. Limits and opportunities that arise from this comparison were described. 
5.      Logan, P.C., Ponnampalam, A.P., Steiner, M. and Mitchell, M.D.   
         Effect of cyclic AMP and estrogen/progesterone on the transcription of DNA   
         methyltransferases during decidualization of human endometrial stromal cells 
         Human Reproduction  25: 2859-2869, 2010 
  Molecular Human Reproduction 19 (5): 302-312, 2013.   Impact Factor 4.542 
This study was one of the first to describe the regulation by steroids of the transcription of  DNA 
methyltransferases. This opened the way for developing novel therapeutic approaches to regulating 
pathways governed by epigenetic mechanisms. 
 
Career summary – (last 5 years)  
2010 -   Director, University of Queensland Centre for Clinical Research 
2003-2009  Deputy Director ( Co-Director 2008-2009) 
National Research Centre for Growth and Development, N.Z. 
2001-2009  Research Director, Liggins Institute, University of Auckland. 
 
Research Funding last 5 years (selected) 
I have received significant infrastructure funding through Therapeutic Innovation Australia (TIA), 
(8.9m-3.4m for UQCCR), A Clinical Academic Fellowship from The Queensland Government 
($375,000), NZ Government funding for Epigenetic Studies in Dairy Cows ($3m - $408,000) to 
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Murray D Mitchell and an ARC Discovery Grant ($300,000). I have also received over $1m for UQ  
infrastructure mainly next generation sequencing items (Hi Seq and Mi Seq). 
Collaborations 
Our team has ongoing collaborations with investigators in Santiago, Chile, University of the Andes 
(Ilanes) and Catholic University of Chile (Sobrevia) (8 grants awarded >5m, 4 reviews, 4 papers – all 
jointly with Prof. G.E. Rice), Singapore (Choolani), Adelaide and several institutions in Brisbane. 
Committees – last 5 years 
I am a member on several hospital committees e.g. (Research Excellence and Academic 
Leadership, Royal Brisbane and Women’s Hospital) and Research Foundations  (RBWH and Prince 
Charles Hospital). I have also served on numerous UQ committees through my position as Director, 
UQCCR. 
Awards & Commendations & Leadership 
In 2012 I received an Award from the Society for Gynecologic Investigation (SGI) in recognition of 
outstanding organization for the 5th SGI International Summit “Prematurity and Stillbirth”: 
Antecedents, Mechanisms and Sequelae”. I developed the idea for this meeting, took it through the 
Society organization, my University organization and then presided over the meeting that attracted 
people from worldwide and opened the way for Perth to bid for a full meeting of the SGI in the near 
future. In 2009 I completed my second term on the SGI Council, having been their first 
International (non-North American) member. 
Presentations, Plenary and Invited Lectures (selected)- last 5 years 
I have been invited to present regularly at International Meetings. In particular I have been invited 
to the GAPPS ‘International Conference on Prematurity and Stillbirth” in Seattle, 2009 and the 
March of Dimes/Burroughs Wellcome Meetings in 2010 and 2012 on Prematurity and Stillbirth. 
These meetings have been the major driving forces in organising global approaches to the issues of 
prematurity and stillbirth. I am invited to the next such meeting in Siena this year prior to the SGI 
meeting in Florence. I have also been invited to speak at the Perinatal Branch of NICHD in a 
special research lectureship. 
Supervision – last 5 years 
In the past 5 years I have supervised (or continue to supervise) 5BSc (Hons), 1 MSc and 13 PhD 
students. Additionally I have mentored 3 postdoctoral Fellows, 3 MBBS Honours students and 1 
Occupational Trainee from Universidad de Chile. My students have a 100% success rate in 
graduating with their degrees. 
Service – last 5 years 
I have received grants to review from the Wellcome Trust (UK) Programme, Canadian Institutes of 
Health Research, National Health and Medical Research Council  (Australia) and Canadian 
Institutes of Health Research (China-Canada Joint Health Research Initiative). Separately, I was 
again asked to be a panel member of the Tertiary Education Commission (New Zealand). I was on 
the Medicine and Public Health Panel (2012) for the Performance Based Research Fund that 
reviewed “quality” measures for all University Researchers in New Zealand (1,000). 
Pertinent – last 5 years 
During the past five years I have moved from Auckland, New Zealand, (USA) to Brisbane, 
Australia (UQ). In my position as Director, UQCCR I have established a significant research 
infrastructure. This has required some time commitments. The developments of a NATA accredited 
Centre for Clinical Diagnostics and a Centre for Clinical Genomics have been a major advance. My 
grants have excellent research infrastructure particularly with regards to mass spectrometry and 
next generation sequencing.  Although this time commitment has reduced my outputs somewhat I 
believe that it is has been more beneficial to the overall research community. 
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Appendix III. Work instructions for experimental procedures   
a. Immunohistochemistry  
b. Myostatin and extravillous trophoblast  
c. Myostatin treatment of first trimester explants  
d. Western blot   
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(a) Working instruction: Immunohistochemistry of first and third 
trimester placental tissues  
This protocol is specific for paraffin sectioning of both first trimester and term gestational tissue 
only. 
 
PROCEDURE 
Tissue preparation-Placenta : Cut placenta into sections small enough to fit cassettes (approx 8mm) 
Wash the placenta sections in warm PBS till the majority (if not all) of the blood is removed.  
Put section in 10% neutral buffer formalin overnight (18 hours) in fridge.  
 
Wash 3 x 15 mins in PBS and continue for processing  
 
Processing  
2x 2 hours in 100% ethanol followed by overnight incubation in 100% ethanol (or keep in 70% 
ethanol for a month) Parrafin imbedding in the vacumn parrafin (at 60C) for 1-2hours in the 
cassetes as the villous  is very  spacious and needs time to  penetrate. -Stainless steel moulds  
Tissue sectioning –Microtome  
Step 1 prepare waterbath. 
Plug in waterbath (plug at the back should be disconnected every day after use). 
Temperature should be set betwen 40-420C (SET ↑↓) Press RUN etc. Fill waterbath with ~1.6 litres 
of RO water (not tap water because of sediments) 
Step 2 Microtome  
Check that the leavers (A and B) at the front and side are in the locked position before attempting to 
place blade or tissue block.  Blade leaver C needs to be released by pulling forward before the blade 
can be slid in. Lock by moving leaver back. Prior to placing the tissue block on the “chuck” the 
rotator must be in the locked position ( otherwise there is a danger of cutting yourself on the blade).  
Pull the leaver F forward and place block inside.  
 
Block preparation: the paraffin block at room temp is softer and harder to cut. Chill the blocks by 
placing the block face down with cut tissues sitting in a small volume of tissue softening solution (9 
parts 60% alcohol and 1 part glycerol) on a weigh boat that is sitting on ice. 
  
206 
 
To prepare for cutting unlock Leaver B and rotate leaver D clockwise to lower the tissue block to 
the the approximate height of the blade. Unlock leaver A and move forward till just touching the 
tissue block.  
  
 
Using leavers 1H and 2H adjust the orientation of the block till completely straight (released by 
leaver H). Rotate leaver D and see if the section cut is even throughout. Cut section at 10microns 
until the tissue section is reached at which point switch to 5microns.  
If the sections are wrinkly.. Cut sections at 5 microns. Place curled sections on a wooden cutting 
board carefully using tweezers and brush them as flat as possible. Then move the tissues on to a 
glass slide (must use superfrost plus!) put a couple of drops of 10%ethanol under the tissue section 
then slide the section into the water bath (it goes whoosh and flies like a little jet plane!) collect the 
section onto a glass slide. Put the tissue section in the oven at 370C or at RT overnight.  
 
Staining Process  
Before starting the staining process the sections need to be baked at 600C for 30 mins.  
Dewaxing in xylene x 3 for 3 mins (minimum- can be kept for longer hours/overnight if needed)  
Hydrating in ethanol x3 for 3mins (minimum- can be kept for longer hours/overnight if needed) 
Place the slides in running water for 3mins-3hours etc 
 
Step 1: Antigen retrieval  
Away 
from 
you! 
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Antigen retrieval solution 100mM sodium citrate+0.5% tween 20 at pH6 dilute 10x (10 in 90). (can 
be reused 2-3times). Place the sections in the retrieval solution and place in decloaking chamber 
with 500ml of RO water (looks like a preassure cooker) carefully place the lid twist and close. 
Decloaking chamber use  
Switch on power at wallpower regulatordecloaker 
Press Display Set till the Actual temp lights up.  The next (SP1) will be the highest temp set to Set 
the temperature to 1250C ()  
Press Display Set to set time at the highest temp (30 seconds)  
Check and start  
It will take approx 12mins to reach this temp only keep the tissues for 5seconds!  
The cooker will start to beep press stop it will take approx 16minutes to cool down to ~900C 
degrees. (it will beep again) 
Remove when the pressure is loweredUSE gloves (it will be HOT). Leave sections at room 
temperature for 20mins to cool down. 
Replace the retrieval solution into bottle (can be reused).  Wash sections with RO water 2-5times 
(fill tub and rinse) 
Dry the back of the slides carefully and around the edges. Using a Dako pen draw boxes around the 
tissue sections on the slide.  
Step 2: staining –using biocare medical MACH 1 UNIVERSAL HRP POLYMER KIT 
Term placenta Primary Secondary DAB Heam 
MSTN HPA021681 1 in 50  overnight 40mins Rabbit ~40 seconds  
KRT-7 HPA007272 1 in 1000 overnight 40mins Rabbit 5 seconds  
VIM HPA001762 1 in 200 overnight 40mins Rabbit 5 seconds  
1st Trimester placenta  Primary Secondary DAB Heam 
MSTN HPA021681 1 in 50  overnight 40mins Rabbit 20-25 seconds  
KRT-7 HPA007272 1 in 2000 overnight 40mins Rabbit 10 seconds  
VIM HPA001762 1 in 400 overnight 40mins Rabbit 10 seconds  
 
Day 1: 
 Blocking Using a Pasteur pipet drop a few drops of peroxidise-1 (PX968M) enough to 
cover the tissue section  leave for 10mins  
 Wash well with MQ water x2 
 3x with PBS for 1-2mins each. 
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 Serum block  (Background snipper /donkey serum) for 10-20mins  
 No wash 
Apply 100ul of primary overnight made in PBS 
Day 2: 
 Wash well with MQ water x2 
 3x with PBS for 1-2mins each. 
 Apply secondary antibody for 45mins  
 Wash well with MQ water  
 3x with PBS for 1-2mins each. 
 DAB – 1ml substrate +  1drop coloured solution  
 100ul of DAB solution (has to be done whilst looking under the microscope (4x focus 
10x focus 4x add DAB  look for clour change under 10x for the colour change) 
approx 5mins (if more needed then increase primary antibody conc) Have a bowl of MQ 
water ready to wash slides 
 Counterstain Hemotoxylin 20-30 seconds  
 Wash with TAP water (different pH)  
 Rinse again with RO water  
 Check staining under microscope  
 Leave to dry completely  
Place coverslip ( dip slide in xylene then place the slide on to cover slip with glue) push down 
gently to remove bubbles. Let dry overnight 
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(b)  Myostatin and extravillous trophoblast  
 
Isolation and Purification of Trophoblasts – (Tarrade, Lai Kuen et al. 2001) 
First trimester tissues were enzymatically digested in HBSS containing 0.125% trypsin (Life 
Technologies Australia Pty Ltd, VIC Australia) and 50 Kunitz/ml DNase (Sigma Aldrich, NSW, 
Australia) for 35 minutes at 37oC without agitation. Supernatant was taken after tissue 
sedimentation and filtered (100 μm pores). Trypsin digestion was stopped with 5% fetal calf serum 
(FCS) (Life Technologies Australia Pty Ltd, VIC Australia). Cells were centrifuged at 300 x g for 
10 minutes and plated with DMEM/F12 with 10% FCS, Antibiotic-Antimycotic, 100 U/ml 
penicillin, and 100 μg/ml streptomycin (Life Technologies Australia Pty Ltd, VIC Australia) onto 
Corning® Costar® 24 well cell culture plates (Sigma Aldrich, NSW, Australia) with autoclaved 
10mm coverslips (Thermo Fisher Scientific Australia Pty Ltd, VIC, Australia) and cell culture 
flasks (Sigma Aldrich, NSW, Australia). Plates and flasks were washed after 3 hours to eliminate 
debris and incubated again in the medium.  
 
Peroxidase Immunocytochemistry– (Tarrade, Lai Kuen et al. 2001) 
After 48 hours of culture, EVCT and ST were fixed in 4% PFA for 20 minutes. Following 48 hours 
of culture, EVT were fixed in 4% PFA for 20 minutes at room temperature and washed in PBS (3 
times). Cells were incubated in H2O2 for 12 minutes, washed in PBS (3 times) and incubated in 7% 
Donkey serum for 30 minutes.  Primary antibodies (Table 1) were incubated overnight (18 hours). 
Following washing with PBS, secondary antibodies (Table 1) were incubated for 2 hours. 3-
Diaminobenzidine (DAB) was used as the chromogen (30-40 second development time) and 
sections were counterstained with Mayer's haematoxylin (40-50 seconds). Sections were mounted 
and coverslips applied using Leica CV Mount (Leica Microsystems Pty Ltd). Staining was viewed 
using a Nikon Eclipse 80i microscope with a Nikon D5-Ri1 camera (Nikon, Tokyo, Japan) and 
NIS-Elements imaging software (Nikon). 
 
IncuCyte Experiments: proliferation and migration of myostatin treated EVT (Salomon, 
Ryan et al. 2013) 
Media used: 
1)RMPI + 10% FBS  
To a 450ml RPMI (no phenol red), add 50ml heat inactivated FBS.  
2) RPMI + 1%AA  NO FBS  
  
210 
 
To a 450ml RPMI (no phenol red), add 5ml Antimycotic/biotic  
Thawing and Initial culture: 
1. Remove cells from Liquid nitrogen (large container) freezer and keep on dry ice till media is 
warmed.  
2. Warm media  
3. Thaw cells at 37oC waterbath.  
4. Transfer Cell Suspension to a sterile 15ml tube with 5ml of warmed media and mix by 
inversion. 
5. Centrifuge for 5-10 mins at 300g. 
6. Aspirate supernatant and resuspend cells in 5ml of media (Do cell count if needed). 
7. Plate cells in 2XT25 flask with 5ml of media. 
8. Change media after 24hrs and then every 36-48 hours. 
 
Sub-Culture: 
1. After cells reach 70-80% confluency, split cells at 1:3 (i.e 4X10,000 cells/cm2).  
2. First aspirate media from flask and wash with HBSS. 2ml Tripsin for 5mins or Tryple-E for 
10mins.  
3. Transfer cells to tube and top up with 5-10mls media. 
4. Spin for 5mins at 300g. 
5. Resuspend in 1ml media and do a cell count. 
6. Plate desired number of cells in a T75 flask. 
7. Change media every 36-48hrs. 
Day 1:  
1. Coat plates with 30ug/ml collagen :  
Stock = 3mg/ml   Dilute in Acetic Acid  
9.633ml H2O + 200ul 1M Acetic acid + 166.7ul collagen  
Incubate for 30mins and wash x3 with PBS    
2. Confluent T75 flasks are trypsinised and cells are centrifuged at 300g for 5 mins  
3. Cell count performed for migration ~500,000 cells required per well and proliferation 
5000 cells per well 
Migration:  
 Plate 100,000 cells into 24/96 wells with FBS for 24 hours for confluence  
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 Make wound treat with mstn media and determine migration with incucyte  
Proliferation:  
 Plate 10,000 cells into wells with treatments determine proliferation using incucyte phase 
contrast imaging  
Myostatin treatments         C1V1 =C2V2 
MSTN 
treatment  
Mstn 
volume 
(ul) 
Mstn 
Stock 
Final 
volume 
2ml  Media 
10 500.0 40.0 2000.0 1500.0 
1 50.0 40.0 2000.0 1950.0 
0.5 25.0 40.0 2000.0 1975.0 
0.05 25.0 4.0 2000.0 1975.0 
0.01 5.0 4.0 2000.0 1995.0 
0.005 25.0 0.4 2000.0 1975.0 
0.001 5.0 0.4 2000.0 1995.0 
 
Materials: 
RPMI-1640 (HyClone, USA), 
Nutrient Mixture F-12 Ham. Sigma. 500ml Cat no. N4888-500ml. AUD 35.70 N488-500mlX6. 
AUD 151.20. 
F 12 Nutrient Mix HAMS. Invitrogen.  Cat no. 11765021 
D-MEM/F-12 (1x)1:1 Glutamax. Invitrogen. 500mlX10. Cat no. 10565042. 
Fetal Bovine Serum, FBS. Qualified. Invitrogen. Cat. No. 10099-141. 500ml. Price AUD 
L-Glutamine. 200mM. Sigma. 100ml Cat no. G7513. Price 24.15. 
Trypsin, 0.5% (10x) with EDTA 4Na, liquid. Invitrogen. 100ml Cat no.15400-054. Price 
AUD25.40 
TrypLE. 100ml Cat no. 
DMSO C6164, Sigma, Cell Freezing Medium-DMSO 1× sterile-filtered, cell culture tested 
 
References  
Salomon, C et al  (2013). PloS one 8(7): e68451. 
Tarrade, A et al (2001).  Lab Invest 81(9): 1199-1211. 
  
  
212 
 
(c) Myostatin treatment on the production of placental cytokines  
 
Interaction between myostatin and TNF-α in muscle has been recently identified 133. 
However, the effect of myostatin on cytokine production from placental tissues is unknown. 
Therefor this experiment will evaluate myostatin production from placental explants cutlutred 
at 1%, 3% and 21% oxygen in the presence or absence of myostatin. Myostatin concentration 
is equivalent to that used by Mitchell et al in 2007 investigating glucose uptake following 
myostatin treatment. 
 
Hypoxia chamber calibration check prior to experiments  
Note 1:  The glove box and hypoxic chambers are controlled by two different regulators, each 
with its own on/off valve. The ‘glove box’ regulator should not be used above 25 psi (under 
no circumstances set it above 40 psi). The on/off valve for the glove box nitrogen supply 
must always be left in the ‘off’ position when the glove box is not in use. 
Note 2:  The hypoxic chamber nitrogen gas supply regulator is set to 70 kPa (approx 10 psi). 
There is no need to set it higher. It will take approximately 60 minutes for the glove box to 
reach 1% oxygen. 
Note 3:  The CO2 gas supply to the hypoxic chamber is set at approximately 35 kPa (5 psi) 
and does not require adjustment. 
Note 4:  Calibration should have been performed within one week prior to use of the hypoxic 
chambers and glove box. Check the calibration forms stored in the plastic folder located near 
the equipment. If calibration is greater than 1 week old, calibrate prior to use and record the 
data on form F 014. 
Calibration of Proox Model 360 (glove box control unit) 
Refer to the Proox Model 360 manual, page 13 for the calibration of oxygen (low oxygen 
control). Two gases are used for the calibration: nitrogen from the wall regulator and room air 
(20.9% oxygen). Calibrated gas mixtures may be used in place of the air. 
Record all calibration data on form F014. 
Calibration of Proox Model C21 (3 x hypoxic chamber control units) 
Note:  This complete calibration procedure should be done no later than the day before the 
planned use. This then provides time overnight for re-equilibration of the hypoxic chambers. 
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Refer to the Proox Model C21 manual, page 16 for the calibration of oxygen and carbon 
dioxide. Oxygen and carbon dioxide controllers are calibrated using two gases: 100% 
nitrogen (for the 0% oxygen check) from the wall regulator and a gas mixture of 5% carbon 
dioxide, 20.9% oxygen in nitrogen. The CO2/O2 mix is contained in a small cylinder stored 
in a blue plastic carry case. This case also contains a dedicated regulator set at a flow rate of 
1.5L/min. Connect the regulator to the cylinder (hand tight). 
The Proox 21 oxygen and carbon dioxide controllers on the three meters are calibrated all at 
once for 0% oxygen and 0% carbon dioxide settings and all at once for the 20.9% oxygen and 
5% carbon dioxide settings. 
0% CO2 and 0% O2 calibration (p16 of the manual) : 
Do not spend excessive time on the calibration check as the gas supply to the hypoxic 
chambers is interrupted during this time. However, allow sufficient time for meter 
readings to stabilise prior to making any calibration adjustments. 
Ensure the hypoxic chamber wall nitrogen supply is ‘ON’(faces 6 O’clock).  
Turn off all three ‘Pump’ switches and all six ‘Gas’ switches on the three meters  (faces 
toward OFF).  
NB. The ‘Pump’, located in each hypoxic chamber, circulates gas over the sensor. The latter 
is also located in each chamber. The ‘Pump’ switch must be off during calibration otherwise 
the sensor will be reading a mixture of calibration gases and hypoxic chamber gases. 
Complete steps 3-6 on p16 of the manual and record the calibration readings on Form F 014. 
Hookup the hose (yellow tubing) from the ‘Bleed gas’ to the ‘Cal gas input’ and open the O2 
controller (brass knob on O2 side)  
Both sensors should respond (nitrogen is flowing in through the systems) and should 
come down to ZERO (0.0)-if not do the next steps 
TO CHANGE TO ZERO acceptable to be 0.2+/- of target 
Hold  down the up and down arrows for 5 seconds to enter the program mode  
Press down arrow to enter level  
Press star (*) and up arrow to go to level 3  
Press up arrow alone to choose ZEro mode 
Hold star and up/down arrows to change final values (sensitive move only one up or one 
down and check first).  
Exit by holding the up and down arrows for 5seconds to exit and check if the value is now 
zero 
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5% CO2 and 20.9% O2 calibration:  
The nitrogen supply must be OFF (turn off valve (brass knob), not regulator, at the wall).  
Connect the CO2/O2 cylinder with the tubing attached to the cylinder to the CO2 connection 
that leads to the three meters (to the tubing which splits into three to reach all the 
sensor/regulator boxes) disconnect from the barb and replace with the lead from the cylinder).   
Complete steps 8-12 on p16 of the manual and record the calibration readings on Form F 014. 
Hook up the hose (yellow tubing) from the ‘CO2 bleed’ to the ‘Cal gas input’ and open the 
CO2 controller (brass knob on CO2 side)  
Both sensors should respond (a mix of 5% CO2/20.9% O2  is flowing in through the systems) 
and the O2 should read 20.9 and the CO2 should read 5   
TO CHANGE TO 20.9% O2 and 5% CO2  acceptable to be 0.2+/- of target  
Hold  down the up and down arrows for 5 seconds to enter the program mode  
Press down arrow to enter level  
Press star (*) and up arrow to go to level 3  
Press up arrow alone to choose SPAn mode 
Hold star and up/down arrows to change final values (sensitive move only one up or one 
down and check first).  
Exit by holding the up and down arrows for 5seconds to exit and check if the value is now 
zero 
Remove all yellow tubing, close all bleed valves, turn all Pump switches to on and turn all 
Gas switches to on. 
Disconnect the CO2/O2 cylinder and reconnect the CO2 feed line to the meters. 
Turn on the nitrogen supply at the wall valve. Ensure the regulator reads 10 psi (70 kPa). 
Sometimes the O2 and CO2 readings do not return to their original levels after calibration. 
This may happen to one or more controllers. Allow 5-10 minutes to observe that the meter 
readings are trending in the right direction. If this does not occur, briefly open (5 seconds) the 
relevant hypoxic chamber(s) and then close. This triggers the gas flows to readjust the 
conditions to the correct setting.  
If the CO2 reading still does not trend towards the correct setting, reconnect the yellow 
calibration tubing between the oxygen bleed hose barb and the ‘Cal Gas Input’ barb of the 
meter and gently open the bleed valve knob until the CO2 drops to near zero. Close the bleed 
valve and remove the tubing. 
The system may take several hours to re-equilibrate. 
  
215 
 
 
Myostatin treatment of first trimester explants  
 
 Control no FBS  Control + FBS 1 1ug/ul mstn TNF -alpha 
1    Sample A 
replicates 3 
2    
3     
 
12 well plates x 4 conditions = 48  wells total  
1ug/ml MSTN  
Myostatin in 4 wells per plate = 16 +2 extra=18  
18 x700ul = 12600 total media required 
(700/40) =17.5 (40ug/ml stock) x 18= 315ul  
12285ul media  +  315ul mstn stock  
 
Principal of the method 
An explant is any portion of living tissue removed from the natural site of growth and placed 
in a medium for culture. 
Explants are chosen as models of study to ensure that the structural and cellular architecture 
of the tissue are preserved. The interactions and responses of the tissue in the study are kept 
as much as possible similar to the situation in vivo. 
In this study, small portions first trimester villous placental tissue are dissected from 
consented placenta and cultured. The explants are then exposed to different oxygen tensions 
and myostatin treatment. Media and tissues are collected and stored for next experiments. 
 
Equipment and Reagents Required 
Culture medium (DMEM/F-12) – with Glutamax supplement or add your own 
Antibiotic-antimycotic (100x) (Invitrogen, liquid,  Cat: 15240-062) 
Gentamicin 
Sterile PBS 
Petri dishes (glass and plastic)- very large  
12-well culture plates 
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Liquid nitrogen container 
Primary tissue culture hood 
Autoclaved gloves, forceps, scissors, slides, cork borer, pipette tips 
MSTN 1ug/ul  
Media recipe  
DMEM High glucose with glutamx* 
1% AM/AB* 
1% Pen/Strep* 
10% FCS* 
20 µg/ml Gentamicin (50,000µgml/20µgml=2500)(500,000µl/2500)=200µl* 
 
Placental collection 
Placental tissue with informed consent from women undergoing elective C-section 
Collect from the MARIES TROPES clinic in Bowen hills phone (JEN) : 32571196 
Check the delivery time by calling hospital on the day before sample is required call the 
morning of and arrange for pick up.   
 
Placental processing  
Prewarm culture medium and PBS +gentamicin to 37° C 
500ml media + 5ml Ab/Am + gentamicin 
Take placenta to the TC Lab(Booking the primary tissue culture hood on the previous day) 
1st trimester  
First trimester tissues are very broken apart and can have fetal pieces contained within 
sample. 
Tip off as  much liquid without any tissues into a large beaker (with bleach)  
Rinse the remaining tissues with PBS + gentamicin  
Take a half or manageable portion of the tissues into a separate large culture plate and rinse 
with PBS + gentamicin 
Select villous tissues from sample (small frond like structions) 
 
The first day-preparation 
Plate tissues into 12-well plates (30-50mg villous per well, 3 replicate wells per treatment) 
Add 1.5ml of media without treatment to well with villous tissues 
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Incubate at 37oC for 24h equilibration at 1/3/8% O2 culture conditions sample  in myostatin 
treatment on first day) 
 
The second day-treatment 
After 24-h equilibration, wash explants twice with PBS 
Add serum-free media and treatment 
Incubate again at the same condition 
Prewarm culture medium (NO FBS) and PBS   
DMEM/F12 
1% AM/AB* 
20 µg/ml Gentamicin (50,000µgml/20µgml=2500)(500,000µl/2500)=200µl* 
 
Control +FBS  
Control no FBS media 
1ug/ul MSTN 65ul in 12935ul (mstn) (20μg/ml stock myostatin) 
 
 
The third day-collection  
After the incubation is terminated, the media are harvested, tissues are weighed and snap 
frozen in liquid nitrogen / dry ice container 
Media are stored at -20oC before immunoassay of cytokines and lactate dehydrogenase (for 
longer storage, keep in -80oC). Minimise freeze thaw cycles.  
Tissues are stored at -80oC before protein or RNA extraction    
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(d) Work instruction: Western Blot  
 
Time needed: 2DAYS  ( Day 1)~5HRS,     (Day 2) ~2HRS 45MIN +EXP TIME 
PREPARATION OF BUFFERS and ANTIBODIES 
RUNNING BUFFER 
50mL MOPS buffer  into 1000mL 
MILLI Q water 
TRANSFER BUFFER  
Reduced conditions 
50mL of 20x Nupage Transfer Buffer  
100mL methanol 
1ml antioxidant 
849ml MQ 
Reduced conditions 
50mL of 20x Nupage Transfer Buffer  
100mL methanol 
850ml MQ 
WASH BUFFERPBS TWEEN 
1mL TWEEN  into 1000mL PBS 
(phosphate buffered saline) Shake to mix  
TBS-T  
BLOCKING BUFFER (BLOTTO) 
1g Skim milk powder into 100mL PBST  
Mix on stirring plate  
Keep in fridge(discard after 48hrs) 
PBS +10% TWEEN =9ML PBS +1ML 
TWEEN 
PBS+0.1% TWEEN = 1000ML 
PBS +1ML  
Blocking buffer odyssey (1:1) 
PBS : ODYSSEY 
VISUALIZING SUBSTRATE  
(0.5ml from white bottle  
0.5ml from brown bottle (light 
sensitive) 
FAST BLUE PRERINSE 
45% Methanol = 225mll 
10% Acetic acid = 50ml 
45% Milli Q = 225ml 
COMASSIE BLUE STAIN  
Dissolve 1g of comassie blue 
(Bio-Rad) ion 1L bottle 
containing 
500ml Methanol 
100ml Glacial Acetic Acid (in 
fume hood) 
400ml Milli Q 
COMASSIE BLUE DESTAIN 
70ml (7%v/v) Glacial acetic acid 
810ml (81%v/v) Milli Q 
120ml (12%v/v) Methanol 
PVDF membranes –soak in 
100% methanol for 5 minutes  
Stripping membranes  
0.2M NaOH, just wash in that 
for five mins, then in milliq for 
5 mins, then twice in PBST. 
Then block etc.   
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PREPARATION OF SAMPLES 
SWITCH ON HEATING BLOCK SET TO 70oC 
Take out samples and leave to thaw 
Make up RUNNING buffer while samples are thawing 
Set up eppendorf tubes according to the table  
Centrifuge for 25seconds  
Put eppendorfs in heating block for 10mins at 70oC (disrupts protein aggregates and gives an 
overall negative charge. 
Centrifuge again for 25seconds  
Western samples were made to a total volume of 30µl   
 
SDS PAGE (RUN GEL) 
Use a 4-12% gradient gel (found in the fridge)  
Remove combs carefully not damaging the wells  
Remove tape from outside (this allows current to flow) 
Set up gel in chamber and lock in.  
Running buffer needs to be poured into the INNER chamber to fill the outer chambers half up the 
sides  
Load 10µl of the ladder 30µl of the samples into wells  
Top with running buffer  
Pipette 500µl invitrogen antioxidant into INNER chamber. 
Run the Gel at 200V for 1 hour. Or as specified for gel type 
NB: Make transfer buffer and blocking buffers  
 
TRANSFER –TURBO BLOT –BIORAD SYSTEM 
Refer to turbo blot guide  
Briefly  
Lay bottom stack with blotting membrane on top on the bottom of cassette (drawer) 
Cut gel and lay on top  
Place top stack on top and close cassette 
Run for appropriate time using pre-set method in blotting system  
NB: always run identical sized gels in draws  
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TRANSFER –Nupage  
NB: Handle membranes by their edges with forceps. Clean forceps with distilled water or ethanol if 
forceps have been dipped in antibody solutions. 
Soak 6 sponges in transfer buffer 
Cut nitrocellulose membrane /PVDF (pvdf needs pre-soaking in methanol to activate) 6x8cm (do 
not touch  
the membrane with fingers/gloves) using tweezers  
put membrane to soak in transfer buffer 
Once gel has run crack open the sides with a gel  
 cracker 
Cut the gel removing the wells and the last bit of gel cut one corner to help with recognition of 
orientation  
Set up chamber: 
3X SPONGES 
FILTER PAPER   
GEL 
MEMBRANE 
FILTER PAPER ROLL  
TO REMOVE AIR BUBBLES  
3XSPONGES  
Place in chamber and lock into place pour in TRANSFER BUFFER   
TRANSFER BUFFER 
25mL of 20% Nupage Transfer Buffer 
50mL methanol 
Milli Q to have a final volume of 500mL (375mL) 
Attach tank to power supply  
Put tank in ice filled chilly bin  set tank inside the chilly bin surrounded by ice 
RUN at 30v 1 hour or 12v overnight  
 
BLOTTING : Day 1 
Unhook the tank and take the chamber out  
Carefully remove the sponges and filter paper briefly wash (5 min ) in wash buffer  
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WASH BUFFERPBS TWEEN(1%) 
1mL TWEEN  into 1000mL PBS (phosphate buffered saline)  
Shake to mix  
 Transfer membrane into blocking buffer (blotto) for 1 hour on rocking Plate 
BLOCKING BUFFER (BLOTTO) 1% (high background increase blotto conc and time ) 
1g Skim milk powder into 100mL PBS T 
Keep in fridge(discard after 48hrs) 
Discard buffer after 1 hour and pour in the 1OANTIBODY   
PRIMARY ANTIBODY 
Incubate over night  IN WALK-IN FRIDGE. 
 
BLOTTING : Day 2 
Wash in PBS-TWEEN for 5 minutes x 4 
Add  2OANTIBODY and leave for 1 hour (2 hours if rat tissues/ MYOSTATIN ) 
SECONDARY ANTIBODY 
1 / 10,000 dilution eg.3µL secondary antibody / 30,000µL blotto 
 
VISUALIZING MEMBRANES 
Book machine ~2hrs 45min ahead of time whilst membrane is in secondary Ab 
Wash in PBS-TWEEN for 5 minutes x 4 
Last five minutes of wash switch machine ON 
Book developing machine and switch on. 
1C 
ut plastic sheets and lay flat x2 
Take membrane out of  wash buffer tap on paper towel to remove excess buffer using tweezers 
Place on plastic sheet 
Pipette visualizing substrate over membranes covering all of membrane carefully. 
Leave in cassette for 5 minutes  
Move into new (2nd ) plastic sheet and roller to remove bubbles  
Put the membranes into dark cassette  and tape down to secure. 
 
DARK ROOM 
Take film/ cassette/ scissors/ vivid / timer with to dark room 
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Turn tap on in the developer  
Make sure the lights are off when handling film  
Open cassette and place film over membrane leave for 5minutes initially  cut left corner and mark 
right to help with orientation  
Feed into developing machine and wait for flashing light to stop and beep noise to occur only 
then is it safe to turn light on  
 
DETECTING β-ACTIN 
Stip the membrane (0.2M NaOH) 
Wash in PBS-TWEEN for 5 minutes remove buffer   
Add 0.2M NaOH and wash for 5minutes  
Wash liberally with PBS-TWEEN for 5 minutes x 4 
Block in 4%  blotto  
Discard buffer after 1 hour and pour in the 1OANTIBODY  and incubate for 1 hour 
PRIMARY ANTIBODY 
1/10,000 dilution eg.1µL primary antibody / 10,000µL blotto 
Wash in PBS-TWEEN for 5 minutes x 4 
Add  2OANTIBODY and leave for 1 hour  for βactin 
SECONDARY ANTIBODY 
1 / 10,000 dilution eg.10µL secondary antibody / 10,000µL blotto 
Wash in PBS-TWEEN for 5 minutes x 4 
VISUALIZING MEMBRANES  and DARK ROOM please see previous sections 
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Appendix IV. Publications with collaborations  
a. McKirdy N. C., Peiris H. N., Rice G. E. and Mitchell M. D Chapter 11- 
Prostaglandins and Parturition. Recent Advances in Obstetrics and Gynaecology. 
JP Medical Ltd, 2014 
b. Chan, H. W., McKirdy N. C., Peiris H. N., Rice G. E. and Mitchell M. D. (2013). The 
role of Endocannabinoids in pregnancy. Reproduction 146(3): R101-R109. 
 
 
REPRODUCTIONREVIEWThe role of endocannabinoids in pregnancy
Hsiu-Wen Chan, Natalie C McKirdy, Hassendrini N Peiris, Gregory E Rice and Murray D Mitchell
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Endocannabinoids are a family of lipid signalling molecules. As with prostaglandins (PGs), endocannabinoids are derived from
polyunsaturated fatty acids and affect cell function via receptor-mediated mechanisms. They also bind to PG receptors, although at a
lower affinity. The endocannabinoid network is regulated in pregnancy from embryo development to labour onset. Even small changes in
endocannabinoid exposure can retard embryo development and affect implantation success. There is now compelling evidence that
aberrant expression of factors involved in the endocannabinoid pathway in the placenta and circulating lymphocytes results in
spontaneous miscarriage and poor pregnancy outcomes. It is likely that competition between endocannabinoids, PGs and other similar
lipids ultimately determines how phospholipid/fatty acid substrates are metabolised and, thus, the balance between the uterotonic and
tocolytic activities. We, therefore, hypothesise that endocannabinoid profiles may be used as a biomarker to predict and/or identify
spontaneous labour onset.
Reproduction (2013) 146 R101–R109Introduction
The endocannabinoid system
Endocannabinoids are endogenous ligands derived from
membrane phospholipids that bind to a family of G
protein-coupled receptors, termed cannabinoid receptors.
Five endocannabinoids have been identified to date in
human tissues: N-arachidonoylethanolamide (ananda-
mide; Devane et al. 1992), 2-arachidonoylglycerol
(2-AG; Sugiura et al. 1995), homo-g-linolenoylethanola-
mide (Hanus et al. 1993), docosatetraenoylethanolamide
(Hanus et al. 1993), noladin ether (Hanus et al. 2001) and
virodhamine (Porter et al. 2002). The two best-charac-
terised endocannabinoids are anandamide and 2-AG, and
of the five family members, only these molecules have
been implicated in the processes of pregnancy and
delivery. This review, therefore, focuses on anandamide
and 2-AG. These endocannabinoids are not stored within
cells, but are synthesised and released in response to
increased substrate availability and synthase activity
(Sugiura et al. 2002). Anandamide is thought to be released
by a two-step enzymatic reaction in which arachidonic
acid is transferred to a phospholipid precursor, phospha-
tidylethanolamine, by N-acyltransferase to produce
N-arachidonoyl-phosphatidylethanolamine (NAPE),
which is then cleaved by phospholipase D (PLD) (Fig. 1;
Di Marzo et al. 1997). 2-AG, however, is synthesised from
diacylglycerol (produced from phosphoinositides byq 2013 Society for Reproduction and Fertility
ISSN 1470–1626 (paper) 1741–7899 (online)phospholipase C) through the action of diacylglycerol
lipase (DAGL; Bisogno et al. 2005). Phospholipase
C-independent routes of 2-AG production involving
retrograde transmission in the brain have also been
reported (Di Marzo et al. 1994). Endocannabinoid
degradation is mediated by integral membrane proteins,
monoacylglyceride lipase (MAGL) and fatty acid amide
hydrolase (FAAH), and results in the generation of
arachidonic acid and subsequently prostaglandins (PG)
(Fig. 1; Pacher et al. 2006). Other studies have
demonstrated that endocannabinoids undergo oxidative
metabolism by a number of fatty oxygenases: cyclo-
oxygenases, lipoxygenases and cytochrome P450s, to
produce PG glycerol esters (for 2-AG) and ethanolamides
(for anandamide) (Bornheim et al. 1993, Edgemond et al.
1998, Kozak et al. 2000). The effects of endocannabinoids
are dependent upon their half-life in the extracellular
matrix, which is a product of the rate of synthesis and
cellular uptake and the rate of degradation.
Two cannabinoid receptors, CB1 and CB2, have been
identified and cloned (Matsuda et al. 1990, Munro et al.
1993). These receptors primarily couple to Gi/o proteins
and activate multiple signalling pathways via both the
a and bg subunits of G proteins: Gia classically leads to
adenylate cyclase inhibition, while Gibg modulates
calcium and potassium channels (Pertwee 2006). Other
important actions include the activation of MAPKs and
class IA and IB PI3K. CB receptors are desensitised (but
not internalised) by the G protein-coupled receptorDOI: 10.1530/REP-12-0508
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Figure 1 Metabolism of endocannabinoids. Ananda-
mide and 2-AG are synthesised by a two-step
enzymatic process from phospholipids, phosphoino-
sitides and phosphatidylethanolamine. The endo-
cannabinoids are converted to arachidonic acid by
FAAH and MAGL respectively. Arachidonic acid is
subsequently metabolised by PGHS-1 and PGHS-2 to
produce prostaglandins (PGs). Alternatively, ananda-
mide and 2-AG may be oxygenated by PGHS-2 and
lipoxygenases to generate PG ethanolamides
(prostamides (PMs)) and glycerol esters (-G). PLC,
phospholipase C; DAGL, diacylglycerol lipase; NAT,
N-acyltransferase; NAPE, N-arachidonoyl-phosphati-
dylethanolamine; PLD, phospholipase D; EA,
ethanolamine.
R102 H-W Chan and otherskinases and b-arrestin-2 (Jin et al. 1999). The CB1
receptor is abundantly expressed in the CNS and
peripheral tissues, whereas the CB2 receptor is pre-
dominantly detected in immune cells (Matsuda et al.
1990, Munro et al. 1993).Local endocannabinoid signalling network
in the placenta
Enzymes and proteins involved in the production
and signalling of endocannabinoids are expressed in
the term placenta, particularly in the villous trophoblast
tissues (Table 1). This suggests that endocannabinoids
can be produced locally in the placenta; however, this
remains to be unequivocally established. Immuno-
histochemical studies have characterised changes
in the expression of endocannabinoid-producing and
-metabolising enzymes as well as cannabinoid receptors
in first-trimester gestational tissue. The expression of
human FAAH and CB1 proteins increases at weeks 9–10
of gestation before returning to basal levels (Habayeb
et al. 2008, Taylor et al. 2011). The implication of
these changes is that the expression of the CB1 receptor
and FAAH is dramatically elevated (week 9) prior to
the commencement of blood flow to the intervillous
space (gestation weeks 10–12). This observation coupled
with the low expression of NAPE-PLD suggests that
local endocannabinoid production is limited and any
available anandamide and 2-AG (presumably from
the maternal circulation) are readily converted to
other products (Fig. 1). The biological significance of
the increased expression of the CB1 receptor remains
to be elucidated.Reproduction (2013) 146 101–109More members of the endocannabinoid signal-
ling network are expressed in the term placenta than
in the first-trimester placenta (Table 1). This may be
an indication that the developed placenta requires
endocannabinoid regulation for the maintenance of
pregnancy and preparation for labour.Endocannabinoids, embryo development
and implantation
Cannabinoid receptor expression during
embryo development
The expression of the CB1 receptor is first detected at
the two-cell to the blastocyst stage in the mouse
embryo, and in later stages it is largely confined to the
trophectoderm (Paria et al. 1995, Yang et al. 1996, Wang
et al. 2003). In contrast, the CB2 receptor is present
from the 1-cell to the blastocyst stage (Yang et al. 1996).
Available data support a critical role of endocannabi-
noids in embryo development; for example, treatment of
embryos with anandamide blocks blastocyst develop-
ment, predominantly at the 8-cell/morula stage with
some embryos arrested at the 2-cell stage (Paria et al.
1998). In the same study, 2-AG treatment arrested
embryos at the 2-cell stage. The effects of both
anandamide and 2-AG are reversible by pre-treatment
with a CB1 receptor antagonist, but not with a CB2
receptor antagonist. Furthermore, the effect of endocan-
nabinoids is primarily mediated by the CB1 receptor.
These data are consistent with the hypothesis that the
regulation of endocannabinoid synthesis is requisite for
successful embryo development.www.reproduction-online.org
Table 1 Presence of expression/activity of endocannabinoid network proteins in the placental tissue.
Product Protein Decidua Trophoblast Amnion Chorion References
First trimester
Anandamide NAPE-PLD C Trabucco et al. (2009) and Taylor et al. (2011)
2-AG PLC
DAGL
Arachidonic acid MAGL C C C C Okazaki et al. (1981a)
FAAH C C C Helliwell et al. (2004), Chamley et al. (2008),
Trabucco et al. (2009), and Taylor et al.
(2011)
Cannabinoid receptors CB1 C C Habayeb et al. (2008), Trabucco et al. (2009),
and Taylor et al. (2011)
CB2 C C Habayeb et al. (2008) and Taylor et al. (2011)
Term
Anandamide NAPE-PLD C C Taylor et al. (2011)
2-AG PLC C C C Okazaki et al. (1981a)
DAGL C C C Okazaki et al. (1981b)
Arachidonic acid MAGL C C C Okazaki et al. (1981a, 1981b)
FAAH C C C Park et al. (2003)
Cannabinoid receptors CB1 C C C Park et al. (2003) and Acone et al. (2009)
CB2
NB,C indicates detectable expression of the protein.
Endocannabinoids regulate labour onset R103Paradoxically, Cnr1K/K and Cnr2K/Kmouse embryos
demonstrate impeded embryo development; by day 3 of
pregnancy when wild-type mouse embryos develop into
the 8-cell stage, these knockout embryos can mostly be
found at the 4-cell stage (Paria et al. 2001, Xie et al.
2012). In agreement with earlier studies, Paria et al.
(2001) also showed that treatment of 2-cell embryos with
anandamide for 72 h significantly reduced the number of
embryos that develop to the blastocyst stage in wild-type
mice, and this has also been observed in the Cnr2K/K
mouse embryos but not in the Cnr1K/K mouse embryos.
Overall, CB receptors are required for embryo develop-
ment, and the inhibitory effect of endocannabinoids on
this process is likely to be mediated in part by receptor-
independent mechanisms.
Endocannabinoid regulation of blastocyst
development and implantation
Endocannabinoids are also instrumental in the embryo
implantation process. The binding of anandamide to the
blastocyst decreases prior to implantation (Paria et al.
2001), and the expression of the CB1 receptor is higher
in the dormant blastocyst than in the activated blastocyst
(Wang et al. 2003). Endocannabinoid signalling is
regulated in the mouse uterus, where anandamide
concentration increases almost threefold as the endome-
trium changes from a blastocyst-receptive to a non-
receptive state (Paria et al. 2001). Once the blastocyst
develops in vitro, anandamide and 2-AG exposure for
48 h promotes trophoblast differentiation and outgrowth,
which occur through the CB1 receptor (Wang et al.
1999, Liu et al. 2002, Sun et al. 2010). After 96 h,
however, the vehicle-treated blastocysts displayed a
phenotype similar to that of the anandamide-treated
cells. Similarly, a low anandamide concentration
(14 nM) accelerated the attachment of blastocysts to awww.reproduction-online.orguterine epithelial cell monolayer, whereas a high
anandamide concentration (56 nM) impeded the attach-
ment (Liu et al. 2002). High anandamide concentrations
also inhibited trophoblast differentiation (Wang et al.
1999). Liu et al. showed that these effects were mediated
by the CB1 receptor, but not by the CB2 receptor.
Recently, it has been reported that Cnr1K/K and
FaahK/K mouse trophoblast stem cells demonstrate
retarded cell migration, attachment and spreading (Xie
et al. 2012) as well as reduced trophoblast stem cell
proliferation (Sun et al. 2010).
Anandamide concentrations increase from days 1 to 4
following implantation in the mouse uterus, whereas
2-AG concentrations remain unchanged at levels that
are markedly higher than that of anandamide (Wang
et al. 2007). Additionally, anandamide and 2-AG are
more abundant in the inter-implantation regions than
in the implantation sites, which would serve to inhibit
blastocyst attachment and trophoblast development
as described earlier. Concomitantly, DAGLa (DAGLA) –
which promotes 2-AG production – is highly expressed
in the luminal epithelium of the inter-implantation
sites and down-regulated in the myometrium after
implantation. NAPE-PLD is expressed in the luminal
epithelium; however, its expression is reduced at the
time of implantation. It is more strongly expressed at
the inter-implantation site, thus corresponding to the
high anandamide concentration at this location (Guo
et al. 2005, Wang et al. 2007). Both FAAH and MAGL
are primarily localised in the luminal and glandular
epithelia at the site of implantation before and after
blastocyst attachment. This ensures low endocannabi-
noid signalling at the time of implantation for successful
blastocyst attachment. In summary, implantation success
requires low anandamide binding and signalling in
the blastocyst, trophoblast and endometrium.Reproduction (2013) 146 101–109
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Surprisingly, the opposite is true for ectopic pregnancies
in the fallopian tube. FAAH, NAPE-PLD, and CB1 and
CB2 receptors can be strongly detected in the luminal
border of the fallopian tube epithelium (Gebeh et al.
2012). FAAH activity in peripheral blood cell membranes
is significantly lower in women with ectopic pregnancies
than in those with normal pregnancies (Gebeh et al.
2013). Similarly, the expression of FAAH mRNA is also
significantly lower in the fallopian tubes of women with
ectopic pregnancies than in those of women in the luteal
or follicular phase of their menstrual cycle (Gebeh et al.
2012). Furthermore, plasma anandamide levels are
significantly higher in women with ectopic pregnancies
than in those with normal pregnancies (Gebeh et al.
2013). Also, oviductal transport of embryos is impaired
in FaahK/K and Cnr1K/Kmice (Wang et al. 2004, 2006).
The absence of expression of the CB1 receptor does not
affect embryo development; however, embryos of the
FaahK/K mice show retarded development.
Presently, the contradictory findings that high plasma
anandamide concentrations are associated with implan-
tation in the fallopian tube (ectopic pregnancy) and
failed implantation in the uterine wall (no pregnancy)
cannot be resolved. The results suggest that the effect of
abnormal anandamide exposure depends on its timing
and location.Endocannabinoids and labour
Changes in cannabinoid receptor expression in
early-pregnancy miscarriages
Theoretically, increased endocannabinoid availability
may up-regulate the activation and function of CB
receptors. There are, however, discrepancies in the
literature regarding the expression of cannabinoid
receptors in miscarriages during the first trimester. It
has been shown that the expression of placental CB1
receptor protein is elevated 2.5-fold in spontaneous
miscarriage in the first trimester compared with levels
observed in voluntary termination (Trabucco et al. 2009).
In addition, Trabucco et al. found that the immunostain-
ing of the CB1 receptor is poorly detected in placental
villi from elective surgical terminations, which supports
earlier observations from our laboratory that the
expression of CB1 receptor mRNA and protein is not
readily detected in the first-trimester placentae (weeks
9–13 of gestation; Helliwell et al. 2004). However, for
gestational age-matched placentae of weeks 7–8, the
expression of CB1 receptor protein in the trophoblast,
mesenchymal core and decidua was approximately
twofold lower in spontaneous miscarriage than in
elective surgical termination (Taylor et al. 2011). The
difference in results could be due to the tissue source
as Trabucco et al. did not indicate which part of the
placenta was analysed.Reproduction (2013) 146 101–109The expression of the CB2 receptor is relatively
unchanged throughout the first trimester (Habayeb
et al. 2008), and its expression in the second and third
trimesters remains to be determined. The expression of
the CB2 receptor in trophoblast cells and decidua is
greatly up-regulated in placentae from spontaneous
abortion compared with those from surgical terminations
(Taylor et al. 2011). The significance of this is unknown,
given that the effects of anandamide appear to be
primarily dependent on the function of the CB1 receptor.
Alterations in endocannabinoid signalling promote
miscarriage in early pregnancy
The expression of the anandamide-generating enzyme
NAPE-PLD may be an indicator of anandamide concen-
trations and pregnancy outcomes; however, similar to
those for the CB receptor, opposing results have been
reported. The expression of NAPE-PLD was not signi-
ficantly altered in the trophoblast, mesenchymal core
or decidua of placentae from spontaneous miscarriage
compared with that in placentae from elective surgical
termination (Taylor et al. 2011). Conversely, the
expression of NAPE-PLD mRNA is at least twofold
higher in the first-trimester (weeks 9–12) placentae from
elective surgical termination than in those from spon-
taneous miscarriage (Trabucco et al. 2009). This suggests
that anandamide concentrations in the placenta are
lower prior to spontaneous miscarriage. In direct
contrast with these observations, several studies have
found that plasma anandamide concentrations measured
in the first trimester of women at risk of miscarriage
are up to threefold higher in those who subsequently
miscarried than in those who progressed to term
(Habayeb et al. 2004, 2008, Taylor et al. 2011). A recent
study, however, has failed to demonstrate a difference
between plasma anandamide concentrations in women
with normal pregnancies and those in women who
subsequently miscarried (Tong et al. 2012). Collectively,
the expression of NAPE-PLD and the content of
anandamide in the placenta and their association
with plasma anandamide concentrations require
further characterisation.
FAAH is responsible for the conversion of anandamide
to arachidonic acid, which then provides a source for
labour-promoting PG production. As expected, ananda-
mide content is higher in the uterus and placenta of
FaahK/K mice than in wild-type mice (Sun et al. 2010).
The expression and activity of FAAH mRNA and
protein in peripheral lymphocytes have been found to
be significantly lower in women who subsequently
miscarried spontaneously or failed to maintain IVF
pregnancy in the first trimester than in gestational
age-matched women undergoing voluntary pregnancy
termination or those whose pregnancies continued to
term (Maccarrone et al. 2000, 2001, 2002). In the
murine model, FaahK/K mice deliver prematurelywww.reproduction-online.org
Endocannabinoids regulate labour onset R105(Wang et al. 2006). Similarly, no immunostaining of
FAAH could be detected in the trophoblast cells of
first-trimester placentae obtained from women who
miscarried, whereas the expression of FAAH could be
observed in the trophoblast cells of placentae obtained
from women who underwent voluntary termination
(Trabucco et al. 2009). The absence of FAAH drives
prostamide (PM), not PG, production (Fig. 1). The
concentrations of PMs F2a, E2 and D2 are at least
threefold higher in the tissues of anandamide-treated
FaahK/K mice than in those of their wild-type controls
(Weber et al. 2004). These findings provide strong
evidence that i) interactions of FAAH and anandamide
are essential for the normal progression of pregnancy
and ii) a decreased activity of FAAH results in increased
PM concentrations, which then have a negative impact
on pregnancy. Other studies have shown that while there
is no difference in the expression of FAAH protein in
trophoblast cells of women with normal pregnancy and
recurrent miscarriage, FAAH is more abundant in the
decidual stromal cells of women with recurrent mis-
carriage than in the normal-pregnancy placentae
(Chamley et al. 2008). These results suggest that the
expression of FAAH is regulated in a tissue-specific
manner and low expression and activity of FAAH are
associated with early delivery.
Anandamide represses myometrial contractions
Anandamide represses oxytocin-induced contractions in
human myometrial tissue (Dennedy et al. 2004).
Inhibition is dose dependent and mediated by the CB1
receptor, but not by the CB2 receptor. In addition, daily
i.p. injections of anandamide into rats during late
pregnancy increased the length of gestation and the
number of stillbirths per litter and decreased the levels of
serum PGs F1a and F2a (Wenger et al. 1997). In support of
these findings, Cnr1K/K mice demonstrated earlier
labour onset compared with wild-type and Cnr2K/K
mice (Wang et al. 2008). The same study also showed
that treatment of wild-type mice with CB1 receptor
antagonists from days 14 to 18 of pregnancy also resulted
in premature labour. The absence of CB1 receptor
signalling altered serum progesterone, oestrogen, corti-
costerone and corticotrophin-releasing hormone
concentrations prior to parturition (Wang et al. 2008).
Interestingly, a marked increase in human plasma
anandamide concentrations has been reported as
pregnancy progressed from the third trimester to term
(but not during labour Habayeb et al. 2004). Because this
was a cross-sectional study, it is difficult to determine
whether or not this elevation plays a significant role in
the timing of labour onset.
Once labour onset has commenced, the role of
anandamide is unclear. When plasma anandamide
concentrations in women undergoing labour induction
by medical intervention were measured, no significantwww.reproduction-online.orgassociations were found for pre-induction plasma
anandamide concentrations and the length of induction
to delivery time (Nallendran et al. 2010). This may be
due to the variety of methods of labour induction that
were used. In contrast, Habayeb et al. (2004) reported a
moderate but positive correlation between plasma
anandamide concentrations and duration of contrac-
tions/cervical dilatation at the time of sampling.
Interestingly, although anandamide impedes labour
induction, its concentration in plasma is elevated during
active labour. Plasma anandamide concentrations were
significantly elevated after induction compared with
before induction; again, this may be confounded by the
various method(s) used for inducing labour (Nallendran
et al. 2010). The results are supported by other studies
that reported a significant 1.7- to 3-fold increase in
plasma anandamide concentrations of women at term in
active labour (without prior intervention) than in women
at term but not in labour (Habayeb et al. 2004, Lam et al.
2008). The expression of the CB1 receptor is markedly
down-regulated in the villi of labouring placentae than
in non-labouring placentae at term (Acone et al. 2009).
This suggests that the increased pool of anandamide
during labour is unlikely to be activating the CB1
receptor. Overall, anandamide has an inhibitory effect
on myometrial contractions and extends gestation, but
does not appear to have an effect once labour
commences.
Endocannabinoids may promote labour
via PG production
PGs are lipid mediators that play a critical role in the
mechanisms of miscarriage (Sugino et al. 2000) and
parturition at both term and preterm (Challis et al. 2000).
Our laboratory demonstrated that endocannabinoids
and a synthetic cannabinoid (CP55, 940) stimulate fetal
membrane production of PGE2 in a CB1 receptor-
dependent manner (Mitchell et al. 2008). Similar results
were also obtained using rat uterus, although in this
tissue anandamide increased the levels of PGE2 and F2a
in a CB2 receptor-dependent manner (Sordelli et al.
2012). PGs E and F have been implicated in the
regulation of uterine contractions, cervical ripening
and membrane rupture. PGI and thromboxanes contri-
bute not only to these processes, but also to the
vasculopathy of preeclampsia (Walsh & Wang 1998,
Challis et al. 2000). Therefore, endocannabinoids have
labour-promoting effects via PG production.
Paradoxical effects of anandamide on labour
The seemingly paradoxical effects of anandamide on
labour onset may be cell- or species-specific; however,
they may also be explained by the actions of PMs.
Anandamide can be converted into two different groups
of fatty acids: it is converted to arachidonic acid by
FAAH and subsequently by PGHS-2 to an intermediateReproduction (2013) 146 101–109
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PGs (Fig. 1). Anandamide can also be directly converted
to PGH2 by PGHS-2 and subsequently metabolised to
form PMs; only anandamide-derived PGH2-ethanola-
mine (PMH2) is metabolised to PMs. Synthetic PG-amide
(Bimatoprost, which activates PM-sensitive receptors)
weakly elicits contractions in both pregnant and non-
pregnant human isolated myometrial tissues, whereas
the tissues are responsive to 17-phenylprostaglandin F2a
(Chen et al. 2005). The weak contractility induced by
PMs could result from their low affinity for PG receptors
(Ross et al. 2002). The affinity of PME2 for PGE2 receptors
is at least 500-fold lower than that of PGE2. If
anandamide is being hydrolysed to PMs, then it may
be that the increased PM concentrations may impede
myometrial contractility and promote labour quiescence
(Fig. 2). The paradox of the activity of anandamide may,
therefore, be resolved by it being dependent upon its
route of metabolism and the concurrent activity of
FAAH; that is, the conditions that result in anandamide-
inducing PG production are not the same as those that
would have an overall relaxant effect on regular
myometrial contractions (Fig. 2). If FAAH activity is
high, increased amounts of anandamide would be
metabolised via the central pathway (shown in Fig. 1),
leading to elevated PG production. Alternatively, if
FAAH activity is low, less amounts of anandamide
would be converted to arachidonic acid, limiting theFAAH absent or reduced
Remains as anandamide
PGHS-2 CB1 bindin
Ananadmid
Prostamides
PG:PM ratio
Prolonged gestation
Weak myometrial contractility
Figure 2 A new model for the spontaneous onset of preterm labour that im
prostaglandin:prostamide (PG:PM) ratio as a biological marker for the risk of
amide hydrolase (FAAH) and PGH synthase (PGHS) are variables in the ne
production of anandamide: FAAH absent or reduced – anandamide is unable
concentrations – i) anandamide may be metabolised by PGHS-2, which in
prolongs labour, ii) anandamide may bind to the CB1 receptor, which has b
lead to an increased PG:PM ratio and drive labour induction and iii) lastly,
arachidonic acid, increasing the availability of PG substrate and, in doing s
Reproduction (2013) 146 101–109rate of PG production, but leaving anandamide available
for PM production via the pathway shown on the right
of Fig. 1.
A new model of preterm spontaneous onset of labour
Based on the studies described above and recent data
from our laboratory, we propose a new model for the
spontaneous onset of labour, where the endocannabi-
noid pathway is coupled to PG synthesis in the placenta
(Fig. 2). According to the new model, increased plasma
anandamide concentrations with normal FAAH activity
predispose to labour onset. We have demonstrated that
synthetic endocannabinoids stimulate the CB1 receptor
and induce the production of labour-promoting PGs. In
contrast, if FAAH activity is low or absent, anandamide
is not readily converted to arachidonic acid and PGs.
Instead, anandamide may be metabolised by PGHS-2 to
produce PMs or may bind to the CB1 receptor, leading to
PG production (Fig. 2). Each scenario results in distinctly
opposing actions. Hence, the establishment of a normal
range of PG:PM ratio for gestational age, and accurate
measurement of the ratio in clinical samples, would be
a useful tool in assessing the risk of premature labour.Challenges in PG quantification
The measurement of PG concentrations in fluids and
tissues is traditionally performed using RIAs or ELISAs.Converted to arachidonic acid
FAAH mormal
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plicates the metabolism of anandamide and its effect on the
initiation of uterine contractions. The presence and absence of fatty acid
w model, leading to three possible outcomes from the introduction or
to be converted to arachidonic acid, resulting in increased anandamide
creases PM production and therefore delays labour induction and
een shown to stimulate PG production by our laboratory, and this may
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Figure 3 Structural similarities between arachidonic
acid and the endocannabinoids, anandamide and
2-arachidonoylglycerol (2-AG), and prostaglandin
(PG) E2 and prostamide (PM) E2. Note that PME2 is
closer in structure to the antigen than PGE2 itself
due to its larger moiety at the carboxyl end. Adapted
from McKirdy NC, Rice GE & Mitchell MD 2013
Eicosanoids as diagnostics for preterm labor.
Reproductive Biology Insights 6 1–10.
100 ‘PGE2’ by RIA
‘PGE2’ by MS
‘PME2’ by MS80
60
40
R
el
at
iv
e 
qu
an
tit
y
20
0
Parturition status
No
 la
bo
ur
La
bo
ur
La
bo
ur
No
 la
bo
ur
La
bo
ur
No
 la
bo
ur
Figure 4 A hypothetical dataset demonstrating the putative confound-
ing effects of antibody cross-reactivity on the quantification of
immunoreactive PGE2. Immunoassay-based measurement of PGE2
(grey squares) is a conflation of antibody reactivity with both PGE2
(open squares) and PME2 (black squares). PGE2 and PME2 contributions
can be resolved using mass spectrometry approaches. Such deconvo-
lution of the immunoassay data, thus, may provide a different insight
into labour-associated changes in the concentrations of these
lipid-derived mediators.
Endocannabinoids regulate labour onset R107The sensitivity of these assays is dependent upon the
sensitivity and specificity of antibodies raised against
PG metabolites. PGs and endogenous cannabinoid
metabolites share the same lipid backbone with differing
polar head groups at exactly the same position (Fig. 3;
reviewed in McKirdy et al. (2013)). Small lipid molecules
display low immunogenicity – to elicit an immune
response, they must be conjugated to a carrier protein
(commonly BSA). We report a major cross-reactivity of
commercial antisera raised against PG PGE2 with its
endocannabinoid counterpart, PM PME2 (Glass et al.
2005). Similarly, this has been observed for PGF2a and
PMF2a. Additionally, these antibodies demonstrate a
higher affinity for the endocannabinoid metabolites than
their supposed PG target.
This has important implications for the current
literature and may change our view of the role that
PGs play in human pregnancy and parturition. To
illustrate, a hypothetical dataset representing the
quantification of eicosanoids by immunoassay and
mass spectrometry is presented in Fig. 4. The RIA data
demonstrate a general increase in PG concentrations
with labour (the two left columns) sufficient for statistical
significance; however, the wide distribution of data
points prevents their clinical utility in diagnostic testing.
The immunoassay-based measurement of PGE2 is a
conflation of antibody reactivity with both PGE2 (middle
two columns) and PME2 (the two right columns). The
contribution of PGE2 and PME2 to the observed
immunoreactivity can be resolved using mass spec-
trometry approaches. Such deconvolution of the
immunoassay data, thus, may provide a different insight
into labour-associated changes in the concentrations of
these lipid-derived mediators. The capacity to establish
labour-associated changes in individual lipid metab-
olites also affords an opportunity to develop multivariate
index assays that may improve diagnostic efficiency to
identify labour onset at both term and preterm.www.reproduction-online.orgSummary
Endocannabinoid signalling is regulated during embryo
development, blastocyst implantation, placentation and
labour. There is direct evidence that alterations in
endocannabinoids and the enzymes that regulate their
production and metabolism lead to retarded embryo
development, poor blastocyst attachment and miscar-
riage. It is becoming increasingly evident that elevated
anandamide concentrations promote spontaneous con-
tractions, and this is likely to be mediated by PG
production. We propose that differences in the profile of
endocannabinoids present in biofluids may be of utility
in the prediction and/or diagnosis of spontaneous labour
onset at both term and preterm.Reproduction (2013) 146 101–109
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 Prostaglandins and Parturition – Book Chapter 
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Introduction 
Each year, 15 million babies are born prematurely [1]. Although there have been great 
advances in obstetric and neonatal care, even if current intervention methods were applied 
globally, the prevention rate of  preterm birth (PTB) would still be less than 20% [2]. Even in 
a socioeconomically privileged country such as Australia, recent rates of PTB have not 
decreased [3, 4]. Preterm labour (PTL) remains the major clinical indication leading to poor 
pregnancy and neonatal outcomes. Not surprisingly, this is due to PTB’s associated 
sequelae; low birth weight, diminished lung function, cognitive difficulties, along with 
increased rates of adult onset disease [1] or in the most severe cases, perinatal morbidity 
[5]. These carry a considerable financial burden [6] which, in addition to the personal 
suffering experienced by preterm babies and their families, presents a compelling 
motivation to continue research into intervention and pregnancy management strategies. 
The most effective intervention is likely to be that which is performed the earliest, which 
relies on early detection of at-risk pregnancies. Such detection, in turn, requires highly 
specific and sensitive diagnostic targets. A promising target that has been the focus of 
reproductive research for decades is the family of arachidonic acid metabolites called 
eicosanoids, including the subfamilies prostaglandins and prostamides, and their 
biosynthetic and metabolising enzymes and substances that regulate their production such 
as cytokines (Figure 1). 
 
Investigations conducted during the 1960s and 1970s were centred upon making use of the 
involvement of prostaglandins in luteolysis for the creation of a new contraceptive, and on 
their ability to induce uterine contractions to effect parturition. The field expanded to 
include the many tissues on which prostaglandins exert an effect, and mapping of the 
interactions with different cell types and other signalling molecules has elucidated a highly 
complex web [7]. 
 
Human intrauterine tissues produce a range of eicosanoids including prostacyclin and 
lipoxygenase products of arachidonic acid metabolism [8, 9] with increased production 
during labour even by the uterine cervix [10]. These eicosanoids have actions that are 
crucial to the onset and progression of labour, as well as cervical softening and dilation; they 
may also regulate fetal physiological processes such as biosynthesis of lung surfactant [11]. 
Indeed neonatal levels of eicosanoids change postpartum after term and preterm labour in 
specific ways [12] and can be regulated by treatment with e.g. inhibitors of prostaglandin 
biosynthesis for closure of a patent ductus arteriosis [13]. Regulation by inhibitors of 
prostaglandin biosynthesis and other agents and physiological conditions is well established 
in animal models such as sheep and pigs [14-16]. 
 
Biosynthesis and regulation 
The term eicosanoid applies to all metabolites of arachidonic acid; these molecules have 
similar chemical structures with subtle differences, depending upon their parent molecule – 
2-arachidonoyl glycerol, arachidonic acid, or anandamide (Figure 1).  
 
Arachidonic acid-derived eicosanoids 
Phospholipids from cell membranes are cleaved by either the direct action of phospholipase 
A2 or indirectly by the action of phospholipase C and diacyl- and mono-acylglycerol lipase 
(DAGL and MAGL, respectively), resulting in the release of arachidonic acid and 
lysophospholipid. Arachidonic acid is converted to the intermediate PGH2 by one of two 
isoforms of cyclooxygenase (COX), also known as prostaglandin H synthase (PGHS); the 
constitutive COX-1 (PGHS-1), or inducible COX-2 (PGHS-2) (Figure 1). This is considered to be 
rate-limiting step in the eicosanoid biosynthesis cascade. PGH2 is further modified by 
terminal synthases to create the prostaglandins (PGD2, PGE2, PGF2α and PGI2), or 
thromboxane A2 (TXA2)[17] (Figure 1).  
 
The endocannabinoid converter, fatty acid amide hydrolase (FAAH) 
Anandamide is the precursor of prostamides (PMs) (Figure 1). The enzyme fatty acid amide 
hydrolase (FAAH) readily converts anandamide to arachidonic acid, providing the substrate 
for labour-promoting prostaglandin (PG) production. As one would expect, anandamide 
concentrations are elevated in the uterus and placenta of FAAH knockout mice when 
compared to the wild-type control[18]. The absence of FAAH restricts anandamide 
metabolism to its own pathway (Figure 1), driving prostamide (PM) production rather than 
PG production. 
 
The rate of biosynthesis, and by extension, the concentration, varies depending upon the 
eicosanoid, tissue/location, and gestational time-point. Concentrations of eicosanoids, their 
precursors, metabolites, and regulating factors have been investigated to varying degrees, 
in an effort to determine normal levels for each stage of gestation. Challis et al proposed 
that maturation of the fetus influences initiation of labour through activation of the fetal 
hypothalamic-pituitary-adrenal axis [19]. Increasing cortisol production from the fetal 
adrenal gland is common in the animal model, yet a synchronous increase in adrenal 
oestrogen precursor nearing term was restricted to primates. Despite mechanisms differing 
between sheep and primate models, the outcome is identical: placental and intrauterine 
tissues increase production of oestrogen approaching the end of gestation. Challis et al 
propose that fetal cortisol acts on the placenta to increase prostaglandin H synthase (PGHS) 
expression and activity, thereby increasing PG concentration within the fetal membranes 
[19]. In addition, fetally-derived cortisol may retard the metabolism of PGs within this 
region, allowing concentrations to rise within proximal tissues to maximally assert the PG 
autocrine/paracrine function. Elevated production of corticotropin releasing hormone (CRH) 
may also feed into this system [19]. 
 
In most animals, a functional withdrawal of progesterone toward term signals imminent 
labour onset, however such withdrawal does not occur in humans. Some hypothesise that 
the high progesterone level which coincides with labour is necessary for the opposing 
activity between upper and lower regions of the uterus: the fundus undergoing contractions 
while the cervix and nearby myometrial tissue relaxes to facilitate the expulsion of the fetus 
[19].  
 
There is no one cause for preterm labour; the maturation of the hypothalamic-pituitary-
adrenal axis may be asynchronous to the rest of the fetus, causing the onset of labour and 
delivery prior to, or after, term; another proposed activator is an ascending intrauterine 
infection whereby the associated leukocyte infiltration into uterine tissues brings about 
cytokine and other pro-inflammatory mediator production in the immediate area [20]. The 
resultant inflammatory response, driven in part by the eicosanoids produced, is thought to 
be instrumental to labour initiated in this manner [20]. Researchers are working to profile 
the physiological, and in some cases pathological, causes of mistimed labour with a view to 
earlier diagnoses allowing closer management of pregnancies at risk of preterm delivery.  
 
Endocannabinoids and their metabolites – the prostaglandin glycerol esters, prostaglandins, 
and prostamides – deliver their cellular function via cell surface receptors (Figure 2); 
although they are specific, receptor subtypes occur for some PGs, e.g. PGE2 may bind to EP1-
EP4. The ratios of expression of the receptors vary between tissues, which enable the range 
of tissue-specific PG responses [20]. 
 
PGs and other eicosanoids act in opposing ways to co-ordinate balance, or homeostasis. 
While some PGs promote vascular dilation, others promote constriction; some promote 
inflammation and yet others, its inhibition; even sleep versus wakefulness [20]. Studies have 
found that the balance is disrupted in pathological processes such as pre-eclampsia and 
cardiovascular disease and that the discordant concentrations can be exacerbated or 
mitigated through exposure to specific cytokines or inhibitors [20].  
 
Evidence is mounting that pro-inflammatory mediators, such as Interlukin-1β and others 
present in an infection-induced preterm labour, instructs transcription of the gene required 
for PGE synthase (PGES). Many biological systems observe the pro-inflammatory milieu 
preceding and promoting simultaneous up-regulation of membrane-bound PGES (mPGES) 
coupled to an increase in COX-2, producing PGE2 [20]. The COX-2:mPGES coupling has been 
implied in the increase in PGE2 immediately preceding ovulation, and cytosolic PGES (cPGES) 
is expressed in murine uterine tissues prior to implantation, suggestive of a role in 
implantation success and, due to the balanced nature of prostanoid actions, may also be 
important for decidualisation when fertilisation does not occur [20]. Until recently, little was 
known about the specific effects of each PGES pertaining to gestation and labour, other 
than these basic interrelationships.  
 
PGES and COX-2 
As gestation progresses and labour advances, there are increases in COX-2 expression and 
activity in fetal/maternal membranes. By extension, mPGES is boosted and PG biosynthesis 
increases, with the major site of PGE2 production being the amnion [21]. The highest 
frequency of immunoreactive mPGES was in the amnion epithelium and chorion laeve 
trophoblasts, while the decidua showed low or no detectible immunoreaction [22]. Similar 
examination of the placenta found that mPGES enzyme occurred at low levels in the 
syncytiotrophoblast and cells proximal to blood vessels, but was mPGES protein increased in 
the chorion but decreased in placenta during labour [22]. This led the investigators to 
suggest that mPGES may be differentially regulated during labour. Similar to mPGES, cPGES 
was found in the amnion epithelium, but also in the fibroblasts and macrophages in the 
chorion trophoblast layer [23]. When examined by Western blot, no difference was found in 
protein level expression between the two synthases with respect to term or preterm labour. 
This suggests that PGE2 biosynthesis is rate-limited at a point higher up in the metabolic 
pathway; Helliwell et al proposed that this may occur at the COX-2 or cPLA-2 level [24]. 
There was, however, a change in distribution pattern of both synthases from a cytosolic 
dispersion at preterm, to clustered at term associated with lipid droplets, the contents of 
which are yet to be determined [23]. PGE2 has a widely accepted role in stimulation of 
myometrial contractions, but due to its many subtypes of receptor and differential 
expression of the same, PGE2 could well have further actions in pregnancy and parturition 
presently currently unknown, such as the recently discovered PGE2 stimulation of matrix 
metalloproteinase 9 in fetal membranes in vitro [25].  
 
PGFS 
PGF2α increases at parturition and is known to affect myometrial contraction and cervical 
relaxation, but little is known of the regulation and expression of its synthase, PGFS, during 
pregnancy [24]. When ovine distribution of PGF2α mRNA was investigated and compared to 
COX-2 by Wu et al, it was found in all tissues examined (myometrium, endometrium, 
maternal and fetal placenta in induced preterm labour and spontaneous term labour). 
Interestingly, both betamethasone-induced preterm labour and spontaneous labour at term 
showed an increase in COX-2 but not PGFS mRNA [26]. This indicates that the rate-limiting 
step in increasing PGF2α is not transcription. 
 
PGIS and TXAS 
Prostacyclin (PGI2) has powerful smooth muscle relaxant effects, yet it has long been 
identified as a major stimulator of uterine contractions, and is the main eicosanoid found in 
myometrial tissue of pregnant animals, including humans [19]. These seemingly 
contradictory effects may be explained by the differential expression of subtypes of PGI 
receptors between regions of tissues.  Its terminal synthase, PGIS, has been observed in 
pregnant and non-pregnant ovine tissues and found to be differentially regulated during 
labour. Inflammatory cytokines, in particular tumour necrosis factor α (TNFα), interleukin-
1α (IL-1α), IL-1β, and IL-6, are known to increase PGI production by inducing expression of 
PGIS mRNA and protein [24].  
 
The ratio of PGI to TXA is thought to be important for homeostasis in vivo as they act in 
opposition to each other. Upon immunohistochemical staining, PGI was seen localised in the 
endothelial cells within the placental villi, whereas TXA was found in the trophoblasts, which 
implicates their roles in the fetal side and maternal side of placental circulation, respectively 
[27].  
 
Maternal plasma concentrations of PGI increase during parturition, yet PGIS concentration 
in myometrial myocytes and vascular smooth muscle cells and endothelial cells from the 
lower uterine segment was found to be inversely proportional to advancing gestational age. 
Instead, cyclic mechanical stretch of the myometrial tissues may induce PGIS expression, 
triggering release of PGI, as was found to be the case in vitro [28].  
 
PGDS 
PGD2 is produced in large amounts by the human placenta when subjected to superfusion 
conditions in vitro, and smaller amounts were liberated by gestational membranes [24]. 
Macrophages, which are known to invade the myometrium in readiness for onset of labour 
at term, are another important source of PGD2. In addition to these mechanisms, laminar 
shear stress stimulates release of PGD2 and upregulates expression of the secreted, 
lipocalin-type PGDS in human umbilical vein endothelial cells [29]. 
 
Biological functionality 
Eicosanoids (including prostaglandins) and endocannabinoids affect their biological activity 
by binding to G-protein-coupled receptors (GPCRs). Depending upon whether the GPCR 
contains a Gi or Gs protein, cyclic adenosine monophosphate (cAMP) production is inhibited 
or stimulated, respectively. 
 
Two cannabinoid receptors, CB1 and CB2, have been documented and cloned [30, 31]. The 
receptors are generally limited to separate regions within the body; CB1 is abundantly 
expressed in the central nervous system and peripheral tissues, whereas the CB2 receptor is 
mostly found in immune cells [30, 31]. CB1 and CB2 largely couple to Gi/o proteins and 
activate multiple signalling pathways through both the α and βγ subunits of G proteins: 
Giα leads to adenylate cyclase inhibition, while Giβγ regulates calcium and potassium 
channels [32]. They also activate MAPKs and class IA and IB PI3K. CB receptors are 
desensitised (but not internalised) by the G protein-coupled receptor kinases and β-arrestin-
2 [33], and such “blocking” processes have allowed valuable negative control tests to be 
carried out in mouse models. Theoretically, activation and function of CB receptors may 
increase with endocannabinoid availability. There are, however, conflicting reports 
regarding the expression of cannabinoid receptors in miscarriages during the first trimester. 
 
Prostaglandins act in a similar fashion; PGE2, for example, may bind to any of four GPCRs, 
(EP1, EP2, EP3 or EP4) working to increase cAMP if bound to EP2 or EP4, but decrease cAMP 
if bound to EP3. These modulations in cAMP concentrations eventually up-regulate COX-2 
gene expression and feed back into the regulatory system[34]. 
 
Physiological effects of prostaglandins are not limited to the reproductive system - being 
observed regulating tissue repair in several organ systems [35]. Of particular importance to 
Obstetricians and Gynaecologists however, are the processes that these molecules trigger in 
the female reproductive system. The hypothesis surrounding the involvement of 
prostanoids in the process of parturition stems from the suggestion that labour is initiated 
by an inflammation-like response. This provides a starting point to identify possible 
mechanisms of inhibition, with the aim of delaying onset of labour until such time as the 
fetus is more fully formed (37+ weeks gestation) and therefore improve the neonatal 
morbidity rate, and decrease sequelae. 
 
Due to their contractile action on myometrium and cervical ripening activity, prostaglandins 
are an ideal candidate for gynaecological applications. Procedures such as cervical 
preparation for nulliparous post-menopausal hysteroscopy [36], medical termination of 
pregnancy [37], and management of missed miscarriage [38] have all benefited from 
advances in the understanding of prostaglandin interactions with the tissues and signalling 
systems of the female reproductive system. Each of the aforementioned applications in the 
reproductive system relies on the ripening and contractive effects that prostaglandins have 
on the cervical and myometrium, respectively. 
 
Mechanisms of action throughout pregnancy 
Blastocyst development and implantation 
Eicosanoids have been detected in gestational tissues from the very early stages of 
conception, and their roles have been elucidated and found to be integral to successful 
pregnancy outcomes. Cannabinoid (CB) receptor mRNA for both CB1 and CB2 were found to 
be expressed in mouse embryos during the pre-implantation phase, from as early as the 2- 
and 1-cell stages, respectively [39]. Treatment of embryos with anandamide or 2-acyl 
glycerol arrested their development at the 2 to 8 cell stage; however, if prior to exposure to 
anandamide or 2-acyl glycerol the embryos were treated with a CB1 receptor agonist, the 
development would progress as normal [40]. The same was not found to be true for pre-
treatment with a CB2 receptor agonist. CB1 receptor expression decreases in the murine 
blastocyst from the dormant to the activated state [41].  
 
Anandamide concentrations within the uterus increased three-fold with the change in 
endometrium from being blastocyst-receptive to non-receptive [42]. Speed of blastocyst 
attachment was found to be proportional to the anandamide concentration, when tested in 
vitro; i.e. the higher the concentration of anandamide, the longer the time taken to attach 
[43]. Similarly, elevated anandamide inhibits trophoblast differentiation [44] and was found 
to exert its effect via the CB1 receptor, but not the CB2 receptor [43]. 
 
Early pregnancy miscarriage 
Endocannabinoids and their receptors play a large role in co-ordinating development and 
implantation of embryos, and are similarly involved in onset of labour and miscarriage.  
 
Low or absent FAAH 
Expression of FAAH mRNA and activity of the protein itself in peripheral lymphocytes was 
significantly reduced in women who went on to spontaneously miscarry or experience an 
IVF pregnancy which failed in the first trimester, compared to levels in tissues collected from 
gestational age-matched pregnancies which underwent voluntary termination and 
pregnancies which continued as normal, to term [45-47]. Immunohistochemically, FAAH 
could not be detected by staining trophoblast cells from first trimester miscarriages, but was 
seen in trophoblasts from voluntary termination placentae [48]. However, another study 
found no difference in FAAH expression in trophoblast cells between normal pregnancy and 
recurrent miscarriage, but did find FAAH to be elevated in the decidual stromal cells of 
women who repeatedly miscarried compared to normal pregnancy placental tissues [49]. In 
addition, mice lacking the ability to express FAAH (FAAH knockout murine model) 
experienced preterm labour [50]. In this way, low or no FAAH activity has been linked to 
early uterine stimulation, loss of pregnancy, and labour onset.  
 
We propose, in the case of low or no FAAH, that anandamide is unable to be readily 
converted by FAAH activity to the PG precursor, arachidonic acid. Anandamide levels 
accumulate, and drive the production of PMs, changing the PG:PM ratio and stimulating 
uterine contractions. In support of this, PMs F2α, E2, and D2 concentrations were found to be 
at least threefold greater in FAAH knockout mice after administering anandamide, than the 
wild-type controls [51]. One can conclude from these findings that interactions of FAAH and 
anandamide are important for normal progression of pregnancy, and that decreased or 
absent FAAH activity leads to increased PM concentrations with detrimental effects on the 
pregnancy. For these reasons, anandamide and FAAH may be candidates for biomarker 
analysis of placental dysfunction and adverse pregnancy outcomes.  
 
CB receptor expression 
Again, conflicting results have been reported: using immunohistochemistry, one study found 
CB1 receptor protein to be 2.5-fold higher in spontaneous first trimester miscarriage, and 
poorly detected in placental villi from elective terminations [48]; but another found CB1 
expression in trophoblast, mesenchymal core and decidual tissues to be twofold higher in 
terminated pregnancies than in spontaneous miscarriage [52]. The discrepancy could be due 
a difference in tissues examined, as Trabucco et al did not specify which section of the 
placenta was tested. A study of the effect of absent CB1 (CB1 knockout murine model) 
produced data congruent with the latter finding; the CB1 knockout mice and wild-type mice 
treated with CB1 receptor agonists experienced labour earlier than the wild-type control 
and CB2 knockout mice [53]. Also, a lack of CB1 receptor signalling was found to alter serum 
progesterone, oestrogen, corticosterone and corticotrophin-releasing hormone (CRH) 
concentrations prior to parturition [53]. 
 
In uncomplicated pregnancy, CB2 receptor expression is stable in the first trimester [54], 
and has not yet been determined for the remainder of pregnancy. CB2 receptor protein was 
expressed far more in the trophoblast cells and decidua of spontaneous human miscarriage 
than surgical termination [52]. Given that anandamide appears to exert its effects via CB1 
receptors, the importance of the CB2 upregulation in this situation is still unknown.  
 
Ectopic pregnancy 
Ectopic pregnancy creates a profile whereby FAAH, NAPE-PLD, and receptors for CB1 and 
CB2 are strongly detectable in the luminal border of fallopian tube epithelium [55]; FAAH 
activity in the membranes of peripheral blood cells is significantly lower than in normal 
pregnancy [56]; expression of FAAH mRNA in the fallopian tubes is significantly lower than 
the luteal or follicular phase of the menstrual cycle [55]; and plasma anandamide 
concentrations are significantly elevated compared to normal pregnancy [56]. 
 
Labour onset and progression 
The exact pathways critical to the onset of labour are yet to be established; this is due, in no 
small part, to the fact that many of the cell types found in fetal membranes are able to 
produce the factors suggested to be involved in parturition, and is compounded by the 
heterogeneity of those tissues denying researchers the ability to attribute production to 
discrete areas or layers of tissue. [5] 
 
Endocannabinoids in labour onset via PG production 
Endocannabinoids promote labour through production of PGs. PGs are lipid molecules that 
play a critical role in the mechanisms of miscarriage [57] and parturition at both term and 
preterm [19]. Recently, the first data was published in evidence of endocannabinoids and 
synthetic cannabinoids stimulating fetal membrane production of PGE2 in a CB1-dependent 
manner [58]. Similar findings were generated by another group using rat uterus exposed to 
anandamide to increase PGE2 and PGF2α, this time in a CB2 receptor-dependent manner 
[59]. PGE and PGF are associated with the regulation of myometrial contractions, cervical 
ripening, and membrane rupture. PG-related compounds, such as prostacyclins and 
thromboxanes, contribute to these changes, but have also been found to coordinate in the 
vasculopathy of pre-eclampsia [19, 60].  
 
Olson and Amman outlined five distinct, sequential physiological events of parturition [61]; 
Rupture of the fetal membranes, dilation of the cervix, contraction of the myometrium, 
separation of the placenta, and uterine involution - all involve PGs, but the most extensively 
studied area of PG involvement is in myometrial contractility. The return to quiescence via 
involution, however, is thought to be mainly orchestrated by oxytocin. Terzidou outlined the 
involvement of eicosanoids such as prostaglandin and prostacyclin (PGI2), along with other 
“pro-labour” factors including relaxin, nitric oxide, oxytocin receptors, corticotropin-
releasing hormone, and parathyroid hormone-related peptide (PTHrP), in the progressing 
phases of parturition [5].  
 
During uterine quiescence, PGI2, relaxin, nitric oxide and act through a variety of 
mechanisms, to increase the concentration of cAMP or cyclic guanosine monophosphate 
(cGMP) within the cells, preventing release of intracellular calcium, denying activation of 
myosin light chain kinase, and hence, inhibiting myometrial contractions [5]. 
 
Activation of uterine function occurs with the involvement of prostaglandins. Corticotropin-
releasing hormone (CRH) and oestrogen rise during this phase, which, with the possible 
inclusion of mechanical stretch, triggers the expression of genes requisite for contractions, 
namely prostaglandins, connexin43, and oxytocin receptors. CRH receptors, expressed on by 
both myometrium and fetal membranes, are bound to cAMP-second messenger G proteins, 
causing upregulation of COX-2 expression, thus positively feeding back into the pathway to 
produce more prostaglandins.  
 
The same urotonins - prostaglandin, oxytocin, and CRH - are responsible for the stimulation 
phase, whereby the intrauterine biochemistry closely resembles an inflammatory response. 
Cytokine IL-8 is known to attract neutrophils into the cervix, and also induce PGE2 
production. At this stage, prostaglandins are responsible for ripening the cervix, relaxing the 
lower portion of the uterus, and stimulating contractions in the upper segment (fundus).  
 
In the same study of gestational age matched tissues as referred to earlier, the expression of 
NAPE-PLD was not significantly altered in the trophoblast, mesenchymal core or decidua of 
placentae from spontaneous miscarriage compared to placentae from elective surgical 
termination [52]. Conversely, NAPE-PLD mRNA expression was found to be at least twofold 
higher in first-trimester (weeks 9–12) placental tissues from surgical termination than in 
spontaneous miscarriage [48]. This suggests that anandamide concentration in the placenta 
is lower prior to spontaneous miscarriage, but this requires confirmatory work. 
 
Circulating anandamide concentrations may not necessarily reflect placental decreases; 
several studies of first trimester plasma anandamide in women at risk of miscarriage found 
concentrations to be up to threefold higher in those whose pregnancies subsequently 
miscarried than those who progressed to term [52, 62, 63], however, a more recent study 
failed to demonstrate a difference in plasma anandamide concentrations between normal 
and subsequent miscarriage groups [64]. Further investigation is therefore required to 
definitively characterise the expression of NAPE-PLD and the concentration of placental 
anandamide along with their association with plasma anandamide concentrations. 
 
Anandamide and the onset of labour 
Investigations of anandamide’s effect on labour have produced conflicting data. When FAAH 
is available, anandamide is readily converted to arachidonic acid and further processed to 
PGs, having a strong stimulatory effect on uterine contractions. If FAAH is reduced or 
absent, anandamide is hydrolysed to PMs, and it may be that the increased PM 
concentrations impede myometrial contractility and promote labour quiescence (Figure 3). 
If reduced or absent FAAH is coupled with reduced or absent COX enzyme activity, 
anandamide will accumulate in the body with adverse effects on pregnancy. 
 
Anandamide can act to repress oxytocin-induced contractions in human myometrium[65] in 
a dose-dependent manner, mediated by CB1 receptors, but not CB2. Daily intra-peritoneal 
admission of anandamide into rats in late pregnancy extended gestation length and 
increased stillbirths per litter, while decreased serum concentrations of PGs F1α and F2α were 
detected [66]. Bimatoprost, a synthetic PG-amide which activates PM-sensitive receptors, 
generates weak contractions in human myometrial tissue explants, regardless of pregnancy 
status (pregnant vs non pregnant) [67]. This could be the result of PM’s low affinity for PG 
receptors, as the affinity of PME2 for PGE2 receptors is at least 500-fold lower than its usual 
target, PGE2. 
 
A marked increase in human plasma anandamide was detected by mass spectrometry at the 
progression of pregnancy from third trimester to term labour [62, 68, 69]. Once labour 
commences, the role of anandamide is less certain. Even though anandamide inhibits labour 
induction, when labour was induced by medical intervention, plasma anandamide 
concentrations were significantly increased (post-induction), but no meaningful relationship 
was found between pre-induction plasma anandamide concentration and length of time 
from induction to delivery [68]; although, this may be due to the variety of labour induction 
methods included in the analysis. Investigations of non-induced labours have produced 
results in agreement with these, reporting a significant 1.7- to 3-fold increase in plasma 
anandamide concentration in women in active labour at term over those not in labour at 
term [62, 69]. Similarly, a moderate positive correlation was found between plasma 
anandamide concentration and length of contraction/cervical dilation at the time of 
sampling [62]. Interestingly, the increased anandamide levels are not likely to be activating 
the CB1 receptor, as CB1 is markedly down-regulated in the villi of labouring placentae 
compared to non-labouring placentae at term [70]. 
 
The paradoxical effect of anandamide on labour may, therefore, be depend upon its route 
of metabolism and the concurrent activity of FAAH and COX enzymes. The literature has 
established an association between anandamide signalling and early labour onset; the exact 
intermediate processes, however, from CB receptor activation to intracellular signalling to 
biological outcome, remain to be determined. 
 
Potential diagnostic ability of eicosanoids 
Cross-reactivity in previous detection methods 
The generation of antibodies for immunological methods of detection (enzyme linked and 
radiolabelled immunoassays) is not a precise science. In order to illicit an immune response 
and raise antisera, the small lipid structures (eicosanoids) are conjugated to a larger 
molecule (bovine serum albumin, BSA) at their point of difference - the polar head group 
(Figure 4, Section C).  Antibodies can be created in recognition of any part of the target 
molecule, but when conjugated thus, antibodies detect areas nearer the conjugation site 
less well, and favour molecules similar to the antigen (target molecule). Hence, if two or 
more molecules share a similar structure, there is a high risk of cross-reactivity. For instance, 
prostamide E2 (PME2) has a larger functional group at its carboxyl terminus than PGE2, so 
not only will an antibody raised against PGE2 recognise and bind PME2 due it its similarity in 
structure, it will bind more avidly to it because, having a larger functional group, it more 
closely resembles the conjugated antigen against which it was raised [71].  
 
With the homology displayed by the eicosanoid family due to their common precursor, 
there is a very small region of distinction between each compound, and hence, and a large 
potential for cross reactivity among antibodies generated against these molecules. This has 
caused misleading data and incorrect conclusions to be drawn in the past, as was evidenced 
by examining commercial antisera raised against BSA-conjugated PGs which demonstrated 
major cross-reactivity with prostamides [71] (Figure 4, Section A and B).The study also found 
evidence that anandamide metabolism by cell line and primary amnion tissue explants, in 
the presence of cytokine stimulation, produced a predominately PM output rather than PGs 
[71]. This was only discovered, however, after separation by thin layer chromatography, 
because the metabolites were first measured by radioimmunoassay and were detected as 
PGs. Hence, it is possible that in inflammatory reactions, the substrate is converted to PM 
rather than PG.  
 
With respect to PTL research, accurate detection of eicosanoids is paramount; the major 
identifiable cause of PTL is intrauterine infection [72], which may trigger increased 
production of PMs which, with previous popularity of antibody-base detection methods, 
may have largely been misidentified as PGs. PM precursor, anandamide, has been shown to 
be released in cases of haemorrhagic shock[73] and exposure of macrophages and human 
peripheral lymphocytes to lipopolysaccharide [74, 75]. Similarly, PGHS-2 is increased in 
response to inflammatory mediators including IL-1β and lipopolysaccharide [76]. The 
concurrent increase in both anandamide and PGHS-2 could direct and increase in PME2. 
 
These findings imply that reliance on antibody-based methods for detection and 
quantification of PGs are lacking in specificity, and could be masking a diagnostically useful 
change in the PG:PM ratio (Figure 5). Instead, physical detection methods such as 
chromatography and mass spectrometry would be better employed in the role of detection 
and quantification of eicosanoids, on the basis of their specificity and sensitivity. Only then 
will we be able to accurately define the temporal relationships at play within the complex 
system, as the variability in previous measurements may have been entirely due to changes 
in the PG:PM ratio. Now, with the ability to physically detect these compounds, we may be 
able to separate normal fluctuations from pathological concentrations of these bioactive 
lipids, potentially harnessing them as a diagnostic for PLT risk.  
 
Conclusions: Compiling an analyte profile for informing preterm labour 
From analysis of the literature, we can draw together a profile of changes in expression and 
concentration of certain analytes which may be strongly indicative of risk of preterm labour. 
A profile is necessary because of the complexity of the labour induction pathway: e.g. Alone, 
high plasma anandamide levels are not enough to characterize risk of PTL; depending on the 
concentrations and activities of other analytes, increased anandamide may have a 
stimulatory or inhibitory effect on labour. Such are the paradoxical clinical indications of 
elevated anandamide in pregnancy. 
 
High plasma anandamide concentration and reduced PGHS activity 
Reduced (or absent) FAAH activity leads to reduced conversion of anandamide to 
arachidonic acid, which then limits substrate availability for conversion to PGs. As PGs have 
a strong stimulatory effect on myometrial contractions, one may conclude that low FAAH 
activity would cause low PG levels, decreasing the risk of spontaneous labour but, if PGHS is 
not available for metabolism to PMs, high plasma anandamide concentrations can increase 
CB receptor expression in placental tissues (Figure 3). CB1 was found to be elevated in 
spontaneous miscarriage, and has been linked to uterine PGE2 production; in this way, 
elevated plasma anandamide may induce labour via PGE2 [45-48]. Conversely, lacking CB1 
receptors or being treated with CB1 receptor agonists caused mice to display preterm onset 
of labour compared to normal and CB2 receptor knockout mice [53].  
 
High plasma anandamide concentration in the presence of active PGHS 
If the increased anandamide concentration occurs in the presence of PGHS, it can be 
metabolized to PMs, driving the PG:PM ratio down, and will have only a weak stimulatory 
effect on uterine contractions and may even prolong gestation (Figure 3). Clearly, regulation 
of the CB mechanisms in normal pregnancy is extremely tight, as variation from the 
physiological norm in either direction, results in pathological activity. 
 
How we propose to use eicosanoids to determine risk/presence of preterm labour 
Due to cross-reactivity of PG and PM species giving rise to erroneous data interpretation 
from antibody-based detection methods, it is possible that a potentially clinically useful role 
for PGs as diagnostic and predictive factors for PTL has been missed in past investigations. 
Advances in mass spectrometry, however, mean that this issue can now be addressed.  
 
Increased intrauterine PG production is considered a critical step in the onset of labour; 
This, coupled with the revelation of PM’s formerly masked presence, the subsequent 
investigation of PM biological activity within reproductive tissues, and the definition of 
factors related to dynamics of eicosanoid production have led to the hypothesis that a panel 
of preterm labour biomarkers may allow earlier detection and more definitive risk analysis 
of PTL. Overall, the current literature informs potential biomarkers for risk of PTL as being 
FAAH, COX, PG:PM, CRH, relaxin, PTHrP, oxytocin receptors, anandamide and CB receptors. 
It has also demonstrated why measurement by methods that do not rely upon antibodies 
(i.e. mass spectrometry) is optimal for obtaining data and conclusions which accurately 
describe and reflect the true biological processes at play.  
 
Future studies would ideally define, for each potential biomarker, the magnitude at which 
divergence from the normal gestational range indicates significant risk of PTL, the positive 
predictive value of each biomarker, and the most efficient combination. Detection of 
pathological changes at the earliest possible gestational age would confer maximum benefit, 
informing clinicians of the need for a higher level of patient management. Ultimately, this 
would enable a prophylactic tocolytic to be administered prior to onset of PTL to improve 
neonatal morbidity and mortality rates. As such, further research may identify a tocolytic 
effective in humans with fewer adverse effects than those currently available [61]. 
 
 
  
Figure 1 
Figure 1 The eicosanoid biosynthesis pathway, demonstrating relationships between eicosanoid 
species and the enzymes involved. 2-AG, 2-arachidonoylglycerol.  FAAH, fatty acid amide hydrolase. 
MAGL, monoacylglycerol lipase. COX, cyclooxygenase (isoforms 1 and 2). As an example of 
metabolite nomenclature, PGH2, prostaglandin H2, or its similar derivatives from 2-AG (PGH2-G, 
prostaglandin H2 glycerol ester), and anandamide (PGH2-EA, prostaglandin H2 ethanolamide). Enzyme 
names italicised and shaded grey. 
 
  
Figure 2 
 
Figure 2: Phospholipases act on cell phospholipid bilayers to liberate the endocannabinoids 2- 
arachidonoylglycerol (2-AG), arachidonic acid (AA), and anandamide (AEA) - the precursors of 
prostamides, prostaglandins and prostaglandin-glycerol esters. An endocannabinoid can be modified 
into its sister molecule by the action of monoacylglycerol lipase (MAGL) or fatty acid amide 
hydrolase (FAAH). While the endocannabinoids exert a biological function themselves, they can be 
further modified by cyclooxygenases (COX 1 or 2) and terminal synthases to produce highly 
specialised functional activities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3  
Figure 3: A new model for the spontaneous onset of preterm labour. The model implies that 
anandamide metabolism effects the prostaglandin:prostamide (PG:PM) ratio. The presence or 
absence of fatty acid amide hydrolase (FAAH) and cyclooxygenase-2 (COX-2) are variable, which may 
lead to three possible outcomes: If FAAH is absent or reduced, anandamide is unable to be 
converted to arachidonic acid which increases the anandamide concentration. The elevated 
anandamide may (i) be metabolised by COX-2, which would increase prostamide production and 
therefore delay labour induction and prolong gestation, or (ii) bind the CB1 receptor, which our 
laboratory has shown to stimulate prostaglandin production, leading to an increased PG:PM ratio 
and labour induction. Lastly, (iii) in the case of normal or increased FAAH, anandamide may be 
converted to arachidonic acid, increasing the availability of prostaglandin substrate, and in doing so, 
increasing the PG:PM ratio and causing labour induction. By this logic, the PG:PM ratio may be useful 
as a biological marker for risk of initiation of uterine contractions (Modified from Chan et al, 2013). 
 
 
  
Figure 4 
 
Figure 4: Sections A and B Cross-reactivity of prostamides with prostaglandins. Standardized 
prostaglandin radioimmunoassays were used to determine the ability of prostamides to displace 
tritiated prostaglandin from the antibody compared with the parent compound. A: Displacement of 
[3H]prostaglandin E2 (PGE2) from in-house-generated antibody by PGE2 (closed triangles) or PGE2-
ethanolamide (PGE2-eth; open triangles). B: Displacement of [3H]prostaglandin F2α (PGF2α) from anti-
PGF2α antibody by PGF2α (open circles) or PGF2α-ethanolamide (PGF2α-eth; closed circles). Error bars 
represent standard error of the mean (Modified from Glass et al., 2005). Section C The similarity 
between structures of prostamide E2 (PME2), prostaglandin E2 (PGE2), and the antigenic 
prostaglandin E2-BSA (bovine serum albumin) conjugate, highlighting the size and location of 
functional groups. Note that prostamide E2 is more similar to the commonly used antigen (PGE2-BSA) 
than PGE2 itself, due to the larger moiety at the carboxyl end (Modified from McKirdy et al, 2013). 
 
  
Figure 5 
 
 
Figure 5: Demonstration of the diagnostic benefit of the higher specificity mass spectrometry (MS) 
method of prostaglandin and prostamide detection and quantitation, versus antibody-based 
methods, for example, radioimmunolabelled assay (RIA). Determining concentration based on the 
interaction of the molecular structure with a calibrated, reproducible, consistent ionisation beam, 
rather than interaction with a biologically derived, and hence, inherently inconsistent antibody, 
enables reliable separation of signal into individual eicosanoid species, for example, prostaglandin E2 
(PGE2) and prostamide E2 (PME2). This enables researchers to attribute the change in concentration 
between No Labour and Labour states to changes in specific eicosanoids. NOTE: Graph depicts a 
hypothetical data set (Modified from Chan et al, 2013). 
 
  
References: 
1. Born Too Soon: The Global Action Report on Preterm Birth, C.P. Howson, M.V. Kinney, and 
J.E. Lawn, Editors. 2012, March of Dimes, The Partnership for Materal Newborn and Child 
Health, Save the Children, World Health Organization: Geneva. 
2. Simmons, L.E., et al., Preventing Preterm Birth and Neonatal Mortality: Exploring the 
Epidemiology, Causes, and Interventions. Seminars in Perinatology, 2010. 34(6): p. 408-415. 
3. Li, Z., et al., Australia’s Mothers and Babies 2009, in Perinatal statistics series. 2011, AIHW 
National Perinatal Epidemiology and Statistics Unit: Sydney. 
4. Li, Z., et al., Australia's Mothers and Babies 2010, in Perinatal statistics series. 2012, AIHW 
National Perinatal Epidemiology and Statistics Unit: Canberra. 
5. Terzidou, V., Biochemical and endocrinological preparation for parturition. Best Practice & 
Research: Clinical Obstetrics & Gynaecology, 2007. 21(5): p. 729-756. 
6. Clements, K.M., et al., Preterm Birth–Associated Cost of Early Intervention Services: An 
Analysis by Gestational Age. Pediatrics, 2007. 119(4): p. e866-e874. 
7. Fernandis, A.Z. and M.R. Wenk, Membrane lipids as signaling molecules. Curr Opin Lipidol, 
2007. 18(2): p. 121-8. 
8. Mitchell, M.D., et al., Possible role for prostacyclin in human parturition. Prostaglandins, 
1978. 16(6): p. 931-7. 
9. Saeed, S.A. and M.D. Mitchell, Formation of arachidonate lipoxygenase metabolites by 
human fetal membranes, uterine decidua vera and placenta. Prostaglandins Leukot Med, 
1982. 8(6): p. 635-40. 
10. Ellwood, D.A., et al., The in vitro production of prostanoids by the human cervix during 
pregnancy: preliminary observations. Br J Obstet Gynaecol, 1980. 87(3): p. 210-4. 
11. Acarregui, M.J., et al., Prostaglandins regulate surfactant protein A (SP-A) gene expression in 
human fetal lung in vitro. Endocrinology, 1990. 127(3): p. 1105-13. 
12. Mitchell, M.D., et al., Plasma prostaglandin levels during early neonatal life following term 
and pre-term delivery. Prostaglandins, 1978. 16(2): p. 319-26. 
13. Lucas, A. and M.D. Mitchell, Plasma-prostaglandins in pre-term neonates before and after 
treatment for patient ductus arteriosus. Lancet, 1978. 2(8081): p. 130-2. 
14. Mitchell, M.D. and A.P. Flint, Use of meclofenamic acid to investigate the role of 
prostaglandin biosynthesis during induced parturition in sheep. J Endocrinol, 1978. 76(1): p. 
101-9. 
15. Silver, M., et al., Prostaglandins in the foetal pig and prepartum endocrine changes in mother 
and foetus. Animal Reproduction Science, 1979. 2(1–3): p. 305-322. 
16. Magness, R.R., et al., Uterine prostaglandin production in ovine pregnancy: effects of 
angiotensin II and indomethacin. Am J Physiol, 1992. 263(1 Pt 2): p. H188-97. 
17. Woodward, D.F., Y. Liang, and A.H. Krauss, Prostamides (prostaglandin-ethanolamides) and 
their pharmacology. British Joural of Pharmacology, 2008. 153(3): p. 410-419. 
18. Sun, X., et al., Endocannabinoid signaling directs differentiation of trophoblast cell lineages 
and placentation. Proceedings of the National Academy of Sciences, 2010. 107(39): p. 
16887-16892. 
19. Challis, J.R.G., et al., Endocrine and Paracrine Regulation of Birth at Term and Preterm. 
Endocrine Reviews, 2000. 21(5): p. 514-550. 
20. Hansen, W.R., et al., Key enzymes of prostaglandin biosynthesis and metabolism. Coordinate 
regulation of expression by cytokines in gestational tissues: a review. Prostaglandins Other 
Lipid Mediat, 1999. 57(4): p. 243-57. 
21. Mitchell, M.D., et al., Prostaglandins and parturition. Reprod Fertil Dev, 1995. 7(3): p. 623-
32. 
22. Alfaidy, N., et al., Expression of membrane prostaglandin E synthase in human placenta and 
fetal membranes and effect of labor. Endocrine, 2003. 20(3): p. 219-25. 
23. Meadows, J.W., et al., Expression and localization of prostaglandin E synthase isoforms in 
human fetal membranes in term and preterm labor. J Clin Endocrinol Metab, 2003. 88(1): p. 
433-9. 
24. Helliwell, R.J.A., L.F. Adams, and M.D. Mitchell, Prostaglandin synthases: recent 
developments and a novel hypothesis. Prostaglandins, Leukotrienes and Essential Fatty 
Acids, 2004. 70(2): p. 101-113. 
25. McLaren, J., D.J. Taylor, and S.C. Bell, Prostaglandin E(2)-dependent production of latent 
matrix metalloproteinase-9 in cultures of human fetal membranes. Mol Hum Reprod, 2000. 
6(11): p. 1033-40. 
26. Wu, W.X., et al., Increase in prostaglandin H synthase 2, but not prostaglandin F2alpha 
synthase mRNA in intrauterine tissues during betamethasone-induced premature labor and 
spontaneous term labor in sheep. J Soc Gynecol Investig, 2001. 8(2): p. 69-76. 
27. Shellhaas, C.S., et al., Intravillous eicosanoid compartmentalization and regulation of 
placental blood flow. J Soc Gynecol Investig, 1997. 4(2): p. 58-63. 
28. Korita, D., et al., Cyclic mechanical stretch augments prostacyclin production in cultured 
human uterine myometrial cells from pregnant women: possible involvement of up-
regulation of prostacyclin synthase expression. J Clin Endocrinol Metab, 2002. 87(11): p. 
5209-19. 
29. Taba, Y., et al., Fluid shear stress induces lipocalin-type prostaglandin D(2) synthase 
expression in vascular endothelial cells. Circ Res, 2000. 86(9): p. 967-73. 
30. Matsuda, L.A., et al., Structure of a cannabinoid receptor and functional expression of the 
cloned cDNA. Nature, 1990. 346(6284): p. 561-564. 
31. Munro, S., K.L. Thomas, and M. Abu-Shaar, Molecular characterization of a peripheral 
receptor for cannabinoids. Nature, 1993. 365(6441): p. 61-65. 
32. Pertwee, R.G., The pharmacology of cannabinoid receptors and their ligands: an overview. 
International Journal of Obesity (London), 2006. 30 Suppl 1: p. S13-18. 
33. Jin, W., et al., Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization 
and Internalization. The Journal of Neuroscience, 1999. 19(10): p. 3773-3780. 
34. Klein, T., et al., Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochimica et 
Biophysica Acta (BBA) - Molecular Cell Research, 2007. 1773(11): p. 1605-1618. 
35. Kalish, B.T., et al., The growing role of eicosanoids in tissue regeneration, repair, and wound 
healing. Prostaglandins & Other Lipid Mediators, 2013. 104–105(0): p. 130-138. 
36. Kant, A., Divyakumar, and U. Priyambada, A randomized trial of vaginal misoprostol for 
cervical priming before hysteroscopy in postmenopausal women. Journal of Midlife Health, 
2011. 2(1): p. 25-27. 
37. Kulier, R., et al. Medical methods for first trimester abortion. Cochrane Database of 
Systematic Reviews, 2011.  DOI: 10.1002/14651858.CD002855.pub4. 
38. Neilson, J.P., et al. Medical treatments for incomplete miscarriage. Cochrane Database of 
Systematic Reviews, 2013.  DOI: 10.1002/14651858.CD007223.pub3. 
39. Paria, B.C., S.K. Das, and S.K. Dey, The preimplantation mouse embryo is a target for 
cannabinoid ligand-receptor signaling. Proceedings of the National Academy of Sciences, 
1995. 92(21): p. 9460-9464. 
40. Paria, B.C., et al., Effects of cannabinoids on preimplantation mouse embryo development 
and implantation are mediated by brain-type cannabinoid receptors. Biology of 
Reproduction, 1998. 58(6): p. 1490-1495. 
41. Wang, H., et al., Differential G protein-coupled cannabinoid receptor signaling by 
anandamide directs blastocyst activation for implantation. Proceedings of the National 
Academy of Sciences, 2003. 100(25): p. 14914-14919. 
42. Paria, B.C., et al., Dysregulated Cannabinoid Signaling Disrupts Uterine Receptivity for 
Embryo Implantation. Journal of Biological Chemistry, 2001. 276(23): p. 20523-20528. 
43. Liu, W.M., E.K. Duan, and Y.J. Cao, Effects of anandamide on embryo implantation in the 
mouse. Life Sciences, 2002. 71(14): p. 1623-1632. 
44. Wang, J., et al., Stage-Specific Excitation of Cannabinoid Receptor Exhibits Differential Effects 
on Mouse Embryonic Development. Biology of Reproduction, 1999. 60(4): p. 839-844. 
45. Maccarrone, M., et al., Low fatty acid amide hydrolase and high anandamide levels are 
associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. 
Molecular Human Reproduction, 2002. 8(2): p. 188-195. 
46. Maccarrone, M., et al., Progesterone Up-Regulates Anandamide Hydrolase in Human 
Lymphocytes: Role of Cytokines and Implications for Fertility. The Journal of Immunology, 
2001. 166(12): p. 7183-7189. 
47. Maccarrone, M., et al., Relation between decreased anandamide hydrolase concentrations in 
human lymphocytes and miscarriage. Lancet, 2000. 355(9212): p. 1326-1329. 
48. Trabucco, E., et al., Endocannabinoid System in First Trimester Placenta: Low FAAH and High 
CB1 Expression Characterize Spontaneous Miscarriage. Placenta, 2009. 30(6): p. 516-522. 
49. Chamley, L.W., et al., Nuclear localisation of the endocannabinoid metabolizing enzyme fatty 
acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent 
miscarriage. Placenta, 2008. 29(11): p. 970-975. 
50. Wang, H., et al., Fatty acid amide hydrolase deficiency limits early pregnancy events. Journal 
of Clinical Investigation, 2006. 116(8): p. 2122-2131. 
51. Weber, A., et al., Formation of prostamides from anandamide in FAAH knockout mice 
analyzed by HPLC with tandem mass spectrometry. Journal of Lipid Research, 2004. 45(4): p. 
757-763. 
52. Taylor, A.H., et al., Modulation of the endocannabinoid system in viable and non-viable first 
trimester pregnancies by pregnancy-related hormones. Reproductive Biology and 
Endocrinology, 2011. 9: p. 152. 
53. Wang, H., H. Xie, and S.K. Dey, Loss of cannabinoid receptor CB1 induces preterm birth. PLoS 
One, 2008. 3(10): p. e3320. 
54. Habayeb, O.M.H., et al., Expression of the Endocannabinoid System in Human First Trimester 
Placenta and Its Role in Trophoblast Proliferation. Endocrinology, 2008. 149(10): p. 5052-
5060. 
55. Gebeh, A.K., et al., Ectopic Pregnancy Is Associated with High Anandamide Levels and 
Aberrant Expression of FAAH and CB1 in Fallopian Tubes. Journal of Clinical Endocrinology & 
Metabolism, 2012. 97(8): p. 2827-2835. 
56. Gebeh, A.K., et al., Elevated Anandamide and Related N-Acylethanolamine Levels Occur in 
the Peripheral Blood of Women With Ectopic Pregnancy and Are Mirrored by Changes in 
Peripheral Fatty Acid Amide Hydrolase Activity. Journal of Clinical Endocrinology & 
Metabolism, 2013. 98(3): p. 1226-1234. 
57. Sugino, N., et al., Decreased superoxide dismutase expression and increased concentrations 
of lipid peroxide and prostaglandin F2α in the decidua of failed pregnancy. Molecular Human 
Reproduction, 2000. 6(7): p. 642-647. 
58. Mitchell, M.D., et al., Cannabinoids stimulate prostaglandin production by human 
gestational tissues through a tissue-and CB1-receptor-specific mechanism. American Journal 
of Physiology-Endocrinology and Metabolism, 2008. 294(2): p. E352-E356. 
59. Sordelli, M.S., et al., Cyclooxygenase-2 prostaglandins mediate anandamide-inhibitory action 
on nitric oxide synthase activity in the receptive rat uterus. Eur J Pharmacol, 2012. 685(1-3): 
p. 174-9. 
60. Walsh, S.W. and Y. Wang, Maternal Perfusion with Low-Dose Aspirin Preferentially Inhibits 
Placental Thromboxane While Sparing Prostacyclin. Hypertension in Pregnancy, 1998. 17(2): 
p. 203-215. 
61. Olson, D.M. and C. Ammann, Role of the prostaglandins in labour and prostaglandin receptor 
inhibitors in the prevention of preterm labour. Frontiers in Bioscience, 2007. 12: p. 1329-43. 
62. Habayeb, O.M.H., et al., Plasma Levels of the Endocannabinoid Anandamide in Women—A 
Potential Role in Pregnancy Maintenance and Labor? Journal of Clinical Endocrinology & 
Metabolism, 2004. 89(11): p. 5482-5487. 
63. Habayeb, O.M.H., et al., Plasma anandamide concentration and pregnancy outcome in 
women with threatened miscarriage. Journal of the American Medical Association, 2008. 
299(10): p. 1135-1136. 
64. Tong, S., et al., Diagnostic accuracy of maternal serum macrophage inhibitory cytokine-1 and 
pregnancy-associated plasma protein-A at 6-10 weeks of gestation to predict miscarriage. 
Obstet Gynecol, 2012. 119(5): p. 1000-8. 
65. Dennedy, M.C., et al., Cannabinoids and the human uterus during pregnancy. American 
Journal of Obstetrics and Gynecology, 2004. 190(1): p. 2-9. 
66. Wenger, T., et al., Effects of anandamide on gestation in pregnant rats. Life Sciences, 1997. 
60(26): p. 2361-71. 
67. Ross, R.A., et al., Pharmacological Characterization of the Anandamide Cyclooxygenase 
Metabolite: Prostaglandin E2 Ethanolamide. Journal of Pharmacology and Experimental 
Therapeutics, 2002. 301(3): p. 900-907. 
68. Nallendran, V., et al., The plasma levels of the endocannabinoid, anandamide, increase with 
the induction of labour. British Journal of Obstetrics and Gynaecology, 2010. 117(7): p. 863-
9. 
69. Lam, P.M.W., et al., Ultra performance liquid chromatography tandem mass spectrometry 
method for the measurement of anandamide in human plasma. Analytical Biochemistry, 
2008. 380(2): p. 195-201. 
70. Acone, G., et al., Low type I cannabinoid receptor levels characterize placental villous in 
labouring delivery. Placenta, 2009. 30(2): p. 203-5. 
71. Glass, M., et al., Misidentification of prostamides as prostaglandins. Journal of Lipid 
Research, 2005. 46(7): p. 1364-1368. 
72. Romero, R., et al., Does Infection Cause Premature Labor and Delivery? Seminars in 
Reproductive Medicine, 1994. 12(04): p. 227-239. 
73. Wagner, J.A., et al., Activation of peripheral CB1 cannabinoid receptors in haemorrhagic 
shock. Nature, 1997. 390(6659): p. 518-521. 
74. Liu, J., et al., Lipopolysaccharide Induces Anandamide Synthesis in Macrophages via 
CD14/MAPK/Phosphoinositide 3-Kinase/NF-κB Independently of Platelet-activating Factor. 
Journal of Biological Chemistry, 2003. 278(45): p. 45034-45039. 
75. Maccarrone, M., et al., Lipopolysaccharide Downregulates Fatty Acid Amide Hydrolase 
Expression and Increases Anandamide Levels in Human Peripheral Lymphocytes. Archives of 
Biochemistry and Biophysics, 2001. 393(2): p. 321-328. 
76. Lin, C.C., et al., Induction of cyclooxygenase-2 expression in human tracheal smooth muscle 
cells by interleukin-1beta: involvement of p42/p44 and p38 mitogen-activated protein 
kinases and nuclear factor-kappaB. Journal of Biomedical Science, 2004. 11(3): p. 377-90. 
 
 
 
 
 
 
 
 
 
 
 
